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Abstract 
Background 
Heart failure (HF) is a major cause of morbidity and mortality worldwide.  HF 
with preserved ejection fraction (HFpEF) now accounts for around half of the HF 
population.  To date, no treatments for HFpEF have proven effect and outcomes 
have not improved in recent decades.  The heterogeneity of the HFpEF 
population and the failure of randomised controlled trials (RCTs) to demonstrate 
effective therapies has led to attempts to identify sub-phenotypes of HFpEF 
which may respond to targeted therapies.   
Recent studies suggest that epicardial coronary artery disease (CAD) and 
coronary microvascular dysfunction (CMD) may play an important role in a 
substantial group of patients with HFpEF.  A novel paradigm has been proposed 
suggesting that endothelium-dependent CMD may play a key role in the unifying 
pathophysiology of HFpEF.   
I performed a systematic review of the literature describing the prevalence of 
epicardial CAD and CMD in HFpEF populations.  Most studies were retrospective 
observational and population-based studies with inconsistent definitions of HF, 
preserved left ventricular ejection fraction (LVEF) and CAD.  Studies which 
documented CAD angiographically were almost exclusively performed in highly-
selected convenience cohorts.  Consequently, prevalence estimates of CAD in 
HFpEF varied considerably between studies.  Similarly, studies assessing CMD in 
HFpEF reported inconsistent results due to variable definitions of CMD and 
methods of assessing coronary microvascular function.  Therefore, the 
prevalence of epicardial CAD and CMD have not been prospectively and 
systematically studied in an unselected HFpEF population.   
Aims 
The main aims of this study were to determine the prevalence of obstructive 
epicardial CAD, CMD and previous myocardial infarction (MI) in an unselected 
cohort of patients hospitalised with HFpEF using reference standard invasive 
investigations.   
3 
Methods  
This was a prospective, multicentre, observational study of patients hospitalised 
with HFpEF.  All patients recruited had a confirmed diagnosis of HFpEF according 
to the 2016 European Society of Cardiology (ESC) HF guidelines.  Participants 
underwent invasive coronary angiography with guidewire-based assessment of 
coronary flow reserve (CFR) and the index of microcirculatory resistance (IMR), 
followed by vasoreactivity testing with intra-coronary acetylcholine.  This 
allowed the comprehensive assessment of epicardial and microvascular structure 
and function to determine the prevalence of CAD, CMD and coronary endothelial 
dysfunction in the cohort.  Adenosine perfusion cardiac magnetic resonance 
(CMR) imaging was also performed to assess the burden of myocardial infarction 
(MI), diffuse fibrosis and inducible ischaemia in the study population.  Patients 
were followed up by electronic medical record linkage for a minimum of 12 
months.   
Results 
Of 2285 near-consecutive patients hospitalised with suspected HF, 628 were 
confirmed to have a diagnosis of HFpEF, and 106 HFpEF patients met the 
inclusion criteria and agreed to participate in the study.  A total of 83 
participants underwent invasive coronary angiography or CMR.  Seventy-five 
participants underwent invasive coronary angiography, 62 had guidewire-based 
coronary physiology testing, and 41 underwent vasoreactivity testing.  Fifty-two 
participants underwent CMR and 44 had both invasive coronary angiography and 
CMR.  Twenty-three patients did not proceed to the study investigations, 
predominantly due to a decline in health, functional status or renal function 
making proceeding with the study investigations inappropriate or unsafe.   
In this unselected hospitalised HFpEF cohort, the prevalence of obstructive 
epicardial CAD on invasive assessment was 51% (95% confidence interval [CI] 39-
62%); half of patients with obstructive epicardial disease had no clinical history 
of CAD.  On invasive coronary physiological testing, 41 patients (66% [95% CI 53-
77%]) had endothelium-independent CMD, and 10 (24% [95% CI 13-40%]) had 
endothelium-dependent CMD.  Overall, 91% of participants had evidence of 
macrovascular and/or microvascular CAD.  Of those who underwent CMR, 27% 
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(95% CI 16-41%) had evidence of previous MI and 32% (95% CI 19-48%) had 
inducible ischaemia.  Over half of patients with CMR-proven MI had no history of 
clinically apparent MI.   
Over a median follow-up period of 18 months, study participants with 
obstructive epicardial CAD had significantly more hospitalisations (for any cause, 
a cardiovascular cause or HF) than those without obstructive CAD.  There was no 
significant difference in outcomes between those with or without endothelium-
independent or -dependent CMD.   
Conclusion 
Both epicardial CAD and CMD are common in the HFpEF population, and there is 
a high prevalence of clinically unrecognised obstructive epicardial CAD and 
previous MI.  Patients with obstructive epicardial CAD had significantly more 
hospitalisations than those without obstructive disease.  Treatments for 
epicardial CAD (e.g. coronary revascularisation) might improve quality of life and 
reduce hospitalisations in HFpEF patients with CAD.   
Although it has been hypothesised that CMD in HFpEF is the result of endothelial 
dysfunction, it appears to be predominantly due to endothelium-independent 
mechanisms.  This may have important implications for future treatments 
directed at CMD in patients with HFpEF.   
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Chapter 1 Introduction 
1.1 What is heart failure with preserved ejection fraction? 
1.1.1 Definition of heart failure with preserved ejection fraction 
Heart failure (HF) is a clinical syndrome resulting from abnormal cardiac 
structure and/or function.  It is characterised by typical symptoms, 
predominantly dyspnoea and fatigue, which may be associated with clinical signs 
of fluid overload.  HF can be classified based upon the duration of symptoms, 
symptom severity, and the left ventricular (LV) ejection fraction (LVEF).   
HF can present with the rapid onset of symptoms requiring hospital admission, 
termed “acute HF”, or with a more insidious course in ambulatory patients, 
known as “chronic HF”.  Acute HF may present “de novo” or, more commonly, 
patients with chronic HF may experience a sudden deterioration in their clinical 
condition, termed “acute decompensated HF”.   
The severity of HF symptoms is most commonly described using the New York 
Heart Association (NYHA) classification (Table 1-1).  This system grades patients 
in relation to their functional limitation due to HF symptoms.  NYHA functional 
class predicts prognosis and is independent of duration of symptoms or LVEF.1   
 
NYHA, New York Heart Association.  
Table 1-1: NYHA functional classification of HF.   
NYHA class Patient symptoms
I No limitation of physical activity. Ordinary physical activity 
dose not cause undue fatigue, palpitation or dyspnoea. 
II Slight limitation of physical activity. Comfortable at rest 
but ordinary physical activity results in fatigue, palpitation 
or dyspnoea. 
III Marked limitation of physical activity. Comfortable at rest 
but less than ordinary activity results in fatigue, 
palpitation or dyspnoea.
IV Unable to carry out any physical activity without 
discomfort. Symptoms at rest. If any physical activity is 
undertaken, discomfort is increased. 
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HF has two broad phenotypes, based upon the LVEF.  This is the most widely 
used estimate of left ventricular systolic function and is typically measured using 
echocardiography.  The classification of HF in relation to LVEF is considered 
important for several reasons, including differences in patient demographics, 
prognosis and response to therapies.  International guidelines distinguish 
between two major HF phenotypes in relation to LVEF.  There is consensus 
between guidelines, randomised controlled trials (RCTs) and epidemiological 
studies that HF with reduced ejection fraction (HFrEF) represents HF in the 
presence of an LVEF of ≤40%.  The definition of HF with preserved ejection 
fraction (HFpEF), however, is more contentious.  The LVEF threshold used to 
define HFpEF varies between studies, ranging from 40% to 55%.  The European 
Society of Cardiology (ESC) defines HFpEF as HF in the presence of a LVEF ≥50% 
(Table 1-2),2 whereas the American College of Cardiology Foundation/American 
Heart Association (ACCF/AHA) considers patients with an intermediate LVEF in 
the range of 40% to 50% to have “borderline” HFpEF (Table 1-3).3  The ESC 
defines this intermediary group by a new term called “HF with mid-range 
ejection fraction” (HFmrEF).2  Patients in this “grey area” appear to have similar 
characteristics and response to therapies as those with HFrEF, but outcomes 
more comparable to HFpEF.4,5   
 
HF, heart failure; HFmrEF, HF with mid-range ejection fraction; HFpEF, HF with preserved ejection 
fraction; HFrEF, HF with reduced ejection fraction; LAE, left atrial enlargement; LVEF, left ventricular 
ejection fraction; LVH, left ventricular hypertrophy.   
Table 1-2: Definitions of HFpEF, HFmrEF and HFrEF (ESC).   
Type of HF HFrEF HFmrEF HFpEF
CR
IT
ER
IA
1 Symptoms and signs Symptoms and signs Symptoms and signs
2 LVEF <40% LVEF 40-49% LVEF ≥50%
3 - 1. Elevated levels of 
natriuretic peptides;
2. At least one 
additional criterion:
a. Relevant structural 
heart disease (LVH 
and/or LAE),
b. Diastolic 
dysfunction.
1. Elevated levels of 
natriuretic peptides;
2. At least one 
additional criterion:
a. Relevant structural 
heart disease (LVH 
and/or LAE),
b. Diastolic 
dysfunction.
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HF, heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; 
LAE, LVEF, left ventricular ejection fraction.   
Table 1-3: Definitions of HFrEF and HFpEF (ACCF/AHA).   
1.1.2 Epidemiology of heart failure with preserved ejection 
fraction 
HF is a major public health issue, affecting over 26 million people worldwide.6  It 
is a significant cause of morbidity and mortality and a large burden on global 
healthcare systems.  In Europe and North America, HF affects 1-3% of the 
population and accounts for 1-2% of healthcare expenditure.  Although the 
incidence of HF appears to have fallen over recent years, the prevalence 
continues to rise.7  Epidemiological studies suggest that the prevalence of HFpEF 
in relation to HFrEF has increased over recent years, with some reporting that 
HFpEF now accounts for over 50% of HF.8  However, most of these studies rely on 
clinical diagnostic codes (e.g. International Classification of Diseases [ICD] 
coding), therefore, there is potential for both under- and over-diagnosis of 
HFpEF.  Furthermore, the LVEF threshold used to define HFpEF in these studies 
is not consistent and many patients with other cardiac conditions generally not 
considered to have HFpEF (e.g. acute coronary syndromes, significant primary 
valve disease) are defined as such in many studies.   
The clinical characteristics of patients with HFpEF are distinct from those with 
HFrEF.  Patients with HFpEF are generally older, more frequently female, and 
have a higher burden of comorbidities.9  The ageing population is thought to 
Classification LVEF Description
HFrEF ≤40% Also referred to as systolic HF. Randomised clinical 
trials have mainly enrolled patients with HFrEF and it 
is only in these patients that efficacious therapies 
have been demonstrated to date. 
HFpEF ≥50% Also referred to as diastolic HF. Several different 
criteria have been used to further define HFpEF. The 
diagnosis of HFpEF is challenging because it is largely 
one of excluding other potential non-cardiac causes 
of symptoms suggestive of HF. To date, efficacious 
therapies have not been identified. 
HFpEF, borderline 41-49% These patients fall into a borderline or intermediate 
groups. Their characteristics, treatment patterns and 
outcomes appear similar to those of patients with 
HFpEF. 
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represent a major reason for the female predisposition, higher rate of associated 
comorbidities, and the increasing prevalence of HFpEF when compared to 
HFrEF.10   
Outcomes relating to HFpEF vary depending on study design, clinical setting and 
LVEF threshold used to define HFpEF.  Patients with HFpEF have significantly 
poorer outcomes when compared with populations with similar age and 
comorbidity profiles without HF.11  Epidemiological studies consistently report 
high mortality rates in HFpEF cohorts, with a 1-year mortality of 20-29% and 5-
year mortality of over 50%.8,12,13  Conversely, HFpEF RCTs report much lower 
annualised mortality rates of around 5% per year.14–16  Although the prognosis in 
HFpEF and HFrEF were thought to be similar, more recent studies suggest that 
patients with HFpEF have better outcomes than those with HFrEF.17  Despite 
this, hospitalisation and mortality rates in HFpEF remain high and, in contrast to 
HFrEF, outcomes have not improved over recent decades.18  
1.1.3 Diagnosis of heart failure with preserved ejection fraction 
The diagnosis of HFpEF can be challenging, especially in ambulatory patients.  
The symptoms of HF are non-specific and patients with HFpEF have a high 
incidence of comorbidities which can mimic HF symptoms (e.g. atrial fibrillation 
[AF], anaemia, chronic lung disease, chronic kidney disease [CKD]).  
Furthermore, incident HFpEF may be characterised by several distinct clinical 
phenotypes.   
Hospitalised patients with HFpEF typically present with dyspnoea and signs of 
congestion on clinical examination.  The diagnosis of HFpEF must be confirmed 
by typical cardiac imaging findings (e.g. preserved LVEF, left atrial [LA] 
enlargement, LV hypertrophy [LVH], evidence of increased LV filling pressures 
and/or pulmonary hypertension [PH]) and elevated natriuretic peptides.2  
However, ambulatory patients frequently experience symptoms only on exertion 
and often have no overt clinical signs of fluid overload.  In these patients, 
echocardiography at rest may not reveal typical findings consistent with 
elevated LV filling pressures and natriuretic peptides may be normal due to 
lower LV wall stress.  Invasive and non-invasive studies report that, in HFpEF 
patients, LV filling pressures may be normal at rest, but increase dramatically 
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with exercise.19,20  Diastolic stress testing may, therefore, be required to 
confirm or exclude the diagnosis of HFpEF in patients presenting with 
unexplained exertional dyspnoea.   
An alternative presentation of HFpEF is that of a breathless patient with 
preserved LVEF and evidence of significant PH on echocardiography.  These 
patients frequently undergo invasive assessment to identify the cause of PH and 
around one third are found to have pulmonary venous hypertension due to 
chronic HF (Group 2 PH).21  This HFpEF subgroup represents an advanced stage of 
the condition and these patients appear to have a poor prognosis (see below).   
1.1.4 Comorbidities in heart failure with preserved ejection 
fraction 
HFpEF is a heterogeneous condition characterised by advancing age and the 
presence of multiple cardiovascular (CV) and non-CV comorbidities.  
Epidemiological studies and RCTs report a greater burden of hypertension, AF, 
obesity, chronic lung disease, anaemia, and diabetes in patients with HFpEF than 
those with HFrEF.18  The high frequency of comorbidities, many of which can 
cause similar symptoms and signs to HF, has led some to suggest that these 
patients do not have HF at all.22  However, a comparison of trial data of patients 
with HFpEF versus those with CV conditions without HF found that the poor 
outcomes associated with HFpEF did not appear to be explained by age or 
comorbidities.11   
The failure of RCTs in HFpEF to demonstrate effective treatments has led to 
attempts to identify sub-phenotypes of HFpEF which may respond favourably to 
specific therapies.  Patients with HFpEF can be phenotyped according to 
associated comorbidities for which treatments exist (e.g. hypertension, AF, 
coronary artery disease [CAD]).23  Furthermore, in a prospective study of 397 
patients, Shah and colleagues used phenomapping to identify three distinct 
HFpEF sub-phenotypes: younger patients with lower natriuretic peptide levels 
(‘early HFpEF’); obese patients with diabetes and obstructive sleep apnoea; and 
older patients with CKD, high natriuretic peptide levels and PH (‘advanced 
HFpEF’).24   
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1.1.5 Pathophysiology of heart failure with preserved ejection 
fraction 
HFpEF is a diverse clinical syndrome and cannot be readily attributed to a single 
aetiological factor.  Consequently, its pathophysiology is not well understood.  
The major underlying pathological mechanism is thought to be LV diastolic 
dysfunction.  However, various other processes have been implicated, including 
subtle LV systolic dysfunction, ventricular-arterial stiffening, LA dysfunction and 
AF, right ventricular (RV) dysfunction and pulmonary vascular disease, 
ventricular interdependence, chronotropic incompetence, peripheral factors and 
endothelial dysfunction.   
LV diastolic dysfunction 
Most patients with HFpEF have evidence of diastolic dysfunction at rest.25,26  
However, in HFpEF patients with exertional symptoms, diastolic dysfunction may 
only become apparent with exercise.19  Conversely, elderly patients without HF 
frequently have echocardiographic evidence of diastolic dysfunction at rest.27  
Diastolic dysfunction may, therefore, play a key role in HFpEF, but other 
mechanisms are evidently involved.    
LV diastolic function is determined by both active relaxation and passive filling.  
Active relaxation is regulated by calcium homeostasis and the phosphorylation 
state or levels of specific proteins (e.g. phospholamban) that modify the 
sarcoplasmic reticulum calcium ATPase pump (SERCA2a).28  Active relaxation 
requires the removal of cytosolic calcium during diastole by SERCA2a, which is 
inhibited by phospholamban in its unphosphorylated state.  Active relaxation is 
an energy-dependent process, therefore, it is vulnerable to ischaemia.29   
Diastolic function is also influenced by the passive elastic properties of the LV.  
Increased passive stiffness was previously thought to be due to myocardial 
fibrosis and changes in extracellular matrix composition, however, diastolic 
stiffness is frequently elevated in patients without fibrosis, and acute changes to 
diastolic stiffness are seen in the context of ischaemia or changes in the 
compliance of the large sarcomeric protein, titin.30,31  
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Cardiomyocyte resting tension is highly dependent on the function of titin, which 
acts as a physiological molecular spring.32  The properties of titin can be altered 
by the expression of different isoforms and by post-translational 
phosphorylation.  Titin exists in two isoforms: N2B (shorter, stiffer) and N2BA 
(longer, more compliant), and there appears to be a shift toward expression of 
the N2B-isoform in patients with HFpEF.33  Phosphorylation of titin can occur at 
various sites.  Protein kinase A (PKA), protein kinase G (PKG), calcium/ 
calmodulin-dependent protein kinase IIδ, and extracellular signal-regulated 
kinase-2 signalling improve titin compliance and, therefore, decrease 
cardiomyocyte resting tension.34–36  Conversely, phosphorylation by protein 
kinase C (PKC) reduces titin compliance, resulting in increased resting tension.37   
Endomyocardial biopsy studies have revealed low PKA and PKG activity in HFpEF, 
and their administration has been shown to acutely reduce cardiomyocyte 
resting tension in vitro.38,39   
LV systolic dysfunction 
Despite having a preserved LVEF, studies using sensitive measures of LV 
contractility (e.g. strain imaging using speckle tracking echocardiography) 
demonstrate that HFpEF patients have subtle LV systolic dysfunction.40  Patients 
with HFpEF also exhibit an inability to increase their LVEF and cardiac output 
with physiological stress, which may contribute to exercise intolerance.41,42   
Ventricular-arterial stiffening 
Patients with HFpEF have increased LV systolic stiffness (end-systolic elastance, 
Ees) and arterial stiffness (arterial elastance, Ea) when compared with healthy 
controls.43,44  Elevated LV and arterial stiffness result in a steep end-systolic 
pressure-volume relationship in HFpEF.  This leads to an augmented blood 
pressure response to changes in preload or afterload, predisposing to both 
hypotensive and hypertensive crises.  Normally, there is a decrease in the Ea/Ees 
ratio with exercise, due to a marked increase in Ees with only a small increase in 
Ea.  In HFpEF, this decrease is attenuated, resulting in an impaired cardiac 
output response to exercise.   
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LA dysfunction and AF 
The LA plays an important role in LV diastolic filling, both as a conduit and via 
atrial contraction.  Patients with HFpEF have chronically elevated LA pressure 
with resulting atrial dilatation, loss of atrial contractile reserve, and electrical 
remodelling.  This predisposes to AF, which affects up to two-thirds of patients 
with HFpEF.45  Whether AF is simply a sign of more advanced HFpEF or if it plays 
a role in the progression of HFpEF is uncertain.   
RV dysfunction and pulmonary vascular disease 
In a community-based study of 244 HFpEF patients, the prevalence of PH 
(defined as an echocardiography-derived pulmonary artery [PA] systolic pressure 
>35mmHg) was 83%.46  Chronic LA pressure overload results in pulmonary venous 
hypertension and post-capillary PH.  However, the patients with HFpEF 
frequently have “out-of-proportion” PH, suggesting an element of pre-capillary 
PH.  It is unclear whether this is a result of reactive changes to the pulmonary 
vasculature due to longstanding pulmonary venous hypertension, or whether 
other processes (e.g. primary pulmonary arterial disease) are involved.  RV 
dysfunction in HFpEF is associated with male sex, AF and CAD.47  It can be a 
consequence of chronic PH, however, there is also evidence of increased RV 
diastolic stiffness and abnormal RV-PA coupling.48  Both PH and RV dysfunction 
are independent predictors of poor outcomes in HFpEF.49   
Ventricular interdependence 
The pericardium contributes around 40% to the LV end-diastolic pressure under 
resting conditions.50  As described above, HFpEF is frequently associated with LA 
and RV dysfunction and dilatation.  This leads to an increase in cardiac size, 
which may augment ventricular interdependence in patients with HFpEF.  The 
role of pericardial constraint and ventricular interdependence in the 
pathophysiology of HFpEF is currently unknown.   
Chronotropic incompetence 
Studies suggest that over half of patients with HFpEF have evidence of 
chronotropic incompetence, suggestive of autonomic dysfunction.51,52  Beta-
blockers and ivabradine have failed to show benefit in HFpEF, possibly due to 
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exacerbation of chronotropic incompetence.4,53  The role of rate-responsive 
pacing in HFpEF patients with chronotropic incompetence has yet to be 
established.   
Peripheral factors 
Various studies have suggested that skeletal muscle abnormalities may 
contribute to exercise intolerance in some patients with HFpEF.54,55  Patients 
with HFpEF have lower lean body mass, increased intramuscular fat content, 
fewer type I (slow-twitch) fibres, and microvascular rarefaction when compared 
with healthy controls.  Interestingly, the benefits of exercise training in HFpEF 
seem to be mediated via peripheral, rather than central, mechanisms (i.e. 
improved skeletal muscle and peripheral microvascular function).56   
Endothelial dysfunction 
That endothelial dysfunction plays a pivotal role in the pathogenesis of HFpEF 
has attracted a great deal of attention recently.  Some studies have reported 
more peripheral endothelial dysfunction in patients with HFpEF compared to 
hypertensive and healthy controls.41,57  However, this finding has not been 
observed in all HFpEF studies.58   
Is there a unifying pathophysiological paradigm of HFpEF? 
Hypertension is very common in the HFpEF population and, traditionally, it has 
been thought to be central to the pathogenesis of HFpEF.59  Longstanding 
hypertension causes activation of the renin-angiotensin-aldosterone system 
(RAAS) and afterload excess, with resultant LV remodelling, LVH and diastolic 
dysfunction.  This leads to LA hypertension and dilatation (with or without AF), 
with pulmonary venous hypertension and, eventually, to right heart dysfunction.  
However, most patients with HFpEF do not have a history of longstanding poorly-
controlled hypertension and over 40% do not have LVH.60  Furthermore, the 
neutral outcomes for several trials of RAAS antagonists do not lend support to 
the hypertensive heart disease hypothesis.  Whilst hypertension evidently plays 
an important role in HFpEF, it does not explain the underlying pathophysiology 
in the majority of patients.   
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A novel paradigm has been proposed suggesting that endothelial dysfunction 
plays a central role in the global pathophysiology of HFpEF.61  This hypothesises 
that multimorbidity induces a systemic inflammatory process, with coronary 
microvascular endothelial inflammation and dysfunction.  This results in reduced 
nitric oxide (NO) bioavailability, cyclic guanosine monophosphate (cGMP) 
content, and PKG activity in adjacent cardiomyocytes.  Low PKG activity favours 
cardiomyocyte hypertrophy and increase resting tension via hypophosphorylation 
of titin.  Both stiff cardiomyocytes and interstitial fibrosis result in LV diastolic 
dysfunction and HF (Figure 1-1).   
 
cGMP, cyclic guanosine monophosphate; CKD, chronic kidney disease; IL-6, interleukin-6; ONOO-, 
peroxynitrite; NO, nitric oxide; PKG, protein kinase G; ROS, reactive oxygen species; sGC, soluble guanylate 
cyclase; sST2, soluble somatostatin receptor type 2; TGF-β, tissue growth factor-β; TNF-α, tissue necrosis 
factor-α; VCAM, vascular cell adhesion molecule.   
Figure 1-1: Microvascular paradigm in HFpEF.  
This concept is based on findings from five studies of human endomyocardial 
biopsies.30,38,39,62,63  Aside from the small numbers of patients included in the 
studies, the patients studied represent a highly-selected group.  The majority of 
patients were referred for endomyocardial biopsy because of suspicion of 
infiltrative cardiomyopathy and, in one study, five out of 12 of the patients 
included were cardiac transplant recipients.30  The mean age of patients was 
considerably younger than the typical HFpEF population and, in all but one of 
the studies, men comprised a majority.   Furthermore, patients with important 
comorbidities, such as CAD and AF, were frequently excluded.  Consequently, 
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extrapolating the findings of these small highly selected populations to a 
universal pathophysiological paradigm for HFpEF should be considered carefully.   
Given the heterogeneity of the HFpEF population, it is unlikely that an 
overarching pathophysiological model will be identified.  As described above, 
HFpEF is a complex and diverse condition characterised by multimorbidity and 
abnormalities in many aspects of CV structure and function.  Patients with 
HFpEF may exhibit a number of functional impairments, and the relative 
contributions of each factor differ between patients.   
1.1.6 Treatment of heart failure with preserved ejection fraction 
To date, no treatment has been shown to provide clear prognostic benefit in 
patients with HFpEF.  International guidelines for HFpEF are currently based on 
expert consensus opinion. These recommend the use of diuretics to improve 
symptoms and signs of fluid retention and the optimal treatment of associated 
comorbidities (e.g. hypertension and CAD).2,3    
Therapies targeting the RAAS system in HFpEF 
Randomised trials testing the effect of RAAS antagonists in HFpEF have 
consistently failed to show benefit.  One moderately large randomised trial (PEP-
CHF) showed that treatment with the ACE inhibitor perindopril had no effect on 
the primary composite endpoint of all-cause mortality or HF hospitalisation in 
elderly patients with HFpEF.16  Two large RCTs also failed to demonstrate 
benefit in composite primary endpoints with the angiotensin receptor blockers 
candesartan (CHARM-Preserved) and irbesartan (I-PRESERVE).15,64  Similarly, the 
mineralocorticoid receptor antagonist spironolactone showed a neutral effect on 
the composite primary outcome of CV death, aborted cardiac arrest, or HF 
hospitalisation in the TOPCAT trial.14  Post hoc analyses have demonstrated 
marked regional variations in TOPCAT, with patients enrolled in Russia and 
Georgia having much lower event rates in the placebo group than those enrolled 
in the Americas.  The majority of patients enrolled in Russia and Georgia were 
included on the basis of a previous HF hospitalisation, rather than elevated 
natriuretic peptide levels, raising concerns that a significant proportion of 
patients in the trial did not have HFpEF.65  In an analysis restricted to those 
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enrolled in the Americas, treatment with spironolactone appeared to be 
beneficial, however, the post hoc nature of this analysis means this should be 
considered with caution.66   
Therapies targeting NO-cGMP-PKG signalling in HFpEF 
Several studies assessing therapies targeting the systemic inflammatory 
paradigm of HFpEF have failed to show any convincing benefit.  In this 
hypothesis, low cGMP activity is thought to play a central role in the 
pathophysiology of HFpEF, however, several studies of therapies which (directly 
or indirectly) increase cGMP levels have failed to meet their primary endpoints.  
The soluble guanylate cyclase stimulator vericiguat failed to demonstrate 
benefit in SOCRATES-PRESERVED.67  When compared with placebo, the 
phosphodiesterase-5 inhibitor sildenafil did not improve exercise capacity or 
clinical status in HFpEF patients in the RELAX trial.68  Treatment with the 
organic NO donor isosorbide mononitrate reduced activity levels (NEAT-HFpEF)69, 
and inhaled inorganic nitrite also failed to improve exercise capacity (INDIE-
HFpEF)70 in patients with HFpEF.     
Neprilysin inhibition prevents the breakdown of biologically active natriuretic 
peptides, leading to increased intracellular cGMP.  The neprilysin inhibitor 
sacubitril in combination with the angiotensin receptor blocker valsartan 
(sacubitril-valsartan) did not show benefit over valsartan alone in HFpEF in a 
large multicentre RCT (PARAGON-HF).71 
Therapies targeting heart rate and exercise intolerance in HFpEF 
Lower heart rates increase the duration of diastole and can facilitate greater LV 
filling.  However, this may exacerbate chronotropic incompetence, which is 
prevalent in HFpEF (discussed above).  The beta-blocker nebivolol was assessed 
in a pre-specified subgroup analysis of a RCT including patients with both HFrEF 
and HFpEF (SENIORS), showing a neutral effect on a composite of all-cause 
mortality and CV hospitalisation.72  The effect of digoxin in HFpEF was assessed 
in a moderately large RCT (the ancillary DIG trial) with no effect on the primary 
endpoint of HF mortality or HF hospitalisation.73  The If current blocker 
ivabradine has also been evaluated in phase II HFpEF trials with mixed 
results.53,74,75  A small study is currently underway to assess the effect of rate-
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responsive pacing in HFpEF patients with chronotropic incompetence (RAPID-HF, 
NCT02145351).   
One small study demonstrated symptomatic benefit with exercise training in 
HFpEF (Ex-DHF-P).76  However, the generalisability of the study has been 
questioned as it recruited a relatively young cohort of patients (mean age 65 
years) and the exercise protocol used is not suitable for many frailer patients 
with HFpEF.  Further studies are ongoing (e.g. SECRET-II [NCT02636439], 
ITISHOPE4HF [NCT03183323]).    
Therapies targeting LA hypertension in HFpEF 
Elevated LA pressure is thought to be one of the central pathophysiological 
findings in HFpEF.  Reducing LA pressure by creating an interatrial shunt has 
been studied in an observational cohort of 64 patients with improved 
haemodynamics and quality of life.77  A small, sham-controlled, blinded RCT 
found reduced exercise PA wedge pressure with this technique78, and a large 
RCT is in progress (REDUCE LAP-HF II, NCT02600234). 
1.1.7 Summary 
Effective treatment strategies for HFpEF represent a large unmet clinical need.  
Its identification can be challenging and there remains inconsistency and debate 
regarding which diagnostic criteria should be used.  The pathophysiology of 
HFpEF remains incompletely understood and it is unlikely that there will be a 
single unifying paradigm.   
The “one-size-fits-all” approach to RCTs in HFpEF has so far failed to 
demonstrate any clinically meaningful benefit.  Future trials are likely to focus 
on assessing targeted therapies in sub-phenotypes of HFpEF.    
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1.2 What is coronary artery disease? 
1.2.1 Functional anatomy of the coronary circulation 
The coronary arterial system can be considered to have three compartments 
with differing functions (Figure 1-2).79  The proximal compartment comprises the 
epicardial coronary arteries (diameter 500 µm–5 mm) which, under normal 
circumstances, offer minimal resistance (~10%) to coronary blood flow (CBF) and 
function primarily as conduit vessels.80  The intermediate compartment is 
represented by the epicardial pre-arterioles (diameter 100-500 µm), which 
maintain arteriolar pressure in response to changes in wall shear stress and 
transmural pressure (myogenic response) and contribute ~25% to coronary 
vascular resistance (CVR).81  The distal compartment consists of the 
intramyocardial arterioles (diameter <100 µm), which regulate CBF in response 
to metabolites (metabolic regulation) and represent the largest proportion 
(~55%) of total CVR.  The capillaries and venules mainly function as capacitance 
vessels and contribute a further ~10% to CVR.  The coronary microcirculation 
consists of the pre-arterioles and arterioles and, therefore, represents the 
majority of resistance to CBF.   
 
Figure 1-2: Functional anatomy of the coronary arterial system.  
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1.2.2 Definition of coronary artery disease 
Coronary artery disease (CAD) is traditionally defined as obstructive 
atherosclerotic narrowing of the epicardial coronary arteries that prevents 
adequate perfusion of the myocardium.  Anatomical thresholds for the severity 
of epicardial CAD vary, however, a widely used cut-off for defining obstructive 
epicardial disease is a stenosis of ≥70% in a main coronary artery (>2.5 mm 
diameter) and ≥50% of the left main coronary artery in one angiographic 
projection.82  However, frequently patients have a clinical diagnosis of CAD 
without imaging of their coronary arteries.  Therefore, the term “CAD” 
encompasses a broad range of clinical phenotypes, including: (i) patients with 
current or previous stable angina or “anginal equivalent” symptoms; (ii) patients 
with imaging evidence of obstructive or non-obstructive epicardial CAD (with or 
without symptoms); (iii) patients with current or previous myocardial infarction 
(MI); and (iv) patients who have previously undergone coronary 
revascularisation.83   
1.2.3 Diagnosis of coronary artery disease 
Clinical features 
CAD can frequently be diagnosed on the basis of clinical history alone.  
Nevertheless, further investigations are usually required to confirm the 
diagnosis, exclude alternative diagnoses, and assess the severity of disease.83,84  
The characteristic clinical presentation of CAD is of angina pectoris.  This may 
be typical (i.e. all three of the following: classical retrosternal chest discomfort, 
provoked by exertion or stress, relieved by rest and/or nitrates) or atypical (two 
of these criteria).  Patients with CAD may present with alternative symptoms, 
usually exertional dyspnoea, caused by myocardial ischaemia (“anginal 
equivalents”).  This is a particularly common presentation in female patients, 
older patients, and those with diabetes.85–87  
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Non-invasive diagnostic testing 
Current guidelines suggest further investigation of suspected CAD depends on 
the pre-test probability (PTP) of CAD, based on the patient’s presentation, age 
and sex (Table 1-4).88  In patients with possible angina but with a low probability 
of significant epicardial CAD (<5-15%), further diagnostic testing is generally not 
advocated.  Patients with a low-intermediate PTP, coronary computed 
tomography (CT) angiography (CTA) is the diagnostic test of choice, due to its 
high negative predictive value.  In patients with a high-intermediate probability 
of obstructive epicardial CAD, non-invasive functional imaging is indicated.  The 
imaging modality used is generally dependent on local expertise and availability.  
In patients with a high PTP, CAD should be diagnosed clinically, and medical 
therapy initiated.  Further testing is generally not indicated for diagnosis, 
however, may be used for risk stratification.  Frequently, patients in this group 
with significant symptoms and/or high-risk features should proceed directly to 
invasive coronary angiography.   
 
Table 1-4: Pre-test probabilities of obstructive CAD. 
Coronary computed tomography angiography 
Coronary CTA has a high sensitivity and negative predictive value, but lower 
specificity and positive predictive value for the identification of epicardial 
CAD.89  The specificity of coronary CTA is significantly reduced in the presence 
of severe coronary calcification.90  The image quality and interpretation are also 
highly dependent on adequate breath holding, body mass index (BMI), and heart 
rate and rhythm.  Coronary CTA is, therefore, of particular use in patients with a 
low-intermediate PTP of significant CAD in whom good image quality can be 
expected.   
Typical Atypical Non-anginal Dyspnoea
Age Men Women Men Women Men Women Men Women
30-39 3% 5% 4% 3% 1% 1% 0% 3%
40-49 22% 10% 10% 6% 3% 2% 12% 3%
50-59 32% 13% 17% 6% 11% 3% 20% 9%
60-69 44% 16% 26% 11% 22% 6% 27% 14%
70+ 52% 27% 34% 19% 24% 10% 32% 12%
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Exercise electrocardiography 
Due to its widespread availability and ease, exercise ECG is routinely used as the 
initial diagnostic test in patients with suspected CAD.  Although non-invasive 
stress imaging is preferred, exercise ECG can still play a role in patients with an 
intermediate PTP of CAD, in whom it has high specificity (85-90%).83,91  However, 
it has a low sensitivity (45-50%), it is not of diagnostic value in the presence of 
significant resting ECG abnormalities, and it is frequently inconclusive due to a 
submaximal test or equivocal ECG changes.  Despite its limitations, exercise ECG 
is frequently used for risk stratification in patients with CAD.  The prognosis for 
patients with a normal exercise ECG and a low clinical risk is excellent, whereas 
patients with a high-risk test have an annual CV mortality of >3%.92  
Non-invasive functional imaging 
Non-invasive functional imaging techniques have comparable sensitivities and 
specificities.83  They are most useful in patients with a high-intermediate PTP of 
CAD, and include: 
• Stress echocardiography – with exercise or pharmacological stress (e.g. 
dobutamine).   
• Myocardial perfusion scintigraphy with single photon emission computed 
tomography (MPS with SPECT) – 99mTc with SPECT and exercise or 
pharmacological stress (e.g. adenosine, dipyridamole).   
• Stress cardiac magnetic resonance (CMR) imaging – first-pass contrast-
enhanced perfusion CMR (e.g. adenosine) or CMR for stress-induced wall 
motion abnormalities (e.g. dobutamine).   
Invasive coronary angiography 
Invasive coronary angiography is the traditional reference standard for the 
diagnosis of epicardial CAD and the distribution and extent of epicardial CAD on 
angiography has prognostic importance.  In the Coronary Artery Surgery Study 
(CASS) registry of medically-managed CAD patients with preserved LVEF, the 12-
year survival rate was 91% with normal coronary arteries, 74% with one-vessel 
disease, 59% with two-vessel disease and 50% with three-vessel disease.93  
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Patients with significant stenosis of the left main coronary artery or left anterior 
descending (LAD) artery have a poor prognosis when treated medically.94  
However, the anatomic assessment of coronary stenoses using coronary 
angiography has several limitations.  Visual assessment of CAD may be inaccurate 
due to a variety of anatomical (e.g. diffuse disease or multiple stenoses in 
proximity) or procedural reasons (e.g. lesion foreshortening, angulations, 
eccentricity).  As a result, there is a poor correlation between visually-assessed 
coronary stenosis severity and the physiological significance of a stenosis.95,96  In 
the FAME trial, only 35% of coronary stenoses with an angiographic severity of 
50-70% on quantitative coronary angiography were flow-limiting on physiological 
testing.97  Even in lesions with a visual severity of 71-90%, 20% were not 
functionally significant.  Therefore, visual assessment of coronary stenosis 
severity may result in both the under- and over-estimation of the functional 
significance of epicardial CAD.   
Fractional flow reserve 
Fractional flow reserve (FFR) is a pressure-derived index of the maximal blood 
flow in a coronary artery in the presence of a stenosis compared to the maximal 
flow in the absence of a stenosis.  During hyperaemia, coronary resistance is 
minimised, and blood flow is linearly related to coronary pressure within the 
physiological range of coronary perfusion pressures.98  In order to assess the 
haemodynamic significance of an epicardial coronary stenosis, a pressure-
sensitive coronary guidewire is positioned distal to the stenosis and hyperaemia 
is achieved with the administration of intravenous adenosine.  FFR is calculated 
from the mean distal coronary pressure (Pd) indexed to the mean aortic pressure 
(Pa) obtained simultaneously during hyperaemia (FFR = hyperaemic Pd/Pa).  The 
theoretical FFR value in a normal coronary artery without obstruction to blood 
flow is a ratio of 1.0.  A threshold of ≤0.80 is used to define a haemodynamically 
significant lesion.97  FFR is commonly used to assess stenoses of intermediate 
severity or where the severity of a stenosis is ambiguous (e.g. diffuse CAD).   
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1.2.4 Treatment of coronary artery disease 
The treatment of CAD patients involves the management of lifestyle factors, 
control of CV risk factors, pharmacological therapy and revascularisation.   
Lifestyle factors 
Smoking is a strong independent CV risk factor and patients with CAD who smoke 
should be encouraged to quit.99  Observational data suggest that smoking 
cessation is associated with a one-third reduction in mortality following MI.100  
Patients should be encouraged to maintain a healthy diet and undertake regular 
physical exercise.  Cardiac rehabilitation programmes can be effective in 
reducing mortality and hospitalisation in patients with CAD.101   
Management of associated comorbidities 
Patients with hypertension and CAD should be adequately treated to achieve a 
target blood pressure of <140/90 mmHg.  CAD patients with diabetes should aim 
to achieve an HbA1c of <53 mmol/L.102   
Pharmacological management 
Aspirin and statin therapy form the cornerstone of secondary prevention in 
patients with CAD.  Both are recommended for all CAD patients for the 
prevention of CV events.83,91  The ESC considers patients with CAD to be a very 
high CV risk and recommends an LDL-C target of <1.4 mmol/L (or ≥50% reduction 
if the target level cannot be achieved).103   
Various medications are used in the symptomatic relief of anginal symptoms.  
These can be used alone or in combination.  International guidelines recommend 
the use of beta-blockers, calcium channel blockers (CCBs) and short-acting 
nitrates as first-line therapy, with other agents (e.g. ivabradine, long-acting 
nitrates) recommended if patients who have contraindications to first-line 
agents, do not tolerate them or remain symptomatic.83,91  However, a recent 
meta-analysis found a lack of data comparing the efficacy of anti-anginal agents 
but no evidence of superiority of one drug over another in the treatment of 
angina.104   
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Coronary revascularisation 
In patients with stable CAD, coronary revascularisation can be considered for 
symptomatic improvement and/or prognostic benefit.  In patients with ongoing 
angina (or “anginal equivalent”) symptoms despite optimal medical therapy, 
revascularisation of haemodynamically significant stenosis can provide 
symptomatic relief.105,106  Revascularisation has previously been demonstrated to 
have prognostic benefit over medical therapy alone in the following 
circumstances: 
• Left main stem or proximal LAD stenosis >50% (with an abnormal FFR or 
documented ischaemia)107–109 
• >10% ischaemia on non-invasive functional testing or abnormal FFR110,111 
• Two- or three-vessel disease (>50% stenosis) and an LVEF ≤35% (with 
abnormal FFR or documented ischaemia)109,112 
• Single remaining patent coronary artery with a stenosis >50% (with 
abnormal FFR or documented ischaemia)113 
The aim of coronary intervention is to achieve complete revascularisation, which 
is associated with significantly better outcomes when compared with incomplete 
revascularisation.114  The decision for percutaneous coronary intervention (PCI) 
versus coronary artery bypass grafting (CABG) is dependent on various patient 
and anatomical factors.  The presence of significant comorbidities, frailty, less 
complex CAD (SYNTAX score 0-22), and surgical contraindications (e.g. porcelain 
aorta) favour a PCI strategy.  Conversely, CABG is generally preferred in patients 
with diabetes, low LVEF (≤35%), complex CAD (SYNTAX score ≥23), severe 
coronary calcification, or a requirement of concomitant cardiac surgery.113 
The recently presented ISCHEMIA trial (AHA 2019, Chicago, IL, USA) has 
challenged the current guideline recommendations for revascularisation in stable 
CAD.  This study randomised 5,179 patients with stable CAD and moderate to 
severe ischaemia on non-invasive stress testing to routine invasive therapy or 
medical therapy and failed to show prognostic benefit from a routine invasive 
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approach over optimal medical therapy.  A symptomatic improvement was 
observed in those with angina; however, the trial was not sham controlled so 
this finding could be biased by the placebo effect.  Patients with left main CAD, 
NYHA III or IV HF, an LVEF <35%, recent acute coronary syndrome and highly 
symptomatic patients were excluded so these findings do not apply to these 
groups.   
To date, no RCTs have evaluated the impact of coronary revascularisation in 
patients with HFpEF.  In patients with HFrEF and CAD, the STICH trial failed to 
demonstrate survival benefit with CABG (versus optimal medical therapy) over a 
median follow-up of 4.6 years.115  However, over extended follow-up (median 
9.8 years), all-cause mortality, CV mortality and CV hospitalisations were 
significantly lower in those treated with CABG.112  A small RCT assessing the role 
of PCI in patients with HFrEF and CAD is currently underway (REVIVED-BCIS2).116   
1.2.5 Summary 
CAD encompasses a broad range of clinical phenotypes but is generally defined 
by the presence of obstructive atherosclerotic narrowing of the epicardial 
coronary arteries.  Invasive coronary angiography (with or without FFR) is the 
reference standard for diagnosis of obstructive epicardial CAD.  Various 
treatment options are available, including management of CV risk factors, 
pharmacological therapies, PCI and CABG.   
There is evidence that coronary revascularisation provides prognostic benefit in 
selected patients with CAD, including those with HFrEF.  To date, no RCTs have 
investigated the role of revascularisation in HFpEF.   
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1.3 What is coronary microvascular dysfunction? 
Conventionally, myocardial ischaemia is thought to be a consequence of 
epicardial atherosclerotic CAD.  However, it has become increasingly recognised 
that abnormalities in coronary microvascular function can cause or contribute to 
ischaemia in various situations.  Over one-third of patients undergoing elective 
coronary angiography for the investigation of angina have no obstructive 
epicardial CAD.117  This group includes patients with coronary microvascular 
and/or endothelial dysfunction.   
1.3.1 Definition of coronary microvascular dysfunction 
Coronary microvascular dysfunction (CMD) is defined as a mismatch of 
myocardial blood supply and oxygen consumption due to a dysfunction of the 
coronary microvessels with a diameter <500 µm.79  The pathophysiology of CMD 
is not well understood.  It can be the result of several pathophysiological 
mechanisms, including structural alterations (e.g. vascular remodelling, vascular 
rarefaction, perivascular fibrosis) and functional abnormalities (e.g. endothelial 
dysfunction, vascular smooth muscle dysfunction).  The relative importance of 
each of these mechanisms varies depending on the aetiology, but they 
frequently coexist in the same patient.   
CMD is currently subcategorised into four distinct types depending on the clinical 
setting (Table 1-5).118  CMD in the absence of myocardial disease or obstructive 
CAD (type 1 CMD) is usually associated with CV risk factors, such as hypertension 
and diabetes mellitus.  This form of microvascular dysfunction is thought to be 
due to functional abnormalities and appears to be at least partially reversible.  
Type 2 CMD occurs in the presence of myocardial diseases (e.g. hypertrophic or 
dilated cardiomyopathy).  This subtype is generally the result of structural 
alterations, such as vascular remodelling, and it is unclear whether this process 
is reversible.  CMD in the context of obstructive epicardial CAD (type 3 CMD) can 
occur in chronic CAD or acute coronary syndrome, and various functional and 
structural factors may be implicated.  In certain circumstances, specific 
interventions can limit or prevent CMD in this context.  The fourth subtype 
represents iatrogenic CMD, typically following coronary revascularisation.  The 
mechanisms involved are coronary vasoconstriction and distal embolisation, 
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which can result in both functional and structural changes.  There is evidence to 
suggest that vasoconstriction can be corrected with pharmacological therapy and 
distal embolisation can be prevented or reduced with specific interventions.   
 
CAD, coronary artery disease.   
Table 1-5: Classification of CMD.  
1.3.2 Diagnosis of coronary microvascular dysfunction 
Clinical features 
Coronary microvascular dysfunction (CMD) most frequently presents with 
symptoms similar to obstructive epicardial CAD.  Microvascular angina (MVA) is 
more prevalent in women and is generally first suspected in patients presenting 
with typical exertional angina who are found to have no obstructive epicardial 
CAD at coronary angiography, especially in those patients with evidence of 
ischaemia on non-invasive stress testing.119  In contrast to classical angina due to 
epicardial CAD, MVA may persist or predominate in the post-exercise period and 
the symptomatic response to nitrates is often less marked than typical angina.120 
 
Clinical setting Main pathogenetic mechanisms
Type 1: in the absence 
of myocardial diseases 
and obstructive CAD
Risk factors
Microvascular angina
Endothelial dysfunction
Smooth muscle cell dysfunction
Vascular remodeling
Type 2: in myocardial 
diseases
Hypertrophic cardiomyopathy
Dilated cardiomyopathy
Anderson-Fabry’s disease
Amyloidosis
Myocarditis
Aortic stenosis
Vascular remodeling
Smooth muscle cell dysfunction
Extramural compression
Luminal obstruction
Type 3: in obstructive 
CAD
Stable angina
Acute coronary syndrome
Endothelial dysfunction
Smooth muscle cell dysfunction
Luminal obstruction
Type 4: iatrogenic Percutaneous coronary 
intervention
Coronary artery bypass grafting
Luminal obstruction
Autonomic dysfunction
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Non-invasive diagnostic testing 
Various non-invasive modalities have been utilised in the diagnosis of CMD.  
Importantly, obstructive epicardial CAD must be excluded before CMD can be 
diagnosed by any method.  Coronary flow reserve (CFR) represents the 
vasodilator capacity of the coronary circulation and is determined by coronary 
blood flow during hyperaemia (with vasodilator stress) divided by blood flow at 
rest.  In the absence of epicardial CAD, CFR represents endothelium-
independent coronary microvascular function.  The normal value of CFR in 
dependent on the technique used, but most studies consider a CFR <2.0 
sufficient to cause ischaemia.79   
Positron emission tomography (PET) is the non-invasive reference standard 
modality to assess coronary microvascular function.  PET-derived CFR is 
measured by quantification of absolute myocardial blood flow at rest and during 
vasodilator stress.119  While PET is an established method for detection of 
CMD,121 its limited availability, cost and exposure to ionising radiation has 
restricted its use in clinical practice.  Quantitative and semi-quantitative CMR 
techniques have been established to diagnose CMD.122  However, to date, their 
use has been limited to small cohorts.  Similarly, transthoracic Doppler 
echocardiography (TTDE) of coronary blood flow (usually the LAD) has been 
assessed in several small studies.  However, this technique can be challenging, 
lacks precision and requires specialist expertise.123  Both CMR and TTDE methods 
require validation in larger populations before they can be considered in routine 
clinical practice.  Novel CT and SPECT techniques are also under evaluation and 
show potential for the determination of CMD.124   
Invasive diagnostic testing 
Invasive coronary guidewire-based physiological testing is the gold standard for 
the diagnosis of endothelium-independent CMD.83,118   
Coronary flow reserve 
CFR is measured invasively using a Doppler velocity wire or by a thermodilution-
derived method using a coronary pressure wire (Figure 1-3).  As described above, 
CFR reflects the combined vasodilator capacity of the epicardial and 
microvascular systems.  Invasively-measured CFR has limited reproducibility as it 
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is affected by haemodynamic conditions and it can be difficult to establish 
resting coronary blood flow during invasive coronary angiography.125  However, 
an abnormal CFR has been shown to be associated with microvascular disease 
and poor prognosis in patients with non-obstructive CAD.126    
Index of microcirculatory resistance 
The index of microvascular resistance (IMR) is a specific measurement of 
microcirculatory resistance, independent of epicardial CAD.  IMR is measured 
invasively by thermodilution and is calculated from distal coronary pressure (Pd) 
multiplied by the mean transit time of room temperature saline during 
hyperaemia (Figure 1-3).  As the hyperaemic transit time is inversely correlated 
with flow, it provides a quantitative measure of coronary microvascular 
resistance.  An IMR ≥25 is consistent with microvascular dysfunction.127–129  As 
IMR is measured during hyperaemia, it is independent of haemodynamic 
variations, therefore, it has better repeatability than CFR.130   
 
*Response to ACh is a function of endothelium and vascular smooth muscle cell responses. 
ACh, acetylcholine; CFR, coronary flow reserve; FFR, fractional flow reserve; IMR, index of microcirculatory 
resistance; Pa, aortic pressure; Pd, distal coronary pressure. 
Figure 1-3: Overview of coronary physiology testing.  
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1.3.3 Treatment of coronary microvascular dysfunction 
Evidence, in terms of RCTs, to support the use of specific treatments for CMD is 
very limited, therefore, treatment is empirical.84  Management of patients with 
CMD is focused on optimal control of CV risk factors.  Patients with MVA are 
generally treated with traditional anti-anginal therapy, similar to those with 
epicardial CAD.  Beta-blockers are preferred as first-line therapy, with evidence 
of symptomatic benefit in small studies.131  In patients with persisting symptoms, 
small trials have suggested that ACE inhibitors and statins may improve 
microvascular function, resulting in improved symptoms and exercise 
tolerance.132–134  One single-centre trial found that stratified medical treatment 
(based on the results of CFR, IMR and acetylcholine [ACh] testing) improved 
symptoms and quality of life compared with standard care in patients with 
ischaemia and no obstructive CAD (INOCA).135 
1.3.4 Summary 
CMD is defined as myocardial ischaemia due to dysfunction of the coronary 
microcirculation.  It is a heterogeneous condition which can be the result of 
various structural and functional abnormalities.  Invasive physiological testing is 
the gold standard for the diagnosis of endothelium-independent CMD.  Evidence 
for specific therapies for CMD is lacking, therefore, treatment is empirical and is 
generally focused on management of CV risk factors.   
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1.4 What is coronary endothelial dysfunction? 
1.4.1 Definition of coronary endothelial dysfunction 
Coronary endothelial dysfunction is defined as pathological endothelium-
dependent vasoconstriction of a vessel or vascular bed.136  This vasoconstriction 
can be focal or diffuse and may affect one or more epicardial coronary arteries 
and/or the microvasculature.   
The vascular endothelium regulates local vascular tone via smooth muscle 
relaxation and vasodilation through release of NO, prostacyclin and 
endothelium-derived hyperpolarising factor, or via vasoconstriction through 
release of thromboxane A2, endothelin-1 and free radicals.137  In endothelial 
dysfunction, there is an imbalance of these factors, with the vasoconstricting 
factors predominating.  Flow-mediated vasodilation is dependent on the 
presence of an intact endothelium.  Under normal circumstances, ACh dilates 
arteries via NO, however, in the presence of endothelial dysfunction, it causes 
muscarinic receptor-mediated vascular smooth muscle contraction and 
vasoconstriction.138   
Coronary endothelial dysfunction is prevalent in patients with INOCA, affecting 
almost two-thirds of 124 patients undergoing intracoronary ACh testing in a 
prospective study.139  It may also be present in patients with concomitant 
obstructive or non-obstructive epicardial CAD, where the diagnosis can be more 
challenging.  In patients with and without epicardial CAD, the presence of both 
epicardial and microvascular coronary endothelial dysfunction independently 
predicted acute CV events.140   
1.4.2 Diagnosis of coronary endothelial dysfunction 
Clinical features 
Coronary endothelial dysfunction typically presents with vasospastic angina, 
characterised by typical ischaemic chest pain, usually at rest, with ST-segment 
deviation on ECG.  Symptoms typically occur at night and there is usually rapid 
symptomatic relief with nitrates.  
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Non-invasive diagnostic testing 
Assessment of coronary endothelial function can be performed with cold pressor 
testing (CPT) in combination with non-invasive flow quantification.  This involves 
immersing the patient’s hand or foot in ice-cold water, which induces flow-
mediated pre-arteriolar coronary vasodilation.141  Impaired CPT response has 
been demonstrated in conditions associated with CMD,142,143 however, it did not 
correlate with coronary blood flow response to intra-coronary ACh in women 
with INOCA.144 
Intracoronary acetylcholine testing 
FFR, CFR and IMR are typically derived using intravenous adenosine, an 
endothelium-independent vasodilator.  Assessment of coronary endothelial 
function can be assessed with intracoronary administration of ACh, an 
endothelium agonist (Figure 1-3).  An abnormal vasomotor response 
(representing coronary endothelial dysfunction) is considered to be present if 
there is: 20-90% luminal constriction and/or ischaemic ECG changes in response 
to ACh.135,145  In patients with chest pain syndromes, reproduction of typical 
ischaemic symptoms are also required to confirm a diagnosis of MVA.  High-dose 
ACh can be administered in a provocation test to detect epicardial vasospasm 
(>90% luminal constriction) secondary to abnormal coronary vasoreactivity.146   
1.4.3 Treatment of coronary endothelial dysfunction 
Management of patients with coronary endothelial dysfunction is directed at 
optimal control of CV risk factors.  Aspirin and smoking cessation are 
recommended in all patients.84  Chronic preventative treatment of vasospastic 
angina is mainly based on the use of CCBs, which prevent spasm in 90% of 
patients.147  Long-acting nitrates can be useful as adjuvant therapy, but beta-
blockers are generally avoided due to the theoretical risk of mediating 
unopposed α-mediated vasoconstriction.  
 
56 
 
1.4.4 Summary 
Coronary endothelial dysfunction represents pathological vasoconstriction of the 
coronary circulation.  It generally presents with vasospastic angina and the 
reference standard diagnostic investigation is vasoreactivity testing with intra-
coronary administration of ACh.  Treatment involves optimal control of CV risk 
factors in addition to CCBs and long-acting nitrates.   
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1.5 How might coronary artery disease and coronary 
microvascular dysfunction play a role in heart failure with 
preserved ejection fraction? 
Recent studies suggest that CAD and its consequences may play an important 
role in the pathophysiology of HFpEF, and (as discussed above) a recent 
paradigm was proposed suggesting that CMD may play a central role in the 
overarching pathophysiology of HFpEF.61,148  
The dyspnoea typical of HFpEF may be caused by myocardial ischaemia, 
representing an “anginal equivalent” in some patients.  This hypothesis is 
plausible as HFpEF predominantly affects women and the elderly, where CAD 
commonly presents with atypical symptoms.85,86   
The diastolic dysfunction that is pathognomonic of HFpEF could be a 
manifestation of myocardial ischaemia resulting from epicardial CAD and/or 
CMD.149  Diastolic dysfunction occurs early in the ischaemic cascade, before the 
development of chest pain, ECG changes or systolic dysfunction (Figure 1-4).150  
Ischaemia impairs active LV relaxation and increases myocardial stiffness and LV 
end-diastolic pressure, causing an upward and leftward shift in the LV pressure-
volume relationship.151  Changes in the diastolic properties of the LV have been 
observed during balloon inflation at coronary angiography,152,153 and abnormal 
diastolic filling has been reported by radionuclide angiography with patients with 
CAD and a preserved LVEF.29   
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Figure 1-4: The ischaemic cascade.  
Longstanding, chronic ischaemia can cause fibrosis which might eventually alter 
LV compliance permanently.154  Additionally, or alternatively, dysfunctional but 
viable (“hibernating”) myocardium, or limited areas of MI, could cause subtle LV 
systolic dysfunction that, in turn, causes HF symptoms in patients with 
HFpEF.149,155  A number of studies using sensitive myocardial strain imaging have 
shown that, compared with both healthy and hypertensive controls, many 
patients with HFpEF have mild systolic dysfunction.156–159  In a recent 
echocardiographic sub-study of the PARAMOUNT trial, longitudinal and 
circumferential strain were significantly lower in the HFpEF group compared 
with both normal controls and age- and sex-matched patients with hypertensive 
heart disease.40  Patients with HFpEF and a history of CAD had lower strain 
compared to HFpEF patients without CAD.  Therefore, it is possible that CAD 
may be the cause of HFpEF in some patients, and contributory in others. 
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1.6 Conclusion 
HFpEF is a major public health issue associated with a high burden of morbidity 
and mortality.  The pathophysiology of HFpEF is characterised by a complex 
interplay of various pathophysiological mechanisms, which is likely to vary 
significantly between patients.  To date, clinical trials have failed to identify 
any effective treatments, in large part due to the heterogeneity of the 
population.   
Establishing the sub-phenotype of HFpEF (e.g. those with a specific CV 
abnormality or comorbidity) might identify more homogeneous groups that 
benefit from specific treatments.  Recent studies suggest that CAD, CMD and 
coronary endothelial dysfunction may play important roles in HFpEF, and each 
may be a therapeutic target.   
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Chapter 2 Systematic review of coronary artery 
disease and coronary microvascular dysfunction 
in heart failure with preserved ejection fraction 
2.1 Introduction 
The prevalence of CAD in patients with HFpEF have been studied primarily in 
retrospective observational and population-based studies with heterogeneous 
definitions of both CAD and HFpEF.  Similarly, the prevalence and potential role 
of CMD in HFpEF has been inconsistently reported in several small studies using 
various different diagnostic techniques and definitions of CMD.  The 
epidemiological and clinical data regarding CAD and CMD in HFpEF vary 
according to study design and setting and, to date, there has been no systematic 
review of the published literature relating to the burden of CAD and CMD in 
HFpEF.   
2.2 Methods 
2.2.1 Search strategy and eligibility criteria 
I performed a comprehensive systematic search (updated to 9 November 2019) 
of the electronic databases Medline and Embase to identify studies that describe 
CAD or CMD in patients with HFpEF.  Various terms relating to HFpEF, CAD and 
CMD were searched in title or abstract to retrieve all potentially relevant 
articles (Table 2-1).  The search was limited to studies in adult human 
participants published in the English language.  Bibliographies of guidelines, 
reviews, and articles identified through the search strategy were also searched 
for additional eligible studies.  The review was conducted according to the 
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidelines.160   
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HFpEF search terms “heart failure” AND (“preserved ejection fraction" OR “normal 
ejection fraction” OR “preserved left ventricular ejection fraction” 
OR “normal left ventricular ejection fraction” OR “preserved EF” OR 
“normal EF” OR “preserved LVEF” OR “normal LVEF” OR “preserved 
systolic function” OR “normal systolic function” OR “preserved left 
ventricular systolic function” OR “preserved LV systolic function” OR 
“normal left ventricular systolic function” OR “normal LV systolic 
function” OR “HFpEF” OR “HFnEF” OR “HF-PEF” OR “HF-NEF” OR 
“diastolic” OR “DHF” OR “nonsystolic” or “non-systolic”) 
CAD/CMD search 
terms 
“coronar*” OR “CAD” OR “CHD” OR “CMD” OR “ischaemi*” OR 
“ischemi*” OR “IHD” OR “infarct*” OR “MI” OR “ACS” OR “STEMI” OR 
“NSTEMI” OR “revasculari*” OR “coronary artery bypass graft*” OR 
“CABG” OR “percutaneous coronary intervention” or “PCI” or 
“angioplasty” OR “stent*” OR “PTCA” OR “angina*” OR 
“microcirculat*” OR “microvascula*” OR “MVD” OR “flow reserve” OR 
“flow velocity reserve” OR “FFR” OR “CFR” OR “CFVR” OR “MFR” OR 
“IMR” OR “rarefaction” 
CAD, coronary artery disease; CMD, coronary microvascular dysfunction; HFpEF, heart failure with 
preserved ejection fraction.  
Table 2-1: Search terms used in systematic review.   
Population thresholds were applied to studies with a clinical definition of CAD 
(or those where CAD was not defined) to ensure the inclusion of only large 
studies – observational studies with greater than 1,000 HFpEF patients and 
randomised controlled trials (RCTs) with greater than 500 HFpEF patients were 
included.  Studies of HFpEF subgroups (e.g. populations with a specific comorbid 
condition) were excluded to avoid bias.  For multiple studies based on the same 
population, the study that presented information for the greatest number of 
patients with HFpEF was selected for inclusion.   
2.2.2 Data extraction, synthesis and statistical analysis 
All titles and abstracts were screened for their potential eligibility.  Data from 
the manuscripts identified through the search criteria were abstracted and 
tabulated.  The articles retrieved were divided into the following categories for 
analysis: 1. Studies which report the prevalence of CAD and/or previous MI in a 
HFpEF population; 2. Studies which report the prevalence of HFpEF complicating 
incident MI; 3. Studies which evaluate the treatment of CAD in a HFpEF 
population; 4. Studies which describe CMD in a HFpEF population.   
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Random effects meta-analyses were performed to estimate the prevalence of 
CAD and previous MI in HFpEF populations.  Heterogeneity was assessed and 
interpreted using the I2 statistic and forest plots.  All statistical analyses were 
performed using Stata v.14.2 (StataCorp, College Station, TX, USA).   
2.3 Results 
2.3.1 Description of included studies 
This search strategy retrieved 3,454 eligible studies.  Five additional studies 
were identified through bibliographies of articles identified through the search 
strategy.  After removal of duplicates and limiting the search to studies of 
humans, English language articles and excluding conference abstracts, 525 titles 
and abstracts were reviewed, and 197 articles were identified for potential 
inclusion (Figure 2-1).  After full text review, 86 studies met the criteria for 
inclusion in the systematic review.  The studies were divided into the four 
categories below:   
1. Studies which report the prevalence of CAD and/or previous MI in a HFpEF 
population: 59 studies   
2. Studies which report the prevalence of HFpEF after incident MI: eight studies   
3. Studies which evaluate the treatment of CAD in a HFpEF population: 11 
studies   
4. Studies which describe CMD in a HFpEF population: 14 studies   
Five studies reported the prevalence and evaluated treatment of CAD in a HFpEF 
population.  One study reported the prevalence of CAD and described CMD in a 
HFpEF population.   
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CAD, coronary artery disease; CMD, coronary microvascular dysfunction; HFpEF, heart failure with 
preserved ejection fraction; MI, myocardial infarction.  
Figure 2-1: Systematic review and study selection.   
2.3.2 CAD in HFpEF 
Of the 59 studies that reported the prevalence of CAD or previous MI in HFpEF 
populations, 48 (including 494,767 patients with HFpEF) reported prevalence 
estimates of CAD in HFpEF populations.  A further three studies reported data on 
2,360,889 hospitalisations for HFpEF (Table 2-2).  The mean age was 73 years 
and 53% of patients were female.  Thirty-four studies, including 447,528 HFpEF 
patients, reported the prevalence of previous MI in HFpEF cohorts.  The mean 
age was 71 years and 51% of patients were female.  A further two studies 
reported data on 30,528 hospitalisations for HFpEF.   
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Definition of CAD   
CAD was reported but not defined in 30 of the 51 studies that reported 
prevalence estimates of CAD in HFpEF cohorts.  The majority of the remaining 
studies defined CAD based on clinical history or “ischaemic aetiology” of HF.  
Angiographic CAD was documented in one prospective study and nine 
retrospective observational studies of convenience cohorts that underwent 
clinically indicated coronary angiography.   
Definition of HFpEF  
HF was defined by the International Classification of Diseases (ICD) coding alone 
in over one-third of observational studies.  Of the 59 studies that reported the 
prevalence of CAD or previous MI, the LVEF cut-off used for preserved LVEF was 
defined as 50% (or equivalent) in 32 studies, 45% in 10 studies, 40% in 15 studies, 
and 35% in one study.  The largest study in this review included data on 
2,330,361 hospitalisations for HFpEF included in the Nationwide Inpatient 
Sample (NIS) of non-federal US hospitals.161  In this study, HFpEF was defined as 
the presence of the ICD-9 code representing acute diastolic HF, and no data on 
LVEF was reported.   
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First author, 
country, year 
of publication 
Study 
period 
Region Definition 
of 
preserved 
LVEF 
Definition of HF Definition of CAD HFpEF 
patients 
(n) 
CAD 
(%) 
MI 
(%) 
PCI/ 
CABG 
(%) 
Angina 
(%) 
Mean 
age 
(y) 
Female 
sex (%) 
NYHA 
class 
Hospital based cohorts 
Cheng, 
Taiwan, 
2019162 
2003-
2012 
Taiwan LVEF ≥50% HFH - 1836 28 - - - 78 37 - 
Greenberg, 
USA, 2019163 
2009-
2016 
USA LVEF ≥50% Primary or 
secondary 
diagnosis with 
ICD-9-CM code 
428 or ICD-10-CM 
code I50 
- 4288 - 4 - - 74 55 - 
Matsushita, 
Japan, 2019 
(Tokyo CCU 
Network)164 
2013-
2015 
Japan LVEF ≥50% Clinical features 
of HF 
Medical history of 
CAD 
2238 24 - - - 80 50 - 
Miró, Spain, 
2019 
(EAHFE)165 
2007, 
2009, 
2011, 
2016 
Spain LVEF >49% HFH 
(Framingham 
criteria) 
Ischaemic 
aetiology of HF 
4393 28 - - - 80 61 - 
Takei, Japan, 
2019 (WET-
HF)166 
2006-
2017 
Japan LVEF ≥50% HFH 
(Framingham 
criteria) 
- 1480 16 - - - 78 53 - 
Guisado-
Espartero, 
Spain, 2018 
(age >50 only) 
(RICA)167 
2008-
2016 
Spain LVEF ≥50% HFH (ESC criteria) Ischaemic 
aetiology of HF 
1664 16 - - - 81 63 - 
Kang, Korea, 
2018 
(KorAHF)168 
2011-
2014 
Korea LVEF ≥50% HFH (signs and/or 
symptoms of HF 
and lung 
congestion or 
evidence of 
Ischaemic 
aetiology of HF 
1295 22 9 12 / 3 - 72 62 - 
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structural heart 
disease) 
Zhang, China, 
2017 (China-
HF)169 
2012-
2015 
China LVEF ≥45% 
and LVEDD 
≤55mm 
HFH (Chinese HF 
guidelines) 
- 4062 68 18 - - 69 47 I-IV 
Goyal, USA, 
2016 (NIS)161 
2003-
2012 
USA - ICD-9-CM code for 
acute diastolic HF 
(428.31 or 
428.33) 
- 2330361
* 
41 - 7 / 10 - 76 64 - 
Zacharias, 
USA, 2016 
(Worcester)170 
1995, 
2000, 
2002, 
2004, 
2006 
USA 
 
LVEF ≥50% HFH (ICD-9 
coding, 
Framingham 
criteria) 
- 2398 46 - - - 77 66 - 
Nichols, USA, 
2015 (KPSC, 
KPNW)171 
2008-
2011  
USA LVEF ≥50% HFH (ICD-9 
coding) with no 
previous HFH in 
the preceding 12 
months 
ICD-9-CM codes 
410-414 
3631 36 - - - 76 55 - 
Kajimoto, 
Japan, 2015 
(ATTEND)172 
2007-
2011 
Japan LVEF >40% 
or 
qualitative 
normal 
LVSF or 
mild LVSD 
HFH (modified 
Framingham 
criteria) 
Ischaemic 
aetiology of HF 
2135 21 - - - 77 54 - 
Caughey, USA, 
2014 (age ≥55 
only) (ARIC)173 
2005-
2010 
USA LVEF ≥40% HFH (ICD-9 
coding) 
- 6414 43 20 - - 77 61 - 
Clarke, USA, 
2013 
(KPMCP)174 
2001-
2008 
USA LVEF >40% 
or 
qualitative 
normal 
LVSF or 
mild LVSD  
HFH (ICD-9 
coding) 
- 1613 - 33 - - 73 57 - 
Steinberg, 
USA, 2012 
(GWTG-HF)175 
2005-
2010 
USA LVEF ≥50% HFH (ICD-9 
coding) 
- 40354 44 - - - 78 63 - 
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West, USA, 
2011 
(ADHERE-I)176 
2005-
2009 
10 
countries: 
SE Asia, 
Australia, 
Latin 
America 
LVEF ≥40% HFH (ICD-9/10 
coding) 
- 4206* 42 21 - - 71 55 - 
Mogensen, 
Denmark, 
2011 
(DIAMOND-
CHF/ECHOS)17
7 
1993-
1996, 
2001-
2002 
Denmark, 
Norway, 
Sweden 
WMI ≥1.5 
(LVEF 
≥45%) 
NYHA III/IV 
symptoms in the 
preceding month 
and treated with 
diuretic 
- 3638 44 23 - - 72 49 III-IV 
Rossi, USA, 
2008 
(OPTIMIZE-
HF)178 
2003-
2004 
USA LVEF ≥40% HFH (ICD-9 
coding) 
Medical history of 
CAD, MI or 
coronary 
revascularisation 
21149 54 18 25 - 75 62 - 
Ezekowitz, 
Canada, 2008 
(EFFECT)179 
1999-
2001  
Canada LVEF >50% First HFH (ICD-9 
coding, 
Framingham 
criteria) 
- 1026 - 19 8 24 76 64 - 
Shah, USA, 
2008 (age ≥65 
only) 
(Medicare / 
NHC)180 
1998-
1999, 
2000-
2001 
USA 
 
LVEF >50% HFH (ICD-9 
coding) 
- 13533 48 21 9 / 17 - 80 70 - 
Yancy, USA, 
2006 
(ADHERE-
US)181 
2001-
2004  
USA LVEF ≥40% HFH (ICD-9 
coding) 
History of clinical 
or angiographic 
CAD 
26322* 50 24 - - 74 62 - 
Owan, USA, 
2006 (Olmsted 
County)8 
1987-
2001 
USA LVEF ≥50% HFH (ICD-9 and 
DRG coding, 
modified 
Framingham 
criteria) 
- 2167 53 - - - 74 56 - 
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Lenzen, 
Netherlands, 
2004 (EHFS-
I)182 
2000, 
2001 
24 ESC 
countries 
LVEF ≥40% ≥1 of: clinical 
diagnosis of HF 
during hospital 
admission or in 
the last 3 years,  
administration of 
loop diuretic 
(except for renal 
failure) or 
pharmacological 
treatment of HF 
within 24 hours of 
death or 
discharge 
- 3148 59 - 12 - 71 55 I-IV 
Ibrahim, USA, 
2003 (age ≥65 
only) 
(CHQC)183 
1992-
1994 
USA LVEF ≥50% HFH (ICD-9 
coding) 
- 1058 46 - - 6 79 70 - 
Community based cohorts 
Fröhlich, 
Norway, 20195 
1995-
2015 
Norway, 
Germany, 
UK 
LVEF ≥50% 
and 
evidence of 
structural 
heart 
disease 
Outpatient 
clinical diagnosis 
of HF 
Primary 
ischaemic 
aetiology of HF 
1146 29 - - - 66 40 I-IV 
Ibrahim, USA, 
2019 (NCDR 
PINNACLE)184 
2008-
2016 
USA LVEF ≥50% First HF patient 
visit 
- 324387 56 15 22 / 
12 
- 70 52 - 
Tromp, 
Singapore, 
2019 (ASIAN-
HF)185 
2013-
2017 
Asia LVEF ≥50% ≥1 HFH or 
treatment for HF 
in outpatient 
clinic 
Angiographically 
documented 
presence of 
significant 
coronary 
obstruction, 
1204 29 - - - 68 50 I-IV 
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history of MI or 
revascularisation 
Iorio, Italy, 
2018186 
2009-
2013 
Italy LVEF ≥50% Outpatient 
clinical diagnosis 
of HF (ESC 2012 
criteria) 
- 1373 40 - - - 79 51 I-IV 
Ather, USA, 
2012 (VA)187 
2000-
2002 
USA LVEF ≥50% Outpatient 
clinical diagnosis 
of HF (ICD-9 
coding) 
- 2843 - 27 - - 71 9 - 
Magaña-
Serrano, 
Mexico, 2011 
(I-PREFER)188 
- 10 
countries: 
Latin 
America, 
Middle 
East, 
North 
Africa 
LVEF ≥45% New or previously 
documented 
diagnosis of CHF 
(Framingham 
criteria) 
- 1291 46 21 - - 65 50 I-IV 
Mixed/unspecified cohorts 
Huusko, 
Finland, 2019 
(Turku CRC)189 
2004-
2013 
Finland LVEF ≥40% Clinical diagnosis 
of HF (ICD-10 
code I50) and NT-
proBNP ≥125 ng/L 
- 1449 - 27 - - 74 51 - 
Vedin, 
Sweden, 2017 
(SwedeHF)190 
2000-
2012 
Sweden LVEF ≥50% Clinician-judged 
HF 
Documented IHD 
or ICD-10 
diagnosis 
corresponding to 
IHD or 
revascularisation 
9957 52 29 28 32 80 54 I-IV 
Chioncel, 
Romania, 
2017 (ESC-HF-
LT)191 
2011-
2015 
Europe, 
Turkey, 
Israel, 
Egypt 
LVEF >50% Outpatients: 
clinical-judged 
chronic HF 
Inpatients: acute 
HF requiring IV 
inotropes, 
vasodilators or 
diuretics 
Primary 
ischaemic 
aetiology of HF 
1462 24 - 14 / 9 - 69 39 - 
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Gerber, USA, 
2015 (Olmsted 
County)13 
2000-
2010  
USA LVEF ≥50% Incident HF (ICD-
9 coding, 
Framingham 
criteria) 
- 1089 28 17 - - 78 64 - 
Nochioka, 
Japan, 2015 
(CHART-2)192 
2006-
2010 
Japan LVEF ≥50% ACC/AHA stage B-
D HF, 
Framingham 
criteria 
- 3124 46 30 32 / 9 - 69 35 I-IV 
Allen, USA, 
2013 
(CVRN)193 
2005-
2008 
USA LVEF ≥50% HFH or ≥3 
ambulatory visits 
with a diagnosis 
of HF (ICD-9 
coding) 
- 14907 - 11 9 / 6 - 76 58 - 
Kaneko, 
Japan, 2013 
(Shinken)194 
2004-
2011 
Japan LVEF >50% NYHA II-IV - 1121 - 10 - - 66 34 II-IV 
Edelmann, 
Germany, 
2011 
(CNHF)195 
2003-
2010 
Germany LVEF ≥50% Clinician-judged 
HF 
- 1294 31 - - - 67 54 I-IV 
Gomez-Soto, 
Spain, 2010 
(Puerto 
Real)196 
2001-
2005 
Spain LVEF ≥50% First diagnosis of 
HF (Framingham 
criteria, and ICD-
9 coding for 
hospitalised 
patients) 
Angina or AMI 1120 36 19 14 17 72 58 I-IV 
Miura, Japan, 
2010 (MetS-
CHF)197 
2006-
2008 
Japan LVEF ≥50% ACC/AHA stage 
C/D CHF 
- 2179 41 - - - 70 36 I-IV 
Castillo, 
Spain, 2009 
(BADAPIC)198 
1999-
2003 
Spain LVEF ≥45% 
and echo 
evidence of 
diastolic 
dysfunction 
Framingham 
criteria 
- 1416 32 18 12 - 71 53 II-IV 
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Randomised controlled trials 
Solomon, USA, 
2019 (age ≥50 
only) 
(PARAGON-
HF)71 
2014-
2018 
25 
countries: 
Europe, 
North 
America, 
South 
America, 
Europe, 
South 
Africa, 
Asia, 
Australia 
LVEF ≥45% 
and 
evidence of 
structural 
heart 
disease on 
echo 
Current HF 
symptoms or HF 
symptoms 
requiring 
treatment with 
diuretic ≥30 days 
prior to 
enrolment, NT-
proBNP ≥300 
pg/mL (≥900 
pg/mL if AF) 
- 4822 43 23 - - 73 52 II-IV 
Pitt, USA, 
2014 (age ≥50 
only) 
(TOPCAT)14 
2006-
2012 
6 
countries: 
North 
America, 
South 
America, 
Europe, 
Russia 
LVEF ≥45% ≥1 sign and ≥1 
symptom of HF 
and HFH or BNP 
≥100 pg/mL or 
NT-proBNP ≥360 
pg/mL within the 
previous 60 days 
History of 
previous MI, 
coronary 
revascularisation, 
or angina 
3445 59 26 24 47 69 52 I-IV 
van 
Veldhuisen, 
Netherlands, 
2009 (age ≥70 
only) 
(SENIORS)72 
2000-
2003 
10 
countries: 
Europe 
LVEF >35% Clinical history of 
chronic HF and 
HFH within the 
previous 12 
months 
Prior history of 
CAD 
752 77 34 2 / 4 - 76 50 I-IV 
Massie, USA, 
2008 (age ≥60 
only) (I-
PRESERVE)15 
2002-
2005 
25 
countries: 
Europe, 
North 
America, 
South 
America, 
South 
Africa, 
Australia 
LVEF ≥45% Current NYHA III-
IV symptoms with 
corroborative 
evidence, or 
current NYHA II-
IV symptoms and 
HFH within 6 
months 
 
History of 
previous MI, 
revascularisation 
or primary 
ischaemic 
aetiology of HF 
4128 36 23 13 40 72 60 II-IV 
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Cleland, UK, 
2006 (age ≥70 
only) (PEP-
CHF)16    
2000-
2003 
8 
countries: 
Europe, 
Russia 
WMI ≥1.4 
(LVEF 
≥40%) and 
evidence of 
diastolic 
dysfunction 
on echo 
3 out of 9 clinical 
HF criteria and a 
CV hospitalisation 
within the 
previous 6 
months 
- 850 - 27 8 / 5 - 75 56 I-IV 
Ahmed, USA, 
2006 (sinus 
rhythm only) 
(DIG-PEF)73 
1991-
1993 
USA, 
Canada 
LVEF >45% Current or past 
HF symptoms, 
signs, or 
radiological 
evidence of 
pulmonary 
congestion 
Principal 
ischaemic 
aetiology of HF 
988 56 49 - 30 67 41 I-IV 
Yusuf, 
Canada, 2003 
(CHARM-
Preserved)64 
1999-
2000 
26 
countries: 
Australia, 
Europe, 
Russia, SE 
Asia, 
North 
America 
LVEF >40% NYHA II-IV ≥4 
weeks (NYHA III-
IV in prior 6 
months if taking 
an ACEI) and 
previous cardiac 
hospitalisation 
Ischaemic 
aetiology of HF 
3023 56  44 17 / 
22 
28 67 40 II-IV 
Angiographic cohorts 
Trevisan, 
France, 
2018199 
2015-
2016 
France LVEF ≥40% Hospitalisation 
with symptoms 
and signs of acute 
HF and BNP 
≥100pg/mL 
>70% stenosis (or 
50-70% stenosis 
with FFR ≤0.80) 
of ≥1 epicardial 
coronary artery 
108 64 - - - 79 54 - 
Hwang, USA, 
2014148 
2004-
2012 
USA LVEF ≥50% HFH (ICD-9 coding 
and Framingham 
criteria or 
elevated invasive 
left heart 
pressures) 
>50% stenosis of 
≥1 epicardial 
coronary artery, 
prior MI or 
coronary 
revascularisation 
376 68 14 19 / 
21 
33 72 53 - 
Koller, 
Austria, 2014 
(LURIC)200 
1997-
2000 
Germany LVEF >45% 
and 
evidence of 
Symptoms and 
signs of HF 
>20% stenosis of 
≥1 epicardial 
coronary artery 
459 76 32 - - 68 37 - 
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diastolic 
dysfunction 
(on 
invasive 
assessment 
or NT-
proBNP 
>220 
pg/mL and 
ECG 
evidence of 
AF) 
Schmaltz, 
Canada, 2008 
(APPROACH)20
1 
1999-
2004 
Canada LVEF >50% Clinician-judged 
HF 
≥50% stenosis of 
≥1 epicardial 
coronary artery 
2159 59 44 5 / 5 - 68 46 - 
Arques, Italy, 
2008 
(hypertensive 
and in sinus 
rhythm only, 
history of 
CAD/angina 
excluded)202 
2002-
2008 
Italy LVEF >50%, 
LVEDV 
<76ml/m2 
and LVEDP 
≥16mmHg 
Clinical and 
radiographic signs 
of acute HF with 
a complete, 
favourable 
response to IV 
diuretics and/or 
nitrates 
>50% stenosis of 
≥1 epicardial 
coronary artery 
23 35 - - - 74 61 IV 
Felker, USA, 
2006 (Duke)203 
1995-
2003 
USA LVEF >40% History of 
symptomatic HF 
(NYHA II-IV 
symptoms) 
≥75% stenosis of 
≥1 epicardial 
coronary artery 
3093 52 23 14 / 
17 
- 64 56 II-IV 
East, USA, 
2004 (Duke)204 
1984-
1996 
USA LVEF >40% History of 
symptomatic HF 
(NYHA II-IV 
symptoms) 
≥75% stenosis of 
≥1 epicardial 
coronary artery 
3303 54 26 12 / 
12 
- 64 55 II-IV 
 
 
             
Arques, Italy, 
2004 (sinus 
rhythm only, 
2001-
2003 
Italy LVEF ≥50% 
with 
pseudo-
Dyspnoea at rest, 
pulmonary rales, 
radiological 
>50% stenosis of 
≥1 epicardial 
coronary artery 
18 39 - - - 73 61 IV 
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history of 
CAD/angina 
excluded)205 
normal or 
restrictive 
mitral 
filling on 
echo  
pulmonary 
oedema with 
favourable 
response to loop 
diuretics and 
nitrates 
Kramer, USA, 
2000206 
1995-
1998 
USA LVEF ≥40% Hospitalisation 
with acute 
respiratory 
distress with 
onset ≤6 hours 
prior to seeking 
medical 
attention, and 
alveolar or 
interstitial 
pulmonary 
oedema on CXR 
>50% stenosis of 
≥1 epicardial 
coronary artery 
27 74 - - - 67 56 IV 
Judge, USA, 
1991 (CASS)207 
1975-
1979 
USA LVEF ≥45% Moderate to 
severe CHF 
symptoms (NYHA 
III-IV) 
≥70% stenosis of 
≥1 epicardial 
coronary artery 
284 67 53 - 70 
(CCS 
III/IV) 
56 44 III-IV 
Autopsy series 
Mohammed, 
USA, 2015208 
 
1986-
2001, 
2003-
2010 
USA LVEF ≥40% Previous HFH or 
outpatient 
diagnosis of HF 
(ICD-9 coding) 
>50% stenosis of 
≥1 epicardial 
coronary artery 
(at post-mortem) 
119 65 20 - - 78 56 - 
 
*Hospitalisations (not patients).  ACEI, angiotensin converting enzyme inhibitor; ACC/AHA, American College of Cardiology/American Heart Association; ADHERE-I, Acute 
decompensated heart failure national registry - international; ADHERE-US, Acute decompensated heart failure national registry - US; AF, atrial fibrillation; AMI, acute myocardial 
infarction; APPROACH, Alberta provincial project for outcome assessment in coronary heart disease; ARIC, Atherosclerosis risk in communities registry; ASIAN-HF, Asian sudden 
cardiac death in heart failure; ATTEND, Acute decompensated heart failure syndromes registry; BADAPIC, Base de datos de pacientes con insuficiencia cardíaca registry; BNP, B-type 
natriuretic peptide; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CASS; Coronary artery surgery study; CCS, Canadian Cardiovascular Society; CCU, Coronary 
care unit; CHARM-Preserved, Candesartan in heart failure assessment of reduction in mortality and morbidity-Preserved; CHART-2, Chronic heart failure analysis and registry in the 
Tohoku district-2 study; CHF; congestive heart failure; CHQC, Cleveland health quality choice program; CM, clinical modification; CNHF, Competence network heart failure; CRC, 
Clinical research center; CV, cardiovascular; CVRN, Cardiovascular research network; CXR, chest x-ray; DIAMOND-CHF, Dofetilide-congestive heart failure; DIG-PEF, Digitalis 
intervention group-preserved ejection fraction; DRG, Diagnosis-related group; EAHFE, Epidemiology of acute heart failure in emergency departments; ECG, electrocardiogram; 
ECHOS, Echocardiography and heart outcome study; EFFECT, Enhanced feedback for effective cardiac treatment study; EHFS-I, Euro heart failure study-I; ESC, European Society of 
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Cardiology; ESC-HF-LT, European Society of Cardiology heart failure long-term registry; FFR, fractional flow reserve; GWTG-HF, Get with the guidelines heart failure registry; HF, 
heart failure; HFH; HF hospitalisation; HFpEF, HF with preserved ejection fraction; ICD, International Classification of Diseases; IHD, ischaemic heart disease; I-PREFER, Identification 
of patients with heart failure and preserved systolic function: an epidemiological regional study; I-PRESERVE, Irbesartan in patients with heart failure and preserved ejection 
fraction; IV, intravenous; KorAHF, Korean acute heart failure registry; KPMCP, Kaiser Permanente medical care program; KPNW, Kaiser Permanente Northwest; KPSC, Kaiser 
Permanente Southern California; LURIC, Ludwigshafen risk and cardiovascular health study; LVEDD, left ventricular end-diastolic dimension; LVEDP, left ventricular end-diastolic 
pressure; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVSF, left ventricular systolic function; MetS-CHF, Metabolic syndrome-chronic heart 
failure study; MI, myocardial infarction; NCDR PINNACLE, National cardiovascular data practice innovation and clinical excellence registry; NHC, National heart care project; NIS, 
National inpatient sample; NT-proBNP, N-terminal prohormone BNP; NYHA, New York Heart Association; OPTIMIZE-HF, Organized program to initiate lifesaving treatment in 
hospitalized patients with heart failure; PARAGON-HF, Prospective comparison of angiotensin receptor-neprilysin inhibitor with angiotensin receptor blocker in heart failure with 
preserved ejection fraction; PCI, percutaneous coronary intervention; PEP-CHF, Perindopril in elderly people with chronic heart failure; RICA, Registro de Insuficiencia Cardiaca; SE, 
South East; SENIORS, Study of the effects of nebivolol intervention on outcomes and rehospitalization in seniors with heart failure; SwedeHF, Swedish heart failure registry; TOPCAT, 
Treatment of preserved cardiac function heart failure with an aldosterone antagonist; VA, Veterans Affairs; WET-HF, West Tokyo heart failure registry; WMI, wall motion index.   
Table 2-2: Prevalence of CAD and previous MI in HFpEF cohorts.  
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Prevalence of CAD and previous MI in HFpEF   
The prevalence of CAD varied widely between the studies, from 16% to 77% 
(Table 2-2).  Previous MI was reported in 36 studies (range 4% to 53%) and a 
history of angina was reported in 10 studies (range 6% to 70%).  CAD, previous MI 
and angina were more prevalent in studies of patients undergoing coronary 
angiography and RCTs than in population-based observational studies.  The 
prevalence of CAD, previous MI and coronary revascularisation in the three large 
hospital-based population registries that reported data on HFpEF hospitalisations 
were similar to that observed in the HFpEF cohorts that reported data for 
individual patients.  When analysed by random effects meta-analysis, the mean 
prevalence of CAD in HFpEF populations was 42% (95% confidence interval [CI] 
40-45%) (Figure 2-2), and the prevalence of previous MI was 22% (95% CI 19-25%) 
(Figure 2-3).   
Prognostic impact of CAD in HFpEF   
The effect of CAD on outcomes in HFpEF populations was reported in 14 studies.  
In population-based observational studies and RCTs, the prognostic impact of 
CAD in HFpEF cohorts was inconsistent.  However, in studies of patients with 
angiographically-proven CAD, the presence and extent of CAD was associated 
with increased all-cause mortality (Table 2-3).   
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ADHERE-I, Acute decompensated heart failure national registry - international; ADHERE-US, Acute 
decompensated heart failure national registry - US; APPROACH, Alberta provincial project for outcome 
assessment in coronary heart disease; ARIC, Atherosclerosis risk in communities registry; ASIAN-HF, Asian 
sudden cardiac death in heart failure; ATTEND, Acute decompensated heart failure syndromes registry; 
BADAPIC, Base de datos de pacientes con insuficiencia cardíaca registry; CAD, coronary artery disease; 
CASS; Coronary artery surgery study; CCU, Coronary care unit; CHARM-Preserved, Candesartan in heart 
failure assessment of reduction in mortality and morbidity-Preserved; CHART-2, Chronic heart failure 
analysis and registry in the Tohoku district-2 study; CHQC, Cleveland health quality choice program; CI, 
confidence interval; CNHF, Competence network heart failure; DIAMOND-CHF, Dofetilide-congestive heart 
failure; DIG-PEF, Digitalis intervention group-preserved ejection fraction; EAHFE, Epidemiology of acute 
heart failure in emergency departments; ECHOS, Echocardiography and heart outcome study; EHFS-I, Euro 
heart failure study-I; ESC-HF-LT, European Society of Cardiology heart failure long-term registry; GWTG-HF, 
Get with the guidelines heart failure registry; HFpEF, heart failure with preserved ejection fraction; I-
PREFER, Identification of patients with heart failure and preserved systolic function: an epidemiological 
regional study; I-PRESERVE, Irbesartan in patients with heart failure and preserved ejection fraction; 
KorAHF, Korean acute heart failure registry; KPNW, Kaiser Permanente Northwest; KPSC, Kaiser 
Permanente Southern California; LURIC, Ludwigshafen risk and cardiovascular health study; MetS-CHF, 
Metabolic syndrome-chronic heart failure study; NCDR PINNACLE, National cardiovascular data practice 
innovation and clinical excellence registry; NHC, National heart care project; NIS, National inpatient 
sample; OPTIMIZE-HF, Organized program to initiate lifesaving treatment in hospitalized patients with heart 
failure; PARAGON-HF, Prospective comparison of angiotensin receptor-neprilysin inhibitor with angiotensin 
receptor blocker in heart failure with preserved ejection fraction; RICA, Registro de Insuficiencia Cardiaca; 
SENIORS, Study of the effects of nebivolol intervention on outcomes and rehospitalization in seniors with 
heart failure; SwedeHF, Swedish heart failure registry; TOPCAT, Treatment of preserved cardiac function 
heart failure with an aldosterone antagonist; WET-HF, West Tokyo heart failure registry.   
Figure 2-2: Meta-analysis – prevalence of CAD in HFpEF cohorts. 
NOTE: Weights are from random effects analysis
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ADHERE-I, Acute decompensated heart failure national registry - international; ADHERE-US, Acute 
decompensated heart failure national registry - US; APPROACH, Alberta provincial project for outcome 
assessment in coronary heart disease; ARIC, Atherosclerosis risk in communities registry; BADAPIC, Base de 
datos de pacientes con insuficiencia cardíaca registry; CAD, coronary artery disease; CASS; Coronary artery 
surgery study; CHARM-Preserved, Candesartan in heart failure assessment of reduction in mortality and 
morbidity-Preserved; CHART-2, Chronic heart failure analysis and registry in the Tohoku district-2 study; CI, 
confidence interval; CRC, Clinical research center; CVRN, Cardiovascular research network; DIAMOND-CHF, 
Dofetilide-congestive heart failure; DIG-PEF, Digitalis intervention group-preserved ejection fraction; 
ECHOS, Echocardiography and heart outcome study; EFFECT, Enhanced feedback for effective cardiac 
treatment study; HFpEF, heart failure with preserved ejection fraction; I-PREFER, Identification of patients 
with heart failure and preserved systolic function: an epidemiological regional study; I-PRESERVE, 
Irbesartan in patients with heart failure and preserved ejection fraction; KorAHF, Korean acute heart 
failure registry; KPMCP, Kaiser Permanente medical care program; LURIC, Ludwigshafen risk and 
cardiovascular health study; NCDR PINNACLE, National cardiovascular data practice innovation and clinical 
excellence registry; NHC, National heart care project; OPTIMIZE-HF, Organized program to initiate 
lifesaving treatment in hospitalized patients with heart failure; PARAGON-HF, Prospective comparison of 
angiotensin receptor-neprilysin inhibitor with angiotensin receptor blocker in heart failure with preserved 
ejection fraction; PEP-CHF, Perindopril in elderly people with chronic heart failure; SENIORS, Study of the 
effects of nebivolol intervention on outcomes and rehospitalization in seniors with heart failure; SwedeHF, 
Swedish heart failure registry; TOPCAT, Treatment of preserved cardiac function heart failure with an 
aldosterone antagonist; VA, Veterans Affairs.   
Figure 2-3: Meta-analysis – prevalence of previous MI in HFpEF cohorts. 
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2.74
2.78
2.32
2.82
2.82
2.82
Weight
2.75
2.83
2.83
2.83
2.82
2.32
19.67
2.82
25.12
2.80
%
2.82
2.56
2.78
8.43
5.65
2.82
2.79
2.82
2.76
2.78
2.69
2.75
22.27
2.78
2.70
2.82
  
1.05 .1 .2 .4 .8
Prevalence of previous MI in HFpEF cohorts
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First author, 
country, year of 
publication 
HFpEF 
patients 
(n) 
Follow-up All-cause mortality CV mortality All-cause 
hospitalisation 
HF hospitalisation 
Hospital based cohorts 
Goyal, USA, 2016 
(NIS)161 
2330361* In-hospital Adjusted HR: 
History of CAD vs. no history of CAD: 0.79 
(0.78-0.80) 
History of CABG vs. no history of CABG: 0.75 
(0.73-0.77) 
History of PCI vs. no history of PCI: 0.64 
(0.62-0.67) 
- - - 
Clarke, USA, 2013 
(KPMCP)174 
1613 4.1 years Estimated HR for predictors of state 
changes: 
History of MI vs. no history of MI: 0.87 (0.70-
1.10) 
- - - 
Rossi, USA, 2008 
(OPTIMIZE-HF)178 
21149 In-hospital 
and post-
discharge 
(60-90 days) 
Adjusted OR: 
History of CAD vs. no history of CAD: 
In-hospital: 1.13 (0.94-1.36) 
Post-discharge: 1.39 (0.95-2.03) 
- - - 
Ezekowitz, 
Canada, 2008 
(EFFECT)179 
1026 1 year Adjusted HR (death or HFH):  
History of MI vs. no history of MI: 1.57 (1.23-
2.02) 
- - - 
Owan, USA, 2006  
(Olmsted County)8 
2167 10 years Adjusted HR:  
History of CAD vs. no history of CAD: 1.03 
(0.98-1.09) 
- - - 
Mixed/unspecified cohorts 
Allen, USA, 2013 
(CVRN)193 
14907 1.8 years Adjusted HR: 
History of MI vs. no history of MI: 1.61 (1.46-
1.78) 
History of CABG vs. no history of CABG: 0.76 
(0.66-0.87) 
History of PCI vs. no history of PCI: 0.87 
(0.77-0.97) 
- Adjusted HR: 
History of MI vs. 
no history of MI: 
1.40 (1.32-1.48) 
History of PCI vs. 
no history of PCI: 
1.10 (1.03-1.17) 
Adjusted HR: 
History of MI vs. no 
history of MI: 1.31 
(1.19-1.44) 
History of CABG vs. no 
history of CABG: 0.90 
(0.78-1.03) 
Kaneko, Japan, 
2013 
1121 1135 days Unadjusted HR: - - - 
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(Shinken)194 History of MI vs. no history of MI: 0.68 (0.24-
1.88) 
Randomised controlled trials 
Badar, UK, 2015 
(CHARM-
Preserved)209 
1553 36.6. months 
(median) 
Adjusted HR: 
Current angina vs. no history of angina: 0.72 
(0.52-1.01) 
Adjusted HR: 
Current angina vs. 
no history of angina: 
0.72 (0.52-1.01) 
- Adjusted HR: 
Current angina vs. no 
history of angina: 0.80 
(0.57-1.12) 
Badar, UK, 2015 
(age ≥60 only) 
(I-PRESERVE)210 
4128 49.5 months Adjusted HR: 
CAD/no angina vs. no CAD/no angina: 1.58 
(1.22-2.04) 
CAD/angina vs. no CAD/no angina: 1.29 
(1.05-1.59) 
Adjusted HR: 
CAD/no angina vs. 
no CAD/no angina: 
1.50 (1.10-2.06) 
CAD/angina vs. no 
CAD/no angina: 1.46 
(1.14-1.86) 
- Adjusted HR: 
CAD/no angina vs. no 
CAD/no angina: 1.03 
(0.75-1.40) 
CAD/angina vs. no 
CAD/no angina: 1.12 
(0.89-1.41) 
Pitt, USA, 2014 
(age ≥50 only) 
(TOPCAT)14 
3445 3.3 years Adjusted HR (CV death, aborted cardiac 
arrest or HFH): 
History of MI vs. no history of MI: 0.84 (0.64-
1.12) 
- - - 
Cleland, UK, 2006 
(age ≥70 only) 
(PEP-CHF)16 
850 2.1 years 
(median) 
All-cause mortality or unplanned HFH: 17% 
(history of MI) vs. 12% (no history of MI) 
- - - 
Angiographic cohorts 
Hwang, USA, 
2014148 
376 1457 days 
(median) 
Adjusted HR: 
History of CAD vs. no history of CAD: 1.71 
(1.03-2.98) 
- - - 
Felker, USA, 2006 
(Duke)203 
3093 3.5 years 
(median) 
Adjusted HR: 
Number of diseased vessels: 1.15 (1.10-1.20) 
- - - 
Judge, USA, 1991 
(CASS)207 
284 6 years Survival: 
92% without CAD, 83% (1- or 2-vessel 
disease), 68% (3-vessel disease), p 0.0001) 
- - - 
*Hospitalisations (not patients).  CABG, coronary artery bypass grafting; CAD, coronary artery disease; CASS; Coronary artery surgery study; CHARM-Preserved, Candesartan in heart 
failure assessment of reduction in mortality and morbidity-Preserved; CV, cardiovascular; CVRN, Cardiovascular research network; EFFECT, Enhanced feedback for effective cardiac 
treatment study; HF, heart failure; HFH; HF hospitalisation; HFpEF, HF with preserved ejection fraction; HR, hazard ratio; I-PRESERVE, Irbesartan in patients with heart failure and 
preserved ejection fraction; KPMCP, Kaiser Permanente medical care program; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NIS, National inpatient sample; 
OPTIMIZE-HF, Organized program to initiate lifesaving treatment in hospitalized patients with heart failure; OR, odds ratio; PCI, percutaneous coronary intervention; PEP-CHF, 
Perindopril in elderly people with chronic heart failure; TOPCAT, Treatment of preserved cardiac function heart failure with an aldosterone antagonist.   
Table 2-3: Prognostic impact of CAD in HFpEF cohorts.  
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Prevalence of HFpEF after incident MI 
Eight studies reported rates of HFpEF after incident MI; seven studies reported 
early (in-hospital) HF and one reported late HF following MI.  HF in the presence 
of preserved LV systolic function occurred following MI in a median of 8% 
(interquartile range [IQR] 7-15%) and accounted for 43% (31-51%) of early HF 
post-MI.  In the one study reporting late-onset HF following MI, HFpEF developed 
in 8% of patients from three days to a mean follow-up of eight years after MI and 
accounted for 42% of HF in this cohort.211  One study described contemporary 
temporal trends in patients who experienced HF following incident MI.212  From 
the 1990s to 2010, a significant reduction in post-MI HF was observed.  The 
incidence of HFrEF declined but there was no change in the rate of HFpEF, 
resulting in an increase in the proportion of patients with both early- and late-
onset post-MI HF with preserved LVEF.  HFpEF complicating MI was consistently 
associated with worse short- and long-term outcomes compared with MI patients 
with preserved LVEF and no HF (Table 2-5).   
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First author, 
country, year 
of publication 
Study 
period 
Region Definition 
of 
preserved 
LVEF 
Definition of HF Definition of MI HFpEF 
patients 
(n) 
Follow-up for 
development 
of HF post-MI 
Incidence 
of post-
MI HF  
Incidence 
of post-MI 
HFpEF 
(proportion 
of HF / 
overall) 
Gerber, USA, 
2016 
(Olmsted 
County)211 
1990-
2010 
 
USA LVEF ≥50% Incident diagnosis of HF 
(ICD-9 coding and 
Framingham criteria) 
Incident MI (ICD-9 coding 
and 2 of the following: 
cardiac pain, elevated 
biomarkers (CK, CK-MB or 
troponin), and ECG 
changes) 
339 Early: <3 days 
Late: >3 days 
to mean 8 
years’ follow-
up 
35% (47% 
early, 53% 
late) 
 
Early: 32%* 
/ 5% 
Late: 42%* 
/ 8% 
 
Desta, Sweden, 
2015 
(SWEDEHEART/ 
RIKS-HIA)213 
1998-
2010 
Sweden LVEF >49% In-hospital diagnosis of 
HF (presence of 
pulmonary rales or use 
of IV diuretics or 
inotropic drugs during 
admission) 
Typical clinical symptoms 
and/or ECG signs of AMI, 
and a documented 
elevation of cardiac 
enzymes (CK, CK-MB or 
troponin) 
7707 In-hospital 42% 
(decrease 
from 55% 
to 34% 
1998-
2010) 
 
20% 
(increase 
from 18% to 
31% 1998-
2010) / 8% 
(static 
1998-2010) 
Antonelli, 
Brazil, 2015 
(Einstein AMI)214 
2005-
2012 
Brazil LVEF ≥50% Clinical diagnosis of HF 
at presentation (Killip 
class >I) 
Typical clinical symptoms 
and/or ECG signs of AMI, 
and a documented 
elevation of cardiac 
enzymes (CK, CK-MB or 
troponin) 
78 At 
presentation 
15% 
 
36% / 5% 
van Diepen, 
Canada, 2014 
(age ≥65 only) 
(CRUSADE)215 
2003-
2006 
USA LVEF ≥40% Clinical diagnosis of HF 
at presentation or 
during hospital 
admission (PND, 
orthopnoea, dyspnoea, 
or lower extremity 
oedema and ≥1 of: 
rales, S3, JVD, elevated 
BNP or NT-proBNP, or 
documented pulmonary 
oedema on CXR) 
NSTEMI – ≥10 minutes of 
ischaemic chest pain at 
rest and elevated cardiac 
enzymes (CK-MB or 
troponin levels above the 
ULN) or ECG changes (ST 
depression or transient 
ST elevation)  
4913 In-hospital 33% 
 
57% / 19% 
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Bennett, USA, 
2007 
(CRUSADE)216 
2001-
2004 
USA LVEF ≥40% Clinical diagnosis of HF 
at presentation 
(symptoms of HF on 
initial history: 
dyspnoea, orthopnoea, 
laboured breathing, 
fatigue at rest or on 
exertion; signs of HF on 
initial physical 
examination: rales, S3 
gallop, JVD, or 
pulmonary oedema on 
initial CXR) 
NSTEACS – ≥10 minutes of 
ischaemic chest pain at 
rest and elevated cardiac 
enzymes (CK-MB or 
troponin levels above the 
ULN) or ECG changes (ST 
depression or transient 
ST elevation) 
11860 In-hospital 23% 
 
55% / 13% 
Hellermann, 
USA, 2005 
(Olmsted 
County)217 
1979-
1998 
USA LVEF ≥50% Incident diagnosis of HF 
(ICD-9 coding and 
Framingham criteria) 
Incident MI (ICD-9 coding 
and 2 of the following: 
cardiac pain, elevated 
biomarkers (CK, CK-MB), 
and ECG changes) 
143 Early: ≤30 
days 
Mid: 30 days – 
1 year 
Late: 1 year to 
mean 7 years’ 
follow-up 
41% (59% 
early, 9% 
mid, 32% 
late) 
29%** / 7% 
Velazquez, USA, 
2004 
(VALIANT)218 
1999-
2001 
9 
countries: 
North 
America, 
Europe, 
Australasia 
LVEF ≥40% ≥1 of: radiological 
pulmonary oedema 
(pulmonary venous 
congestion with 
interstitial or alveolar 
oedema on CXR) or 
clinical diagnosis of HF 
(pulmonary oedema, 
bilateral rales and/or S3 
gallop) 
Physician-determined 
clinical diagnosis of MI 
377 In-hospital 23% 50%** / 7% 
Møller, 
Denmark, 2003 
(BEAT)219 
1998-
1999 
Denmark WMI ≥1.3 
(LVEF 
≥40%) 
Killip class ≥II during 
hospitalisation or a 
history of CHF treated 
with a diuretic on 
admission 
Typical clinical symptoms 
and/or ECG signs of AMI, 
and a documented 
elevation of cardiac 
enzymes (CK and CK-MB) 
to at least twice the ULN 
717 In-hospital 46% 49% / 23% 
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*19% of patients with no LVEF data – multiple imputations used; **excluding patients with no LVEF data.  AMI, acute myocardial infarction; BEAT, Bucindolol evaluation in acute 
myocardial infarction trial; BNP, B-type natriuretic peptide; CHF, chronic heart failure; CK, creatine kinase; CK-MB, creatine kinase myocardial band; CRUSADE, Can rapid risk 
stratification of unstable angina patients suppress adverse outcomes with early implementation of the American College of Cardiology/American Heart Association guidelines; CXR, 
chest x-ray; ECG, electrocardiogram; HF, heart failure; HFpEF, HF with preserved ejection fraction; ICD, International Classification of Diseases; IV, intravenous; JVD, jugular venous 
distention; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSTEACS, non-ST-elevation acute coronary syndrome; NT-proBNP, N-terminal prohormone BNP; PND, 
paroxysmal nocturnal dyspnoea; RIKS-HIA, Register of information and knowledge about Swedish heart intensive care admissions; SWEDEHEART, Swedish web-system for enhancement 
and development of evidence-based care in heart disease evaluated according to recommended therapies registry; ULN, upper limit of normal; VALIANT, Valsartan in acute 
myocardial infarction trial; WMI, wall motion index.   
Table 2-4: Rates of HFpEF after incident MI. 
First author, country, year of 
publication 
HFpEF patients 
(n) 
Follow-
up 
All-cause mortality   CV mortality Non-CV mortality 
Gerber, USA, 2016 
(Olmsted County)211 
339 8 years Adjusted HR: 2.37 (1.96-2.87) 
 
Adjusted HR: 2.65 (2.02-
3.49) 
Adjusted HR: 2.12 (1.64-
2.74) 
Desta, Sweden, 2015 
(SWEDEHEART/ RIKS-HIA)213 
7707 1 year Adjusted HR: 1.9 (1.8-2.0) - - 
Antonelli, Brazil, 2015 
(Einstein AMI)214 
78 In-
hospital 
Adjusted OR: 2.91 (1.35-6.27) - - 
van Diepen, Canada, 2014  
(age ≥65 only) 
(CRUSADE)215 
4913 30 days /  
1 year 
Adjusted HR (30 days): 1.99 (1.64-
2.41) 
Adjusted HR (1 year): 1.79 (1.61-
1.98) 
- - 
Bennett, USA, 2007 
(CRUSADE)216 
11860 In-
hospital 
Adjusted OR: 2.30 (2.05-2.59) 
 
- - 
Velazquez, USA, 2004 
(VALIANT)218 
377 In-
hospital 
7.7% (vs. 2.3% for preserved LVEF 
and no HF) 
- - 
Møller, Denmark, 2003 
(BEAT)219 
717 In-
hospital 
Adjusted HR: 2.10 (1.74-2.55) - - 
AMI, acute myocardial infarction; BEAT, Bucindolol evaluation in acute myocardial infarction trial; CRUSADE, Can rapid risk stratification of unstable angina patients suppress adverse 
outcomes with early implementation of the American College of Cardiology/American Heart Association guidelines; CV, cardiovascular; HF, heart failure; HFpEF, HF with preserved 
ejection fraction; HR, hazard ratio; LVEF, left ventricular ejection fraction; OR, odds ratio; RIKS-HIA, Register of information and knowledge about Swedish heart intensive care 
admissions; SWEDEHEART, Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies registry; 
VALIANT, Valsartan in acute myocardial infarction trial.  
Table 2-5: Prognostic impact of HFpEF after incident MI.  
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Treatment of CAD in HFpEF 
A total of 11 studies reported outcomes based on CAD treatments in HFpEF 
cohorts – one subgroup analysis of an RCT and 10 observational studies.  There 
were no RCTs which assessed the impact of treatment of CAD in a HFpEF 
population.  In a post hoc subgroup analysis of the PEP-CHF trial, the primary 
endpoint (composite of all-cause mortality and hospitalisation for HF) was 
reduced in HFpEF patients with a history of MI treated with perindopril, while no 
such benefit was observed in patients without a history of MI.16  In four studies, 
patients with HFpEF had poorer outcomes than patients with preserved LVEF and 
no HF who underwent percutaneous or surgical coronary revascularisation (Table 
2-6).  One retrospective single-centre observational study compared patients 
with HFpEF that underwent either percutaneous coronary intervention (PCI) or 
coronary artery bypass grafting (CABG).  There was no difference in mortality 
between the groups, however, PCI was associated with more major adverse 
cardiac and cerebrovascular events (MACCE) at a median 18 months’ follow-
up.220  One large population-based study observed a mortality benefit at 60 to 90 
days following hospital discharge in patients with HFpEF and a clinical history of 
CAD or previous MI who were revascularised, compared to patients with HFpEF 
and CAD who were not revascularised.178  A single-centre retrospective study 
also observed lower all-cause mortality in patients who were completely 
revascularised compared to those who were either incompletely revascularised 
or not revascularised.148  Conversely, in patients with HFpEF and CAD in the CASS 
registry, surgical revascularisation did not appear to confer a survival benefit.207  
Furthermore, one small prospective study, including 20 patients with 
hypertensive pulmonary oedema and CAD, found that revascularisation had no 
significant effect on the recurrence of pulmonary oedema or death.206    
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First author, 
country, year of 
publication 
Study patient 
characteristics 
Definition 
of 
preserved 
LVEF 
Definition of 
HF 
Definition of CAD HFpEF-
CAD 
patients 
(n) 
Follow-up All-cause 
mortality 
Cardiac 
mortality 
HF 
readmission 
Sun, Canada, 
2018 (CorHealth 
Ontario)221 
Patients with 
HFpEF vs. 
patients with 
preserved LVEF 
and no HF who 
underwent 
primary isolated 
CABG (≥40 years) 
LVEF ≥50% Physician billing 
for HFH or ≥2 
outpatient HF 
claims within 1 
year 
Angiographically 
documented CAD 
amenable to 
CABG 
2752 All-cause 
mortality: 
30 days / 4 
years 
(mean) 
30 days: 
Adjusted HR 
2.57 (1.96-3.36) 
4 years (mean): 
Adjusted HR 
2.06 (1.86-2.27) 
- - 
Dalén, Sweden, 
2016 
(SWEDEHEART)222 
Patients with 
HFpEF vs. 
patients with 
preserved LVEF 
and no HF who 
underwent CABG 
LVEF ≥50% Pre-CABG 
diagnosis of HF 
(ICD-10 coding) 
Angiographically 
documented CAD 
amenable to 
CABG 
1216 All-cause 
mortality: 
30 days / 6 
years 
(mean) 
HFH and HF 
mortality: 
5 years 
(mean) 
30 days: 
Adjusted HR 
1.83 (1.26-2.66) 
6 years (mean): 
Adjusted HR 
1.62 (1.46-1.80) 
 
- Composite 
all-cause 
mortality 
and HFH: 
Adjusted HR 
1.64 (1.47-
1.82) 
Marui, Japan, 
2015 (CREDO-
Kyoto CABG-2)223 
Patients with 
HFpEF vs. 
patients with 
preserved LVEF 
and no HF who 
underwent CABG 
LVEF >50% Clinical-judged 
ACC/AHA stage 
C/D HF 
Angiographically 
documented CAD 
amenable to 
CABG 
152 5 years Adjusted HR 
1.42 (1.02-1.97) 
Adjusted 
HR 2.14 
(1.32-
3.49) 
Adjusted HR 
1.93 (1.20-
3.11) 
Hwang, USA, 
2014148 
Patients with 
HFpEF and 
angiographic CAD 
(complete 
revascularisation 
vs. no or 
incomplete 
revascularisation) 
 
LVEF ≥50% HFH (ICD-9 
coding and 
Framingham 
criteria or 
elevated left 
heart pressures 
at 
catheterisation) 
>50% stenosis of 
≥1 epicardial 
coronary artery, 
prior MI, or any 
prior coronary 
revascularisation 
255 4-year all-
cause 
mortality 
Adjusted HR 
0.56 (0.33-0.93) 
- - 
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Xue, China, 
2012220 
Patients with 
HFpEF and 
angiographic CAD 
who underwent 
CABG or PTCA 
LVEF ≥50% HF signs and 
symptoms 
(NYHA II-IV) 
Angiographically 
documented CAD 
amenable to 
revascularisation 
920 All-cause 
mortality 
and MACCE 
(median 
follow-up 
18 months) 
2.3% PCI vs. 
3.5% CABG 
(adjusted p 
0.423) 
1.1% PCI 
vs. 2.6% 
CABG 
(adjusted 
p 0.237) 
- 
Rossi, USA, 2008 
(OPTIMIZE-HF)178 
Patients with 
HFpEF with a 
clinical history of 
CAD vs. patients 
with HFpEF with 
no clinical history 
of CAD 
LVEF ≥40% HFH (ICD-9 
coding) 
History of clinical 
CAD, MI or 
coronary 
revascularisation 
11405 In-hospital 
and post-
discharge 
(60-90 day) 
all-cause 
mortality 
In-hospital: 
Adjusted OR 
1.16 (0.94-1.43) 
CRS- vs. no CAD 
/ 1.08 (0.86-
1.37) CRS+ vs. 
no CAD 
Post-discharge: 
Adjusted OR 
1.58 (1.05-2.39) 
CRS- vs. no CAD 
/ 1.06 (0.62-
1.80) CRS+ vs. 
no CAD 
- - 
Holper, USA, 
2007 (BARI)224 
Patients with 
HFpEF and 
multivessel CAD 
vs. patients with 
no HF and 
multivessel CAD 
who underwent 
revascularisation 
LVEF ≥50% Positive 
response to the 
question: “Does 
the patients 
have a history 
of CHF requiring 
treatment?” on 
baseline data 
form 
Clinically severe 
angina or 
objective 
evidence of 
ischaemia 
requiring 
revascularisation 
and 
angiographically 
documented CAD 
involving 2 or 3 
vessels 
amendable to 
CABG or PTCA 
 
 
124 10-year 
cardiac 
mortality 
- 10-year: 
Adjusted 
HR 1.55 
(1.05-
2.31) 
- 
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Holper, USA, 
2006 (NHLBI 
PTCA/Dynamic)22
5 
Patients with 
HFpEF vs. 
patients with 
preserved LVEF 
and no HF and 
angiographic CAD 
who underwent 
their first 
coronary 
intervention 
LVEF ≥50% History of PND, 
dyspnoea on 
exertion, or 
pulmonary 
congestion on 
CXR 
Angiographic CAD 
amendable to PCI 
134 In-hospital 
and 1-year 
all-cause 
mortality 
- In-
hospital: 
0.7% 
HFpEF vs. 
0.4% 
preserved 
LVEF with 
no HF 
1-year: 
10.0% vs. 
3.0% 
- 
Cleland, UK, 
2006 (age ≥70 
only) (PEP-CHF)16     
Patients ≥70 
years with HFpEF 
WMI ≥1.4 
(LVEF 
≥40%) and 
≥2 echo 
criteria for 
diastolic 
dysfunction 
3 out of 9 
clinical HF 
criteria and a 
CV 
hospitalisation 
within the 
previous 6 
months 
History of MI 226 All-cause 
mortality 
or HFH at 1 
year 
- - Composite 
all-cause 
mortality 
and HFH: 
0.38 (0.19-
0.75) with MI 
vs. 0.92 
(0.58-1.46) 
without MI 
Kramer, USA, 
2000206 
Patients admitted 
with flash 
pulmonary 
oedema and 
preserved LVEF 
LVEF ≥40% Hospitalisation 
with acute 
respiratory 
distress with 
onset ≤6 hours 
prior to seeking 
medical 
attention, and 
alveolar or 
interstitial 
pulmonary 
oedema on CXR 
 
 
 
 
>50% stenosis of 
≥1 epicardial 
coronary artery 
20 HFH and 
all-cause 
death at 3 
years 
6-month 
recurrence of 
pulmonary 
oedema was 
50% (no 
difference 
between 
HFpEF/HFrEF or 
CAD/no CAD, 
revascularised/ 
not 
revascularised)  
- - 
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Judge, USA, 1991 
(CASS)207 
Patients with 
NYHA III-IV HF 
symptoms and 
preserved LVEF 
with known or 
suspected CAD 
that underwent 
coronary 
angiography 
LVEF ≥45% Moderate to 
severe 
symptoms of 
CHF (NYHA III-
IV) 
≥70% stenosis of 
≥1 epicardial 
coronary artery 
284* All-cause 
mortality 
at 6 years 
CABG did not 
confer a 
statistically 
significant 
survival 
advantage (p = 
0.26) 
- - 
*154 with treatment data available.  ACC/AHA, American College of Cardiology/American Heart Association; BARI, Bypass angioplasty revascularization investigation trial; CABG, 
coronary artery bypass grafting; CAD, coronary artery disease; CASS, Coronary artery surgery study; CHF, chronic heart failure; CREDO-Kyoto CABG-2, Coronary revascularization 
demonstrating outcome study in Kyoto coronary artery bypass grafting registry cohort-2; CRS, coronary revascularisation status; CV, cardiovascular; CXR, chest x-ray; HF, heart 
failure; HFH, HF hospitalisation; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; HR, hazard ratio; ICD, International Classification of Diseases; 
LVEF, left ventricular ejection fraction; MACCE, major adverse cardiac and cerebrovascular events; MI, myocardial infarction; NHLBI, National heart, lung and blood institute; NYHA, 
New York Heart Association; OPTIMIZE-HF, Organized program to initiate lifesaving treatment in hospitalized patients with heart failure; OR, odds ratio; PCI, percutaneous coronary 
intervention; PEP-CHF, Perindopril in elderly people with chronic heart failure; PND, paroxysmal nocturnal dyspnoea; PTCA, percutaneous transluminal coronary angioplasty; 
SWEDEHEART, Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies registry; WMI, wall 
motion index.   
Table 2-6: Treatment of CAD in HFpEF cohorts.   
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2.3.3 CMD in HFpEF 
Thirteen studies investigated the prevalence or potential role of CMD in HFpEF 
(Table 2-7).   
Invasive studies   
One small prospective study investigated the burden of CMD using pressure wire-
derived coronary flow reserve (CFR) and index of microcirculatory resistance 
(IMR) in a small convenience cohort of HFpEF patients (n = 30) referred for 
clinically indicated coronary angiography.226  This study reported “overt CMD” 
(defined as CFR ≤2.0 and IMR ≥23) in 37% of patients (n = 11), with a further 37% 
of patients (n = 11) having some abnormality of coronary microvascular function 
(CFR ≤2.0 or IMR ≥23).  A follow-up study reported that those with “overt CMD” 
had lower survival free of HF hospitalisation at one year than those without 
overt CMD.227  In another small prospective study, nine HFpEF patients 
underwent invasive assessment of rest and stress haemodynamics and 
transcardiac oxygen gradients.228  Patients with HFpEF had an impaired 
transcardiac oxygen gradient with exercise and this inversely correlated with 
pulmonary capillary wedge pressure, suggesting that the abnormal diastolic 
reserve observed in HFpEF may be explained by CMD.  Two retrospective 
convenience cohort of patients with a positive non-invasive stress test and no 
angiographically significant CAD reported greater evidence of CMD (using 
pressure wire-derived CFR/IMR and angiographic indices of microvascular 
function [TIMI frame count, myocardial blush grade], respectively) in patients 
with HFpEF than those without HFpEF.229,230   
Non-invasive studies   
A prospective multicentre study (PROMIS-HFpEF) recruited 202 ambulatory 
HFpEF patients and assessed CMD using echocardiography-derived CFR of the left 
anterior descending (LAD) coronary artery.231  CMD was reported in 75% of 
patients, using a CFR threshold of <2.5.  A small cardiac magnetic resonance 
(CMR) study (n = 19) reported CMD in 69% of HFpEF patients (defined as 
myocardial perfusion reserve <2.5).232  Coronary microvascular function was 
assessed non-invasively in two further studies, using CMR phase-contrast cine 
imaging233 and Rb-82 positron emission tomography (PET),234 respectively.  Both 
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studies reported evidence of impaired coronary microvascular function in 
patients with HFpEF relative to hypertensive and healthy controls.   
Biopsy series   
A series of small human biopsy studies (n = 12 to 36) evaluated coronary 
microvascular endothelial function in patients with HFpEF.30,38,39,235,236  These 
studies reported evidence of coronary microvascular endothelial activation 
which was associated with increased cardiomyocyte resting tension.  
Cardiomyocyte tension was higher in patients with HFpEF than those with HFrEF, 
aortic stenosis, or control samples from cardiac transplant recipients.    
Autopsy series   
An autopsy series (n = 124) reported lower coronary microvascular density (MVD) 
in patients with a pre-mortem diagnosis of HFpEF relative to age- and sex-
matched controls who died of non-cardiac causes.208  The differences in 
microvascular density were independent of the severity of epicardial CAD and 
myocardial fibrosis was inversely associated with microvascular density, 
suggesting that microvascular rarefaction may contribute to chronic ischaemia 
and diastolic dysfunction in HFpEF.  
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First author, 
country, year 
of publication 
Study patient 
characteristics 
Definition 
of 
preserved 
LVEF 
Definition of HF Assessment of 
coronary 
microvascular 
function 
HFpEF 
patients 
(n) 
Findings Conclusion 
Invasive studies 
Dryer, USA, 
2018226 
Patients with 
previous HFpEF with 
previous HFH and 
clinical indication 
for coronary 
angiography with no 
significant 
angiographic CAD 
(≥50% stenosis of ≥1 
epicardial coronary 
artery) 
LVEF ≥50% HFH, BNP 
>100pg/mL or 
administration 
≥2 doses of IV 
diuretics 
Coronary pressure 
wire-derived CFR, 
(abnormal ≤2.0) and 
IMR (abnormal ≥23) 
30 HFpEF patients had 
lower CFR and higher 
IMR (cf. controls with no 
HF, a clinical indication 
of coronary angiography 
and no significant 
angiographic CAD) 
HFpEF patients had 
more abnormalities of 
coronary flow and 
resistance than 
asymptomatic control 
patients, suggesting 
that CMD may play a 
role in HFpEF 
Xu, China, 
2018229 
Patients with HFpEF 
with a positive 
stress test that 
underwent coronary 
angiography with no 
significant 
angiographic CAD 
(>50% stenosis or 
FFR ≤0.80 of ≥1 
epicardial coronary 
artery) 
LVEF >50% Signs and symptoms 
of HF and LVEDP >16 
mmHg 
Coronary pressure 
wire-derived CFR 
and IMR 
56 HFpEF patients had 
higher IMR (cf. controls 
with no HF, a positive 
stress test and no 
significant angiographic 
CAD) and IMR correlated 
with LVEDP. Patients 
aged >65 years had a 
higher IMR than those 
≤65 years. 
Older HFpEF patients 
have more 
microvascular 
dysfunction than 
younger HFpEF 
patients and controls 
without HF 
Sucato, Italy, 
2015230 
Patients with HFpEF 
with angina, a 
positive stress test 
and no significant 
angiographic CAD or 
history of IHD 
LVEF >50% Echo evidence of 
diastolic dysfunction 
and LVH 
Angiographic indices 
of coronary 
microvascular 
disease - TFC, MBG 
155 Patients with HFpEF had 
a longer TFC and lower 
MBG of the three major 
coronary arteries (cf. 
non-HFpEF patients) 
HFpEF patients with 
stable angina, a 
positive stress test 
and no significant 
epicardial CAD had 
angiographic evidence 
of greater CMD than 
patients without 
HFpEF 
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van Empel, 
Australia, 
2014228 
Outpatients with 
HFpEF 
LVEF >45% Exertional dyspnoea 
and E/e’ >15 or 
exercise PCWP >25 
mmHg 
Peak exercise PCWP, 
transcardiac oxygen 
gradient 
9 Despite a lower 
workload, peak exercise 
PCWP was markedly 
higher and transcardiac 
oxygen gradient was 
significantly lower in 
HFpEF patients (cf. 
hypertensive and 
healthy controls) 
The abnormal 
diastolic reserve 
observed during 
exertion in HFpEF 
patients may be 
explained by impaired 
myocardial oxygen 
delivery due to CMD 
Non-invasive studies 
Löffler, USA, 
2019232 
Patients with HFpEF 
and no clinical 
history of CAD or MI 
LVEF >45% NYHA ≥II or BNP 
≥150 pg/mL and 
≥grade 1 diastolic 
dysfunction on echo 
or elevated PWCP 
Global LV MFR 
(stress/rest 
myocardial blood 
flow) by CMR 
(abnormal <2.5) 
19 69% of patients with 
HFpEF had CMD 
HFpEF patients have a 
high prevalence of 
CMD 
Shah, USA, 2018 
(PROMIS-
HFpEF)231 
Patients with a 
confirmed diagnosis 
of chronic HFpEF 
without suspected 
IHD or non-
revascularised 
epicardial CAD 
LVEF ≥40% Signs and symptoms 
of HF (NYHA II-IV 
class) and ≥1 of: a. 
elevated NT-proBNP 
or BNP; b. HFH 
within 12 months 
and LAE or LVH on 
echo; c. PCWP >15 
mmHg at rest or >25 
mmHg with 
exercise; d. E/e’ 
≥15 at rest 
Echocardiography 
pulse wave Doppler-
derived CFR 
(abnormal <2.5) 
202 75% of patients with 
HFpEF have CMD. Low 
CFR correlated with 
lower RHI and TAPSE 
and right ventricular 
free wall strain, and 
higher uACR and NT-
proBNP. 
There is a high 
prevalence of CMD in 
HFpEF and it is 
associated with signs 
of systemic 
endothelial 
dysfunction and HF 
severity 
Srivaratharajah, 
Canada, 2016234 
Patients with HFpEF 
undergoing clinically 
indicated Rb-82 
cardiac PET with 
data available for 
MFR, no history of 
CAD and summed 
stress score <4 
LVEF ≥50% NYHA I-IV class HF 
symptoms and 
confirmed diagnosis 
of HFpEF from 
review of medical 
records 
Global and regional 
LV MFR (stress/rest 
myocardial blood 
flow) by Rb-82 PET 
78 HFpEF was associated 
with a significant 
reduction in global MFR 
(cf. hypertensive and 
healthy controls) 
HFpEF in the absence 
of known history of 
CAD is associated with 
reduced MFR 
independent of other 
risk factors 
Kato, USA, 
2016233 
Patients with HFpEF 
with no significant 
LVEF >50% Patients with HF 
syndrome and E/e’ 
CFR (coronary sinus 
flow during ATP 
25 76% of HFpEF patients 
had abnormal CFR 
CMD might be a 
pathophysiological 
94 
 
coronary stenosis on 
coronary CTA 
>15, or 8<E/e′<15 
and BNP >200 pg/dL 
infusion / coronary 
sinus flow at rest) by 
phase-contrast cine-
CMR (CFR <2.5 
abnormal) 
CFR was significantly 
lower in HFpEF patients 
(cf. hypertensive LVH 
and healthy controls) 
CFR independently and 
significantly correlated 
with serum BNP level 
factor for HFpEF and 
might be related to HF 
severity 
Biopsy studies 
Franssen, 
Netherlands, 
2016235 
Patients with HFpEF 
undergoing clinically 
indicated LV 
endomyocardial 
biopsy with no 
evidence of 
infiltrative or 
inflammatory 
cardiomyopathy and 
no significant 
angiographic CAD 
(HFpEF compared 
with HFrEF and AS 
samples) 
LVEF >50% HFH, LVEDVI <97 
ml/m2, LVEDP >16 
mmHg 
ICAM-1 and E-
selectin 
concentrations 
(microvascular 
inflammation and 
macrophage 
activation); H2O2 
concentration and 
NOX expression 
(oxidative stress); 
myocardial 
nitrite/nitrate 
concentrations (NO 
bioavailability), 
eNOS (NO synthase 
uncoupling) 
36 In the myocardium of 
HFpEF patients, E-
selectin and ICAM-1 
expression levels were 
upregulated and there 
was uncoupling of 
endothelial NO 
synthase, which was 
associated with reduced 
myocardial 
nitrite/nitrate 
concentration 
HFpEF is associated 
with coronary 
microvascular 
endothelial activation 
and oxidative stress. 
These lead to a 
reduction of NO-
dependent signalling 
from endothelial cells 
to cardiomyocytes, 
which can contribute 
to the high 
cardiomyocyte 
stiffness and 
hypertrophy observed 
in HFpEF. 
van Heerebeek, 
Netherlands, 
201239 
Patients with HFpEF 
undergoing clinically 
indicated LV 
endomyocardial 
biopsy with no 
evidence of 
infiltrative or 
inflammatory 
cardiomyopathy and 
no significant 
angiographic CAD 
(HFpEF compared 
LVEF >50% HFH, LVEDVI <97 
ml/m2, LVEDP >16 
mmHg 
Measures of 
cardiomyocyte 
resting tension and 
hypertrophy, and 
nitrosative/oxidative 
stress: Fpassive, 
cardiomyocyte 
diameter, 
myocardial PKG 
activity, cGMP 
concentration, 
nitrotyrosine 
expression 
36 Lower PKG activity in 
HFpEF than in aortic 
stenosis or HFrEF was 
associated with higher 
Fpassive and related to 
lower cGMP 
concentration and 
higher 
nitrosative/oxidative 
stress. Higher Fpassive in 
HFpEF was corrected by 
in vitro PKG 
administration. 
Low myocardial PKG 
activity in HFpEF was 
associated with raised 
cardiomyocyte Fpassive 
and was related to 
increased myocardial 
nitrosative/oxidative 
stress. The latter was 
probably induced by 
the high prevalence in 
HFpEF of metabolic 
comorbidities. 
Correction of 
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with HFrEF and AS 
samples) 
myocardial PKG 
activity could be a 
target for specific 
HFpEF treatment. 
van Heerebeek, 
Netherlands, 
2008236 
Patients with HFpEF 
undergoing clinically 
indicated LV 
endomyocardial 
biopsy with no 
evidence of 
infiltrative or 
inflammatory 
cardiomyopathy and 
no significant 
angiographic CAD 
(HFpEF with and 
without DM 
compared with 
HFrEF with and 
without DM) 
LVEF >50% HFH, LVEDVI <97 
ml/m2, LVEDP >16 
mmHg 
Measures of 
cardiomyocyte 
resting tension, 
hypertrophy and 
fibrosis: Fpassive, 
cardiomyocyte 
diameter, CVF 
28 Diabetic HF patients had 
increased diastolic LV 
stiffness irrespective of 
LVEF. DM increased the 
myocardial CVF only in 
patients with HFrEF, 
and increased Fpassive 
only in patients with 
HFpEF. 
Increased 
cardiomyocyte resting 
tension is an 
important mechanism 
responsible for the 
diastolic stiffness seen 
in patients with HFpEF 
with and without DM 
van Heerebeek, 
Netherlands, 
200638 
Patients with HFpEF 
undergoing clinically 
indicated LV 
endomyocardial 
biopsy with no 
evidence of 
infiltrative or 
inflammatory 
cardiomyopathy and 
no significant 
angiographic CAD 
(HFpEF compared 
with HFrEF samples) 
LVEF >45% HFH, LVEDP >16 
mmHg 
Measures of 
cardiomyocyte 
resting tension, 
hypertrophy and 
fibrosis: Fpassive, 
cardiomyocyte 
diameter, CVF, 
myofibrillar density 
22 Cardiomyocyte diameter 
was higher in DHF, but 
collagen volume 
fraction was equally 
elevated. Myofibrillar 
density was lower in 
SHF. Cardiomyocytes of 
DHF patients had higher 
Fpassive, but their total 
force was comparable. 
After administration of 
PKA to the 
cardiomyocytes, the 
drop in Fpassive was larger 
in DHF than in SHF. 
LV myocardium in SHF 
and DHF differ in both 
cellular architecture 
and function and 
suggests SHF and DHF 
to be associated with 
phenotypically distinct 
cardiomyocyte 
abnormalities. These 
differences support 
the clinical 
discrimination of HF 
patients into SHF and 
DHF groups. 
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Borbély, 
Netherlands, 
200530 
Patients with HFpEF 
undergoing clinically 
indicated LV 
endomyocardial 
biopsy with no 
evidence of 
infiltrative or 
inflammatory 
cardiomyopathy and 
no significant 
angiographic CAD 
(HFpEF compared 
with transplant 
recipient samples) 
LVEF >45% HFH, LVEDP >16 
mmHg, HF signs and 
symptoms 
Measures of 
cardiomyocyte 
resting tension, 
hypertrophy and 
fibrosis: Fpassive, 
cardiomyocyte 
diameter, CVF 
12 Patients with DHF had 
higher Fpassive and CVF 
than controls. 
Administration of PKA to 
DHF cardiomyocytes 
lowered Fpassive to 
control values. 
DHF patients have 
stiffer cardiomyocytes 
than controls. 
Correction of high 
resting tension with 
PKA suggests that 
reduced 
phosphorylation of 
sarcomeric proteins is 
involved in DHF. 
Autopsy series 
Mohammed, 
USA, 2015208 
 
Subjects with a pre-
mortem diagnosis of 
HFpEF who 
underwent autopsy 
LVEF ≥40% Previous HFH or 
outpatient diagnosis 
of HF (ICD-9 coding) 
Myocardial fibrosis, 
MVD 
124 Subjects with HFpEF 
had more LVH and LV 
fibrosis, and lower MVD 
(cf. healthy controls). 
LVH, fibrosis and MVD 
were similar in HFpEF 
patients with and 
without epicardial CAD. 
Adjusting for MVD 
attenuated the group 
differences in fibrosis. 
Microvascular 
endothelial 
inflammation is a 
plausible trigger for 
the microvascular 
rarefaction and 
myocardial fibrosis 
observed in HFpEF 
AS, aortic stenosis; BNP, B-type natriuretic peptide; CAD, coronary artery disease; CFR, coronary flow reserve; cGMP, cyclic guanosine monophosphate; CMD, coronary microvascular 
dysfunction; CMR, cardiac magnetic resonance; CVF, collagen volume fraction; CTA, computed tomography angiography; DHF, diastolic heart failure; DM, diabetes mellitus; eNOS, 
endothelial nitric oxide synthase; FFR, fractional flow reserve; Fpassive, cardiomyocyte resting tension; ICD, International Classification of Diseases; IHD, ischaemic heart disease; HF, 
heart failure; HFH, HF hospitalisation; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; ICAM-1, intercellular adhesion molecule-1; IMR, index 
of microcirculatory resistance; LAE, left atrial enlargement; LV, left ventricle; LVEDP, LV end-diastolic pressure; LVEDVI, indexed LV end-diastolic volume; LVEF, LV ejection 
fraction; LVH, LV hypertrophy; MBG, myocardial blush grade; MFR, myocardial flow reserve; MI, myocardial infarction; MVD, microvascular density; NO, nitric oxide; NT-proBNP, N-
terminal prohormone BNP; NOX, nicotinamide adenine dinucleotide phosphate oxidase; NYHA, New York Heart Association; PCWP, pulmonary capillary wedge pressure; PET, positron 
emission tomography; PKA, protein kinase A; PKG, protein kinase G; RHI, reactive hyperaemia index; SHF, systolic HF; TAPSE, tricuspid annular plane systolic excursion; TFC, 
Thrombolysis in myocardial infarction frame count; uACR, urinary albumin-to-creatinine ratio.   
Table 2-7: CMD in HFpEF cohorts.  
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2.4 Discussion 
2.4.1 CAD in HFpEF 
The prevalence of CAD in HFpEF has been studied primarily in retrospective 
observational and population-based studies with varied definitions of HF, 
preserved LVEF and CAD.  Consequently, this review found that the rates of CAD 
reported in HFpEF populations varied widely.  In studies which documented 
angiographic CAD, the prevalence of CAD was significantly higher than that 
reported in population-based studies or RCTs.  However, these were highly 
selected convenience cohorts that had undergone clinically indicated coronary 
angiography and, therefore, were subject to considerable referral bias.  One 
prospective single-centre study of 108 patients with HFpEF and HFmrEF found 
obstructive CAD (defined as >70% stenosis or ≥50% stenosis and fractional flow 
reserve ≤0.80) in 64% of patients.199  An autopsy series of patients with a 
premortem diagnosis of HF and LVEF ≥40% reported “anatomically significant” 
CAD (defined as ≥50% luminal stenosis) in 65% of patients.208  The relatively high 
burden of CAD reported in these studies is likely a reflection of the inclusion of 
patients with HFmrEF, with similar demographics to patients with HFrEF.   
The prevalence of previous MI reported in HFpEF cohorts was variably reported.   
Almost half of patients with HF complicating MI had preserved LVEF, and poorer 
outcomes were observed in these patients when compared to MI patients with 
preserved LVEF and no HF.  However, transient HF with preserved LV systolic 
function in the setting of acute MI does not meet standard definitions of HFpEF, 
and how it is related to the syndrome of HF is unclear.   
Clinical trials in HFpEF have tested standard CAD drug therapies, including beta-
blockers, angiotensin converting enzyme inhibitors and angiotensin receptor 
blockers, with neutral results.  In the PEP-CHF trial, the use of perindopril in 
HFpEF patients did not improve outcomes.  However, there was symptomatic 
improvement and mortality benefit in the subgroup of patients who had a 
previous MI.16  Observational data also suggests possible beneficial effects of 
statins in patients with HFpEF.237  Data on the impact of coronary 
revascularisation in patients with HFpEF and CAD are limited and conflicting.  
One small prospective study, including 20 patients with an LVEF >40%, found 
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that pulmonary oedema recurred in patients with CAD and acute hypertensive 
HF despite revascularisation.206  In the historical CASS registry (1975-1979), CABG 
in patients with HFpEF did not improve mortality.207  Conversely, two recent 
retrospective studies have reported survival benefit in patients with HFpEF and 
CAD that were revascularised.148,178  However, to date, no RCTs have evaluated 
the impact of coronary revascularisation in HFpEF patients.   
Better understanding of the prevalence of obstructive CAD is potentially of 
clinical importance.  For example, in studies of patients with angiographic CAD, 
the presence and extent of epicardial CAD appears to be associated with 
increased mortality.  However, all these data were obtained from registries, 
RCTs and retrospective studies with heterogeneous definitions of HFpEF and 
CAD, and none have addressed the importance of microvascular disease.   
2.4.2 CMD in HFpEF   
Recent studies suggest that CMD and may be implicated in the pathogenesis of 
HFpEF and a number of non-invasive and small invasive studies have reported 
evidence of impaired coronary microvascular function in patients with HFpEF.  
An autopsy series demonstrated microvascular rarefaction and more severe 
fibrosis in patients with HFpEF compared with controls (non-cardiac death, no 
pre-mortem HF diagnosis).208  The differences in microvascular density were 
independent of the severity of epicardial CAD and myocardial fibrosis was 
inversely associated with microvascular density, suggesting that CMD may 
contribute to chronic ischaemia, fibrosis and diastolic dysfunction in HFpEF.  
These studies suggest that CMD is prevalent in HFpEF, however, the potential 
mechanisms of CMD in a representative HFpEF cohort have yet to be explored.  
2.5 Conclusion 
CAD and CMD appear to be common in the HFpEF population.  However, the 
prevalence of CAD and CMD in patients with HFpEF have not been prospectively 
and systematically studied, so the true burden is unknown.  As epicardial CAD is 
a treatable comorbidity in HFpEF, its identification is of potential clinical 
significance.  Ischaemia due to CMD may also play an important role in the 
pathogenesis of HFpEF in some patients and may be amenable to treatment.  
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Chapter 3 Methods 
3.1 Introduction 
This chapter will outline the methods used in the study.  This was a prospective 
cross-sectional study of unselected patients admitted to hospital with HFpEF.  
Patients who consented to participation in the study underwent invasive 
coronary angiography with guidewire-based physiological testing, vasoreactivity 
(endothelial function) testing, and adenosine stress perfusion cardiac magnetic 
resonance (CMR) imaging (where possible).  These investigations were used to 
determine the burden of epicardial coronary artery disease (CAD), coronary 
microvascular dysfunction (CMD), and myocardial ischaemia, infarction and 
fibrosis in the study population.  The study was approved by the West of 
Scotland Research Ethics Committee (REC) in July 2016, reference 16/WS/0111.   
3.2 Study aims 
1.  To assess the prevalence of obstructive epicardial CAD in patients with 
 HFpEF. 
2. To determine the prevalence of endothelium-independent CMD in 
 patients with HFpEF. 
3. To determine the prevalence of coronary endothelial dysfunction in 
patients with HFpEF. 
4.  To determine the prevalence of previous MI in patients with HFpEF.   
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3.3 Study population 
I prospectively screened unselected patients hospitalised with suspected HF at 
three centres: the Queen Elizabeth University Hospital (Glasgow), Glasgow Royal 
Infirmary (Glasgow) and Royal Alexandra Hospital (Paisley).  The combined 
catchment population of these hospitals is over one million people.  Patients 
were recruited over a 19-month period (1st January 2017 to 1st August 2018).  
All patients admitted with symptoms and signs of HF were screened for potential 
inclusion.  A diagnosis of HFpEF was confirmed, according to the 2016 ESC 
guidelines for the diagnosis and treatment of acute and chronic HF 
recommendations, when all of the following conditions were met: 
1. Typical symptoms and signs of HF 
2. LVEF ≥50% on echocardiography 
3. Evidence of relevant structural heart disease and/or diastolic dysfunction on 
echocardiography 
4. Elevated natriuretic peptides2 
Relevant structural heart disease was defined as at least one of: left ventricular 
hypertrophy (LVH) (i.e. maximal diastolic LV septal or posterior wall thickness 
≥13 mm), or LA dilatation (indexed LA volume ≥34 ml/m2).  Evidence of diastolic 
dysfunction was defined as E/e’ >13 with a mean e’ <9 cm/s on tissue Doppler 
imaging, as per the ESC guidelines.2  Natriuretic peptides play a central role in 
the diagnosis of HFpEF.  Rule-out thresholds of less than 100 pg/mL for B-type 
natriuretic peptide (BNP) and less than 300 pg/mL for N-terminal prohormone 
BNP (NT-proBNP) have been shown to have excellent diagnostic accuracy to 
exclude acute HF.238  Patients with a confirmed diagnosis of HFpEF based on the 
above criteria were considered for participation in the study, provided no 
exclusion criteria are present. 
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3.3.1 Inclusion criteria 
• Written informed consent 
• Male or non-pregnant female patients ≥18 years of age 
• Hospitalisation with symptoms and signs of HF 
• LVEF ≥50% on echocardiography 
• Presence of relevant structural heart disease (i.e. LVH, LA dilatation) 
and/or elevated LV filling pressures 
• BNP ≥100 pg/mL or NT-proBNP ≥300 pg/mL  
3.3.2 Exclusion criteria 
• Patients unwilling to participate in the study 
• Patients who are unable to provide valid consent for the study 
• Patients unable to take part in the study due to geographical or social 
reasons 
• Patients with severe frailty (i.e. Clinical Frailty Scale [CFS] >6)239 in whom 
invasive coronary angiography was considered clinically inappropriate 
and/or to carry excessive risk 
• Patients with significant heart valve disease (greater than moderate valve 
disease) 
• Patients with a previous LVEF <40% 
• Patients with known or suspected hypertrophic/infiltrative 
cardiomyopathy or constrictive pericarditis 
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• Patients with non-CV comorbidity likely to cause death within 12 months 
(e.g. terminal cancer) 
• Patients with severe renal impairment (eGFR <30 ml/min/1.73m2) to 
allow safe administration of contrast agents in imaging studies 
• Patients <18 years of age 
• Female patients who are breastfeeding 
• Patients with a history of allergy to contrast, adenosine, acetylcholine 
(ACh), nitrates or excipients 
• Patients with a contraindication to adenosine (sick sinus syndrome, 
second or third-degree atrioventricular block, chronic obstructive lung 
disease with evidence of bronchospasm, or long QT syndrome) 
• Patients with a severe concurrent medical condition that would prevent 
participation in study procedures 
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3.4 Study protocol 
This was a prospective observational study of patients admitted to hospital with 
a primary diagnosis of HFpEF.  Patients were extensively characterised during 
their inpatient stay by collecting demographic, echocardiographic, biomarker 
and physiological data.  Following discharge from hospital, study participants 
underwent invasive coronary angiography with guidewire-based physiological 
testing and vasoreactivity testing.  Those with no contraindication also 
underwent adenosine stress perfusion CMR imaging.   
3.4.1 Identification of participants 
All potential study participants were identified by screening of patients at three 
hospital sites: the Queen Elizabeth University Hospital (Glasgow), Glasgow Royal 
Infirmary (Glasgow) and Royal Alexandra Hospital (Paisley).  I screened the case 
notes (electronic medical record and/or paper case notes) of patients admitted 
through the medical receiving units, cardiology wards and coronary care units at 
the three sites.  Potential participants were first approached by their usual 
clinical team and were asked if they would be interested in being considered for 
participation in the study.  I then approached patients who wished to learn more 
about the study.  The details of the study were explained, and written 
information was provided.  
3.4.2 Consent 
Two-stage consent process 
Consent was a two-stage process for 51 patients (48%); the remaining 55 patients 
underwent a single-stage consent process (discussed below).  The first stage 
involved consenting to a blood test for NT-proBNP to confirm the suspected 
diagnosis of HF.  A blood sample (150 µL) was analysed for NT-proBNP using a 
validated, point-of-care assay (Roche Cobas h232).  The details of the study 
were discussed, and patients were provided with a patient information sheet 
(Appendix I).  Patients were given at least one hour to decide whether they 
would like to participate in the first stage.  Patients were informed that if their 
NT-proBNP level was elevated, they would be invited to participate in the 
second stage of the study.  Those with an NT-proBNP <300 pg/mL were 
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excluded.  All patients underwent echocardiography prior to recruitment.  LVEF 
was measured using Simpson’s biplane method; if this was not possible due to a 
poor echocardiographic acoustic window, the LVEF was estimated by the 
sonographer and independently verified by an independent observer.   
The second stage of the study involved consenting to invasive coronary 
angiography with guidewire-based coronary physiological assessment and 
vasoreactivity testing, where possible.  Patients with no contraindication to 
magnetic resonance imaging (MRI) also consented to undergo adenosine stress 
perfusion CMR.  In addition, blood (10 mL) and urine samples were collected 
from each patient.  These samples were stored in the Queen Elizabeth University 
Hospital Clinical Research Biochemistry Laboratory in a locked and secure 
freezer.  Lastly, patients consented to being "flagged" with the Information and 
Services Division (ISD) of NHS Scotland for follow-up data on hospital readmission 
or death.  All patients were provided with verbal and written information 
(Appendix II) about the second stage of the study and were given a minimum of 
24 hours to decide whether they would like to proceed.  
Single-stage consent process 
During the course of the recruitment period, BNP was introduced throughout NHS 
Greater Glasgow and Clyde for routine clinical use.  Both BNP and NT-proBNP are 
recommended by international guidelines for the diagnosis of HF, and both have 
similar diagnostic performance.238  Therefore, patients that had plasma BNP 
measured as part of routine standard of care did not require to have NT-proBNP 
measured in addition.  Consequently, 55 patients (52%) underwent a single-stage 
consent process, similar to the second stage of the two-stage process (Appendix 
III).   
The consent forms for the two-stage and single-stage processes can be found in 
Appendices IV-VI.  At hospital discharge, a letter was sent to the general 
practitioner (GP) of each study participant providing information regarding the 
study and contact information for the research team (Appendix VII).  An 
overview of the consent process and patient flow through the study is shown in 
Figure 3-1.   
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BNP, B-type natriuretic peptide; CMR, cardiac magnetic resonance; GJNH, Golden Jubilee National 
Hospital; HF, heart failure; ISD, Information Services Division; LVEF, left ventricular ejection fraction; NT-
proBNP, N-terminal prohormone BNP; QEUH, Queen Elizabeth University Hospital; RAH, Royal Alexandra 
Hospital.   
Figure 3-1: Overview of patient flow through study.  
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3.4.3 Inpatient assessment 
During the inpatient stay, detailed demographic and clinical data were collected 
for each patient.  Data were obtained through history, clinical examination and 
review of medical records.  Laboratory results, echocardiographic data and 
radiology results were acquired from various hospital database systems.   
Data were recorded on a secure online Good Clinical Practice (GCP)-approved 
electronic case report form (eCRF) (Castor EDC, Amsterdam, Netherlands).  Each 
study participant was allocated a unique and anonymous study identification 
number.  Baseline data were recorded on the eCRF during the index 
hospitalisation under the following headings: demographics, HF symptoms, 
medical history (including HF and CAD history), medications (at hospital 
admission and discharge), in-hospital treatment, vital signs, cardiovascular (CV) 
examination findings, and electrocardiography (ECG), chest X-ray (CXR), 
haematology, biochemistry and echocardiography findings.    
3.4.4 Study procedures 
Following hospital discharge, participants attended for invasive coronary 
angiography with guidewire-based coronary physiology testing and coronary 
vasoreactivity testing (where possible).  In the absence of any contraindication 
to magnetic resonance imaging (MRI) (e.g. pacemaker, severe claustrophobia), 
participants also underwent adenosine stress perfusion CMR.   
Invasive coronary angiography 
Invasive coronary assessment was performed at a large regional cardiac centre 
(Golden Jubilee National Hospital, Clydebank) by three operators with extensive 
experience in invasive coronary physiology (Professor Keith Oldroyd, Dr Paul 
Rocchiccioli, Dr Mitchell Lindsay).  Coronary angiography was performed as per 
standard practice with cardiac catheter laboratory equipment 
(Innova/Centricity, GE Healthcare, Chicago, IL, USA).  LV end-diastolic pressure 
(LVEDP) was routinely measured in all patients.  The coronary anatomy of study 
participants was described based on the interpretation of the attending 
interventional cardiologist and quantitative coronary angiography (QCA) analysis 
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performed using computer-assisted angiographic analysis (QAngio XA 7.3, Medis, 
Leiden, Netherlands) (Figure 3-2).   
 
Figure 3-2: Example of QCA.   
Guidewire-based coronary physiology testing 
Comprehensive coronary guidewire assessment was performed on a single major 
epicardial coronary artery.  The left anterior descending (LAD) artery was 
preferred as the vessel of choice, however, if technical factors precluded 
guidewire-based assessment of this vessel (e.g. severe coronary stenosis, 
tortuosity), the left circumflex (LCx) or right coronary artery (RCA) was 
selected.  A pressure- and temperature-sensitive coronary guidewire 
(PressureWire Certus, Abbott Vascular, IL, USA) was used with the appropriate 
software and interface (RadiAnalyzer Xpress, Abbot Vascular, IL, USA) (Figure 3-
3).  The guidewire was calibrated outside the body and equalised in the guiding 
catheter before being advanced to the distal portion of the vessel of interest via 
the catheter.  A 6-French coronary guiding catheter was routinely used, and all 
patients received an initial intra-arterial bolus of 5000 units of unfractionated 
heparin with additional bolus(es) as required to maintain an activated clotting 
time of 250 to 300 seconds.   
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Figure 3-3: Example of output from RadiAnalyzer Xpress.  
Hyperaemia 
Adenosine was infused by intravenous infusion (140 µg/kg/min) for a minimum of 
two minutes to induce hyperaemia and the patient was assessed for a 
symptomatic and physiological response.  If there was an inadequate response, 
the dose was increased to 210 µg/kg/min to achieve maximal hyperaemia.  A 
200 µg bolus of intra-coronary glyceryl trinitrate (GTN) was administered prior to 
the adenosine infusion to minimise the potential effects of coronary vasospasm 
on the readings.  The mean aortic (Pa) and distal coronary (Pd) pressures were 
measured simultaneously under resting and hyperaemic conditions.    
Thermodilution 
Thermodilution was performed by intra-coronary injection of 3 mL of room 
temperature saline.  The mean resting transit time (Tmn) was taken as the 
average of three transit times measured during resting conditions.  Care was 
taken to obtain consistent and reproducible thermodilution curves.  During 
maximal hyperaemia, these measurements were repeated to give the mean 
hyperaemic Tmn (Figure 3-3).    
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Using the resting and hyperaemic pressures and transit times, the fractional flow 
reserve (FFR), coronary flow reserve (CFR), and index of microcirculatory 
resistance (IMR) were calculated (see Chapter 1: Figure 1-3).   
Fractional flow reserve 
FFR (abnormal ≤0.80) was used to assess for flow-limiting epicardial CAD and was 
calculated as the distal coronary to aortic pressure ratio (Pd/Pa) at maximal 
hyperaemia.97  All intermediate coronary lesions (50-70% stenosis) were assessed 
with FFR.  In patients with a significant epicardial stenosis (i.e. ≥70% stenosis or 
50-70% stenosis with an FFR ≤0.80), CFR and IMR were measured in another (non-
obstructed) coronary artery to facilitate accurate assessment of coronary 
microvascular function.   
Coronary flow reserve 
CFR (abnormal <2.0) represents the coronary vasodilator capacity (epicardial and 
microvascular) and was calculated as the resting Tmn divided by the hyperaemic 
Tmn.79,240  
Index of microcirculatory resistance 
The IMR (abnormal ≥25) reflects the minimum resistance offered by the coronary 
microvasculature (independent of epicardial CAD) and was calculated as the 
product of the mean distal coronary artery pressure and the Tmn measured 
simultaneously at maximal hyperaemia.127–129   
Coronary vasoreactivity testing 
In suitable patients, endothelium-dependent coronary vasomotor function was 
then assessed using sequential intra-coronary infusions of incremental doses of 
acetylcholine (ACh) via the guiding catheter.  Of note, coronary vasoreactivity 
testing was contraindicated in the majority of patients with obstructive 
epicardial CAD due to the risk of acute myocardial ischaemia from the 
combination of obstructive epicardial stenosis and coronary artery vasospasm.241  
Intra-coronary administration of ACh is an off-label use and is rarely used during 
standard NHS procedures.  For this study, ACh was provided in pre-prepared 
packs by the Pharmacy Production Unit of NHS Greater Glasgow and Clyde.  
These packs were issued by the Trials Pharmacy on a named-patient basis on the 
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day the patient attended for coronary angiography.  I prepared the reconstituted 
solutions in advance of the procedure for immediate administration in the 
catheter laboratory.   
The infused doses of ACh were 0.364 µg, 3.64 µg, and 36.4 µg over 2 minutes 
followed by coronary vasospasm provocation testing (100 µg ACh bolus for left 
coronary artery or 50 µg for the right coronary artery over 20 seconds).242  
Finally, non-endothelial vasodilator function was assessed by intra-coronary 
administration of 300 µg of GTN.   
At the end of each ACh infusion, following the ACh bolus and following GTN 
administration, coronary angiography and a 12-lead ECG were performed, and 
the patient was asked if they were experiencing any symptoms.  I performed 
QCA of the target coronary artery using computer-assisted angiographic analysis 
(QAngio XA 7.3, Medis, Leiden, Netherlands).  The coronary artery 
measurements were performed in the region where the greatest change had 
occurred during coronary reactivity testing.  End-diastolic cine frames that best 
demonstrated the segment were selected, and calibration of the cine images 
was performed.  Coronary artery diameter change (% from baseline) was 
measured in response to both ACh and GTN.243  Angiographic evidence of 
significant endothelial dysfunction was defined by ≥20% luminal constriction 
during the ACh infusions.244,245  A second trained observer (Dr Thomas Ford) 
performed QCA on a consecutive sample of 20% of cases, with high concordance 
for measurements of percentage lumen diameter change during ACh infusions 
(intra-class correlation coefficient for average measures 0.95 [95% confidence 
interval (CI) 0.82-0.99; p <0.001]).  Ischaemic ECG changes were defined as ≥1 
mm horizontal or down-sloping ST-segment depression or ST-segment elevation, 
or pathological T-wave inversion.   
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Adenosine perfusion cardiac magnetic resonance imaging 
CMR acquisition 
CMR was performed with gadolinium contrast, T1 mapping, and adenosine stress 
perfusion.  All scans were performed on a 3.0 Telsa magnetic resonance imaging 
(MRI) scanner (MAGNETOM Prisma, Siemens Healthcare, Erlangen, Germany) 
based at the Glasgow Clinical Research Imaging Facility, Queen Elizabeth 
University Hospital, Glasgow.  Patients were instructed to abstain from caffeine 
for 24 hours prior to the examination.  All patients underwent a standardised 
protocol summarised in Figure 3-4.   
 
bSSFP, balanced steady-state free precession; FLASH, fast low-angle shot; HLA, horizontal long-axis; LVOT, 
left ventricular outflow tract; MOLLI, modified Look-Locker inversion-recovery; PSIR, phase-sensitive 
inversion-recovery; SA, short-axis; VLA, vertical long-axis. 
Figure 3-4: Standardised CMR protocol.   
I was present throughout all the MRI scans to provide medical cover.  Prior to the 
examination, each patient had a peripheral venous cannula sited in each arm for 
administration of the gadolinium contrast and adenosine during the scan.  A 
blood pressure cuff, ECG electrodes and a phased-array surface body coil 
(Siemens Body 60, Erlangen, Germany) were applied.  I prepared an infusion of 
180 mg adenosine diluted with 0.9% sodium chloride to a volume of 180 mL (1 
mg/mL).  All patients had ECG monitoring throughout the scan.   
The CMR protocol included cine (balanced steady-state free precession [bSSFP]) 
imaging, rest and stress perfusion imaging, late gadolinium enhancement (LGE) 
phase-sensitive inversion-recovery (PSIR) acquisitions, and T1 mapping (pre- and 
post-contrast) sequences.   
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Balanced steady-state free precession cine imaging 
bSSFP cine imaging (using multi-slice single-shot breath-hold true fast imaging) 
was used for functional assessment and a short-axis (SA) cine stack of the LV 
from base to apex was acquired, consisting of 7 mm slices with a 3 mm interslice 
gap.  Cine images were also obtained in the horizontal long-axis (HLA), vertical 
long-axis (VLA) and left ventricular outflow tract (LVOT) planes (Figure 3-5).  
 
Figure 3-5: Example of HLA, VLA, LVOT and SA bSSFP cine imaging.  
Rest and stress perfusion imaging 
Perfusion imaging was performed at rest and under stress conditions.  
Intravenous infusion of adenosine at 140 to 210 µg/kg/min was administered to 
achieve an adequate haemodynamic stress response with the acquisition of three 
matched SA stress and rest perfusion images.  Hyperaemia was confirmed by a 
haemodynamic response (i.e. systolic blood pressure drop >10 mmHg, heart rate 
increase of >10 beats per minute) and/or the onset of typical symptoms (i.e. 
dyspnoea, chest tightness, flushing) in response to adenosine infusion.  A total 
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dose of 0.15 mmol/kg gadolinium-based contrast (Gadovist) was administered 
(0.05 mmol/kg bolus for first-pass stress perfusion, 0.05 mmol/kg bolus for first-
pass rest perfusion and 0.05 mmol/kg top-up bolus for LGE imaging) (Figure 3-6).   
 
Figure 3-6: Example of inducible anterior/anteroseptal perfusion defect.   
Late gadolinium enhancement imaging 
Late gadolinium enhancement (LGE) images were acquired 10-15 minutes after 
intravenous injection of the third 0.05 mmol/kg bolus of Gadovist.  A segmented 
PSIR turbo fast low-angle shot (FLASH) sequence was used to acquire multiple 
short and long axis images covering the entire LV (Figure 3-7).246   
 
Figure 3-7: Example of subendocardial inferior MI on LGE imaging.   
Stress Rest
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T1 mapping (pre- and post-contrast) 
A modified Look-Locker inversion-recovery (MOLLI) sequence was used for T1 
mapping and performed in three matched SA slices (basal, mid and apical) in 
mid-diastole prior to (for native T1) and 20 minutes after contrast (for 
quantification of extracellular volume [ECV]) (Figure 3-8).   
 
Figure 3-8: Example of pre- and post-contrast T1 mapping.   
CMR image analysis 
The CMR images were independently analysed on dedicated workstations by two 
observers with European Association of Cardiovascular Imaging accreditation in 
CMR analysis (myself [Level 2] and Professor Colin Berry [Level 3]).   
Ventricular structure and function 
Post-processing was performed using dedicated software (QMass 8.1, Medis, 
Leiden, Netherlands).  End-systole was chosen as the point where the total 
ventricular blood pool was smallest and end-diastole as the point where it was 
largest at the mid-ventricular level.  The most basal LV slice at both end-
diastole and end-systole was defined as that in which the blood pool was 
surrounded by ≥50% of ventricular myocardium.  The endocardial and epicardial 
borders were outlined using computer-assisted planimetry to obtain LV mass, 
end-diastolic and end-systolic volumes, and LVEF.  The papillary muscles were 
included as part of the myocardial blood pool.  The RV endocardial borders were 
outlined at end-diastole and end-systole to calculate the RV volumes and 
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ejection fraction.  The normal reference ranges used for cardiac structure and 
function were derived from the UK Biobank population cohort.247   
Perfusion imaging and myocardial-perfusion reserve index 
Baseline stress and rest perfusion images were analysed using QMass 8.1 (Medis, 
Leiden, Netherlands).  The endocardial and epicardial contours were manually 
outlined to the myocardial endocardial and epicardial borders with care being 
taken to avoid encroaching on the LV cavity.  These contours were used to 
obtain the intensity over time curves at rest and stress using the American Heart 
Association (AHA) coronary arterial 17-segment model248 (Figure 3-9); the apical 
segment was not calculated as the perfusion images were only acquired in SA.  A 
blood-pool region of interest was also defined.  The myocardial and blood-pool 
curves were then inspected, and the contours were re-adjusted if required to 
optimise the segmental time intensity curve slopes.  The slope of the first-pass 
contrast enhancement for each of the myocardial segment was divided by the LV 
blood-pool slope to correct for changes in the input function caused by the 
haemodynamic effects of adenosine. The ratio of the myocardial perfusion index 
during stress to rest was defined as the myocardial-perfusion reserve index 
(MPRI).249,250  Inducible ischaemia was defined as a global MPRI of <1.4; this 
threshold was previously reported to accurately detect obstructive epicardial 
CAD and CMD in patients with angina.251   
 
Figure 3-9: Example of myocardial and blood-pool perfusion curves. 
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LGE imaging 
The presence of MI was established based on LGE imaging.  MI was considered 
present if subendocardial or transmural LGE was confirmed in the distribution of 
a coronary artery territory on both short- and long-axis acquisitions.   
T1 mapping and ECV 
Gadolinium-based contrast agents distribute throughout the extracellular space 
and shorten T1 relaxation times of myocardium proportional to the local 
concentration of gadolinium.252  Therefore, areas of myocardial fibrosis have 
shorter T1 relaxation times.  The ECV can be estimated from myocardial and 
blood T1 before and after administration of contrast and the patient’s 
haematocrit (cellular fraction of blood) according to Figure 3-10.253 
 
ECV, extracellular volume; T1blood, T1 of blood; T1myo, T1 of myocardium.   
Figure 3-10: ECV formula.   
Native T1 and ECV maps were generated based on inline-generated, motion-
corrected raw images using QMap 2.2.24 (Medis, Leiden, Netherlands) for 
quantification of global native T1 and ECV.  LV contours were delineated with 
computer-assisted planimetry on the raw pre- and post-contrast T1 images.  The 
contours were then copied onto the colour-encoded spatially co-registered maps 
with care being taken to avoid partial volume effects.254  The patient’s 
haematocrit (obtained at time of the CMR scan) was then entered into the QMap 
software to produce an ECV map (Figure 3-11).  Myocardial segments (AHA 
model) with focal ischaemic LGE were excluded from native T1 and ECV analysis.  
Several studies have demonstrated that normal participants scanned at 3.0 Tesla 
can have an ECV of up to 30%.255  Therefore, in this study an ECV of >30% was 
considered abnormal.   
ECV = (1 – haematocrit)
1 1
post-contrast T1myo native T1myo
1 1
post-contrast T1blood native T1blood
-
-
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Figure 3-11: Example of ECV map.  
3.4.5 Follow-up 
All consenting patients were followed-up passively using record linkage through 
ISD of NHS Scotland.  All participants were followed up for a minimum of 12 
months.  The dates of hospital admissions, reason for hospital admissions, date 
and cause of death were extracted.  The cause of hospital admission and death 
were determined using the primary discharge diagnosis and cause of death, 
respectively.  Electronic records for each participant were also reviewed to 
validate hospital discharge diagnoses and ensure that the follow-up data was 
complete and accurate.   
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3.5 Outcome measures 
1. Obstructive epicardial CAD was defined as:  
• ≥70% stenosis of a major epicardial coronary artery (≥50% stenosis if the 
left main coronary artery) 
• 50-70% stenosis with an FFR ≤0.80 
2. Endothelium-independent CMD was defined as at least one of: 
• CFR <2.0 
• IMR ≥25  
3. Coronary endothelial dysfunction was defined as an abnormal response to 
 intra-coronary ACh: 
• Epicardial endothelial dysfunction – epicardial coronary vasospasm (>90% 
luminal constriction) in association with ischaemic ECG changes in 
response to intra-coronary ACh infusion or bolus146 
• Microvascular endothelial dysfunction (endothelium-dependent CMD) – 20-
90% luminal constriction and/or ischaemic ECG changes in response to 
intra-coronary ACh infusion135,145 
4. CMR-proven MI was defined as subendocardial or transmural LGE in the 
 distribution of a coronary artery territory 
3.6 Sample size calculation 
The prior literature suggests that the prevalence of CAD in patients with HFpEF 
is around 40-50% (see Chapter 2).  To detect a prevalence of 50%, with an 8% 
margin of error at a 95% confidence interval, I estimated that 150 patients would 
require to be studied, using the following formula for an unlimited population: 
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n = z2*p*(1-p)/ε2 
where:  
• n is the population size 
• z is the critical value of the normal distribution (z = 1.96 for a 95% CI) 
• p is the estimated population proportion (p = 0.5 for an estimated 
population proportion of 50%) 
• ε is the margin of error (ε = 0.08 for a margin of error of 8%) 
so: 
n = 1.962*0.5*(1-0.5)/0.082 
n = 150 
The sample size required to detect an estimated prevalence of 50% is larger than 
that required to detect any other estimated proportion, so this sample size was 
predicted to be more than sufficient to detect the prevalence of the other study 
endpoints (i.e. prevalence of CMD, coronary endothelial dysfunction and MI) with 
the same or narrower margin of error.   
3.7 Data handling and statistical analysis 
3.7.1 Data handling 
All participant data were recorded on a secure online GCP-approved data 
management system (Castor EDC, Amsterdam, Netherlands).  I manually entered 
all data manually into the eCRF.  No patient identifying material was entered 
into the electronic database; patients were anonymised and identified by their 
unique study identification number.  All data were checked manually and also 
underwent pre-specified electronic data validation checks.  All queries were 
investigated, and data appropriately amended in the eCRF.  This robust system 
ensured quality control of the data.     
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3.7.2 Statistical analysis 
Using the above definitions, I calculated the prevalence and 95% CI of 
obstructive epicardial CAD, CMD (endothelium-independent), coronary 
endothelial dysfunction and CMR-proven MI in the study participants.  We then 
divided the participants into those with and those without obstructive epicardial 
CAD, CMD, coronary endothelial dysfunction and CMR-proven MI, and compared 
clinical characteristics, laboratory data, and echocardiographic and CMR 
parameters.   
Normally distributed continuous variables are presented as means with standard 
deviation (SD).  Non-parametric continuous variables were presented as median 
with interquartile range (IQR).  Comparison of categorical variables was 
performed using Chi-square or Fisher’s exact tests.  Differences in continuous 
variables between groups were assessed with the t-test or Wilcoxon rank sum 
test.  Pearson tests were used for correlation analyses, where the Pearson 
correlation coefficient (r) represents the correlation between two continuous 
variables, the point-biserial correlation coefficient (rpb) represents the 
correlation between a continuous and categorical variable, and the phi 
correlation coefficient (ϕ) represents the correlation between two categorical 
variables.  A random effects model was used to compute the intra-class 
correlation coefficient for the reliability of QCA assessment of percentage lumen 
diameter change during ACh vasoreactivity testing measured by two independent 
observers on a consecutive sample of 20% of cases.  Time-to-event analysis for 
hospitalisations and mortality were analysed using the Kaplan-Meier method.  All 
p-values were two-sided, and a p-value of ≥0.05 indicated the absence of a 
statistically significant effect.  All statistical analyses were performed using 
Stata v.14.2 (StataCorp, College Station, TX, USA).    
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Chapter 4 Recruitment and baseline 
characteristics 
In this chapter I will describe the screening and recruitment process of the 
study.  I will also describe the baseline characteristics of the cohort recruited, 
including medical history, physical examination findings, laboratory findings, and 
results of baseline investigations including echocardiography.  I will then 
compare the recruited cohort to those in other studies and reflect on the 
generalisability of the study population.   
4.1 Recruitment 
4.1.1 Screening 
Patients admitted to the medical receiving units, cardiology wards and coronary 
care units (CCUs) at the Queen Elizabeth University Hospital (QEUH, Glasgow), 
Glasgow Royal Infirmary (GRI, Glasgow) and Royal Alexandra Hospital (RAH, 
Paisley) were screened for eligibility for inclusion.  I screened case notes 
(electronic and/or paper) looking for patients with possible symptoms and signs 
of HF.  I also screened inpatient echocardiography referrals and further 
investigated requests for suspected HF.   
I prospectively screened admissions over a 19-month period between 1st January 
2017 and 1st August 2018.  I routinely screened all patients admitted to medicine 
and cardiology with suspected HF on weekdays over the recruitment period.  I 
screened near-consecutive admissions, therefore, I was able to recruit an 
unselected cohort of ‘real world’ patients hospitalised with HFpEF.  Potential 
participants who had not had BNP checked as part of standard clinical care were 
recruited in a two-stage consent process.  Firstly, they consented to testing for 
NT-proBNP to confirm the suspected diagnosis of HF.  Those with an elevated 
NT-proBNP were there then invited to participate in the full study, including 
invasive coronary angiography, guidewire-based coronary physiology testing, 
coronary vasoreactivity testing, CMR imaging, and passive follow-up via record 
linkage with Information Services Division (ISD) of NHS Scotland.  Potentially 
eligible patients that had an elevated BNP as part of their standard clinical care 
were recruited via a single-stage process to the full study.   
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4.1.2 Screening log 
I screened a total of 2285 patients admitted with suspected HF during the 
recruitment period.  During further screening through history, examination, 
natriuretic peptides and echocardiography, 1657 patients were excluded as they 
did not meet the inclusion criteria for a diagnosis of HFpEF.  The primary reasons 
for exclusion were: a left ventricular (LV) ejection fraction (LVEF) <50% (n = 
1116); significant (greater than moderate) valvular heart disease (n = 317); 
normal natriuretic peptides (n = 83); cor pulmonale (n = 43); the absence of 
structural heart disease or diastolic dysfunction on echocardiography (n = 28); 
infiltrative or hypertrophic cardiomyopathy (n = 27); pericardial pathology (n = 
25); and congenital heart disease (n= 18) (Figure 4-1).   
 
HFpEF, heart failure with preserved ejection fraction; LVEF, left ventricular ejection fraction.   
Figure 4-1: Diagnoses in unselected patients admitted with suspected HF.  
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27%
14%
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LVEF <50% (n = 1116) HFpEF (n = 628)
Valve disease (n = 317) Normal natriuretic peptides (n = 83)
Cor pulmonale (n = 43) No strucutral heart disease (n = 28)
Cardiomyopathy (n = 27) Pericardial disease (n = 25)
Congenital heart disease (n = 18)
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A total of 628 patients were confirmed to have a diagnosis of HFpEF.  Of these, 
522 were excluded.  The most common reasons for exclusion were: patients with 
severe frailty (i.e. Clinical Frailty Scale [CFS] >6)239 in whom invasive coronary 
angiography was considered clinically inappropriate and to carry excessive risk 
(n = 196); renal impairment (i.e. estimated glomerular filtration rate [eGFR] <30 
ml/min/1.73m2) to allow the safe administration of contrast agents during the 
study investigations (n = 104); and cognitive impairment (n = 88) (Figure 4-2).  A 
further 80 patients were excluded for miscellaneous reasons, including patients 
unable to participate due to geographical reasons and those participating in 
another study.    
 
Figure 4-2: Reasons for exclusion of HFpEF patients.   
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Table 4-1 details selected baseline characteristics of the 522 HFpEF patients who 
were excluded from the study.  The mean age (standard deviation [SD]) of 
excluded HFpEF patients was 81 (10) years and 66% were female.  Cardiovascular 
(CV) comorbidities were common, natriuretic peptides were significantly 
elevated and echocardiographic signs of elevated LV filling pressures were highly 
prevalent in the excluded HFpEF group.   
 
Excluded HFpEF patients  
(n = 522) 
Demographics  
Age (years) 81 [10] 
Female sex 345 (66) 
Hospitalisation details  
Length of stay (days) 10 [5-18] 
Past medical history  
Any CAD 209 (40) 
Hypertension 407 (78) 
AF 318 (61) 
Biochemistry  
BNP (pg/mL) 712 [377-1127] 
NT-proBNP (pg/mL) 2714 [817-4341] 
Echocardiography  
LVH 355 (68) 
LA dilatation 449 (86) 
Diastolic dysfunction 350 (67) 
Values are mean [standard deviation], median [Q1-Q3], or n (%). AF, atrial fibrillation; BNP, B-type 
natriuretic peptide; CAD, coronary artery disease; HFpEF, heart failure with preserved ejection fraction; 
LA, left atrial; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal prohormone BNP.  
Table 4-1: Selected baseline characteristics of excluded HFpEF patients.   
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A total of 106 HFpEF patients met the inclusion criteria and agreed to 
participate in the study.  Twenty-three participants did not undergo the study 
investigations after recruitment.  This was predominantly due to a decline in 
participants’ health and/or functional status making proceeding with the 
investigations inappropriate.  A total of 83 participants underwent invasive 
coronary angiography or CMR.  Seventy-five participants (71%) underwent 
invasive coronary angiography.  Sixty-two participants (58%) had guidewire-based 
coronary physiology testing and 41 (39%) underwent vasoreactivity testing.  
Fifty-two participants (49%) underwent CMR and 44 (42%) had both invasive 
coronary angiography and CMR (Figure 4-3).   
 
BNP, B-type natriuretic peptide; CMR, cardiac magnetic resonance; HF, heart failure; HFpEF, HF with 
preserved ejection fraction; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal prohormone 
BNP. 
Figure 4-3: Screening and recruitment.   
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Predicted life expectancy           
<12 months: n = 32
Refusal to consent: n = 22
Other: n = 80 Withdrawn from study
n = 23
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4.2 Baseline characteristics 
A total of 106 patients agreed to participate in the study.  Of these, 83 
underwent study investigations.  All 106 patients agreed to long-term follow-up 
via electronic medical record linkage.   
4.2.1 Demographics 
The baseline demographics of the recruited patients are shown in Table 4-2.  
The mean age was 72 (9) years, with a broad overall age range of 45 to 87 years.  
Half of the entire cohort were female; 97% were Caucasian and the remaining 3% 
were South Asian.   
The mean body mass index (BMI) was 33 (8) kg/m2; 84% of participants were 
overweight (i.e. BMI ≥25 kg/m2) and 62% were obese (i.e. BMI ≥30 kg/m2).  
Sixteen percent of patients were current smokers and 44% were ex-smokers; 12% 
had current or previous excessive alcohol intake and 41% consumed alcohol 
within recommended limits.  Those recruited to the study that did not undertake 
the study investigations had a longer hospital stay (median 12 vs. 7 days; p 
<0.01) and were more likely to have a smoking history (83% vs. 53%; p = 0.011) 
than those that underwent the study investigations.   
Sixty-one patients (58%) were recruited from the QEUH, 37 (35%) from GRI and 
eight (8%) from the RAH.  The median duration of hospitalisation was eight (6-
13) days.  Most patients were referred to hospital by their general practitioner 
(67%), 28% presented to the emergency department, and 5% were admitted from 
an outpatient clinic.  Ninety-five percent of the cohort recruited were managed 
on the cardiology wards; the remaining 5% were treated on general medical 
wards.   
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All patients 
 
(n = 106) 
Had study 
investigations 
(n = 83) 
Did not have study 
investigations 
(n = 23) 
p-value 
Demographics 
Age (years) 72 [9] 72 [9] 71 [10] 0.69 
Female sex 53 (50) 40 (48) 13 (57) 0.48 
Ethnicity 
Caucasian 103 (97) 81 (98) 22 (96) 0.62 
South Asian 3 (3) 2 (2) 1 (4) 
 
Height (m) 1.65 [0.10] 1.66 [0.10] 1.65 [0.10] 0.67 
Weight (kg) 91 [25] 90 [24] 93 [28] 0.64 
BMI (kg/m2) 33 [8] 33 [7] 34 [10] 0.39 
BSA (m2) 1.96 [0.27] 1.96 [0.27] 1.97 [0.27] 0.88 
Obesity 53 (50) 39 (47) 14 (61) 0.24 
Clinical Frailty Score 
1 = Very fit 2 (2) 2 (2) 0 (0) 0.96 
2 = Well 23 (22) 19 (23) 4 (17) 
 
3 = Managing well 40 (38) 31 (37) 9 (39) 
 
4 = Vulnerable 20 (19) 15 (18) 5 (22) 
 
5 = Mildly frail 17 (16) 13 (16) 4 (17) 
 
6 = Moderately frail 4 (4) 3 (4) 1 (4) 
 
Smoking history 63 (59) 44 (53) 19 (83) 0.011 
Current smoker 17 (27) 13 (29) 4 (21) 0.81 
Ex-smoker (≤12 months) 3 (5) 2 (4) 1 (5) 
 
Ex-smoker (>12 months) 44 (69) 30 (67) 14 (74) 
 
Alcohol intake 56 (53) 42 (51) 14 (61) 0.38 
Within recommended 
limits 
43 (77) 35 (83) 8 (57) 0.081 
Current excess 6 (11) 4 (10) 2 (14) 
 
Previous excess 7 (12) 3 (7) 4 (29) 
 
Hospitalisation details 
Length of stay (days) 8 [6-13] 7 [5-11] 12 [7-18] <0.01 
Recruitment site 
QEUH 61 (58) 50 (60) 11 (48) 0.074 
GRI 37 (35) 25 (30) 12 (52) 
 
RAH 8 (8) 8 (10) 0 (0) 
 
Referral source 
GP referral 71 (67) 57 (69) 14 (61) 0.62 
ED via ambulance 18 (17) 12 (14) 6 (26) 
 
ED self-presentation 12 (11) 10 (12) 2 (9) 
 
OPC 5 (5) 4 (5) 1 (4) 
 
Admission ward 
Cardiology ward 82 (77) 61 (73) 21 (91) 0.071 
CCU 19 (18) 17 (20) 2 (9) 0.19 
General medical ward 3 (3) 3 (4) 0 (0) 0.35 
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Medical receiving ward 2 (2) 2 (2) 0 (0) 0.45 
Values are mean [standard deviation], median [Q1-Q3], or n (%). BMI, body mass index; BSA, body surface 
area; CCU, coronary care unit; ED, emergency department; GP, general practitioner; GRI, Glasgow Royal 
Infirmary; OPC, outpatient clinic; QEUH, Queen Elizabeth University Hospital; RAH, Royal Alexandra 
Hospital.   
Table 4-2: Demographics of study participants.  
4.2.2 Clinical features 
Typical symptoms and signs of HF were very common in the HFpEF cohort (Table 
4-3).  The most frequently reported symptoms were fatigue (95%) and ankle 
swelling (92%); 68% experienced orthopnoea and 45% had paroxysmal nocturnal 
dyspnoea (PND).  Most patients were in New York Heart Association (NYHA) 
functional class III at presentation (56%), with 42% reporting NYHA IV symptoms 
and only 2% in NYHA class II.  No patients were in NYHA class I.   
On clinical examination, the most common clinical sign was peripheral oedema 
(91%).  Sixty-two percent of patients had mild to moderate oedema (to below 
the knee) and 28% had significant oedema to the thigh, sacrum and/or abdomen.  
Jugular venous distention (JVD) was detected in 72%.  Pulmonary crepitations 
were detected in 77% of patients, and 42% had evidence of pleural effusion(s) 
(usually bilateral) on clinical examination.   
 
All patients 
 
(n = 106) 
Had study 
investigations 
(n = 83) 
Did not have study 
investigations 
(n = 23) 
p-value 
HF symptoms 
NYHA functional class 
II 2 (2) 2 (2) 0 (0) 0.28 
III 59 (56) 43 (52) 16 (70) 
 
IV 45 (42) 38 (46) 7 (30) 
 
Orthopnoea 72 (68) 56 (67) 16 (70) 0.85 
PND 48 (45) 39 (47) 9 (39) 0.50 
Ankle swelling 98 (92) 76 (92) 22 (96) 0.51 
Wheeze 18 (17) 13 (16) 5 (22) 0.49 
Palpitations 12 (11) 11 (13) 1 (4) 0.23 
Fatigue 101 (95) 79 (95) 22 (96) 0.92 
Admission vital signs 
HR (bpm) 83 [25] 83 [26] 80 [24] 0.62 
SBP (mmHg) 149 [29] 151 [29] 144 [29] 0.31 
DBP (mmHg) 78 [19] 80 [19] 72 [16] 0.09 
MAP (mmHg) 102 [18] 103 [18] 96 [17] 0.087 
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HF signs 
JVD 76 (72) 58 (70) 18 (78) 0.43 
Murmur 27 (25) 23 (28) 4 (17) 0.31 
Crepitations 82 (77) 64 (77) 18 (78) 0.91 
Pleural effusion(s) 45 (42) 35 (42) 10 (43) 0.91 
Right 4 (9) 4 (11) 0 (0) 0.36 
Left 2 (4) 1 (3) 1 (10) 
 
Bilateral 39 (87) 30 (86) 9 (90) 
 
Oedema 96 (91) 74 (89) 22 (96) 0.35 
Ankle 15 (16) 12 (16) 3 (14) 0.40 
Knee 51 (53) 39 (53) 12 (55) 
 
Thigh 12 (12) 8 (11) 4 (18) 
 
Sacrum 9 (9) 9 (12) 0 (0) 
 
Abdomen 9 (9) 6 (8) 3 (14) 
 
Ascites 6 (6) 4 (5) 2 (9) 0.48 
Values are mean [standard deviation] or n (%). DBP, diastolic blood pressure; HF, heart failure; HR, heart 
rate; JVD, jugular venous distention; MAP, mean arterial pressure; NYHA, New York Heart Association; PND, 
paroxysmal nocturnal dyspnoea; SBP; systolic blood pressure.  
Table 4-3: Clinical features of study participants.  
4.2.3 Past medical history 
HF history 
The majority of the study participants (65%) presented with de novo HF (Table 4-
4).  Of those with a previous diagnosis of HF, 59% had been diagnosed in the 
preceding two years and 65% were under the care of a cardiologist.  Fourteen 
patients had been admitted to hospital with HF in the preceding six months.   
 
All patients 
 
(n = 106) 
Had study 
investigations 
(n = 83) 
Did not have study 
investigations 
(n = 23) 
p-value 
History of HF 
Previous HF diagnosis 37 (35) 30 (36) 7 (30) 0.61 
HF diagnosis >2 years 15 (14) 14 (17) 1 (4) 0.13 
Previous HFH 24 (23) 18 (22) 6 (26) 0.66 
HFH <6 months 14 (13) 9 (11) 5 (22) 0.17 
Values are n (%). HF, heart failure; HFH, HF hospitalisation.   
Table 4-4: HF history of study participants.  
CAD history 
Overall, 36% of the cohort had a previous history of CAD (Table 4-5).  A history of 
CAD was defined as at least one of: a clinical history of CAD (angiographically-
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documented CAD or angina requiring treatment); previous myocardial infarction 
(MI); or coronary revascularisation.  Twenty-four patients (23%) had a previous 
history of MI.  Nineteen patients were treated for angina for a median duration 
of 7 (4-15) years; nine patients had current symptoms of angina.  Thirty-three 
patients had previous undergone coronary angiography; 17 had previously had 
percutaneous coronary intervention (PCI) and five had previous coronary artery 
bypass grafting (CABG).   
 
All patients 
 
(n = 106) 
Had study 
investigations 
(n = 83) 
Did not have study 
investigations 
(n = 23) 
p-value 
History of CAD 
Any CAD  38 (36) 28 (34) 10 (43) 0.39 
MI 24 (23) 18 (22) 6 (26) 0.65 
Angina 19 (18) 13 (16) 6 (26) 0.25 
Current angina 9 (8) 6 (7) 3 (13) 0.37 
Previous coronary 
angiography 
33 (31) 26 (31) 7 (30) 0.93 
Revascularisation 20 (19) 14 (17) 6 (26) 0.32 
PCI 17 (16) 12 (14) 5 (22) 0.40 
CABG 5 (5) 4 (5) 1 (4) 0.93 
Values are n (%). CABG, coronary artery bypass grafting; CAD, coronary artery disease; MI, myocardial 
infarction; PCI, percutaneous coronary intervention.   
Table 4-5: CAD history of study participants.  
Other comorbidities 
Table 4-6 demonstrates the burden of comorbid conditions in the cohort.  The 
typical comorbidities associated with HFpEF were highly prevalent, with 
hypertension and atrial fibrillation (AF) being the most common (75% and 62%, 
respectively).  One patient with AF had a CHA2DS2VASc score of <2; the majority 
had a score of 3 to 5.   
Diabetes was present in 51% of the cohort; the majority of whom were managed 
with oral hypoglycaemic agents.  Despite excluding patients with an eGFR <30 
mL/min/1.73m2, 29% of patients had chronic kidney disease (CKD, i.e. baseline 
eGFR 30-60 mL/min/1.73m2).  Other non-CV comorbidities commonly seen were 
obstructive airways disease (28%), anaemia (25%), and osteoarthritis (21%).  
There were no significant differences in the prevalence of comorbidities 
between those who did and did not undergo the study investigations.   
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 All patients 
 
(n = 106) 
Had study 
investigations 
(n = 83) 
Did not have study 
investigations 
(n = 23) 
p-value 
CV comorbidities 
Hypertension 80 (75) 61 (73) 19 (83) 0.37 
Dyslipidaemia 13 (12) 8 (10) 5 (22) 0.12 
CVD 17 (16) 15 (18) 2 (9) 0.28 
PAD 11 (10) 9 (11) 2 (9) 0.77 
AF 66 (62) 55 (66) 11 (48) 0.11 
Permanent 31 (29) 27 (33) 4 (17) 0.16 
Persistent 17 (16) 15 (18) 2 (9) 0.28 
Paroxysmal 11 (10) 6 (7) 5 (22) 0.043 
New diagnosis 8 (8) 8 (10) 0 (0) 0.12 
CHA2DS2VASc score 
1 1 (2) 1 (2) 0 (0) 0.49 
2 3 (5) 3 (5) 0 (0) 
 
3 12 (18) 12 (22) 0 (0) 
 
4 22 (33) 18 (33) 4 (36) 
 
5 20 (30) 14 (25) 6 (55) 
 
6 1 (2) 1 (2) 0 (0) 
 
7 5 (8) 4 (7) 1 (9) 
 
8 2 (3) 2 (4) 0 (0) 
 
Valve disease 
(mild/moderate) 
21 (20) 17 (20) 4 (17) 0.74 
AS 10 (9) 7 (8) 3 (13) 0.50 
AR 5 (5) 5 (6) 0 (0) 0.23 
MS 3 (3) 2 (2) 1 (4) 0.62 
MR 8 (8) 7 (8) 1 (4) 0.51 
TR 3 (3) 3 (4) 0 (0) 0.35 
Valve replacement 5 (5) 4 (5) 1 (4) 0.92 
Non-CV comorbidities 
Diabetes 54 (51) 44 (53) 10 (43) 0.42 
CKD 31 (29) 23 (28) 8 (35) 0.51 
Chronic liver disease 2 (2) 1 (1) 1 (4) 0.33 
Depression 5 (5) 4 (5) 1 (4) 0.92 
Cancer 10 (9) 6 (7) 4 (17) 0.14 
COPD 22 (21) 19 (23) 3 (13) 0.30 
Asthma 8 (8) 5 (6) 3 (13) 0.26 
Anaemia 26 (25) 21 (25) 5 (22) 0.73 
Hypothyroidism 14 (13) 12 (14) 2 (9) 0.47 
Osteoarthritis 23 (22) 18 (22) 5 (22) 1.0 
Values are n (%). AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; CKD, chronic kidney 
disease; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; CVD, cerebrovascular disease; 
MR, mitral regurgitation; MS, mitral stenosis; PAD, peripheral arterial disease; TR, tricuspid regurgitation.   
Table 4-6: Past medical history of study participants.  
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4.2.4 Drug history – medication on admission 
Table 4-7 shows the frequency of prescription of CV and non-CV medication at 
the time of hospital admission.  The most commonly prescribed medications 
were statins (68%), for CV risk reduction and hypercholesterolaemia, and beta-
blockers (63%), principally for AF and hypertension.  Angiotensin converting 
enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) (62%) and 
calcium channel blockers (CCBs) were also frequently prescribed (42%), 
predominantly for hypertension.  Other medication used for the treatment of 
angina, such as long-acting nitrates and nicorandil, were not commonly 
prescribed (11% and 8%, respectively).   
Forty-six patients (43%) were treated with loop diuretics on admission.  Eighty 
percent were treated with furosemide and 20% with bumetanide; the median 
furosemide equivalent dose (i.e. 40 mg furosemide = 1 mg bumetanide) was 80 
(40-120) mg.  A minority of patients were treated with a thiazide (11%) or 
mineralocorticoid receptor antagonist (MRA) (5%).   
Forty-nine patients (46%) were treated with an anticoagulant (84% of those with 
AF were anticoagulated) and 34% were on antiplatelet therapy.  Eighty-one 
percent of patients with diabetes were on treatment; 61% were treated with a 
biguanide, 31% with a sulphonylurea, and 31% with insulin.    
In terms of non-CV medication, bronchodilator therapy and antidepressants were 
commonly prescribed (30% and 26%, respectively).   
 All patients 
 
(n = 106) 
Had study 
investigations 
(n = 83) 
Did not have study 
investigations 
(n = 23) 
p-value 
CV medication 
Antiplatelet 36 (34) 29 (35) 7 (30) 0.69 
Aspirin 24 (23) 19 (23) 5 (22) 0.91 
Other antiplatelet 13 (12) 11 (13) 2 (9) 0.56 
Anticoagulant 49 (46) 41 (49) 8 (35) 0.21 
DOAC 27 (25) 23 (28) 4 (17) 0.31 
Warfarin 22 (21) 18 (22) 4 (17) 0.65 
Statin 72 (68) 58 (70) 14 (61) 0.41 
Loop diuretic 46 (43) 38 (46) 8 (35) 0.35 
Furosemide 37 (80) 32 (84) 5 (62) 0.16 
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Bumetanide 9 (20) 6 (16) 3 (38) 
 
Furosemide-equivalent 
dose (mg) 
80 [40-120] 80 [40-120] 80 [40-160] 0.87 
Thiazide 12 (11) 8 (10) 4 (17) 0.30 
MRA 5 (5) 3 (4) 2 (9) 0.31 
ACEI/ARB 66 (62) 54 (65) 12 (52) 0.26 
ACEI 45 (42) 39 (47) 6 (26) 0.073 
ARB 22 (21) 16 (19) 6 (26) 0.48 
Beta-blocker 67 (63) 54 (65) 13 (57) 0.45 
CCB 45 (42) 34 (41) 11 (48) 0.56 
Long-acting nitrate 12 (11) 7 (8) 5 (22) 0.075 
Nicorandil 9 (8) 6 (7) 3 (13) 0.38 
Amiodarone 5 (5) 3 (4) 2 (9) 0.31 
Digoxin 8 (8) 6 (7) 2 (9) 0.81 
 
Diabetic medication 
(n = 54)          
44 (81) 
(n = 44)        
37 (84) 
(n = 10)         
7 (70) 
 
0.30 
Insulin 17 (31) 16 (36) 1 (10) 0.11 
Biguanide 33 (61) 28 (64) 5 (50) 0.42 
Sulphonylurea 17 (31) 13 (30) 4 (40) 0.52 
Thiazolidinedione 1 (2) 1 (2) 0 (0) 0.63 
DPP-4 inhibitor 3 (6) 2 (5) 1 (10) 0.50 
GLP-1 receptor 
antagonist 
2 (4) 2 (5) 0 (0) 0.49 
SGLT-2 inhibitor 2 (4) 1 (2) 1 (10) 0.24 
Non-CV medication 
Inhalers 
Bronchodilator 32 (30) 24 (29) 8 (35) 0.59 
Steroid  23 (22) 20 (24) 3 (13) 0.26 
Antidepressant 28 (26) 19 (23) 9 (39) 0.12 
NSAID 2 (2) 1 (1) 1 (4) 0.33 
Values are median [Q1-Q3] or n (%). ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; CCB, calcium channel blocker; CV, cardiovascular; DOAC, direct oral anticoagulant; DPP-
4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; MRA, mineralocorticoid receptor antagonist; 
NSAID, non-steroidal anti-inflammatory drug; SGLT-2, sodium-glucose co-transporter-2. 
Table 4-7: Admission medication of study participants.  
4.2.5 Drug history – medication during admission and at 
discharge 
Table 4-8 summarises the treatment patients received during admission.  Almost 
all patients (98%) were treated with loop diuretics.  Ninety-six patients (91%) 
received intravenous (IV) furosemide; 87 were given more than one IV dose and 
nine had a single dose followed by oral therapy.  Eight patients (8%) were 
treated with oral diuretics.  Five percent of participants were treated with IV 
nitrate during admission and one patient was treated with dopamine.  Forty-
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eight patients (45%) required oxygen therapy, two patients were treated with 
continuous positive airway pressure (CPAP) and no patients required intubation.   
 All patients 
 
(n = 106) 
Had study 
investigations 
(n = 83) 
Did not have study 
investigations 
(n = 23) 
p-value 
In-hospital treatment 
Furosemide 104 (98) 81 (98) 23 (100) 0.45 
IV (>1 dose) 87 (84) 67 (83) 20 (87) 0.79 
IV (1 dose) 9 (9) 7 (9) 2 (9) 
 
Oral 8 (8) 7 (9) 1 (4) 
 
IV nitrate 5 (5) 4 (5) 1 (4) 0.92 
Dopamine 1 (1) 0 (0) 1 (4) 0.056 
Oxygen 48 (45) 37 (45) 11 (48) 0.78 
FiO2 (%) 28 [24-35] 28 [24-35] 28 [24-35] 0.79 
CPAP 2 (2) 1 (1) 1 (4) 0.33 
Values are median [Q1-Q3] or n (%). CPAP, continuous positive airway pressure; FiO2, fraction of inspired 
oxygen; IV, intravenous.   
Table 4-8: In-hospital treatment of study participants.  
Table 4-9 details the prescribed drug therapy at hospital discharge.  There was 
no change in ACEI/ARB use at discharge.  Beta-blocker and digoxin use increased 
(63% to 75% and 8% to 29%, respectively), use of CCBs decreased (42% to 25%) 
and there was no significant change in the use of long-acting nitrates or 
nicorandil.   
The use of diuretic therapy increased markedly, with almost all patients being 
treated with a loop diuretic at the time of hospital discharge (43% on admission 
to 98% at discharge).  Again, 80% of patients were treated with furosemide and 
20% with bumetanide, and the median furosemide-equivalent dose was 80 (80-
160) mg.  MRA use also increased (5% to 23%) but use of thiazide diuretics 
decreased (11% to 7%).   
The proportion of patients anticoagulated increased from 46% at admission to 
67% at discharge; warfarin use declined, and more direct oral anticoagulants 
were prescribed.  A new diagnosis of AF was made in eight patients and a further 
eight patients with established AF and a high CHA2DS2VASc score were not 
anticoagulated prior to admission.   
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 All patients 
 
(n = 106) 
Had study 
investigations 
(n = 83) 
Did not have study 
investigations 
(n = 23) 
p-value 
CV medication 
Antiplatelet 30 (28) 24 (29) 6 (26) 0.79 
Aspirin 18 (17) 14 (17) 4 (17) 0.95 
Other antiplatelet 13 (12) 11 (13) 2 (9) 0.56 
Anticoagulant 71 (67) 56 (67) 15 (65) 0.84 
DOAC 56 (53) 43 (52) 13 (57) 0.69 
Warfarin 15 (14) 13 (16) 2 (9) 0.40 
Statin 72 (68) 58 (70) 14 (61) 0.41 
Loop diuretic 104 (98) 81 (98) 23 (100) 0.45 
Furosemide 83 (80) 69 (85) 14 (61) 0.01 
Bumetanide 21 (20) 12 (15) 9 (39) 
 
Furosemide-
equivalent dose (mg) 
80 [80-160] 80 [80-120] 80 [80-160] 0.14 
Thiazide 7 (7) 5 (6) 2 (9) 0.65 
ACEI/ARB 62 (58) 53 (64) 9 (39) 0.033 
ACEI 45 (42) 37 (45) 8 (35) 0.40 
ARB 17 (16) 16 (19) 1 (4) 0.084 
MRA 24 (23) 16 (19) 8 (35) 0.12 
Beta-blocker 79 (75) 62 (75) 17 (74) 0.94 
CCB 27 (25) 21 (25) 6 (26) 0.94 
Long-acting nitrate 15 (14) 9 (11) 6 (26) 0.063 
Nicorandil 8 (8) 6 (7) 2 (9) 0.81 
Amiodarone 4 (4) 2 (2) 2 (9) 0.16 
Digoxin 31 (29) 26 (31) 5 (22) 0.37 
 
Diabetic medication 
(n = 54) 
45 (83) 
(n = 44) 
37 (84) 
(n = 10) 
8 (80) 
 
0.75 
Insulin 18 (33) 17 (39) 1 (10) 0.083 
Biguanide 32 (59) 28 (64) 4 (40) 0.17 
Sulphonylurea 15 (28) 11 (25) 4 (40) 0.34 
Thiazolidinedione 0 (0) 0 (0) 0 (0) 
 
DPP-4 inhibitor 2 (4) 1 (2) 1 (10) 0.24 
GLP-1 receptor 
antagonist 
2 (4) 2 (5) 0 (0) 0.49 
SGLT-2 inhibitor 4 (7) 2 (5) 2 (20) 0.092 
Values are median [Q1-Q3] or n (%). ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; CCB, calcium channel blocker; CV, cardiovascular; DOAC, direct oral anticoagulant; DPP-
4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; MRA, mineralocorticoid receptor antagonist; 
SGLT-2, sodium-glucose co-transporter-2. 
Table 4-9: Discharge medication of study participants.  
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4.2.6 Investigations 
Electrocardiography 
All patients had an electrocardiogram (ECG) performed on admission to hospital.  
The ECG findings are presented in Table 4-10.  The mean heart rate (HR) was 84 
(24) bpm.  Fifty-three percent of patients were in AF on the admission ECG, 39% 
were in sinus rhythm, 6% had a paced rhythm and 3% had first-degree 
atrioventricular (AV) block.  Eleven percent of participants had a bundle branch 
block pattern, 9% had ECG criteria for left ventricular hypertrophy (LVH) and 9% 
had Q waves.  The mean QRS duration was 98 (27) ms and mean corrected QT 
interval was 451 (36) ms.   
 All patients 
 
(n = 106) 
Had study 
investigations 
(n = 83) 
Did not have study 
investigations 
(n = 23) 
p-value 
ECG 
Rate (bpm) 84 [24] 86 [24] 78 [23] 0.19 
Rhythm 
Sinus rhythm 41 (39) 30 (36) 11 (48) 0.49 
AF 56 (53) 47 (57) 9 (39) 
 
AV block (first 
degree) 
3 (3) 2 (2) 1 (4) 
 
Paced rhythm 6 (6) 4 (5) 2 (9) 
 
Bundle branch block 12 (11) 11 (13) 1 (4) 0.23 
Left 7 (58) 6 (55) 1 (100) 0.68 
Right 4 (33) 4 (36) 0 (0) 
 
Indeterminate 1 (8) 1 (9) 0 (0) 
 
LVH 10 (9) 8 (10) 2 (9) 0.89 
Q waves 10 (9) 10 (12) 0 (0) 0.08 
Poor R-wave 
progression 
 
30 (28) 26 (31) 4 (17) 0.19 
ST depression 11 (10) 9 (11) 2 (9) 0.77 
T-wave inversion 50 (47) 38 (46) 12 (52) 0.59 
LA enlargement 4 (4) 2 (2) 2 (9) 0.16 
QRS duration (ms) 98 [27] 100 [28] 93 [22] 0.29 
QTc (ms) 451 [36] 450 [35] 457 [40] 0.44 
Values are mean [standard deviation] or n (%). AF, atrial fibrillation; AV, atrioventricular; ECG, 
electrocardiogram; LA, left atrial; LVH, left ventricular hypertrophy.   
Table 4-10: ECG findings of study participants.  
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Chest x-ray 
All patients had a chest x-ray (CXR) performed on presentation to hospital and 
the major findings are detailed in Table 4-11.  Radiological signs of HF were 
frequently seen.  The most common findings were cardiomegaly (75%), upper 
lobe venous diversion (73%) and pleural effusion(s) (55%), which were typically 
bilateral.  Evidence of pulmonary congestion was present in most patients; 
alveolar oedema was seen in 57% and perihilar oedema in 44%.   
 All patients 
 
(n = 106) 
Had study 
investigations 
(n = 83) 
Did not have study 
investigations 
(n = 23) 
p-value 
CXR 
Cardiomegaly 79 (75) 63 (76) 16 (70) 0.54 
Upper lobe venous 
diversion 
77 (73) 57 (69) 20 (87) 0.082 
Interstitial oedema 27 (25) 18 (22) 9 (39) 0.089 
Alveolar oedema 60 (57) 48 (58) 12 (52) 0.63 
Perihilar oedema 47 (44) 35 (42) 12 (52) 0.39 
Pleural effusion(s) 58 (55) 42 (51) 16 (70) 0.11 
Right 14 (24) 13 (31) 1 (6) 0.13 
Left 2 (3) 1 (2) 1 (6) 
 
Bilateral 42 (72) 28 (67) 14 (88) 
 
Values are n (%). CXR, chest x-ray.   
Table 4-11: CXR findings of study participants.  
Laboratory tests 
The laboratory results are summarised in Table 4-12.  Urea and electrolytes, 
liver function tests, C-reactive protein (CRP) and full blood count were routinely 
measured in all patients on admission to hospital.  Plasma glucose was measured 
in 89% of participants, high-sensitivity troponin I (hsTnI) in 65%, thyroid function 
tests in 56%, and cholesterol/triglycerides in 29%.   
B-type natriuretic peptide (BNP) was measured as part of routine clinical 
practice in 65% of patients at a median of 1 (1-2) days following admission; N-
terminal prohormone BNP (NT-proBNP) was assessed in 51 patients (48%) at a 
median of 4 (2-6) days.  As elevated natriuretic peptides were required for study 
inclusion, all patients had an elevated BNP or NT-proBNP.  The natriuretic levels 
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were generally markedly elevated (median BNP, 382 pg/mL; median NT-proBNP, 
1532 pg/mL).    
The median hsTnI in the cohort was 16 (7-27) ng/L.  The reference range of this 
assay is different for men (0-34 ng/L) and women (0-16 ng/L); the median levels 
for men and women were 19 ng/L and 14 ng/L, respectively.  A total of 19 
patients (28%) had a hsTnI level above the reference range.  Patients presenting 
with a primary diagnosis of acute coronary syndrome were excluded from the 
study, however, troponin leaks are frequently observed in patients with HF 
decompensation, therefore, patients with an elevated troponin were included in 
the absence of other symptoms and signs suggestive of acute ischaemia.256    
Urea and electrolytes and liver function tests were measured in all patients on 
admission.  Forty-one patients (39%) had renal impairment (eGFR 30-60 
mL/min/1.73m2); four patients were hyponatraemic (Na+ <133 mmol/L) on 
admission.  Hypoalbuminaemia was common, with 53% of patients having an 
albumin below the normal reference range (35-50 g/L).   
The median CRP was 12 mg/L and the majority of study participants (57%) had a 
CRP above the reference range (0-10 mg/L) on admission; one-quarter had a 
neutrophilia (neutrophils >7.0 x 109/L) and 18% had an elevated total white cell 
count (WCC, >10.0 x 109/L).   
Anaemia was highly prevalent in the cohort; 49 patients (46%) had a 
haemoglobin below the normal reference range (130-180 g/L and 115-165 g/L for 
men and women, respectively) on admission.  The majority of patients (71%) had 
a normal mean corpuscular volume (MCV); 9% had microcytic and 4% had 
macrocytic anaemia.  Haematinics and iron studies were not routinely measured 
to further investigate the aetiology of anaemia.   
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 All patients 
 
(n = 106) 
Had study 
investigations 
(n = 83) 
Did not have study 
investigations 
(n = 23) 
p-value 
Haematology 
Hb (g/L) 122 [18] 122 [19] 120 [14] 0.61 
Anaemia 49 (46) 37 (45) 12 (52) 0.52 
MCV (fL) 91 [8] 91 [7] 93 [9] 0.26 
Haematocrit (%) 38 [5] 38 [5] 38 [4] 0.98 
WCC (x109/L) 8.2 [2.3] 8.1 [2.3] 8.6 [2.4] 0.35 
Neutrophils (x109/L) 6.0 [2.1] 5.9 [2.1] 6.4 [2.1] 0.30 
Lymphocytes (x109/L) 1.3 [0.6] 1.3 [0.6] 1.3 [0.4] 0.99 
Platelets (x109/L) 241 [103] 235 [106] 262 [91] 0.26 
Biochemistry 
NT-proBNP 51 (48) 41 (49) 10 (43) 0.62 
NT-proBNP (pg/mL) 1532 [845-3076] 1385 [978-3076] 1579 [384-2799] 0.55 
BNP 69 (65) 52 (63) 17 (74) 0.32 
BNP (pg/mL) 382 [197-794] 339 [181-829] 459 [332-545] 0.60 
hsTnI 69 (65) 55 (66) 14 (61) 0.63 
hsTnI (ng/L) 16 [7-27] 16 [7-29] 11 [5-24] 0.58 
Elevated hsTnI 19 (28) 16 (29) 3 (21) 0.57 
Na+ (mmol/L) 138 [2] 138 [3] 139 [4] 0.93 
Hyponatraemia 4 (4) 3 (4) 1 (4) 0.87 
K+ (mmol/L) 4.4 [0.5] 4.4 [0.6] 4.4 [0.5] 0.60 
Cl- (mmol/L) 104 [5] 104 [5] 103 [4] 0.83 
Urea (mmol/L) 7.7 [3.8] 7.9 [4.0] 7.2 [2.7] 0.46 
Creatinine (µmol/L) 94 [32] 96 [33] 89 [29] 0.39 
eGFR (mL/min/1.73m2) 66 [20] 65 [20] 68 [22] 0.47 
eGFR <60 mL/min/ 
1.73m2 
41 (39) 32 (39) 9 (39) 0.96 
Bilirubin (µmol/L) 15 [8] 16 [8] 14 [7] 0.31 
ALT (U/L) 19 [13-26] 20 [15-36] 13 [12-19] <0.01 
AST (U/L) 21 [18-28] 21 [17-33] 19 [18-22] 0.083 
Alkaline phosphatase 
(U/L) 
106 [87-124] 99 [82-120] 118 [101-160] 0.036 
Albumin (g/L) 34 [4] 34 [4] 34 [5] 0.95 
Hypoalbuminaemia 56 (53) 42 (51) 14 (61) 0.38 
CRP (mg/L) 12 [5-25] 12 [5-23] 12 [8-39] 0.43 
Elevated CRP 60 (57) 46 (55) 14 (61) 0.64 
Glucose (mmol/L) 6.7 [5.4-8.6] 6.6 [5.3-8.6] 7.0 [5.8-7.9] 0.92 
Values are mean [standard deviation], median [Q1-Q3], or n (%). ALT, alanine transaminase; AST, aspartate 
transaminase; BNP, B-type natriuretic peptide; Cl-, chloride; CRP, C-reactive protein; eGFR, estimated 
glomerular filtration rate; Hb, haemoglobin; hsTnI, high-sensitivity troponin I; K+, potassium; MCV, mean 
corpuscular volume; Na+, sodium; NT-proBNP, N-terminal prohormone BNP; WCC, white cell count.   
Table 4-12: Laboratory results of study participants.  
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Echocardiography 
All patients had an echocardiogram performed as part of the diagnostic work-up 
for suspected HF.  The main echocardiography findings are presented in Table 4-
13.  LV systolic function was assessed (where possible) by Simpson’s biplane 
method for quantification of LVEF.  This technique requires adequate 
transthoracic imaging to achieve endocardial definition and was possible in 80% 
of patients.  In the other participants, the LVEF was estimated subjectively.  
Participants were required to have an LVEF of ≥50% for inclusion in the study; 
the mean LVEF was 59% (6%).   
The mean left ventricular (LV) size, as assessed by the LV internal diameter and 
LV volume in diastole and systole indexed to body surface area (BSA), was within 
normal limits.  The mean LV septal wall thickness in diastole was 13 mm and 
posterior wall thickness was 12 mm; 58% of participants had echocardiographic 
evidence of LVH (defined as LV septal and/or posterior wall thickness ≥13 mm).  
The mean right ventricular (RV) size, as assessed by the mid-RV diameter in 
diastole, was near the upper limit of normal (34 mm; abnormal >35 mm).  The 
mean RV systolic function, as assessed by the tricuspid annular plane systolic 
excursion (TAPSE) was preserved (20 mm; abnormal <16 mm).   
The majority of patients (84%) had left atrial (LA) dilatation, as defined by the 
2016 ESC HF guidelines (i.e. LA volume indexed to BSA >34 mL/m2).2  The mean 
indexed LA volume was 44 (15) mL/m2.  Fifty participants (57% of those with 
tissue Doppler imaging) had echocardiographic evidence of diastolic dysfunction, 
as per the ESC HF guidelines (i.e. mean E/e’ >13 and e’ <9 cm/sec).2  The mean 
E/e’ was 15.0 (6.6).   
Patients with greater than moderate valve disease were excluded from the 
study, however, mild or moderate valvular heart disease was common in the 
overall cohort (73%).  The most frequently observed valve lesions were mild 
tricuspid and mitral regurgitation (69% and 63%, respectively).   
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 All patients 
 
(n = 106) 
Had study 
investigations 
(n = 83) 
Did not have study 
investigations 
(n = 23) 
p-value 
LV structure and systolic function 
LVEDD (mm/m2) 24 [3] 24 [3] 24 [3] 0.87 
LVESD (mm/m2) 16 [4] 15 [5] 16 [3] 0.37 
LVEDV (mL/m2) 45 [15] 44 [15] 47 [18] 0.56 
LVESV (mL/m2) 19 [8] 18 [7] 20 [9] 0.31 
LVSV (mL/m2) 26 [9] 26 [9] 26 [10] 0.77 
LVEF measurement 
Biplane 85 (80) 68 (82) 17 (74) 0.39 
Estimated 21 (20) 15 (18) 6 (26)  
LVEF (%) 59 [6] 59 [6] 58 [6] 0.41 
S' lateral (cm/s) 7.1 [2.3] 6.9 [2.1] 8.2 [2.6] 0.039 
Septal wall thickness 
(mm) 
13 [2] 12 [2] 13 [2] 0.48 
Posterior wall 
thickness (mm) 
12 [2] 12 [2] 12 [2] 0.57 
LVH 62 (59) 49 (59) 13 (57) 0.83 
LV diastolic function 
E (m/s) 1.1 [0.3] 1.1 [0.3] 1.1 [0.3] 0.72 
A (m/s) 0.9 [0.3] 0.9 [0.3] 0.8 [0.4] 0.38 
E/A 1.4 [1.0] 1.2 [0.9] 1.7 [1.1] 0.16 
Deceleration time 
(ms) 
217 [78] 218 [85] 215 [46] 0.87 
E' average (cm/s) 7.8 [2.6] 7.7 [2.6] 8.1 [2.8] 0.55 
E/E' lateral 13.3 [6.5] 13.2 [6.1] 13.9 [8.3] 0.70 
E/e' septal 17.8 [8.5] 18.2 [8.9] 16.3 [6.7] 0.44 
E/e' average 15.0 [6.6] 15.0 [6.5] 14.7 [7.4] 0.88 
Diastolic 
dysfunction 
50 (57) 41 (57) 9 (56) 0.96 
LA volume 
(mL/m2) 
44 [15] 45 [16] 40 [13] 0.17 
LA dilatation 88 (84) 71 (87) 17 (74) 0.14 
RV structure and function 
RVEDD (mm) 34 [6] 34 [7] 34 [5] 0.99 
TAPSE (mm) 20 [5] 20 [5] 20 [5] 0.77 
TR max (mmHg) 29 [14] 30 [14] 26 [11] 0.36 
Estimated RAP 
(mmHg) 
9 (4) 9 (4) 8 (4) 0.52 
Estimated RVSP 
(mmHg) 
38 [15] 40 [15] 30 [11] 0.033 
Valve disease 
Mild/moderate 
valve disease 
77 (73) 61 (73) 16 (70) 0.71 
AS 12 (16) 10 (16) 2 (12) 0.70 
AR 21 (27) 18 (30) 3 (19) 0.39 
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MS 5 (6) 5 (8) 0 (0) 0.24 
MR 54 (70) 46 (75) 8 (50) 0.048 
TR 51 (66) 39 (64) 12 (75) 0.40 
PR 8 (10) 7 (11) 1 (6) 0.54 
Values are mean [standard deviation] or n (%). AR, aortic regurgitation; AS, aortic stenosis; LA, left atrial; 
LV, left ventricular; LVEDD, LV end-diastolic dimension; LVEDV, LV end-diastolic volume; LVEF, LV ejection 
fraction; LVESD, LV end-systolic dimension; LVESV, LV end-systolic volume; LVH, LV hypertrophy; LVSV, LV 
stroke volume; MR, mitral regurgitation; MS, mitral stenosis; PR, pulmonary regurgitation; RAP, right atrial 
pressure; RV, right ventricular; RVEDD, RV end-diastolic dimension; RVSP, RV systolic pressure; TAPSE, 
tricuspid annular plane systolic excursion; TR, tricuspid regurgitation.   
Table 4-13: Echocardiography findings of study participants.  
4.2.7 Summary 
This chapter details the study screening and recruitment process in addition to 
the baseline characteristics of the participants.  Contemporary population-based 
HF studies suggest that HFpEF now accounts for around half of prevalent HF.18   
However, the definition of HF and thresholds used to classify preserved LVEF 
vary markedly between studies.  A recent review of studies using an LVEF 
threshold of ≥50% reported estimates of HFpEF as a proportion of total prevalent 
HF ranging from 24% to 55%.18  In this study, 1116 (49%) of the patients that I 
screened had a diagnosis of HF with an LVEF <50%.  Of the 1169 patients (51%) 
with preserved LVEF, 541 had an alternative diagnosis (e.g. significant valve 
disease, primary cardiomyopathy or pericardial disease).  Importantly, these 
patients are often erroneously given a diagnosis of HFpEF in epidemiological 
studies.257  A total of 628 patients (27% of all patients screened) had a confirmed 
diagnosis of HFpEF.  Excluding those patients with an alternative diagnosis, 64% 
of those with confirmed HF had an LVEF <50% and 36% had an LVEF ≥50% (Figure 
4-4).  I assessed patients hospitalised with HF, therefore, the relative 
proportions of patients with HFpEF and HF with reduced ejection fraction 
(HFrEF) are likely to differ in ambulatory cohorts.   
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LVEF, left ventricular ejection fraction. 
Figure 4-4: Screened patients stratified by LVEF.   
The inclusion criteria for this study were designed to include as broad a range of 
hospitalised patients with HFpEF as possible that would be eligible for detailed 
coronary investigation.  By necessity, specific groups of patients were excluded 
for reasons of safety.  Notably, those with an eGFR <30mL/min/1.73m2 were 
excluded to facilitate the safe administration of contrast agents during the study 
investigations.  Patients with severe frailty (i.e. CFS >6), in whom invasive 
coronary angiography was considered to be clinically inappropriate and/or to 
carry excessive risk, were also excluded.  Although these patients accounted for 
a reasonable number of exclusions, they represent a group that would not 
otherwise be considered for invasive investigation on the basis of general health 
and functional status.   
Selected baseline characteristics of HFpEF patients that were recruited and 
those excluded are presented in Table 4-14.  The excluded HFpEF patients were 
older (mean age 81 vs. 72 years; p <0.001) and more frequently female (66% vs. 
50%; p = 0.002) than those recruited to the study.  Natriuretic peptides were 
higher in the excluded patients than those recruited (median BNP 712 vs. 382; p 
= 0.001, respectively), but CV comorbidities and echocardiographic signs of 
elevated LV filling pressure were not significantly different.  Predictably, 
64%
36%
LVEF <50% (n = 1116) LVEF ≥50% (n = 628)
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therefore, the excluded HFpEF group represent a higher risk group who are likely 
to have poorer outcomes than the recruited cohort.   
 
Recruited HFpEF patients 
(n = 106) 
Excluded HFpEF 
patients (n = 522) 
p-value 
Demographics    
Age (years) 72 [9] 81 [10] <0.001 
Female sex 53 (50) 345 (66) 0.002 
Hospitalisation details    
Length of stay (days) 8 [6-13] 10 [5-18] 0.11 
Past medical history    
Any CAD 38 (36) 209 (40) 0.42 
Hypertension 80 (75) 407 (78) 0.57 
AF 66 (62) 318 (61) 0.80 
Biochemistry    
BNP (pg/mL) 382 [197-794] 712 [377-1127] 0.001 
NT-proBNP (pg/mL) 1532 [845-3076] 2714 [817-4341] 0.55 
Echocardiography    
LVH 62 (59) 355 (68) 0.059 
LA dilatation 88 (84) 449 (86) 0.56 
Diastolic dysfunction 50 (57) 350 (67) 0.062 
Values are mean [standard deviation], median [Q1-Q3], or n (%). AF, atrial fibrillation; BNP, B-type 
natriuretic peptide; CAD, coronary artery disease; HFpEF, heart failure with preserved ejection fraction; 
LA, left atrial; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal prohormone BNP.  
Table 4-14: Selected baseline characteristics of recruited and excluded 
HFpEF patients.   
Due to the logistics of performing this study within the limits of a busy regional 
clinical service, there was a significant delay in performing invasive coronary 
angiography (median 97 days from presentation).  The delay in performing the 
invasive coronary assessment may have affected the results of coronary 
microvascular testing (see Chapter 6).   
Twenty-three patients that were recruited did not undergo the study 
investigations.  For the majority, this was due to a decline in health and 
functional status prior to the investigations being performed; one patient died 
prior to investigation.  A number of patients developed a decline in their renal 
function; it was, therefore, not safe to proceed with the imaging studies.  Those 
who subsequently withdrew are likely to represent a higher risk group and might 
have been expected to have a higher burden of CAD and CMD.  However, 
reassuringly, there were no major differences in the clinical characteristics or 
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outcomes of those who did and did not undergo the study investigations 
(Appendix VIII, IX).   
As a result of the above issues with recruitment, I did not meet the proposed 
sample size for recruitment (see Chapter 3).  Consequently, the margin of error 
to detect a prevalence of obstructive epicardial CAD of 50% at a 95% CI increased 
from 8% to 11%.   
I believe that this cohort has a number of strengths.  I screened near-
consecutive patients prospectively at three large hospitals.  All patients enrolled 
had a clear-cut diagnosis of HFpEF as per the 2016 ESC HF guidelines 
(necessitating clinical symptoms and signs of HF, preserved LV systolic function, 
elevated natriuretic peptides, and evidence of structural and/or functional heart 
disease on echocardiography).  Median natriuretic peptides were markedly 
elevated and the vast majority of patients (92%) had structural heart disease 
(i.e. LVH or LA dilatation); the remainder had diastolic dysfunction.  
Furthermore, almost all patients were treated with diuretics during hospital 
admission and at discharge.  The baseline characteristics of this cohort are 
consistent with contemporary population-based studies in HFpEF.257,258  One 
notable exception is regarding the ethnicity of enrolled patients.  Almost all 
participants in this study are Caucasian, with only 3% coming from minority 
ethnic backgrounds.  Although this is relatively representative of the Scottish 
population (4% of the population was from ethnic minority groups in the 2011 
Census259), patients from minority ethnic populations are under-represented in 
clinical research studies.260   
Overall, I feel my study cohort is representative of ‘real world’ patients 
hospitalised with HFpEF.  In this study, selection bias was minimised due to the 
prospective and near-consecutive screening process.  The recruited patients all 
had a robust diagnosis of HFpEF in accordance with the contemporary guidelines 
and the demographics and clinical characteristics of the cohort are comparable 
to epidemiological HFpEF populations.  However, the generalisability of the 
study is slightly reduced by the design (employing an invasive investigation 
strategy), limiting the recruitment of elderly and frail patients.    
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Chapter 5 Results – Coronary artery disease in 
heart failure with preserved ejection fraction 
In this chapter I will report the prevalence of obstructive epicardial coronary 
artery disease (CAD) in the study population.  I will describe the clinical 
characteristics, investigation results and correlates of the population based on 
the presence or absence of obstructive CAD.  Finally, I will report clinical 
outcomes (mortality and hospitalisations) based on the presence or absence of 
epicardial CAD.   
5.1 Prevalence of obstructive epicardial coronary artery 
disease 
A total of 75 participants underwent invasive coronary angiography.  Invasive 
coronary angiography revealed obstructive epicardial CAD in 38 participants, 
giving an estimated prevalence in the HFpEF population of 51% (95% confidence 
interval [CI] 39-62%) (Figure 5-1).   
 
CAD, coronary artery disease; FFR, fractional flow reserve.   
Figure 5-1: Prevalence of obstructive epicardial CAD in study cohort.  
As discussed in Chapter 3, obstructive epicardial CAD was defined as: a ≥70% 
stenosis of a major epicardial coronary artery (>2.5 mm diameter); a ≥50% 
stenosis of the left main coronary artery; or a 50-70% stenosis of a major 
coronary artery with an FFR ≤0.80.  Thirty-five patients (47%) were diagnosed 
with obstructive CAD on the basis of at least one epicardial stenosis ≥70% (≥50% 
if left main coronary artery) on QCA.  Six patients (8%) had a maximum stenosis 
Coronary angiography
n = 75
No obstructive CAD
n = 37 (49%)
Obstructive CAD
n = 38 (51%)
Only stenoses 50-70%
n = 6 (8%)
All stenoses <50%
n = 34 (45%)
At least one stenosis >70%
n = 35 (47%)
FFR >0.80
n = 3 (4%)
FFR £0.80
n = 3 (4%)
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of 50-70%, all of which were assessed with fractional flow reserve (FFR); three 
patients (8%) had an FFR ≤0.80 and three (8%) had an FFR >0.80 (Figure 5-1).  
Traditionally, “significant” epicardial CAD has been defined as a ≥50% stenosis of 
a major epicardial artery.261  However, two-thirds of patients with an 
intermediate (50-70%) stenosis do not have functionally significant disease when 
interrogated with FFR.262  Using the traditional cut-off of a ≥50% epicardial 
stenosis, the prevalence of epicardial CAD in the cohort is 56% (95% CI 44-67%).   
5.2 Clinical characteristics by obstructive epicardial 
coronary artery disease 
5.2.1 Demographics and clinical features 
Table 5-1 details the demographics and clinical features of the study 
participants based on the presence or absence of obstructive epicardial CAD.  
The groups were similar with regards to age, frailty, smoking history and 
duration of hospitalisation.  Those with obstructive epicardial CAD were more 
frequently male (63% vs. 38%; p = 0.028) and had a lower mean HR at 
presentation (76 vs. 90 bpm; p = 0.012) than those without obstructive CAD.  
The most frequent finding on clinical examination was oedema, which was 
generally of mild to moderate severity.  There were no significant differences in 
HF symptoms or signs between the groups.   
 
All angiography 
(n = 75) 
No obstructive CAD 
(n = 37) 
Obstructive CAD 
(n = 38) 
p-value 
Demographics 
Age (years) 72 [9] 72 [9] 73 [9] 0.40 
Female sex 37 (49) 23 (62) 14 (37) 0.028 
BMI (kg/m2) 33 [8] 34 [8] 31 [7] 0.084 
Obesity 35 (47) 20 (54) 15 (39) 0.21 
Smoking history 42 (56) 20 (54) 22 (58) 0.74 
Hospitalisation details 
Length of stay (days) 7 [5-11] 7 [5-10] 7 [6-12] 0.28 
HF symptoms 
NYHA functional class 
II 2 (3) 1 (3) 1 (3) 0.94 
III 40 (53) 19 (51) 21 (55) 
 
IV 33 (44) 17 (46) 16 (42) 
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Orthopnoea 51 (68) 26 (70) 25 (66) 0.68 
PND 35 (47) 17 (46) 18 (47) 0.90 
Ankle swelling 68 (91) 33 (89) 35 (92) 0.66 
Admission vital signs 
HR (bpm) 83 [25] 90 [28] 76 [21] 0.012 
SBP (mmHg) 150 [29] 152 [31] 148 [29] 0.58 
DBP (mmHg) 79 [20] 80 [21] 78 [19] 0.64 
MAP (mmHg) 103 [19] 104 [20] 102 [18] 0.54 
HF signs 
JVD 52 (69) 26 (70) 26 (68) 0.86 
Murmur 22 (29) 11 (30) 11 (29) 0.94 
Crepitations 59 (79) 29 (78) 30 (79) 0.95 
Pleural effusion(s) 30 (40) 15 (41) 15 (39) 0.92 
Oedema 66 (88) 33 (89) 33 (87) 0.75 
Ascites 3 (4) 0 (0) 3 (8) 0.081 
Values are mean [standard deviation], median [Q1-Q3], or n (%). BMI, body mass index; CAD, coronary 
artery disease; DBP, diastolic blood pressure; HF, heart failure; HR, heart rate; JVD, jugular venous 
distention; MAP, mean arterial pressure; NYHA, New York Heart Association; PND, paroxysmal nocturnal 
dyspnoea; SBP; systolic blood pressure.  
Table 5-1: Demographics and clinical features stratified by obstructive 
epicardial CAD.  
5.2.2 Past medical history 
The past medical history based on the presence or absence of obstructive CAD is 
presented in Table 5-2.  A similar proportion of patients in each group presented 
with de novo HF and had a previous HF hospitalisation.  Those with obstructive 
CAD were more likely to have a previous history of CAD (50% vs. 19%; p <0.01), 
previous MI (34% vs. 11%; p = 0.016), and previous PCI (24% vs. 5%; p = 0.025) 
than those without obstructive CAD.  Only three patients had previous CABG, all 
of whom had obstructive epicardial CAD on angiography (i.e. evidence of 
obstructive disease of both native coronary artery and bypass graft supply to ≥1 
epicardial coronary artery territory).  A clinical history of angina was not 
significantly different between those with and without obstructive CAD (8% vs. 
21%; p = 0.11, respectively).   
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The rates of most common comorbidities were similar between those with and 
without obstructive epicardial disease, including hypertension (71% vs. 76%; p = 
0.65, respectively), AF (61% vs. 70%; p = 0.38, respectively), and anaemia (26% 
vs. 22%; p = 0.63, respectively).  Patients with obstructive CAD had a higher 
prevalence of CKD (42% vs. 16%; p = 0.014) and diabetes (63% vs. 41%; p = 0.05) 
than those with no obstructive disease.   
 All angiography 
(n = 75) 
No obstructive CAD 
(n = 37) 
Obstructive CAD 
(n = 38) 
p-value 
History of HF 
Previous HF diagnosis 28 (37) 13 (35) 15 (39) 0.70 
Previous HFH 17 (23) 10 (27) 7 (18) 0.37 
History of CAD 
Any CAD 26 (35) 7 (19) 19 (50) <0.01 
MI 17 (23) 4 (11) 13 (34) 0.016 
Angina 11 (15) 3 (8) 8 (21) 0.11 
Current angina 5 (7) 2 (5) 3 (8) 0.67 
Revascularisation 12 (16) 2 (5) 10 (26) 0.014 
PCI 11 (15) 2 (5) 9 (24) 0.025 
CABG 3 (4) 0 (0) 3 (8) 0.081 
CV comorbidities 
Hypertension 55 (73) 28 (76) 27 (71) 0.65 
Dyslipidaemia 6 (8) 3 (8) 3 (8) 0.97 
CVD 15 (20) 5 (14) 10 (26) 0.17 
PAD 8 (11) 2 (5) 6 (16) 0.15 
AF 49 (65) 26 (70) 23 (61) 0.38 
Valve disease 
(mild/moderate) 
17 (23) 8 (22) 9 (24) 0.83 
Non-CV comorbidities 
Diabetes 39 (52) 15 (41) 24 (63) 0.05 
CKD 22 (29) 6 (16) 16 (42) 0.014 
Chronic liver disease 0 (0) 0 (0) 0 (0) 
 
Depression 4 (5) 1 (3) 3 (8) 0.32 
Cancer 5 (7) 3 (8) 2 (5) 0.62 
COPD 18 (24) 8 (22) 10 (26) 0.63 
Asthma 5 (7) 4 (11) 1 (3) 0.16 
Anaemia 18 (24) 8 (22) 10 (26) 0.63 
Hypothyroidism 11 (15) 6 (16) 5 (13) 0.71 
Osteoarthritis 18 (24) 8 (22) 10 (26) 0.63 
Values are n (%). AF, atrial fibrillation; CABG, coronary artery bypass grafting; CAD, coronary artery 
disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; 
CVD, cerebrovascular disease; HF, heart failure; HFH, HF hospitalisation; MI, myocardial infarction; PAD, 
peripheral arterial disease; PCI, percutaneous coronary intervention.  
Table 5-2: Past medical history stratified by obstructive epicardial CAD.  
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5.2.3 Drug history – medication on admission 
The admission medication of participants based on the presence or absence of 
obstructive epicardial CAD is described in Table 5-3.  Those with obstructive CAD 
were more likely to be prescribed an antiplatelet than those without (50% vs. 
22%; p = 0.01, respectively), but rates of statin prescription were similar (76% 
vs. 62%; p = 0.18, respectively).  Those without obstructive disease were more 
likely to be treated anticoagulated on admission than those with CAD (59% vs. 
34%; p = 0.028, respectively), despite similar rates of AF.  Almost half of 
patients were prescribed a loop diuretic on admission, with no significant 
difference in the prescription rates (47% vs. 49%; p = 0.91) or furosemide-
equivalent dose (median 80 mg vs. 70 mg; p = 0.52) between those with and 
without obstructive coronary disease.  Use of other CV medication, including 
renin-angiotensin-aldosterone system (RAAS) antagonists and anti-anginal 
medications, were similar.   
 All angiography 
(n = 75) 
No obstructive CAD 
(n = 37) 
Obstructive CAD 
(n = 38) 
p-value 
CV medication 
Antiplatelet 27 (36) 8 (22) 19 (50) 0.01 
Anticoagulant 35 (47) 22 (59) 13 (34) 0.028 
Statin 52 (69) 23 (62) 29 (76) 0.18 
Loop diuretic 36 (48) 18 (49) 18 (47) 0.91 
Furosemide-
equivalent dose (mg) 
80 [40-120] 70 [40-120] 80 [40-120] 0.52 
Thiazide 5 (7) 4 (11) 1 (3) 0.16 
MRA 3 (4) 1 (3) 2 (5) 0.57 
ACEI/ARB 50 (67) 22 (59) 28 (74) 0.19 
Beta-blocker 48 (64) 22 (59) 26 (68) 0.42 
CCB 28 (37) 14 (38) 14 (37) 0.93 
Digoxin 6 (8) 4 (11) 2 (5) 0.38 
 
Diabetic medication 
(n = 39) 
33 (85) 
(n = 15) 
12 (80) 
(n = 24) 
21 (88) 
 
0.53 
Insulin 13 (33) 4 (27) 9 (38) 0.49 
Non-CV medication 
Bronchodilator 23 (31) 12 (32) 11 (29) 0.74 
Antidepressant 18 (24) 8 (22) 10 (26) 0.63 
Values are median [Q1-Q3] or n (%). ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; CAD, coronary artery disease; CCB, calcium channel blocker; CV, cardiovascular; MRA, 
mineralocorticoid receptor antagonist.   
Table 5-3: Admission medication stratified by obstructive epicardial CAD.  
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5.2.4 Drug history – in-hospital treatment and medication at 
discharge 
The in-hospital treatment and discharge medication of participants based on the 
presence or absence of obstructive epicardial CAD is summarised in Table 5-4.  
All but one of the participants that underwent invasive coronary angiography 
were treated with loop diuretics during admission, 90% of whom received 
intravenous furosemide.  Very few patients received IV nitrate (n = 3) and no 
patients received IV inotropes.  Around half of patients required oxygen therapy, 
with no significant difference between those with and without obstructive CAD.  
One patient was treated with CPAP and no patients required intubation.   
When compared with admission mediation, fewer patients with obstructive CAD 
were prescribed an antiplatelet (50% vs. 39%) and more were prescribed an 
anticoagulant (34% vs. 55%) at discharge.  There was no significant difference in 
the rates of antiplatelet or anticoagulant use at discharge between those with 
and without obstructive CAD.   
Loop diuretic use in both groups doubled from admission to discharge, from 49% 
to 97% in those without obstructive CAD, and 47% to 100% in those with 
obstructive CAD.  The furosemide-equivalent dose at discharge was the same in 
each group (median 80 mg).  The use of MRAs also increased in those with no 
obstructive CAD (3% to 14%) and those with obstructive disease (5% to 24%).   
Beta-blocker and digoxin use increased in both groups, and the use of digoxin in 
those with no obstructive coronary disease was significantly higher than those 
with obstructive disease (43% vs. 21%; p = 0.039, respectively).   
 All angiography 
(n = 75) 
No obstructive CAD 
(n = 37) 
Obstructive CAD 
(n = 38) 
p-value 
In-hospital treatment 
Furosemide 74 (99) 36 (97) 38 (100) 0.31 
IV (>1 dose) 61 (82) 27 (75) 34 (89) 0.17 
IV (1 dose) 7 (9) 4 (11) 3 (8) 
 
Oral 6 (8) 5 (14) 1 (3) 
 
IV nitrate 3 (4) 2 (5) 1 (3) 0.54 
Dopamine 0 (0) 0 (0) 0 (0) 
 
Oxygen 34 (45) 15 (41) 19 (50) 0.41 
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CPAP 1 (1) 0 (0) 1 (3) 0.32 
CV medication 
Antiplatelet 24 (32) 9 (24) 15 (39) 0.16 
Anticoagulant 49 (65) 28 (76) 21 (55) 0.063 
Statin 52 (69) 23 (62) 29 (76) 0.18 
Loop diuretic 74 (99) 36 (97) 38 (100) 0.31 
Furosemide-
equivalent dose (mg) 
80 [80-120] 80 [80-120] 80 [80-160] 0.91 
Thiazide 5 (7) 3 (8) 2 (5) 0.62 
ACEI/ARB 49 (65) 23 (62) 26 (68) 0.57 
MRA 14 (19) 5 (14) 9 (24) 0.26 
Beta-blocker 56 (75) 26 (70) 30 (79) 0.39 
Calcium channel 
blocker 
17 (23) 9 (24) 8 (21) 0.74 
Digoxin 24 (32) 16 (43) 8 (21) 0.039 
 
Diabetic medication 
(n = 39) 
33 (85) 
(n = 15) 
12 (80) 
(n = 24) 
21 (88) 
 
0.53 
Insulin 14 (36) 4 (27) 10 (42) 0.34 
Values are median [Q1-Q3] or n (%). ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; CAD, coronary artery disease; CCB, calcium channel blocker; CPAP, continuous positive 
airway pressure; CV, cardiovascular; IV, intravenous; MRA, mineralocorticoid receptor antagonist.   
Table 5-4: In-hospital treatment and discharge medication stratified by 
obstructive epicardial CAD.  
5.2.5 Baseline investigations 
Table 5-5 details the ECG, CXR and laboratory results for the participants 
according to the presence of absence of obstructive CAD.  Participants with 
obstructive CAD had a lower mean HR (79 vs. 94 bpm; p <0.01) and were more 
likely to have Q waves on ECG (24% vs. 3%; p <0.01) than those without 
obstructive CAD.  The CXR findings was similar in those with and without 
obstructive coronary disease.     
BNP was measured in 61% and NT-proBNP was measured in 51% of patients that 
underwent coronary angiography.  There was no significant difference in 
natriuretic peptide levels between those with and without obstructive CAD 
(median 315 vs. 323 pg/mL; p = 0.90 [BNP] and 1132 vs. 1532 pg/mL; p = 0.37 
[NT-proBNP], respectively).  hsTnI was measured in 65% of patients and there 
was no difference in peak hsTnI levels between those without and without CAD 
(median 18 vs. 16 ng/L; p = 0.89, respectively).  Twenty-nine percent of 
participants had an hsTnI above the reference range and there was no difference 
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between those with and without obstructive CAD (27% vs. 30%; p = 0.86, 
respectively).    
As those with obstructive disease had a higher prevalence of CKD, they had a 
lower mean estimated glomerular filtration rate (eGFR) than those without 
obstructive CAD (61 vs. 68 mL/min/1.73m2; p = 0.17, respectively).  Rates of 
hyponatraemia and hypoalbuminaemia were similar in each group, as was CRP 
(median 12 vs. 15 mg/L; p = 0.80).  Anaemia was significantly more common in 
those with obstructive CAD than those without (55% vs. 30%; p = 0.025, 
respectively), however, the mean haemoglobin was similar (121 vs. 125 g/L; p = 
0.43, respectively).   
 All angiography 
(n = 75) 
No obstructive CAD 
(n = 37) 
Obstructive CAD 
(n = 38) 
p-value 
ECG 
Rate (bpm) 86 [25]         94 [28] 79 [18] <0.01 
AF 42 (56) 24 (65) 18 (47) 0.18 
Bundle branch block 10 (13) 4 (11) 6 (16) 0.53 
LVH 7 (9) 3 (8) 4 (11) 0.72 
Q wave 10 (13) 1 (3) 9 (24) <0.01 
T-wave inversion 35 (47) 17 (46) 18 (47) 0.90 
QRS duration (ms) 99 [28] 97 [29] 102 [28] 0.48 
QTc (ms) 450 [35] 445 [36] 455 [34] 0.20 
CXR 
Cardiomegaly 56 (75) 31 (84) 25 (66) 0.073 
Upper lobe venous 
diversion 
53 (71) 28 (76) 25 (66) 0.35 
Interstitial oedema 15 (20) 7 (19) 8 (21) 0.82 
Alveolar oedema 43 (57) 19 (51) 24 (63) 0.30 
Perihilar oedema 31 (41) 15 (41) 16 (42) 0.89 
Pleural effusion(s) 35 (47) 18 (49) 17 (45) 0.73 
Haematology 
Hb (g/L) 123 [19] 125 [18] 121 [20] 0.43 
Anaemia 32 (43) 11 (30) 21 (55) 0.025 
WCC (x 109/L) 8.2 [2.3] 8.6 [2.0] 7.9 [2.6] 0.21 
Biochemistry 
NT-proBNP 38 (51) 17 (46) 21 (55) 0.42 
NT-proBNP (pg/mL) 1376 [894-2819] 1532 [1287-2819] 1132 [818-2494] 0.37 
BNP 46 (61) 21 (57) 25 (66) 0.42 
BNP (pg/mL) 319 [173-856] 323 [185-717] 315 [167-904] 0.90 
hsTnI 49 (65) 27 (73) 22 (58) 0.17 
hsTnI (ng/L) 16 [9-29] 16 [10-27] 18 [7-34] 0.89 
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Elevated hsTnI 14 (29) 8 (30) 6 (27) 0.86 
Na+ (mmol/L) 138 [3] 138 [3] 138 [3] 0.95 
Hyponatraemia 3 (4) 3 (8) 0 (0) 0.073 
K+ (mmol/L) 4.4 [0.6] 4.3 [0.6] 4.5 [0.5] 0.046 
Urea (mmol/L) 8.0 [4.2] 7.5 [4.7] 8.5 [3.5] 0.29 
Creatinine (µmol/L) 96 [34] 91 [39] 102 [27] 0.14 
eGFR 
(mL/min/1.73m2) 
64 [20] 68 [21] 61 [19] 0.17 
eGFR <60mL/min/ 
1.73m2 
31 (41) 12 (32) 19 (50) 0.12 
Albumin (g/L) 34 [4] 34 [4] 34 [3] 0.77 
Hypoalbuminaemia 38 (51) 17 (46) 21 (55) 0.42 
CRP (mg/L) 14 [5-23] 12 [4-24] 15 [5-18] 0.80 
Elevated CRP 43 (57) 20 (54) 23 (61) 0.57 
Glucose (mmol/L) 6.6 [5.3-8.6] 6.2 [5.3-8.3] 7.0 [5.3-9.6] 0.39 
Values are mean [standard deviation], median [Q1-Q3], or n (%). AF, atrial fibrillation; AV, atrioventricular; 
BNP, B-type natriuretic peptide; CAD, coronary artery disease; CRP, C-reactive protein; CXR, chest x-ray; 
ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; hsTnI, high-
sensitivity troponin I; K+, potassium; LVH, left ventricular hypertrophy; Na+, sodium; NT-proBNP, N-terminal 
prohormone BNP; WCC, white cell count.    
Table 5-5: ECG, CXR and laboratory results stratified by obstructive 
epicardial CAD.  
The echocardiography findings of the participants based on the presence of 
absence of obstructive CAD are presented in Table 5-6.  The LVEF was similar in 
those with and without obstructive CAD (mean 58% vs. 60%; p = 0.37, 
respectively), but the LVESD was slightly larger in those with obstructive disease 
(mean 17 vs. 15 mm/m2; p = 0.038).  There were no differences in the rates of 
LVH or LA dilatation between the groups.  However, participants with 
obstructive CAD had a higher mean E/e’ and more diastolic dysfunction (defined 
as E/e’ ≥13 and e’ <9 cm/s) than those without obstructive CAD (16.4 vs. 12.9; p 
= 0.027, and 67% vs. 39%; p = 0.029, respectively).  Those without obstructive 
disease had significantly higher rates of mild or moderate valvular heart disease 
than those without obstructive disease (89% vs. 63%; p <0.01).   
 All angiography 
(n = 75) 
No obstructive CAD 
(n = 37) 
Obstructive CAD 
(n = 38) 
p-value 
LV structure and systolic function 
LVEDD (mm/m2) 24 [3] 24 [3] 25 [3] 0.061 
LVESD (mm/m2) 16 [4] 15 [4] 17 [4] 0.038 
LVEF (%) 59 [6] 60 [6] 58 [6] 0.37 
S' lateral (cm/s) 6.7 [2.0] 7.1 [2.6] 6.4 [1.3] 0.16 
Septal wall 
thickness (mm) 
13 [2] 13 [2] 13 [2] 0.51 
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Posterior wall 
thickness (mm) 
12 [2] 12 [2] 12 [2] 0.90 
LVH 46 (61) 23 (62) 23 (61) 0.88 
LV diastolic function 
E/A 1.2 [1.0] 1.0 [0.3] 1.3 [1.2] 0.44 
Deceleration time 
(ms) 
222 [82] 228 [75] 217 [89] 0.58 
E' average (cm/s) 7.7 [2.5] 8.6 [2.8] 7.0 [2.0] <0.01 
E/e' average 14.9 [6.3] 12.9 [4.3] 16.4 [7.3] 0.027 
Diastolic 
dysfunction        
35 (55) 11 (39) 24 (67) 0.029 
LA volume (mL/m2) 45 [16] 47 [16] 44 [16] 0.37 
LA dilatation 65 (88) 33 (92) 32 (84) 0.33 
RV structure and function 
RVEDD (mm) 35 [7] 35 [8] 34 [6] 0.35 
TAPSE (mm) 20 [5] 21 [4] 20 [5] 0.75 
Estimated RVSP 
(mmHg) 
40 [16] 38 [13] 41 [19] 0.57 
Valve disease 
Mild/moderate 
valve disease 
57 (76) 33 (89) 24 (63) <0.01 
Values are mean [standard deviation] or n (%). CAD, coronary artery disease; LA, left atrial; LV, left 
ventricular; LVEDD, LV end-diastolic dimension; LVEF, LV ejection fraction; LVESD, LV end-systolic 
dimension; LVH, LV hypertrophy; RV, right ventricular; RVEDD, RV end-diastolic dimension; RVSP, RV 
systolic pressure; TAPSE, tricuspid annular plane systolic excursion.   
Table 5-6: Echocardiography findings stratified by obstructive epicardial 
CAD.  
5.2.6 Cardiac magnetic resonance imaging 
Table 5-7 details the cardiac magnetic resonance (CMR) imaging findings based 
on the presence or absence of obstructive epicardial CAD.  Twenty patients with 
no obstructive CAD and 24 patients with obstructive disease underwent CMR.  
Similar to the echocardiographic findings, the LVEF was similar in those with and 
without obstructive CAD (mean 58% vs. 61%; p = 0.17, respectively), but the 
LVESV was larger in those with obstructive disease (mean 35 vs. 27 mL/m2; p = 
0.047, respectively).  The rate of LVH was similar in both groups, but the 
proportion of patients with LA dilatation were greater in those without 
obstructive disease than those with epicardial CAD (84% vs. 48%; p = 0.014, 
respectively).   
Ischaemic late gadolinium enhancement (LGE) was more frequent in those with 
obstructive CAD (46% vs. 10%; p <0.01), whereas non-ischaemic LGE was similar 
in those with and without epicardial CAD.  Native T1 values were similar but the 
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mean extracellular volume (ECV) and the proportion of patients with a high ECV 
(>30%) were significantly greater in those with obstructive CAD than those 
without CAD (29.9% vs. 26.6%; p = 0.011, and 64% vs. 22%; p <0.01, respectively).  
The median global myocardial-perfusion reserve index (MPRI) and the proportion 
of patients with CMR evidence of inducible ischaemia (i.e. global MPRI <1.4) 
were not significantly different between those with and without obstructive 
epicardial CAD (1.41 vs. 1.65; p = 0.23, and 45% vs. 29%; p = 0.33, respectively).   
 All angiography 
(n = 44) 
No obstructive CAD 
(n = 20) 
Obstructive CAD 
(n = 24) 
p-value 
LV structure and function 
LVEDV (mL/m2) 76 [22] 69 [21] 81 [22] 0.061 
LVESV (mL/m2) 31 [13] 27 [11] 35 [13] 0.047 
LVSV (mL/m2) 44 [11] 42 [12] 47 [11] 0.16 
CI (L/min/m2) 3.2 [0.9] 3.2 [0.9] 3.3 [0.9] 0.70 
LVEF (%) 59 [7] 61 [6] 58 [7] 0.17 
MAPSE (mm) 13 [3] 13 [4] 13 [3] 1.0 
WMSI 1.1 [0.2] 1.0 [0.1] 1.1 [0.2] 0.049 
LV mass (g/m2) 67 [16] 65 [19] 69 [13] 0.50 
LVH 26 (58) 10 (50) 16 (64) 0.34 
LA structure 
LA volume (mL/m2) 68 [22] 70 [15] 65 [26] 0.44 
LA dilatation 27 (64) 16 (84) 11 (48) 0.014 
RV structure and function 
RVEDV (mL/m2) 80 [27] 75 [25] 83 [29] 0.33 
RVESV (mL/m2) 38 [15] 36 [15] 39 [16] 0.65 
RVSV (mL/m2) 42 [16] 39 [14] 44 [18] 0.27 
RVEF (%) 53 [9] 52 [9] 54 [8] 0.43 
TAPSE (mm) 18 [5] 18 [5] 19 [5] 0.64 
LGE 
Any LGE 27 (61) 9 (45) 18 (75) 0.042 
Ischaemic LGE 13 (30) 2 (10) 11 (46) <0.01 
Non-ischaemic LGE 16 (36) 7 (35) 9 (38) 0.86 
T1 mapping 
Native T1 (ms) 1283 [64] 1268 [74] 1296 [53] 0.17 
ECV (%) 28.4 [4.2] 26.6 [3.3] 29.9 [4.3] 0.011 
ECV >30% 18 (45) 4 (22) 14 (64) <0.01 
Adenosine stress perfusion imaging 
MPRI 1.49 [1.33-1.85] 1.65 [1.39-1.87] 1.41 [1.26-1.75] 0.23 
MPRI <1.4 13 (38) 4 (29) 9 (45) 0.33 
Values are mean [standard deviation], median [Q1-Q3], or n (%). CAD, coronary artery disease; CI, cardiac 
index; ECV, extracellular volume; LA, left atrial; LGE, late gadolinium enhancement; LV, left ventricular; 
LVEDV, LV end-diastolic volume; LVEF, LV ejection fraction; LVESV, LV end-systolic volume; LVH, LV 
hypertrophy; LVSV, LV stroke volume; MAPSE, mitral annular plane systolic excursion; MPRI, myocardial-
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perfusion reserve index; RV, right ventricular; RVEDV, RV end-diastolic volume; RVEF, RV ejection fraction; 
RVESV, RV end-systolic volume; RVSV, RV stroke volume; TAPSE, tricuspid annular plane systolic excursion; 
WMSI, wall motion score index.  
Table 5-7: CMR findings stratified by obstructive epicardial CAD.  
5.2.7 Invasive coronary physiology and haemodynamics 
Table 5-8 describes the invasive coronary physiology and haemodynamics of 
those with and without obstructive CAD.  Coronary physiology testing was 
performed in 36 of those no obstructive CAD and 26 of those with obstructive 
CAD.  The prevalence of endothelium-independent CMD was similar in both those 
with and without epicardial CAD (62% vs. 69%; p = 0.52, respectively).  CFR was 
not significantly different in those with and without obstructive CAD (median 2.0 
vs. 2.4; p = 0.059, respectively), but the median IMR was higher in those without 
than with obstructive epicardial disease (27 vs. 18; p = 0.015, respectively).  
Endothelium-dependent CMD was present in 24% of the 36 participants with no 
obstructive CAD, whereas none of the five patients with obstructive epicardial 
disease that underwent endothelial function testing had evidence of coronary 
endothelial dysfunction.   
LVEDP was measured invasively in 69 of the 75 patients (92%) that underwent 
coronary angiography.  The median LVEDP was 12 mmHg and 31 patients (45%) 
had an elevated LVEDP (≥12 mmHg).  Of note, coronary angiography was 
performed at an interval of around three months (median 97 days) from 
recruitment and all but one (99%) were discharged from hospital on a loop 
diuretic.  Those without obstructive CAD were more likely to have an elevated 
LVEDP (≥12 mmHg) than those with obstructive disease (60% vs 29%; p = 0.011, 
respectively).   
 All angiography 
 
No obstructive 
CAD 
Obstructive CAD p-value 
 (n = 62) (n = 36) (n = 26)  
Endothelium-
independent CMD 
41 (66) 25 (69) 16 (62) 0.52 
CFR 2.1 [1.4-2.7] 2.4 [1.5-3.1] 2.0 [1.2-2.4] 0.059 
CFR <2.0 28 (45) 15 (42) 15 (50) 0.52 
IMR 23 [15-39] 27 [19-43] 18 [12-26] 0.015 
IMR ≥25 32 (52) 21 (58) 11 (42) 0.21 
 (n = 41) (n = 36) (n = 5)  
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Endothelium-
dependent CMD 
10 (24) 10 (28) 0 (0) 0.18 
 (n = 69) (n = 35) (n = 34)  
LVEDP (mmHg) 12 [9-15] 13 [10-15] 10 [8-15] 0.25 
LVEDP ≥12 mmHg 31 (45) 21 (60) 10 (29) 0.011 
Values are median [Q1-Q3] or n (%). CAD, coronary artery disease; CFR, coronary flow reserve; CMD, 
coronary microvascular dysfunction; IMR, index of microcirculatory resistance; LVEDP, left ventricular end-
diastolic pressure.   
Table 5-8: Invasive coronary physiology and haemodynamics stratified by 
obstructive epicardial CAD.  
5.3 Correlates of obstructive epicardial coronary artery 
disease 
The correlates of obstructive epicardial CAD on invasive coronary angiography 
are presented in Table 5-9.  Obstructive epicardial CAD was associated with a 
past history of CAD (ϕ = 0.33; p <0.01), MI (ϕ = 0.28; p = 0.015), revascularisation 
(ϕ = 0.29; p = 0.013) and CKD (ϕ = 0.28; p = 0.013).  Epicardial CAD was also 
correlated with ischaemic LGE (ϕ = 0.39; p <0.01), ECV (rpb = 0.40; p = 0.011) 
and an elevated ECV (ϕ = 0.41; p <0.01) on CMR.  It was inversely correlated with 
female sex (ϕ = -0.25; p = 0.028), CFR (rpb = -0.27; p = 0.035) and an elevated 
LVEDP (ϕ = -0.31; p = 0.01).   
 
Obstructive CAD p-value 
Female sex -0.25 0.028 
History of CAD 0.33 <0.01 
History of MI 0.28 0.015 
History of revascularisation 0.29 0.013 
CKD 0.28 0.013 
E/e' 0.28 0.027 
Ischaemic LGE 0.39 <0.01 
ECV (%) 0.40 0.011 
ECV >30% 0.41 <0.01 
CFR -0.27 0.035 
LVEDP ≥12 mmHg -0.31 0.01 
BMI, body mass index; CAD, coronary artery disease; CFR, coronary flow reserve; CKD, chronic kidney 
disease; CMR, cardiac magnetic resonance imaging; LGE, late gadolinium enhancement; LVEDP, left 
ventricular end-diastolic volume; MI, myocardial infarction.   
Table 5-9: Correlates of obstructive epicardial CAD.  
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5.4 Pattern and severity of coronary artery disease 
Of the 38 participants with obstructive epicardial CAD, 20 (53%) had single-vessel 
and 18 (47%) had multi-vessel CAD (13 [34%] with two-vessel and five [13%] with 
three-vessel disease) (Figure 5-2).  Five patients (13%) had a ≥50% stenosis of the 
left main coronary artery; this was considered to represent two-vessel CAD.  
Twenty-five patients (66%) had obstructive disease in the left anterior 
descending (LAD) artery, 16 (42%) in the right coronary artery (RCA), and 15 
(39%) in the left circumflex (LCx) artery (Figure 5-3).  Of those with two-vessel 
CAD, five (38%) had obstructive LAD and LCx (or left main coronary artery) 
disease, five (38%) had LAD and RCA lesions, and three (23%) had LCx and RCA 
disease.   
 
1VD, single-vessel disease; 2VD, two-vessel disease; 3VD, three-vessel disease.   
Figure 5-2: Number of diseased epicardial coronary arteries in study 
participants with obstructive epicardial CAD. 
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LAD, left anterior descending artery; LCx, left circumflex artery; LM, left main coronary artery; RCA, right 
coronary artery.   
Figure 5-3: Location of obstructive epicardial coronary stenoses in study 
cohort.  
Of the 37 participants with no obstructive epicardial CAD, 11 (30%) had normal 
coronary arteries and 26 (70%) had minor non-obstructive CAD (Figure 5-4).   
 
CAD, coronary artery disease.   
Figure 5-4: Normal coronary arteries and non-obstructive CAD in study 
participants with no obstructive CAD.   
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5.5 Outcomes related to obstructive epicardial coronary 
artery disease 
Mortality 
Over a median follow-up of 18 months, there were no significant differences in 
mortality rates between those with and without obstructive epicardial CAD 
(Figures 5-5, 5-6, 5-7, 5-8).  However, there were very few deaths during the 
follow-up period.   
 
Figure 5-5: Kaplan-Meier curves for all-cause mortality by obstructive CAD.   
0
10
20
30
40
50
60
70
80
90
10
0
Cu
m
ula
tiv
e 
pe
rc
en
ta
ge
 (%
)
38 38 35 35 33 28 17Obstructive CAD
37 37 34 34 30 27 21No obstructive CAD
Number at risk:
0 3 6 9 12 15 18
Months since recruitment
No obstructive CAD
Obstructive CAD
All-cause mortality
Log-rank p-value 0.75
162 
 
 
Figure 5-6: Kaplan-Meier curves for CV mortality by obstructive CAD.   
 
Figure 5-7: Kaplan-Meier curves for HF mortality by obstructive CAD.   
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Figure 5-8: Kaplan-Meier curves for non-CV mortality by obstructive CAD.   
Hospitalisations 
Participants with CAD had significantly more hospitalisations for any reason 
(Figure 5-9), for a CV cause (Figure 5-10), and for HF (Figure 5-11) than those 
with no obstructive CAD.  Non-CV hospitalisations were similar in both groups 
(Figure 5-12).   
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Figure 5-9: Kaplan-Meier curves for all-cause hospitalisation by obstructive 
CAD.   
 
Figure 5-10: Kaplan-Meier curves for CV hospitalisation by obstructive CAD.   
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Figure 5-11: Kaplan-Meier curves for HF hospitalisation by obstructive CAD.   
 
Figure 5-12: Kaplan-Meier curves for non-CV hospitalisation by obstructive 
CAD.   
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Following invasive coronary assessment as part of the study, eight participants 
(21% of those with obstructive CAD) subsequently underwent PCI.  The reasons 
given by clinicians for revascularisation in these subjects were: “prognostically 
significant disease” or angina/“anginal equivalent” symptoms despite medical 
therapy.  The number of patients revascularised was very small, so I was unable 
to evaluate the association between revascularisation and outcomes.   
5.6 Complications of invasive coronary angiography 
There were no procedural complications related to invasive coronary 
angiography in any of the study participants.  Two patients (3%) required 
hospitalisation for treatment of acute kidney injury (AKI) following coronary 
angiography.  Both patients had established stage 3 CKD before cardiac 
catheterisation and had a stable eGFR on blood testing in the week prior to 
angiography.   
One patient had significant urological problems which were felt to have 
contributed to the deterioration in renal function in addition to contrast-induced 
nephropathy.  His AKI was managed with IV fluids and temporary discontinuation 
of nephrotoxic medication with full renal recovery.  The other patient had an 
arrangement to have his renal function checked by the general practitioner (GP) 
three days after angiography.  This showed a significant decline in his eGFR and 
the GP advised hospital admission, but the patient declined.  He subsequently 
developed oligoanuria and was hospitalised three days later.  He required 
temporary haemodialysis for four days after which there was full renal recovery.   
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5.7 Summary 
In this hospitalised HFpEF cohort, over half of patients had obstructive CAD on 
invasive coronary angiography.  Those with obstructive disease were more often 
male and had a high burden of previous CAD, CKD and diabetes.  There was no 
significant difference in natriuretic peptide levels between those with and 
without obstructive CAD.  Interestingly, there was also no difference in troponin 
levels, suggesting that significant acute myocardial ischaemia was not a major 
cause of HF decompensation.  Patients with obstructive CAD had higher 
estimated LV filling pressures on echocardiography than those without.  
Therefore, it is possible that sub-clinical ischaemia might contribute to diastolic 
dysfunction and decompensation in HFpEF.  On CMR, participants with 
obstructive CAD had more ischaemic LGE and higher ECV than those without 
significant coronary disease.  This suggests that myocardial ischaemia not only 
results in MI, but also contributes to diffuse myocardial fibrosis, which may play 
an important role in those with HFpEF and CAD.   
Although the prevalence of AF was similar in those with and without obstructive 
CAD, those with non-obstructive disease had larger LA volumes on CMR and were 
more frequently prescribed digoxin at hospital discharge, suggesting that atrial 
remodelling and AF with sub-optimal rate-control may have played a role in HF 
decompensation in those without obstructive CAD.  Those without obstructive 
disease had higher rates of mild or moderate valve disease than those with 
significant epicardial CAD.  Nonetheless, the majority of patients both with and 
without obstructive CAD had a degree of valve disease on echocardiography, so 
it is possible that seemingly non-significant valve disease may play a role in 
precipitating decompensation in HFpEF patients, regardless of the presence of 
obstructive CAD.  All echocardiograms were performed at rest, therefore, the 
possibility of worsening of valve dysfunction under stress conditions (e.g. 
exercise) cannot be excluded.  Indeed, previous studies have reported that mild 
functional mitral regurgitation can become significant during stress and is 
associated with increased adverse events in HFpEF.263,264   
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In the 2019 Scottish Health Survey, the prevalence of ischaemic heart disease 
(IHD, defined as a history of MI or angina) in the Scottish population was 5% (7% 
in men, 4% in women).265  For comparison with my study population (mean age 
72 years), the prevalence of IHD in the Scottish population was 13% (17% in men, 
9% in women) in those aged 65-74 years, and 23% (30% in men, 18% in women) in 
those aged >75 years.  However, data on the prevalence of angiographically 
documented CAD in unselected patients is extremely limited.  A pooled analysis 
assessed the prevalence of obstructive CAD (determined by invasive coronary 
angiography and FFR) in patients referred for investigation of suspected CAD.88  
In patients presenting with dyspnoea, the prevalence of obstructive CAD in those 
aged 60-69 years was 27% in men and 14% in women, and in those aged >70 years 
was 32% in men and 12% in women.  Therefore, the prevalence of 
angiographically documented CAD in my HFpEF cohort (51% overall, 63% in men, 
38% in women) is significantly higher than would be expected in patients of the 
same age in the general population.   
Over a median follow-up period of 18 months, there was no significant 
difference in mortality rates between those with and without obstructive 
epicardial CAD.  However, there were few deaths during the follow-up period.  
Nonetheless, patients with obstructive CAD had significantly more 
hospitalisations for any reason, for a CV cause and for HF than those with no 
obstructive CAD.  Of note, HF re-hospitalisation was defined as a primary 
discharge diagnosis of HF, therefore, it is possible that some re-hospitalisations 
attributed to HF could have been due to an alternative cause.   
These findings suggest that obstructive epicardial CAD may contribute to HF 
decompensation in many patients with HFpEF and, therefore, coronary 
revascularisation might result in reduced hospitalisations and improved quality 
of life.  Only eight study participants (21% of those with obstructive CAD) 
subsequently underwent PCI for clinical indications, therefore, I was unable to 
assess the association between revascularisation and outcomes in this cohort.   
Reported outcomes in HFpEF patients vary depending on study design, clinical 
setting and LVEF threshold used to define HFpEF.  Epidemiological studies report 
high mortality rates in HFpEF patients, with a 1-year mortality of 20-29%,8,12,13 
whilst randomised controlled trials (RCTs) have much lower annualised mortality 
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rates of 4-5% per year.14–16  The annualised mortality rate in my cohort was 9%, 
suggesting that I recruited a higher risk group than that enrolled in RCTs 
(generally younger with less comorbidities), but a lower risk group than 
unselected HFpEF patients in epidemiological studies (generally older with a 
greater burden of comorbidities and frailty).  In terms of hospitalisations, 
epidemiological studies report a >50% rate of re-hospitalisation within one year 
of a hospitalisation with HFpEF.18  In my cohort, the annualised re-
hospitalisation rate was 43%, slightly lower than that reported in epidemiological 
studies, again reflecting the lower risk nature of my study population.   
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Chapter 6 Results – Endothelium-independent 
coronary microvascular dysfunction in heart 
failure with preserved ejection fraction 
In this chapter I will report the prevalence of endothelium-independent coronary 
microvascular dysfunction (CMD) in the study cohort.  I will describe the clinical 
characteristics, investigation results and correlates of the population based on 
different measures of endothelium-independent coronary microvascular 
function, based on coronary flow reserve (CFR) and the index of microcirculatory 
reserve (IMR).  Finally, I will report clinical outcomes (mortality and 
hospitalisations) on the basis of these assessments of coronary microvascular 
function.   
6.1 Prevalence of endothelium-independent coronary 
microvascular dysfunction 
A total of 62 participants underwent guidewire-based invasive coronary 
physiology testing for quantification of CFR and IMR.  Endothelium-independent 
CMD (defined as CFR <2.0 and/or IMR ≥25) was present in 41 of the 62 
participants (66% [95% CI 53-77%]) that underwent guidewire-based coronary 
physiology testing (Figure 6-1).   
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CFR, coronary flow reserve; EI-CMD, endothelium-independent coronary microvascular dysfunction; IMR, 
index of microcirculatory resistance.   
Figure 6-1: Prevalence of endothelium-independent CMD in study cohort.  
Forty-two patients (68%) had microvascular assessment of the LAD, 11 (18%) had 
RCA, and nine (15%) had assessment of the LCx.  If a patient was found to have a 
functionally significant epicardial stenosis, coronary microvascular function was 
performed in another non-obstructed artery; this was the case in three patients.   
6.2 Clinical characteristics by endothelium-independent 
coronary microvascular dysfunction 
6.2.1 Demographics and clinical features 
The baseline demographics and clinical features of the participants on the basis 
of endothelium-independent coronary microvascular function are described in 
Table 6-1.  The groups had similar demographics, including age, sex, frailty, BMI 
and smoking history.  There were no major differences in NYHA functional class 
or HF symptoms and signs at presentation between those with and without CMD.  
 
Guidewire-based invasive
coronary physiology testing
n = 62
IMR high
IMR high
CFR 
low
CFR 
low
CFR 
high
CFR 
high
IMR low
IMR low
19 
(31%)
9 
(15%)
13 
(21%)
21 
(34%)
EI-CMD
n = 41 (66%)
No EI-CMD
n = 21 (34%)
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All pressure wire 
studies 
(n = 62) 
No endothelium-
independent CMD 
(n = 21) 
Endothelium-
independent CMD 
(n = 41) 
p-value 
Demographics 
Age (years) 72 [9] 74 [8] 72 [9] 0.41 
Female sex 33 (53) 11 (52) 22 (54) 0.92 
BMI (kg/m2) 33 [8] 33 [9] 33 [7] 0.80 
Obesity 28 (45) 9 (43) 19 (46) 0.79 
Smoking history 34 (55) 11 (52) 23 (56) 0.78 
Hospitalisation details 
Length of stay 
(days) 
7 [5-11] 6 [6-9] 7 [5-11] 0.56 
HF symptoms 
NYHA functional class 
II 2 (3) 1 (5) 1 (2) 0.68 
III 31 (50) 9 (43) 22 (54) 
 
IV 29 (47) 11 (52) 18 (44) 
 
Orthopnoea 42 (68) 14 (67) 28 (68) 0.90 
PND 30 (48) 11 (52) 19 (46) 0.65 
Ankle swelling 56 (90) 20 (95) 36 (88) 0.35 
Admission vital signs 
HR (bpm) 85 [26] 89 [22] 82 [20] 0.36 
SBP (mmHg) 151 [31] 155 [33] 149 [30] 0.44 
DBP (mmHg) 81 [20] 81 [22] 82 [20] 0.89 
MAP (mmHg) 105 [20] 106 [20] 104 [20] 0.75 
HF signs 
JVD 45 (73) 16 (76) 29 (71) 0.65 
Murmur 17 (27) 8 (38) 9 (22) 0.18 
Crepitations 48 (77) 15 (71) 33 (80) 0.42 
Pleural effusion(s) 25 (40) 10 (48) 15 (37) 0.40 
Oedema 56 (90) 20 (95) 36 (88) 0.35 
Ascites 1 (2) 0 (0) 1 (2) 0.47 
Values are mean [standard deviation], median [Q1-Q3], or n (%). BMI, body mass index; CMD, coronary 
microvascular dysfunction; DBP, diastolic blood pressure; HF, heart failure; HR, heart rate; JVD, jugular 
venous distention; MAP, mean arterial pressure; NYHA, New York Heart Association; PND, paroxysmal 
nocturnal dyspnoea; SBP; systolic blood pressure.  
Table 6-1: Demographics and clinical features stratified by endothelium-
independent CMD.    
6.2.2 Past medical history 
Table 6-2 details the past medical history of participants according to the 
presence or absence of endothelium-independent CMD.  Thirty-one percent of 
those who underwent microvascular function testing had a previous history of 
CAD.  There were no significant differences between the groups in rates of 
173 
 
previous CAD, MI, revascularisation or angina.  Comorbidities including 
hypertension (76%), AF (65%) and diabetes (53%) were frequent.  There were no 
major differences in the comorbidity profile of the two groups.   
 All pressure 
wire studies 
(n = 62) 
No endothelium-
independent CMD 
(n = 21) 
Endothelium-
independent CMD 
(n = 41) 
p-value 
History of HF 
Previous HF diagnosis 23 (37) 5 (24) 18 (44) 0.12 
Previous HFH 15 (24) 5 (24) 10 (24) 0.96 
History of CAD 
Any CAD 19 (31) 7 (33) 12 (29) 0.74 
MI 13 (21) 4 (19) 9 (22) 0.79 
Angina 6 (10) 3 (14) 3 (7) 0.38 
Current angina 5 (8) 2 (10) 3 (7) 0.76 
Revascularisation 8 (13) 2 (10) 6 (15) 0.57 
PCI 8 (13) 2 (10) 6 (15) 0.57 
CABG 1 (2) 0 (0) 1 (2) 0.47 
CV comorbidities 
Hypertension 47 (76) 15 (71) 32 (78) 0.56 
Dyslipidaemia 5 (8) 1 (5) 4 (10) 0.49 
CVD 13 (21) 6 (29) 7 (17) 0.29 
PAD 7 (11) 4 (19) 3 (7) 0.17 
AF 40 (65) 11 (52) 29 (71) 0.15 
Valve disease 
(mild/moderate) 
12 (19) 6 (29) 6 (15) 0.19 
Non-CV comorbidities 
Diabetes 33 (53) 11 (52) 22 (54) 0.92 
CKD 19 (31) 9 (43) 10 (24) 0.14 
Chronic liver disease 0 (0) 0 (0) 0 (0) 
 
Depression 4 (6) 1 (5) 3 (7) 0.70 
Cancer 5 (8) 2 (10) 3 (7) 0.76 
COPD 15 (24) 5 (24) 10 (24) 0.96 
Asthma 5 (8) 0 (0) 5 (12) 0.095 
Anaemia 14 (23) 3 (14) 11 (27) 0.26 
Hypothyroidism 9 (15) 5 (24) 4 (10) 0.14 
Osteoarthritis 15 (24) 5 (24) 10 (24) 0.96 
Values are n (%). AF, atrial fibrillation; CABG, coronary artery bypass grafting; CAD, coronary artery 
disease; CKD, chronic kidney disease; CMD, coronary microvascular dysfunction; COPD, chronic obstructive 
pulmonary disease; CV, cardiovascular; CVD, cerebrovascular disease; HF, heart failure; HFH, HF 
hospitalisation; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary 
intervention.  
Table 6-2: Past medical history stratified by endothelium-independent CMD.    
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6.2.3 Drug history – medication on admission, in-hospital 
treatment and medication at discharge 
Table 6-3 summarises the admission medication, in-hospital treatment and 
discharge medication in those with and without endothelium-independent CMD.  
There were no significant differences in the rates of prescription of CV or non-CV 
drugs at either hospital admission or discharge.  During hospitalisation, all those 
without CMD treated with diuretics received regular IV doses, compared with 
only 73% of those with CMD; 15% with microvascular dysfunction received a 
single dose of IV diuretic and 12% received oral diuretic therapy (p = 0.038).   
 All pressure wire 
studies 
(n = 62) 
No endothelium-
independent CMD 
(n = 21) 
Endothelium-
independent CMD 
(n = 41) 
p-value 
Admission medication 
CV medication 
Antiplatelet 21 (34) 9 (43) 12 (29) 0.28 
Anticoagulant 31 (50) 8 (38) 23 (56) 0.18 
Statin 42 (68) 12 (57) 30 (73) 0.20 
Loop diuretic 28 (45) 8 (38) 20 (49) 0.42 
Furosemide-
equivalent dose 
(mg) 
80 [40-140] 80 [40-120] 80 [40-160] 0.62 
Thiazide 5 (8) 1 (5) 4 (10) 0.49 
MRA 1 (2) 0 (0) 1 (2) 0.47 
ACEI/ARB 42 (68) 13 (62) 29 (71) 0.48 
Beta-blocker 42 (68) 14 (67) 28 (68) 0.90 
CCB 23 (37) 7 (33) 16 (39) 0.66 
Digoxin 6 (10) 2 (10) 4 (10) 0.98 
 
Diabetic 
medication 
(n = 33) 
27 (82) 
(n = 11) 
10 (91) 
(n = 22) 
17 (77) 
 
0.34 
Insulin 11 (33) 4 (36) 7 (32) 0.79 
Non-CV medication 
Bronchodilator 20 (32) 5 (24) 15 (37) 0.31 
Antidepressant 14 (23) 6 (29) 8 (20) 0.42 
In-hospital treatment 
Furosemide 61 (98) 20 (95) 41 (100) 0.16 
IV (>1 dose) 50 (82) 20 (100) 30 (73) 0.038 
IV (1 dose) 6 (10) 0 (0) 6 (15) 
 
Oral 5 (8) 0 (0) 5 (12) 
 
IV nitrate 3 (5) 1 (5) 2 (5) 0.98 
Dopamine 0 (0) 0 (0) 0 (0) 
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Oxygen 28 (45) 11 (52) 17 (41) 0.41 
CPAP 1 (2) 0 (0) 1 (2) 0.47 
Discharge medication 
CV medication 
Antiplatelet 21 (34) 10 (48) 11 (27) 0.10 
Anticoagulant 41 (66) 11 (52) 30 (73) 0.10 
Statin 42 (68) 12 (57) 30 (73) 0.20 
Loop diuretic 61 (98) 20 (95) 41 (100) 0.16 
Furosemide-
equivalent dose 
(mg) 
80 [80-120] 80 [80-140] 80 [80-120] 0.76 
Thiazide 5 (8) 1 (5) 4 (10) 0.49 
ACEI/ARB 41 (66) 14 (67) 27 (66) 0.95 
MRA 10 (16) 2 (10) 8 (20) 0.31 
Beta-blocker 46 (74) 16 (76) 30 (73) 0.80 
CCB 15 (24) 6 (29) 9 (22) 0.56 
Digoxin 22 (35) 8 (38) 14 (34) 0.76 
 
Diabetic 
medication 
(n= 33) 
27 (82) 
(n = 11) 
10 (91) 
(n = 22) 
17 (77) 
 
0.34 
Insulin 12 (36) 5 (45) 7 (32) 0.44 
Values are mean [standard deviation] or n (%). ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; CCB, calcium channel blocker; CMD, coronary microvascular dysfunction; 
CPAP, continuous positive airway pressure; CV, cardiovascular; IV, intravenous; MRA, mineralocorticoid 
receptor antagonist.   
Table 6-3: Admission medication, in-hospital treatment and discharge 
medication stratified by endothelium-independent CMD.   
6.2.4 Baseline investigations 
The baseline ECG, CXR and laboratory results of those with and without 
endothelium-independent CMD are presented in Table 6-4.  ECG and CXR findings 
were generally similar in both groups, but those with CMD had more radiological 
interstitial oedema than those without CMD (27% vs. 5%; p = 0.037, respectively).  
Most routine haematology and biochemistry results were comparable between 
the groups.  The proportion of those with renal impairment and anaemia was 
similar in both groups.  BNP was measured in 60% of patients and those with CMD 
had significantly higher levels than those without CMD (median 569 vs. 197 
pg/mL; p = 0.036, respectively).  However, NT-proBNP was measured in 53% of 
patients and was only slightly higher in those with CMD than those without 
(median 1459 vs. 1366; p = 0.37, respectively).  hsTnI levels were similar in 
those with CMD and those with no CMD (median 16 vs. 20 ng/L; p = 0.22, 
respectively).    
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 All pressure 
wire studies 
(n = 62) 
No endothelium-
independent CMD 
(n = 21) 
Endothelium-
independent CMD 
(n = 41) 
p-value 
ECG 
Rate (bpm) 87 [26] 92 [32] 84 [23] 0.25 
AF 36 (58) 10 (48) 26 (63) 0.66 
Bundle branch block 8 (13) 3 (14) 5 (12) 0.82 
LVH 7 (11) 3 (14) 4 (10) 0.59 
Q waves 6 (10) 2 (10) 4 (10) 0.98 
T-wave inversion 28 (45) 11 (52) 17 (41) 0.41 
QRS duration (ms) 98 [26] 100 [22] 97 [29] 0.62 
QTc (ms) 445 [32] 444 [33] 446 [32] 0.82 
CXR 
Cardiomegaly 48 (77) 14 (67) 34 (83) 0.15 
Upper lobe venous 
diversion 
42 (68) 17 (81) 25 (61) 0.11 
Interstitial oedema 12 (19) 1 (5) 11 (27) 0.037 
Alveolar oedema 33 (53) 10 (48) 23 (56) 0.53 
Perihilar oedema 22 (35) 5 (24) 17 (41) 0.17 
Pleural effusion(s) 29 (47) 9 (43) 20 (49) 0.66 
Haematology 
Hb (g/L) 123 [19] 119 [20] 125 [19] 0.32 
Anaemia 26 (42) 10 (48) 16 (39) 0.52 
WCC (x 109/L) 8.3 [2.3] 8.4 [2.2] 8.2 [2.4] 0.81 
Biochemistry 
NT-proBNP 33 (53) 13 (62) 20 (49) 0.33 
NT-proBNP (pg/mL) 1385 [1040-2819] 1366 [414-2494] 1459 [1152-2948] 0.37 
BNP 37 (60) 11 (52) 26 (63) 0.40 
BNP (pg/mL) 355 [177-904] 197 [123-623] 569 [189-1253] 0.036 
hsTnI 41 (66) 14 (67) 27 (66) 0.95 
hsTnI (ng/L) 16 [7-29] 20 [14-36] 16 [5-25] 0.22 
Elevated hsTnI 12 (29) 4 (29) 8 (30) 0.94 
Na+ (mmol/L) 138 [3] 139 [2] 138 [4] 0.14 
Hyponatraemia 3 (5) 0 (0) 3 (7) 0.20 
K+ (mmol/L) 4.4 [0.6] 4.4 [0.5] 4.4 [0.6] 0.81 
Urea (mmol/L) 7.9 [4.3] 7.6 [3.1] 8.1 [4.9] 0.65 
Creatinine (µmol/L) 96 [36] 95 [25] 97 [41] 0.85 
eGFR 
(mL/min/1.73m2) 
65 [21] 63 [15] 66 [24] 0.58 
eGFR <60 mL/min/ 
1.73m2 
24 (39) 8 (38) 16 (39) 0.94 
Albumin (g/L) 34 [4] 35 [4] 34 [4] 0.47 
Hypoalbuminaemia 29 (47) 9 (43) 20 (49) 0.66 
CRP (mg/L) 13 [5-21] 9 [4-22] 13 [7-21] 0.61 
Elevated CRP 34 (55) 10 (48) 24 (59) 0.41 
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Glucose (mmol/L) 6.4 [5.3-8.5] 6.2 [5.3-8.2] 6.5 [5.3-8.6] 0.75 
Values are mean [standard deviation], median [Q1-Q3], or n (%). AF, atrial fibrillation; AV, atrioventricular; 
BNP, B-type natriuretic peptide; CMD, coronary microvascular dysfunction; CRP, C-reactive protein; CXR, 
chest x-ray; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; hsTnI, 
high-sensitivity troponin I; K+, potassium; LVH, left ventricular hypertrophy; Na+, sodium; NT-proBNP, N-
terminal prohormone BNP; WCC, white cell count.    
Table 6-4: ECG, CXR and laboratory results stratified by endothelium-
independent CMD.   
Table 6-5 details the echocardiography findings of patients stratified by 
endothelium-independent CMD; there were no significant differences between 
the groups.   
 All pressure 
wire studies 
(n = 62) 
No endothelium-
independent CMD 
(n = 21) 
Endothelium-
independent CMD 
(n = 41) 
p-value 
LV structure and systolic function 
LVEDD (mm/m2) 24 [3] 25 [3] 24 [4] 0.78 
LVESD (mm/m2) 16 [4] 15 [4] 16 [4] 0.42 
LVEF (%) 58 [6] 60 [6] 57 [5] 0.06 
S' lateral (cm/s) 6.8 [2.2] 6.9 [2.3] 6.7 [2.1] 0.73 
Septal wall thickness 
(mm) 
13 [3] 13 [2] 13 [3] 0.42 
Posterior wall 
thickness (mm) 
12 [2] 13 [2] 12 [2] 0.31 
LVH 36 (58) 14 (67) 22 (54) 0.33 
LV diastolic function 
E/A 1.3 [1.1] 1.0 [0.4] 1.4 [1.3] 0.43 
Deceleration time (ms) 226 [83] 224 [81] 227 [84] 0.88 
E' average (cm/s) 7.8 [2.5] 8.0 [1.6] 7.7 [2.9] 0.62 
E/e' average 14.1 [4.9] 13.5 [4.2] 14.4 [5.3] 0.54 
Diastolic dysfunction 27 (52) 11 (58) 16 (48) 0.51 
LA volume (mL/m2) 46 [15] 43 [11] 47 [17] 0.26 
LA dilatation 56 (92) 19 (90) 37 (92) 0.78 
RV structure and function 
RVEDD (mm) 35 [7] 34 [6] 36 [7] 0.34 
TAPSE (mm) 21 [4] 20 [3] 21 [5] 0.32 
Estimated RVSP 
(mmHg) 
39 [14] 42 [16] 36 [12] 0.25 
Valve disease 
Mild/moderate valve 
disease 
50 (81) 17 (81) 33 (80) 0.97 
Values are mean [standard deviation] or n (%). CMD, coronary microvascular disease; LA, left atrial; LV, left 
ventricular; LVEDD, LV end-diastolic dimension; LVEF, LV ejection fraction; LVESD, LV end-systolic 
dimension; LVH, LV hypertrophy; RV, right ventricular; RVEDD, RV end-diastolic dimension; RVSP, RV 
systolic pressure; TAPSE, tricuspid annular plane systolic excursion.   
Table 6-5: Echocardiography findings stratified by endothelium-independent 
CMD.   
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6.2.5 Cardiac magnetic resonance imaging 
Table 6-6 details the CMR findings stratified by endothelium-independent 
coronary microvascular function.  Again, there were no statistically significant 
differences between the groups.   
 All pressure 
wire studies 
(n = 35) 
No endothelium-
independent CMD 
(n = 11) 
Endothelium-
independent CMD 
(n = 24) 
p-value 
LV structure and function 
LVEDV (mL/m2) 74 [22] 75 [19] 74 [23] 0.91 
LVESV (mL/m2) 31 [13] 32 [12] 31 [14] 0.93 
LVSV (mL/m2) 43 [10] 43 [10] 43 [11] 0.89 
CI (L/min/m2) 3.2 [0.8] 3.2 [0.7] 3.1 [0.9] 0.75 
LVEF (%) 59 [7] 58 [7] 59 [7] 0.94 
MAPSE (mm) 13 [3] 12 [3] 13 [3] 0.32 
WMSI 1.1 [0.2] 1.1 [0.2] 1.1 [0.2] 0.50 
LV mass (g/m2) 67 [15] 70 [18] 65 [12] 0.29 
LVH 21 (58) 8 (73) 13 (52) 0.25 
LA structure 
LA volume (mL/m2) 67 [22] 65 [14] 68 [25] 0.69 
LA dilatation 21 (64) 7 (70) 14 (61) 0.62 
RV structure and function 
  
RVEDV (mL/m2) 76 [22] 84 [27] 73 [18] 0.17 
RVESV (mL/m2) 37 [14] 44 [20] 34 [11] 0.065 
RVSV (mL/m2) 39 [11] 40 [10] 39 [12] 0.78 
RVEF (%) 52 [9] 49 [8] 53 [9] 0.22 
TAPSE (mm) 18 [5] 20 [5] 18 [5] 0.38 
LGE 
Any LGE 22 (63) 7 (64) 15 (62) 0.95 
Ischaemic LGE 10 (29) 3 (27) 7 (29) 0.91 
Non-ischaemic LGE 13 (37) 4 (36) 9 (38) 0.95 
T1 mapping 
Native T1 (ms) 1279 [67] 1308 [70] 1266 [63] 0.10 
ECV (%) 28.0 [4.2] 29.5 [3.4] 27.4 [4.5] 0.23 
ECV >30% 12 (39) 4 (44) 8 (36) 0.68 
Adenosine stress perfusion imaging 
MPRI 1.66 [1.39-1.87] 1.55 [1.33-1.85] 1.70 [1.39-1.97] 0.37 
MPRI <1.4 7 (28) 3 (30) 4 (27) 0.86 
Values are mean [standard deviation], median [Q1-Q3], or n (%). CMD, coronary microvascular dysfunction; 
CI, cardiac index; ECV, extracellular volume; LA, left atrial; LGE, late gadolinium enhancement; LV, left 
ventricular; LVEDV, LV end-diastolic volume; LVEF, LV ejection fraction; LVESV, LV end-systolic volume; 
LVH, LV hypertrophy; LVSV, LV stroke volume; MAPSE, mitral annular plane systolic excursion; MPRI, 
myocardial-perfusion reserve index; RV, right ventricular; RVEDV, RV end-diastolic volume; RVEF, RV 
ejection fraction; RVESV, RV end-systolic volume; RVSV, RV stroke volume; TAPSE, tricuspid annular plane 
systolic excursion; WMSI, wall motion score index.   
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Table 6-6: CMR findings stratified by endothelium-independent CMD.  
6.2.6 Invasive coronary angiography, physiology and 
haemodynamics  
Table 6-7 summarises the invasive coronary angiography, physiology and 
haemodynamics stratified by the presence or absence of endothelium-
independent CMD.  There were no significant differences in the proportion of 
patients with epicardial CAD between the groups.  Of the 41 participants with 
endothelium-independent CMD, only six (21%) had evidence of endothelium-
dependent CMD, whereas four of the 21 patients (33%) without endothelium-
independent CMD had evidence of endothelium-dependent CMD.  The median 
LVEDP and the proportion of those with an LVEDP ≥12 mmHg was similar in those 
with and without CMD (13 vs. 11 mmHg; p = 0.41, and 53% vs. 33%; p = 0.15, 
respectively).   
 All pressure 
wire studies 
No endothelium-
independent CMD 
Endothelium-
independent CMD 
p-value 
 (n = 62) (n = 21) (n = 41)  
Obstructive epicardial 
CAD 
26 (42) 10 (48) 16 (39) 0.52 
 (n = 41) (n = 12) (n = 29)  
Endothelium-dependent 
CMD 
10 (24) 4 (33) 6 (21) 0.39 
 (n = 59) (n = 21) (n = 38)  
LVEDP (mmHg) 12 [9-15] 11 [10-13] 13 [9-15] 0.41 
LVEDP ≥12 mmHg 27 (46) 7 (33) 20 (53) 0.15 
Values are median [Q1-Q3] or n (%). CAD, coronary artery disease; CMD, coronary microvascular 
dysfunction; LVEDP, left ventricular end-diastolic pressure.   
Table 6-7: Invasive coronary angiography, physiology and haemodynamics 
stratified by endothelium-independent CMD.  
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6.3 Correlates of endothelium-independent coronary 
microvascular dysfunction 
There were no statistically significant correlates of endothelium-independent 
CMD (Table 6-8).  Of note, there was no association between endothelium-
independent and -dependent CMD (ϕ = -0.13; p = 0.40).   
 
Endothelium-independent CMD p-value 
BNP (pg/mL) 0.32 0.057 
hsTnI (ng/L) -0.26 0.097 
LVEF (%) - echocardiography -0.25 0.06 
Obstructive CAD -0.082 0.52 
Endothelium-dependent CMD -0.13 0.40 
BNP, B-type natriuretic peptide; CAD, coronary artery disease; CMD, coronary microvascular dysfunction; 
CMR, cardiac magnetic resonance; hsTnI, high-sensitivity troponin I; LVEF, left ventricular ejection fraction. 
Table 6-8: Correlates of endothelium-independent CMD.   
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6.4 Mechanisms of endothelium-independent coronary 
microvascular dysfunction 
6.4.1 Coronary flow reserve 
Coronary flow reserve (CFR) represents the vasodilator capacity of the epicardial 
and microvascular circulation and has been traditionally used to assess coronary 
microvascular function in the absence of obstructive epicardial CAD.  Thresholds 
to define CMD on the basis of CFR vary between 2.0 and 2.5.145  Contemporary 
studies and guidelines use an invasive CFR cut-off of <2.0, however, non-invasive 
studies continue to use the higher threshold of <2.5.  Using a threshold of <2.0, 
28 of the 62 participants (45% [95% CI 33-58%]) had an abnormal CFR (Figure 6-
2).231  Using the higher threshold of <2.5, 40 of the 62 patients (65% [95% CI 52-
76%]) would be diagnosed with CMD.   
 
CFR, coronary flow reserve.   
Figure 6-2: Study participants stratified by CFR.   
Baseline characteristics 
Table 6-9 details selected baseline characteristics according to a normal or 
abnormal CFR.  Symptoms and signs of HF were similar, and there were no 
significant differences in the prevalence of major comorbidities (including 
previous CAD) between the groups.  Natriuretic peptide and hsTnI levels were 
28
34
CFR <2.0 CFR ≥2.0
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similar in those with a normal and abnormal CFR, and the echocardiography 
findings of both groups were comparable.     
 
Normal CFR 
(n = 34) 
Abnormal CFR 
(n = 28) 
p-value 
Demographics 
Age (years) 74 [8] 71 [10] 0.17 
Female sex 19 (56) 14 (50) 0.64 
BMI (kg/m2) 33 [8] 33 [8] 0.81 
History of CAD 
Any CAD 9 (26) 10 (36) 0.43 
MI 5 (15) 8 (29) 0.18 
Revascularisation 2 (6) 6 (21) 0.069 
Biochemistry 
NT-proBNP (pg/mL) 1376 [845-2819] 1915 [1041-3676] 0.73 
BNP (pg/mL) 197 [145-785] 522 [285-1028] 0.12 
hsTnI (ng/L) 16 [5-34] 16 [10-25] 0.90 
CRP (mg/L) 14 [5-22] 12 [5-21] 0.84 
Echocardiography 
LVEF (%) 58 [6] 58 [6] 0.93 
LVH 22 (65) 14 (50) 0.24 
Diastolic dysfunction 16 (50) 11 (55) 0.73 
LA dilatation 32 (94) 24 (89) 0.46 
Values are mean [standard deviation], median [Q1-Q3], or n (%). BMI, body mass index; BNP, B-type 
natriuretic peptide; CAD, coronary artery disease; CFR, coronary flow reserve; CRP, C-reactive protein; 
hsTnI, high-sensitivity troponin I; LA, left atrial; LVEF, left ventricular ejection fraction; LVH, left 
ventricular hypertrophy; MI, myocardial infarction; NT-proBNP, N-terminal prohormone BNP.   
Table 6-9: Selected baseline characteristics stratified by CFR.  
Study investigations 
Table 6-10 details selected findings of CMR and invasive coronary assessment 
based on CFR.  There were no significant differences in cardiac structure and 
function between the groups.  The proportion of patients with epicardial CAD 
and endothelium-independent CMD was similar in both groups.  Those with an 
abnormal CFR were more likely to have an abnormal IMR than those with a 
normal CFR (68% vs. 38%; p = 0.02, respectively).   
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 Normal CFR Abnormal CFR p-value 
CMR (n = 20) (n = 15)  
LVEF (%) 59 [7] 58 [8] 0.71 
LVH 12 (60) 9 (56) 0.82 
LA dilatation 13 (68) 8 (57) 0.51 
Ischaemic LGE 4 (20) 6 (40) 0.19 
Non-ischaemic LGE 7 (35) 6 (40) 0.76 
Native T1 (ms) 1268 [76] 1295 [52] 0.29 
ECV (%) 27.8 [3.7] 28.4 [5.0] 0.72 
ECV >30% 7 (39) 5 (38) 0.98 
MPRI 1.70 [1.47-1.87] 1.47 [1.24-1.97] 0.68 
MPRI <1.4 4 (24) 3 (38) 0.47 
Invasive coronary assessment (n = 34) (n = 28)  
Obstructive epicardial CAD 13 (38) 13 (46) 0.52 
IMR 20 [13-32] 27 [20-44] 0.039 
IMR ≥25 13 (38) 19 (68) 0.02 
 (n = 22) (n = 19)  
Endothelium-dependent CMD 5 (23) 5 (26) 0.79 
 (n = 24) (n = 25)  
LVEDP (mmHg) 12 [9-15] 12 [10-15] 0.62 
Values are mean [standard deviation], median [Q1-Q3], or n (%). CAD, coronary artery disease; CFR, 
coronary flow reserve; CMD, coronary microvascular dysfunction; CMR, cardiac magnetic resonance; ECV, 
extracellular volume; IMR, index of microcirculatory resistance; LA, left atrial; LGE, late gadolinium 
enhancement; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction; LVH, 
left ventricular hypertrophy; MPRI, myocardial-perfusion reserve index.   
Table 6-10: Selected CMR and invasive coronary assessment findings 
stratified by CFR. 
Correlates of CFR 
Tables 6-11 and 6-12 show the correlates of CFR expressed as a binary and 
continuous variable, respectively.  An abnormal CFR was not associated with 
obstructive epicardial CAD or endothelium-dependent CMD but did correlate 
with an abnormal IMR (ϕ = 0.30; p = 0.02) and IMR expressed as a continuous 
variable (rpb = 0.26; p = 0.042).  When expressed as a continuous variable, CFR 
was negatively correlated with obstructive epicardial CAD on invasive coronary 
angiography (rpb = -0.27; p = 0.035).   
 
CFR <2.0 p-value 
Obstructive CAD 0.083 0.52 
IMR 0.26 0.042 
IMR ≥25 0.30 0.02 
Endothelium-dependent CMD 0.042 0.80 
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CAD, coronary artery disease; CFR, coronary flow reserve; CMD, coronary microvascular dysfunction; IMR, 
index of microcirculatory resistance.   
Table 6-11: Correlates of CFR <2.0 (binary).  
 
CFR p-value 
Obstructive CAD -0.27 0.035 
IMR -0.24 0.066 
IMR ≥25 -0.18 0.16 
Endothelium-dependent CMD 0.044 0.79 
CAD, coronary artery disease; CFR, coronary flow reserve; CMD, coronary microvascular dysfunction; CMR, 
cardiac magnetic resonance; IMR, index of microcirculatory resistance; LVEDV, left ventricular end-diastolic 
volume.   
Table 6-12: Correlates of CFR (continuous).   
6.4.2 Index of microcirculatory resistance 
The index of microcirculatory resistance (IMR) represents the minimum 
resistance offered by the microcirculation.  Based on several studies, an 
abnormal value is defined as an IMR ³25.127–129  Using this threshold, 32 of the 62 
participants (52% [95% CI 39-64%]) that had invasive physiology testing had an 
abnormal IMR (Figure 6-3).   
 
IMR, index of microcirculatory resistance.   
Figure 6-3: Study participants stratified by IMR.   
32
30
IMR ≥25 IMR <25
185 
 
Baseline characteristics 
Table 6-13 summarises selected baseline characteristics of the cohort based on 
the IMR.  The baseline demographics and clinical features of patients with a 
normal or abnormal IMR were similar.  The prevalence of comorbidities, 
including a previous history of CAD, MI and previous coronary intervention were 
similar in both groups.  ECG and CXR findings were similar in both groups, but 
those with an abnormal IMR more frequently had radiological evidence of 
cardiomegaly than those with a normal IMR (91% vs. 63%; p = 0.01, respectively).  
There were no significantly significant differences in natriuretic peptides, hsTnI 
or echocardiography findings between the groups.   
 
Normal IMR 
(n = 30) 
Abnormal IMR 
(n = 32) 
p-value 
Demographics 
Age (years) 72 [9] 72 [9] 0.94 
Female sex 17 (57) 16 (50) 0.60 
BMI (kg/m2) 34 [8] 32 [7] 0.41 
Past medical history 
Previous HF diagnosis 8 (27) 15 (47) 0.10 
Any CAD 11 (37) 8 (25) 0.32 
MI 8 (27) 5 (16) 0.29 
Revascularisation 4 (13) 4 (12) 0.92 
CXR 
Cardiomegaly 19 (63) 29 (91) 0.01 
Biochemistry 
NT-proBNP (pg/mL) 1204 [414-2494] 1532 [1273-3076] 0.18 
BNP (pg/mL) 259 [173-676] 569 [187-1028] 0.33 
hsTnI (ng/L) 19 [7-29] 16 [7-25] 0.51 
Echocardiography 
LVEF (%) 59 [6] 58 [6] 0.39 
LVH 21 (70) 15 (47) 0.065 
Diastolic dysfunction 15 (60) 12 (44) 0.26 
LA dilatation 26 (90) 30 (94) 0.56 
Values are mean [standard deviation], median [Q1-Q3], or n (%). BMI, body mass index; BNP, B-type 
natriuretic peptide; CAD, coronary artery disease; CRP, C-reactive protein; hsTnI, high-sensitivity troponin 
I; IMR, index of microcirculatory resistance; LA, left atrial; LVEF, left ventricular ejection fraction; LVH, 
left ventricular hypertrophy; MI, myocardial infarction; NT-proBNP, N-terminal prohormone BNP.   
Table 6-13: Selected baseline characteristics stratified by IMR.   
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Study investigations 
Table 6-14 summarises selected findings of CMR and invasive coronary 
assessment on the basis of IMR.  Cardiac structure and function were similar in 
both groups.  Those with a low IMR had higher native T1 values (mean 1312 vs. 
1250 ms; p <0.01) and ECV (30.0% vs. 26.4%; p = 0.014) than those with a high 
IMR.  The prevalence of obstructive epicardial CAD was similar in those with a 
normal and abnormal IMR (50% vs. 34%; p = 0.21, respectively).   
 Normal IMR Abnormal IMR p-value 
CMR (n = 17) (n = 18)  
LVEF (%) 58 [7] 60 [7] 0.37 
LVH 12 (71) 9 (47) 0.16 
LA dilatation 10 (67) 11 (61) 0.74 
Ischaemic LGE 7 (41) 3 (17) 0.11 
Non-ischaemic LGE 6 (35) 7 (39) 0.83 
Native T1 (ms) 1312 [66] 1250 [55] <0.01 
ECV (%) 30.0 [3.7] 26.4 [4.0] 0.014 
ECV >30% 8 (57) 4 (24) 0.056 
MPRI 1.49 [1.33-1.85] 1.71 [1.44-1.95] 0.28 
MPRI <1.4 4 (31) 3 (25) 0.75 
Invasive coronary assessment (n = 30) (n = 32)  
Obstructive epicardial CAD 15 (50) 11 (34) 0.21 
CFR 2.4 [1.7-2.9] 1.8 [1.3-2.6] 0.14 
CFR <2.0 9 (30) 19 (59) 0.02 
 (n = 19) (n = 4)  
Endothelium-dependent CMD 6 (33) 4 (17) 0.24 
 (n = 30) (n = 29)  
LVEDP (mmHg) 11 [10-15] 13 [9-15] 0.70 
Values are mean [standard deviation], median [Q1-Q3], or n (%). CAD, coronary artery disease; CFR, 
coronary flow reserve; CMD, coronary microvascular dysfunction; CMR, cardiac magnetic resonance; ECV, 
extracellular volume; IMR, index of microcirculatory resistance; LA, left atrial; LGE, late gadolinium 
enhancement; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction; LVH, 
left ventricular hypertrophy; MPRI, myocardial-perfusion reserve index.   
Table 6-14: CMR and invasive coronary assessment findings stratified by 
IMR.    
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Correlates of IMR 
Table 6-15 and 6-16 describe the correlates of IMR expressed as a binary and 
continuous variable, respectively.  An abnormal IMR was correlated with an 
abnormal CFR (ϕ = 0.45; p <0.001) and was negatively associated with 
obstructive epicardial CAD (ϕ = 0.28; p = 0.015) and ECV (rpb = -0.40; p <0.01).  
When expressed as a continuous variable, IMR correlated with BNP (r = 0.40; p = 
0.021) and was negatively associated with ischaemic LGE (rpb = -0.42; p = 0.012) 
and ECV (r = -0.41; p = 0.023) on CMR.  Figure 6-4 illustrates the association 
between IMR and ECV.   
 
IMR ≥25 p-value 
ECV (%) -0.40 <0.01 
ECV >30% -0.27 0.061 
Obstructive CAD -0.28 0.015 
CFR -0.18 0.16 
CFR <2.0 0.45 <0.001 
Endothelium-dependent CMD -0.18 0.25 
CAD, coronary artery disease; CFR, coronary flow reserve; CMD, coronary microvascular dysfunction; ECV, 
extracellular volume; IMR, index of microcirculatory resistance.   
Table 6-15: Correlates of IMR ≥25 (binary).  
 
IMR p-value 
BNP (pg/mL) 0.40 0.021 
Ischaemic LGE -0.42 0.012 
ECV (%) -0.41 0.023 
ECV >30% -0.38 0.036 
Obstructive CAD -0.20 0.11 
CFR -0.24 0.066 
CFR <2.0 0.20 0.13 
Endothelium-dependent CMD -0.29 0.069 
AF, atrial fibrillation; BNP, B-type natriuretic peptide; CAD, coronary artery disease; CFR, coronary flow 
reserve; CMD, coronary microvascular dysfunction; ECV, extracellular volume; IMR, index of 
microcirculatory resistance; LGE, late gadolinium enhancement; MI, myocardial infarction.   
Table 6-16: Correlates of IMR (continuous). 
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ECV, extracellular volume; IMR, index of microcirculatory resistance.   
Figure 6-4: Scatterplot of correlation between IMR and ECV.  
6.4.3 Microvascular status groups 
CFR and IMR were both normal in 21 patients (34%); 13 patients (21%) had 
normal CFR but high IMR (i.e. preserved flow reserve and high microvascular 
resistance); nine patients (15%) had low CFR and normal IMR (i.e. impaired flow 
reserve and normal microvascular resistance), and 19 patients (31%) had low CFR 
and high IMR (i.e. impaired flow reserve and high microvascular resistance) 
(Figure 6-5).   
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Figure 6-5: Microvascular status groups based on CFR and IMR.   
6.5 Outcomes related to endothelium-independent 
coronary microvascular dysfunction 
6.5.1 Endothelium-independent coronary microvascular 
dysfunction 
Mortality 
Mortality rates were low during the follow-up period and no significant 
difference in mortality rates was observed between those with and without 
endothelium-independent CMD (Figure 6-6, 6-7, 6-8).  There were no non-CV 
deaths during follow-up.   
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Figure 6-6: Kaplan-Meier curves for all-cause mortality by endothelium-
independent CMD.   
 
Figure 6-7: Kaplan-Meier curves for CV mortality by endothelium-
independent CMD.   
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Figure 6-8: Kaplan-Meier curves for HF mortality by endothelium-
independent CMD.   
Hospitalisations 
There were no statistically significant differences in hospitalisations between 
those and without endothelium-independent CMD (Figures 6-9, 6-10, 6-11, 6-12).   
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Figure 6-9: Kaplan-Meier curves for all-cause hospitalisation by 
endothelium-independent CMD.   
 
Figure 6-10: Kaplan-Meier curves for CV hospitalisation by endothelium-
independent CMD.   
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Figure 6-11: Kaplan-Meier curves for HF hospitalisation by endothelium-
independent CMD.   
 
Figure 6-12: Kaplan-Meier curves for non-CV hospitalisation by non-
endothelium-independent CMD.   
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6.5.2 Coronary flow reserve 
Mortality and hospitalisations 
No differences were observed in mortality or hospitalisations in participants 
based on CFR (Figures 6-13, 6-14).   
 
Figure 6-13: Kaplan-Meier curves for all-cause mortality by CFR.   
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Figure 6-14: Kaplan-Meier curves for all-cause mortality by CFR.   
6.5.3 Index of microcirculatory resistance 
Mortality and hospitalisations  
No significant differences in mortality or hospitalisation rates were observed 
between the groups based on IMR (Figures 6-15, 6-16).   
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Figure 6-15: Kaplan-Meier curves for all-cause mortality by IMR.   
 
Figure 6-16: Kaplan-Meier curves for all-cause hospitalisation by IMR.   
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6.6 Complications of coronary guidewire-based coronary 
physiology testing 
There were no procedural complications related to the use of the coronary 
guidewire.  The majority of patients (76%) experienced typical symptoms during 
the adenosine infusion (i.e. dyspnoea, chest tightness, flushing), all of which 
subsided with discontinuation of the infusion.  No arrhythmia was documented in 
any patient during the adenosine infusion.   
6.7 Summary 
Endothelium-independent CMD was present in two-thirds of the 62 participants 
that underwent guidewire-based coronary physiology testing.  Participants with 
endothelium-independent CMD had a higher burden of AF than those without, 
but the prevalence of other comorbidities was similar in both groups.  There 
were no significant differences in the echocardiography or CMR findings between 
those with and without CMD.  The burden of myocardial LGE was similar in both 
groups, and there was no significant difference in ECV or MPRI in participants 
with and without endothelium-independent CMD.   
The prevalence of obstructive epicardial CAD was similar in those with and 
without endothelium-independent CMD, and no association was observed 
between endothelium-independent and -dependent CMD.   
Of those that underwent coronary microvascular assessment, 45% had an 
abnormal CFR (<2.0) and 52% had an abnormal IMR (³25).  Of participants with 
endothelium-independent CMD, 32% had high microvascular resistance (abnormal 
IMR), 22% had impaired flow reserve (abnormal CFR), and 46% had both high 
microvascular resistance and impaired flow reserve (abnormal CFR and IMR).  
There were no major differences in the characteristics of those with a normal or 
abnormal CFR.  The prevalence of obstructive epicardial CAD was similar in 
those with a normal or abnormal CFR or IMR.  Of interest, patients with a normal 
IMR had significantly higher ECV than those with an abnormal IMR, suggesting 
that increased microvascular resistance is independent of diffuse myocardial 
fibrosis in HFpEF patients.   
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The definition of endothelium-independent CMD used in this study (i.e. CFR <2.0 
and/or IMR ≥25) is consistent with the contemporary literature in other 
populations.  However, CFR and IMR are continuous measures and the thresholds 
used do not accurately represent the spectrum of coronary microvascular 
function.  Furthermore, invasively assessed CFR and (especially) IMR have been 
performed predominantly in patients presenting with chest pain and have not 
been validated in the HFpEF population.   
The delay between recruitment and performing the invasive coronary assessment 
(median 97 days) may have impacted on the results of coronary microvascular 
testing.  It is recognised that the elevated LV filling pressures can cause or 
contribute to CMD as a result of extravascular compression of arterioles.266  
LVEDP was normal in the majority of the study participants, but this likely would 
not have been the case had the invasive assessment been performed during the 
index hospitalisation.   
Invasive assessment of CFR and IMR are not routinely performed in clinical 
practice.  However, the operators who performed the invasive coronary 
assessments in this study have extensive experience in performing these 
measurements in other research studies.  Both CFR and IMR incorporate the 
thermodilution principle (using intra-coronary injection of saline) and an average 
of three consistent transit times was used to ensure the measurement was 
reliable and reproducible.  Furthermore, in a previous study of patients with ST-
elevation MI, repeated IMR measurements obtained by four operators (including 
two of the operators who performed the invasive assessments in this study) were 
highly correlated (r = 0.99; p <0.001), suggesting minimal inter-observer 
variability with this technique.267   
As discussed in Chapter 5, event rates in the study cohort were lower than 
expected, but no significant differences in mortality or hospitalisation rates 
were observed based on the presence or absence of abnormal coronary 
microvascular function, CFR or IMR.   
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Chapter 7 Results – Endothelium-dependent 
coronary microvascular dysfunction in heart 
failure with preserved ejection fraction 
In this chapter I will report the prevalence of endothelium-dependent coronary 
microvascular dysfunction (CMD) in the study cohort.  I will describe the clinical 
characteristics, investigation results and correlates of the population based on 
the presence or absence of endothelium-dependent CMD.  Finally, I will report 
clinical outcomes (mortality and hospitalisations) stratified by endothelium-
dependent CMD.   
7.1 Prevalence of endothelium-dependent coronary 
microvascular dysfunction 
A total of 41 participants underwent coronary vasoreactivity testing during intra-
coronary acetylcholine (ACh) administration to assess epicardial and 
microvascular coronary endothelial function.  Of these, 10 had evidence of 
endothelium-dependent CMD, giving an estimated prevalence estimate of 24% 
(95% CI 13-40%) in the HFpEF population (Figure 7-1).  None of the participants 
had evidence of epicardial coronary vasospasm.   
 
CMD, coronary microvascular dysfunction; ECG, electrocardiogram.   
Figure 7-1: Prevalence of endothelium-dependent CMD in study cohort.  
Coronary vasoreactivity testing
n = 41
Epicardial vasomotor 
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n = 7 (17%)
Epicardial spasm
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endothelial dysfunction
n = 0 (0%)
Normal coronary endothelial 
function
n = 31 (76%)
Normal epicardial 
response
n = 34 (83%)
Endothelium-dependent CMD
n = 10 (24%)
Ischaemic ECG changes
No
n = 31
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n = 3
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7.2 Clinical characteristics by endothelium-dependent 
coronary microvascular dysfunction 
7.2.1 Demographics and clinical features 
Table 7-1 describes the baseline demographics and clinical features of the study 
participants that underwent vasoreactivity testing based on the presence or 
absence of coronary endothelial microvascular dysfunction.  Those with 
endothelium-dependent CMD were more frequently female (90% vs. 52%; p = 
0.03) and were less likely to have a smoking history (20% vs. 68%; p <0.01) than 
those with no endothelial dysfunction.  The groups were similar with regards to 
age, frailty, BMI, duration of hospitalisation and HF symptoms and signs.     
 
All endothelial 
function testing 
(n = 41) 
No endothelium-
dependent CMD  
(n = 31) 
Endothelium-
dependent 
CMD 
(n = 10) 
p-value 
Demographics 
Age (years) 71 [9] 71 [10] 71 [9] 0.84 
Female sex 25 (61) 16 (52) 9 (90) 0.03 
BMI (kg/m2) 34 [8] 34 [8] 34 [10] 0.82 
Obesity 20 (49) 15 (48) 5 (50) 0.93 
Smoking history 23 (56) 21 (68) 2 (20) <0.01 
Hospitalisation details 
Length of stay (days) 7 [5-10] 8 [4-11] 7 [5-10] 0.69 
HF symptoms 
NYHA functional class 
II 2 (5) 2 (6) 0 (0) 0.64 
III 21 (51) 15 (48) 6 (60) 
 
IV 18 (44) 14 (45) 4 (40) 
 
Orthopnoea 28 (68) 21 (68) 7 (70) 0.89 
PND 19 (46) 16 (52) 3 (30) 0.23 
Ankle swelling 37 (90) 29 (94) 8 (80) 0.21 
Admission vital signs 
HR (bpm) 90 [27] 89 [27] 92 [27] 0.74 
SBP (mmHg) 152 [30] 155 [32] 142 [18] 0.22 
DBP (mmHg) 82 [20] 82 [20] 83 [24] 0.94 
MAP (mmHg) 105 [19] 106 [20] 102 [19] 0.58 
HF signs 
JVD 29 (71) 23 (74) 6 (60) 0.39 
Murmur 10 (24) 7 (23) 3 (30) 0.63 
Crepitations 32 (78) 22 (71) 10 (100) 0.054 
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Pleural effusion(s) 15 (37) 11 (35) 4 (40) 0.80 
Oedema 37 (90) 29 (94) 8 (80) 0.21 
Ascites 1 (2) 1 (3) 0 (0) 0.57 
Values are mean [standard deviation], median [Q1-Q3], or n (%). BMI, body mass index; DBP, diastolic blood 
pressure; HF, heart failure; HR, heart rate; JVD, jugular venous distention; MAP, mean arterial pressure; 
NYHA, New York Heart Association; PND, paroxysmal nocturnal dyspnoea; SBP; systolic blood pressure.  
Table 7-1: Demographics and clinical features stratified by endothelium-
dependent CMD.   
7.2.2 Past medical history 
The past medical history of participants stratified by endothelium-dependent 
coronary microvascular function is detailed in Table 7-2.  As vasoreactivity 
testing was contraindicated in the majority of patients with obstructive 
epicardial CAD on angiography, the prevalence of previous CAD was low, with no 
significant difference between those with and without endothelial dysfunction 
(23% vs. 20%; p = 0.86, respectively).  Most comorbidities were similarly 
prevalent in both groups, but those with endothelium-dependent CMD had a 
higher prevalence of AF (100% vs. 58%; p = 0.013) and lower rates of COPD (0% 
vs. 35%; p = 0.028) than those without endothelial dysfunction.   
 All endothelial 
function testing 
(n = 41) 
No endothelium-
dependent CMD 
(n = 31) 
Endothelium-
dependent CMD 
(n = 10) 
p-value 
History of HF 
Previous HF 
diagnosis 
15 (37) 11 (35) 4 (40) 0.80 
Previous HFH 12 (29) 9 (29) 3 (30) 0.95 
History of CAD 
Any CAD 9 (22) 7 (23) 2 (20) 0.86 
MI 6 (15) 5 (16) 1 (10) 0.63 
Angina 3 (7) 2 (5) 1 (10) 0.71 
Current angina 2 (5) 2 (5) 0 (0) 0.41 
Revascularisation 4 (10) 2 (6) 2 (20) 0.21 
PCI 4 (10) 2 (5) 2 (20) 0.21 
CABG 0 (0) 0 (0) 0 (0) 
 
CV comorbidities 
Hypertension 31 (76) 24 (77) 7 (70) 0.63 
Dyslipidaemia 4 (10) 4 (13) 0 (0) 0.23 
CVD 7 (17) 6 (19) 1 (10) 0.49 
PAD 3 (7) 3 (10) 0 (0) 0.31 
AF 28 (68) 18 (58) 10 (100) 0.013 
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Valve disease 
(mild/moderate) 
8 (20) 4 (13) 4 (40) 0.06 
Non-CV comorbidities 
Diabetes  18 (44) 15 (48) 3 (30) 0.31 
CKD 8 (20) 8 (26) 0 (0) 0.073 
Chronic liver 
disease 
0 (0) 0 (0) 0 (0) - 
Depression 2 (5) 2 (6) 0 (0) 0.41 
Cancer 3 (7) 2 (6) 1 (10) 0.71 
COPD 11 (27) 11 (35) 0 (0) 0.028 
Asthma 4 (10) 2 (6) 2 (20) 0.21 
Anaemia 9 (22) 6 (19) 3 (30) 0.48 
Hypothyroidism 6 (15) 4 (13) 2 (20) 0.58 
Osteoarthritis 12 (29) 11 (35) 1 (10) 0.12 
Values are n (%). AF, atrial fibrillation; CABG, coronary artery bypass grafting; CAD, coronary artery 
disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; 
CVD, cerebrovascular disease; HF, heart failure; HFH, HF hospitalisation; MI, myocardial infarction; PAD, 
peripheral arterial disease; PCI, percutaneous coronary intervention.  
Table 7-2: Past medical history stratified by endothelium-dependent CMD.   
7.2.3 Drug history – medication on admission, in-hospital 
treatment and medication at discharge 
The drug history of patients according to the presence or absence of coronary 
endothelial dysfunction is presented in Table 7-3.  Given the higher prevalence 
of AF, those with coronary endothelial dysfunction were more often treated with 
an anticoagulant and digoxin than those with no endothelial dysfunction, both on 
admission and at discharge.  The use of statins, beta-blockers, RAAS antagonists 
and diuretics were similar in both groups.   
 All endothelial 
function testing 
(n = 41) 
No endothelium-
dependent CMD 
(n = 31) 
Endothelium-
dependent CMD 
(n = 10) 
p-value 
Admission medication 
CV medication 
Antiplatelet 11 (27) 10 (32) 1 (10) 0.17 
Anticoagulant 24 (59) 15 (48) 9 (90) 0.02 
Statin 28 (68) 22 (71) 6 (60) 0.52 
Loop diuretic 20 (49) 14 (45) 6 (60) 0.41 
Furosemide-
equivalent dose (mg) 
80 [40-120] 50 [40-120] 100 [80-120] 0.56 
Thiazide 4 (10) 4 (13) 0 (0) 0.23 
MRA 1 (2) 1 (3) 0 (0) 0.57 
ACEI/ARB 26 (63) 21 (68) 5 (50) 0.31 
Beta-blocker 25 (61) 17 (55) 8 (80) 0.16 
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CCB 16 (39) 14 (45) 2 (20) 0.16 
Digoxin 5 (12) 2 (6) 3 (30) 0.048 
 
Diabetic medication 
(n = 18) 
14 (78) 
(n = 15) 
12 (80) 
(n = 3) 
2 (67) 
 
0.61 
Insulin 5 (28) 3 (20) 2 (67) 0.099 
Non-CV medication 
Bronchodilator 14 (34) 12 (39) 2 (20) 0.28 
Antidepressant 10 (24) 8 (26) 2 (20) 0.71 
In-hospital treatment 
Furosemide 40 (98) 30 (97) 10 (100) 0.57 
IV (>1 dose) 31 (78) 24 (80) 7 (70) 0.71 
IV (1 dose) 4 (10) 3 (10) 1 (10) 
 
Oral 5 (12) 3 (10) 2 (20) 
 
IV nitrate 2 (5) 2 (6) 0 (0) 0.41 
Dopamine 0 (0) 0 (0) 0 (0) 
 
Oxygen 18 (44) 16 (52) 2 (20) 0.08 
CPAP 0 (0) 0 (0) 0 (0) 
 
Discharge medication 
CV medication 
Antiplatelet 12 (29) 11 (35) 1 (10) 0.12 
Anticoagulant 30 (73) 20 (65) 10 (100) 0.028 
Statin 28 (68) 22 (71) 6 (60) 0.52 
Loop diuretic 40 (98) 30 (97) 10 (100) 0.57 
Furosemide-
equivalent dose (mg) 
80 [80-120] 80 [80-120] 100 [80-120] 0.63 
Thiazide 4 (10) 4 (13) 0 (0) 0.23 
ACEI/ARB 26 (63) 21 (68) 5 (50) 0.31 
MRA 6 (15) 5 (16) 1 (10) 0.63 
Beta-blocker 29 (71) 20 (65) 9 (90) 0.12 
CCB 10 (24) 9 (29) 1 (10) 0.22 
Digoxin 18 (44) 10 (32) 8 (80) <0.01 
 
Diabetic medication 
(n = 18) 
14 (78) 
(n = 15) 
12 (80) 
(n = 3) 
2 (67) 
 
0.61 
Insulin 5 (28) 3 (20) 2 (67) 0.099 
Values are median [Q1-Q3] or n (%). ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; CCB, calcium channel blocker; CPAP, continuous positive airway pressure; CV, 
cardiovascular; IV, intravenous; MRA, mineralocorticoid receptor antagonist.   
Table 7-3: Admission medication, in-hospital treatment and discharge 
medication stratified by endothelium-dependent CMD.     
7.2.4 Baseline investigations 
Table 7-4 details the ECG, CXR and laboratory results of those with and without 
coronary microvascular endothelial dysfunction.  Those with endothelial 
dysfunction had a higher mean HR (107 vs. 86 bpm; p = 0.036) and shorter mean 
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QRS duration (82 vs. 105 ms; p = 0.03) than those without.  Radiological signs of 
HF were similar in both groups.  There were no statistically significant 
differences in routine haematology and biochemistry laboratory results.   
 All endothelial 
function testing 
(n = 41) 
No endothelium-
dependent CMD 
(n = 31) 
Endothelium-
dependent CMD 
(n = 10) 
p-value 
ECG 
Rate (bpm) 92 [28] 86 [25] 107 [32] 0.036 
AF 26 (63) 16 (52) 10 (100) 0.054 
Bundle branch block 6 (15) 6 (19) 0 (0) 0.13 
LVH 3 (7) 3 (10) 0 (0) 0.31 
Q waves 2 (5) 2 (6) 0 (0) 0.41 
T-wave inversion 18 (44) 12 (39) 6 (60) 0.24 
QRS duration (ms) 100 [30] 105 [32] 82 [11] 0.03 
QTc (ms) 447 [35] 452 [35] 430 [31] 0.088 
CXR 
Cardiomegaly 34 (83) 26 (84) 8 (80) 0.78 
Upper lobe venous 
diversion 
29 (71) 21 (68) 8 (80) 0.46 
Interstitial oedema 7 (17) 5 (16) 2 (20) 0.78 
Alveolar oedema 23 (56) 18 (58) 5 (50) 0.65 
Perihilar oedema 17 (41) 14 (45) 3 (30) 0.40 
Pleural effusion(s) 18 (44) 15 (48) 3 (30) 0.31 
Haematology 
Hb (g/L) 126 [19] 126 [21] 124 [10] 0.68 
Anaemia 12 (29) 10 (32) 2 (20) 0.46 
WCC (x 109/L) 8.6 [1.9] 8.7 [1.6] 8.3 [2.7] 0.55 
Biochemistry 
NT-proBNP 21 (51) 15 (48) 6 (60) 0.52 
NT-proBNP (pg/mL) 1385 [1132-2819] 1366 [1132-3076] 1562 [540-2108] 0.97 
BNP 23 (56) 19 (61) 4 (40) 0.24 
BNP (pg/mL) 323 [177-794] 355 [177-1017] 254 [154-559] 0.57 
hsTnI 29 (71) 21 (68) 8 (80) 0.46 
hsTnI (ng/L) 16 [10-25] 16 [10-29] 16 [9-25] 0.68 
Elevated hsTnI 9 (31) 6 (29) 3 (38) 0.64 
Na+ (mmol/L) 138 [3] 138 [4] 139 [2] 0.47 
Hyponatraemia 3 (7) 3 (10) 0 (0) 0.31 
K+ (mmol/L) 4.3 [0.5] 4.3 [0.6] 4.1 [0.4] 0.32 
Urea (mmol/L) 7.3 [4.6] 7.6 [5.1] 6.3 [2.1] 0.46 
Creatinine (µmol/L) 89 [38] 94 [42] 73 [12] 0.13 
eGFR 
(mL/min/1.73m2) 
69 [22] 67 [23] 75 [17] 0.37 
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eGFR <60 mL/min/ 
1.73m2 
12 (29) 11 (35) 1 (10) 0.12 
Albumin (g/L) 34 [4] 34 [4] 33 [4] 0.52 
Hypoalbuminaemia 19 (46) 13 (42) 6 (60) 0.32 
CRP (mg/L) 12 [5-24] 14 [7-35] 5 [4-18] 0.14 
Elevated CRP 22 (54) 19 (61) 3 (30) 0.084 
Glucose (mmol/L) 6.2 [5.3-8.2] 6.6 [5.5-8.3] 5.3 [5.1-6.8] 0.069 
Values are mean [standard deviation], median [Q1-Q3], or n (%). AF, atrial fibrillation; AV, atrioventricular; 
BNP, B-type natriuretic peptide; CRP, C-reactive protein; CXR, chest x-ray; ECG, electrocardiogram; eGFR, 
estimated glomerular filtration rate; Hb, haemoglobin; hsTnI, high-sensitivity troponin I; K+, potassium; 
LVH, left ventricular hypertrophy; Na+, sodium; NT-proBNP, N-terminal prohormone BNP; WCC, white cell 
count.    
Table 7-4: ECG, CXR and laboratory results stratified by endothelium-
dependent CMD.   
The echocardiography findings of patients stratified by endothelium-dependent 
CMD are detailed in Table 7-5.  Those without endothelial dysfunction had 
greater mean LV wall thickness (13 vs. 11 mm) than those with endothelial 
dysfunction, but there were similar rates of LVH (65% vs. 50%; p = 0.41, 
respectively) and no other significant differences between the groups.   
 All endothelial 
function testing 
(n = 41) 
No endothelium-
dependent CMD 
(n = 31) 
Endothelium-
dependent CMD 
(n = 10) 
p-value 
LV structure and systolic function 
LVEDD (mm/m2) 24 [3] 24 [3] 24 [4] 0.87 
LVESD (mm/m2) 15 [4] 15 [5] 15 [4] 0.71 
LVEF (%) 59 [6] 58 [6] 62 [7] 0.11 
S' lateral (cm/s) 7.1 [2.5] 6.7 [2.0] 8.7 [4.0] 0.072 
Septal wall thickness 
(mm) 
13 [2] 13 [2] 11 [3] 0.013 
Posterior wall thickness 
(mm) 
12 [2] 13 [2] 11 [2] 0.024 
LVH 25 (61) 20 (65) 5 (50) 0.41 
LV diastolic function 
E/A 1.4 [1.4] 1.4 [1.4] 1.5 0.19 
Deceleration time (ms) 226 [78] 219 [66] 251 [114] 0.32 
E' average (cm/s) 8.3 [2.7] 7.8 [2.3] 10.7 [3.4] 0.016 
E/e' average 12.8 [4.0] 13.0 [4.1] 11.9 [3.6] 0.56 
Diastolic dysfunction 13 (39) 10 (37) 3 (50) 0.56 
LA volume (mL/m2) 47 [17] 45 [17] 55 [17] 0.15 
LA dilatation 37 (92) 28 (90) 9 (100) 0.33 
RV structure and function 
RVEDD (mm) 35 [7] 35 [7] 35 [9] 0.84 
TAPSE (mm) 21 [4] 21 [4] 20 [3] 0.45 
Estimated RVSP (mmHg) 37 [13] 36 [14] 40 [12] 0.45 
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Valve disease 
Mild/moderate valve 
disease 
35 (85) 26 (84) 9 (90) 0.63 
Values are mean [standard deviation] or n (%). LA, left atrial; LV, left ventricular; LVEDD, LV end-diastolic 
dimension; LVEF, LV ejection fraction; LVESD, LV end-systolic dimension; LVH, LV hypertrophy; RV, right 
ventricular; RVEDD, RV end-diastolic dimension; RVSP, RV systolic pressure; TAPSE, tricuspid annular plane 
systolic excursion.   
Table 7-5: Echocardiography findings stratified by endothelium-dependent 
CMD.   
7.2.5 Cardiac magnetic resonance imaging 
Table 7-6 describes the CMR findings of participants based on the presence or 
absence of coronary endothelial dysfunction.  Those with endothelial dysfunction 
had less LGE than those with no evidence of coronary endothelial dysfunction 
(0% vs. 61%; p = 0.027, respectively).   
 All endothelial 
function testing 
(n = 22) 
No endothelium-
dependent CMD 
(n = 18) 
Endothelium-
dependent CMD 
(n = 4) 
p-value 
LV structure and function 
LVEDV (mL/m2) 71 [21] 74 [21] 58 [17] 0.16 
LVESV (mL/m2) 30 [13] 32 [13] 20 [4] 0.12 
LVSV (mL/m2) 42 [11] 42 [10] 37 [13] 0.39 
CI (L/min/m2) 3.2 [0.9] 3.2 [0.8] 3.4 [1.4] 0.73 
LVEF (%) 59 [7] 58 [7] 64 [5] 0.17 
MAPSE (mm) 13 [4] 13 [4] 13 [4] 0.86 
WMSI 1.1 [0.2] 1.1 [0.2] 1.0 [0] 0.21 
LV mass (g/m2) 64 [16] 67 [17] 52 [9] 0.12 
LVH 12 (52) 10 (53) 2 (50) 0.92 
LA structure 
LA volume (mL/m2) 71 [24] 71 [26] 71 [9] 0.98 
LA dilatation 16 (73) 12 (67) 4 (100) 0.18 
RV structure and function 
RVEDV (mL/m2) 75 [22] 78 [22] 61 [20] 0.20 
RVESV (mL/m2) 36 [14] 38 [15] 28 [6] 0.23 
RVSV (mL/m2) 39 [13] 40 [12] 33 [15] 0.35 
RVEF (%) 52 [9] 52 [10] 53 [6] 0.89 
TAPSE (mm) 18 [5] 18 [5] 22 [6] 0.19 
LGE 
Any LGE 11 (50) 11 (61) 0 (0) 0.027 
Ischaemic LGE 4 (22) 4 (22) 0 (0) 0.30 
Non-ischaemic LGE 8 (73) 8 (44) 0 (0) 0.095 
T1 mapping 
Native T1 (ms) 1276 [75] 1272 [74] 1295 [90] 0.59 
207 
 
ECV (%) 27.4 [4.1] 27.4 [4.2] 27.7 [4.4] 0.88 
ECV >30% 6 (30) 5 (31) 1 (25) 0.81 
Adenosine stress perfusion imaging 
MPRI 1.60 [1.39-1.87] 1.60 [1.39-1.87] 1.60 [1.49-1.71] 0.87 
MPRI <1.4 4 (27) 4 (31) 0 (0) 0.36 
Values are mean [standard deviation], median [Q1-Q3], or n (%). CI, cardiac index; ECV, extracellular 
volume; LA, left atrial; LGE, late gadolinium enhancement; LV, left ventricular; LVEDV, LV end-diastolic 
volume; LVEF, LV ejection fraction; LVESV, LV end-systolic volume; LVH, LV hypertrophy; LVSV, LV stroke 
volume; MAPSE, mitral annular plane systolic excursion; MPRI, myocardial-perfusion reserve index; RV, right 
ventricular; RVEDV, RV end-diastolic volume; RVEF, RV ejection fraction; RVESV, RV end-systolic volume; 
RVSV, RV stroke volume; TAPSE, tricuspid annular plane systolic excursion; WMSI, wall motion score index.   
Table 7-6: CMR findings stratified by endothelium-dependent CMD.  
7.2.6 Invasive coronary angiography, physiology and 
haemodynamics 
Table 7-7 summarises the invasive coronary angiography, physiology and 
haemodynamics stratified by coronary endothelial dysfunction.  None of the five 
patients with obstructive epicardial CAD that underwent vasoreactivity testing 
had evidence of coronary endothelial dysfunction.  There was no significant 
difference in proportion of patients with endothelium-independent CMD in those 
with and without endothelium-dependent CMD (60% vs. 74%; p = 0.39, 
respectively) and no difference in LVEDP between the groups (median 14 vs. 13 
mmHg; p = 0.99, respectively).   
 All endothelial 
function testing 
(n = 41) 
No endothelium-
dependent CMD 
(n = 31) 
Endothelium-
dependent CMD 
(n = 10) 
p-value 
Obstructive epicardial 
CAD 
5 (12) 5 (16) 0 (0) 0.18 
Endothelium-independent 
CMD 
29 (71) 23 (74) 6 (60) 0.39 
CFR 2.3 [1.4-3.0] 2.4 [1.3-3.0] 2.0 [1.5-3.8] 0.99 
CFR <2.0 19 (46) 14 (45) 5 (50) 0.79 
IMR 26 [18-42] 29 [20-50] 21 [14-28] 0.071 
IMR ≥25 23 (56) 19 (61) 4 (40) 0.24 
 (n = 40) (n = 30) (n = 10)  
LVEDP (mmHg) 13 [9-15] 13 [9-16] 14 [7-15] 0.99 
LVEDP ≥12 mmHg 22 (55) 16 (53) 6 (60) 0.71 
Values are median [Q1-Q3] or n (%). CAD, coronary artery disease; CFR, coronary flow reserve; CMD, 
coronary microvascular dysfunction; IMR, index of microcirculatory resistance; LVEDP, left ventricular end-
diastolic pressure.   
Table 7-7: Invasive coronary angiography, physiology and haemodynamics 
stratified by endothelium-dependent CMD.  
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7.3 Correlates of endothelium-dependent coronary 
microvascular dysfunction 
There was no correlation between endothelium-dependent and endothelium-
independent CMD (φ = -0.13; p = 0.40) (Table 7-8).  Endothelium-dependent CMD 
was associated with AF (φ = 0.39; p = 0.012) and had a negative correlation with 
a smoking history (φ = -0.41; p <0.01) and LGE on CMR (φ = -0.47; p = 0.027).   
 
Endothelium-dependent CMD p-value 
Smoking history -0.41 <0.01 
AF 0.39 0.012 
Any LGE -0.47 0.027 
Obstructive CAD -0.21 0.18 
Endothelium-independent CMD -0.13 0.40 
AF, atrial fibrillation; CAD, coronary artery disease; CFR, coronary flow reserve; CKD, chronic kidney 
disease; CMD, coronary microvascular dysfunction; CRP, C-reactive protein; IMR, index of microcirculatory 
resistance; LGE, late gadolinium enhancement.   
Table 7-8: Correlates of endothelium-dependent CMD.   
7.4 Endothelium-independent and endothelium-
dependent coronary microvascular dysfunction 
Of the 41 participants that underwent coronary vasoreactivity testing, eight 
(20%) had neither endothelium-independent nor -dependent CMD; 23 (56%) had 
endothelium-independent CMD but no endothelium-dependent CMD; four (10%) 
had endothelium-dependent CMD but no endothelium-independent CMD; and six 
(15%) had both endothelium-independent and -dependent CMD (Figure 7-2).   
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ED-CMD, endothelium-dependent coronary microvascular dysfunction; EI-CMD, endothelium-independent 
coronary microvascular dysfunction.  
Figure 7-2: Study participants stratified by endothelium-independent and 
endothelium-dependent CMD.  
7.5 Outcomes related to endothelium-dependent 
coronary microvascular dysfunction 
Mortality 
Mortality rates were low during the follow-up period and no significant 
difference in mortality rates was observed between those with and without 
coronary microvascular endothelial dysfunction (Figures 7-3, 7-4, 7-5).     
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Figure 7-3: Kaplan-Meier curves for all-cause mortality by endothelium-
dependent CMD.   
 
Figure 7-4: Kaplan-Meier curves for CV mortality by endothelium-dependent 
CMD.   
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Figure 7-5: Kaplan-Meier curves for HF mortality by endothelium-dependent 
CMD.   
Hospitalisations 
There were no significant differences in hospitalisations in those with and 
without coronary endothelial dysfunction (Figures 7-6, 7-7, 7-8, 7-9). 
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Figure 7-6: Kaplan-Meier curves for all-cause hospitalisation by 
endothelium-dependent CMD.   
 
Figure 7-7: Kaplan-Meier curves for CV hospitalisation by endothelium-
dependent CMD.   
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Figure 7-8: Kaplan-Meier curves for HF hospitalisation by endothelium-
dependent CMD.   
 
Figure 7-9: Kaplan-Meier curves for non-CV hospitalisation by endothelium-
dependent CMD.   
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7.6 Complications of coronary vasoreactivity testing 
There were no serious adverse events related to intracoronary ACh 
administration.  Fourteen patients (34%) experienced chest tightness during 
vasoreactivity testing, all of which subsided with discontinuation of the infusion.  
Transient AV block occurred in 12 patients (29%), all of which recovered 
spontaneously with no treatment.   
7.7 Summary 
Of the 41 study participants that invasive coronary endothelial function testing, 
10 (24%) had evidence of endothelium-dependent CMD.  None of the participants 
had evidence of epicardial coronary vasospasm.  Those with endothelium-
dependent CMD were more frequently female and were less likely to have a 
smoking history than those with no endothelial dysfunction.  Endothelium-
dependent CMD was associated with a higher prevalence of AF but lower rates of 
COPD than those without endothelial dysfunction.  Patients with coronary 
endothelial dysfunction had less myocardial LGE than those without endothelial 
dysfunction.  There was no difference in MPRI or ECV between those with and 
without endothelium-dependent CMD.  Importantly, there was no correlation 
between endothelium-dependent and -independent CMD.  Recent studies have 
suggested that measures of endothelium-independent CMD may be a surrogate 
for coronary microvascular endothelial dysfunction231, however, these data do 
not support this claim.   
In this study, coronary microvascular endothelial dysfunction appeared to 
represent a distinct clinical entity characterised by a female preponderance, 
high prevalence of AF and low burden of focal myocardial fibrosis.  Participants 
with coronary endothelial dysfunction had a higher mean HR on their admission 
ECG and higher prescription of digoxin at discharge (with a marked increase in 
prescription rates from pre-admission) than those without endothelial 
dysfunction, suggesting that AF with sub-optimal rate-control contributed to HF 
decompensation in a large proportion of this group.   
I defined endothelium-dependent CMD based on the contemporary literature and 
the international standards for the diagnostic criteria of coronary vasomotion 
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disorders developed by the Coronary Vasomotion Disorders International Study 
Group (COVADIS).146  However, the published literature on invasive 
vasoreactivity testing has been performed almost exclusively in patients 
presenting with chest pain and this technique has not been validated in the 
HFpEF population.   
Accepting that patient numbers were small and event rates low (see Chapter 5), 
no significant differences in outcomes were observed between those with and 
without coronary endothelial dysfunction.   
216 
Chapter 8 Results – Cardiac magnetic resonance 
imaging in heart failure with preserved ejection 
fraction 
In this chapter I will describe the clinical characteristics of the study 
participants based on CMR imaging findings.  I will report the prevalence of 
ischaemic myocardial scar (based on late gadolinium enhancement [LGE] 
imaging) to define the prevalence of previous MI in the study population.  I will 
describe the burden of diffuse myocardial fibrosis (using quantification of 
extracellular volume [ECV]) and inducible ischaemia (using semi-quantitative 
assessment of myocardial-perfusion reserve index [MPRI]) in the study 
participants.  Finally, I will report the clinical outcomes (mortality and 
hospitalisations) on the basis of the CMR findings.   
8.1 Prevalence of previous myocardial infarction 
A total of 52 participants underwent contrast enhanced CMR, 48 had pre- and 
post-contrast T1 mapping, and 46 had rest and adenosine stress perfusion 
imaging.  Of the 52 participants that underwent CMR, 14 had ischaemic LGE 
consistent with previous MI, giving a prevalence estimate of 27% (95% CI 16-41%) 
for CMR-proven MI in the HFpEF population.  Twenty of the 52 participants (38% 
[95% CI 26-53%]) had evidence of non-ischaemic (mid-wall or epicardial) LGE on 
CMR, consistent with focal myocardial fibrosis, and 32 (62% [95% CI 47-74%]) had 
any LGE (ischaemic or non-ischaemic) (Figure 8-1).   
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LGE, late gadolinium enhancement.   
Figure 8-1: Prevalence of LGE in study cohort.   
Of those with ischaemic LGE, seven patients (50%) had <50% subendocardial scar, 
five (36%) had ≥50% subendocardial (or transmural) scar and two (14%) had areas 
of both <50% and ≥50% scar.  The majority of patients with ischaemic LGE had an 
inferior MI (nine patients [64%]), two (14%) had an anterior MI and two (14%) had 
a lateral infarct.  One patient (7%) had imaging evidence of two (inferior and 
lateral) infarcts (Figure 8-2).   
 
LGE, late gadolinium enhancement.   
Figure 8-2: Patterns of ischaemic LGE in study cohort.   
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8.2 Clinical characteristics by previous myocardial 
infarction 
8.2.1 Demographics and clinical features 
The demographics and clinical features of the cohort based on the presence and 
absence of ischaemic LGE are presented in Table 8-1.  Patients with CMR-proven 
previous MI had a longer hospital stay than those with no CMR evidence of MI 
(median 10 vs. 6 days; p = 0.026, respectively), but here were no significant 
differences in demographics or HF symptoms and signs between the groups.   
 
All CMR 
(n = 52) 
No CMR-proven MI 
(n = 38) 
CMR-proven MI 
(n = 14) 
p-value 
Demographics 
Age (years) 72 [9] 73 [9] 69 [10] 0.14 
Female sex 24 (46) 17 (45) 7 (50) 0.74 
BMI (kg/m2) 32 [6] 31 [6] 33 [4] 0.21 
Obesity 22 (42) 15 (39) 7 (50) 0.50 
Smoking history 27 (52) 19 (50) 8 (57) 0.65 
Hospitalisation details 
Length of stay 
(days) 
7 [5-11] 6 [5-10] 10 [7-15] 0.026 
HF symptoms 
NYHA functional class 
II 0 (0) 0 (0) 0 (0) 0.77 
III 24 (46) 18 (47) 6 (43) 
 
IV 28 (54) 20 (53) 8 (57) 
 
Orthopnoea 39 (75) 26 (68) 13 (93) 0.071 
PND 25 (48) 16 (42) 9 (64) 0.16 
Ankle swelling 46 (88) 33 (87) 13 (93) 0.55 
Admission vital signs 
HR (bpm) 82 [24] 85 [27] 75 [14] 0.21 
SBP (mmHg) 152 [29] 154 [29] 146 [28] 0.39 
DBP (mmHg) 81 [19] 82 [19] 78 [18] 0.53 
MAP (mmHg) 104 [18] 106 [18] 101 [17] 0.37 
HF signs 
JVD 37 (71) 27 (71) 10 (71) 0.98 
Murmur 15 (29) 11 (29) 4 (29) 0.98 
Crepitations 40 (77) 29 (76) 11 (79) 0.86 
Pleural 
effusion(s) 
24 (46) 17 (45) 7 (50) 0.74 
Oedema 45 (87) 32 (84) 13 (93) 0.42 
Ascites 2 (4) 2 (5) 0 (0) 0.38 
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Values are mean [standard deviation], median [Q1-Q3], or n (%). BMI, body mass index; CMR, cardiac 
magnetic resonance; DBP, diastolic blood pressure; HF, heart failure; HR, heart rate; JVD, jugular venous 
distention; MAP, mean arterial pressure; NYHA, New York Heart Association; PND, paroxysmal nocturnal 
dyspnoea; SBP; systolic blood pressure.  
Table 8-1: Demographics and clinical features stratified by CMR-proven MI.    
8.2.2 Past medical history 
Table 8-2 details the past medical history of those with and without CMR-proven 
previous MI.  Those with ischaemic LGE were more likely to have had a previous 
hospitalisation for HF than those without (43% vs. 13%; p = 0.02, respectively).  
Participants with CMR-proven MI more commonly had a previous clinical history 
of CAD (57% vs. 18%; p <0.01), MI (43% vs. 5%; p <0.001), and coronary 
revascularisation (43% vs. 11%; p <0.01) than those with no CMR evidence of MI.  
Eight patients (57% of those with CMR-proven MI) had no clinical history of MI.  
Of the 44 participants with no clinical history of MI, 18% had evidence of MI on 
CMR.   
The prevalence of diabetes was similar in those with and without imaging 
evidence of MI (55% vs. 57%; p = 0.90, respectively), however, those with CMR-
proven MI were more often treated with insulin than those without (75% vs. 19%; 
p <0.01, respectively).  Those with ischaemic LGE had less AF (36% vs. 76%; p 
<0.01), but more osteoarthritis (50% vs. 13%; p <0.01) and depression (21% vs. 
3%; p = 0.024) than those without ischaemic LGE.   
 All CMR 
(n = 52) 
No CMR-proven MI 
(n = 38) 
CMR-proven MI 
(n = 14) 
p-value 
History of HF 
Previous HF 
diagnosis 
19 (37) 12 (32) 7 (50) 0.22 
Previous HFH 11 (21) 5 (13) 6 (43) 0.02 
History of CAD 
Any CAD 15 (29) 7 (18) 8 (57) <0.01 
MI 8 (15) 2 (5) 6 (43) <0.001 
Angina 7 (13) 6 (16) 1 (7) 0.42 
Current angina 3 (6) 2 (5) 1 (7) 0.80 
Revascularisation 10 (19) 4 (11) 6 (43) <0.01 
PCI 8 (15) 3 (8) 5 (36) 0.014 
CABG 3 (6) 1 (3) 2 (14) 0.11 
CV comorbidities 
Hypertension 40 (77) 30 (79) 10 (71) 0.57 
Dyslipidaemia 6 (12) 3 (8) 3 (21) 0.18 
220 
 
CVD 8 (15) 5 (13) 3 (21) 0.46 
PAD 6 (12) 4 (11) 2 (14) 0.71 
AF 34 (65) 29 (76) 5 (36) <0.01 
Valve disease 
(mild/moderate) 
13 (25) 10 (26) 3 (21) 0.72 
Non-CV comorbidities 
Diabetes 29 (56) 21 (55) 8 (57) 0.90 
CKD 17 (33) 11 (29) 6 (43) 0.34 
Chronic liver 
disease 
1 (2) 1 (3) 0 (0) 0.54 
Depression 4 (8) 1 (3) 3 (21) 0.024 
Cancer 4 (8) 3 (8) 1 (7) 0.93 
COPD 9 (17) 5 (13) 4 (29) 0.19 
Asthma 3 (6) 3 (8) 0 (0) 0.28 
Anaemia 11 (21) 8 (21) 3 (21) 0.98 
Hypothyroidism 7 (13) 4 (11) 3 (21) 0.31 
Osteoarthritis 12 (23) 5 (13) 7 (50) <0.01 
Values are mean [standard deviation], median [Q1-Q3], or n (%). AF, atrial fibrillation; CABG, coronary 
artery bypass grafting; CAD, coronary artery disease; CKD, chronic kidney disease; CMR, cardiac magnetic 
resonance; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; CVD, cerebrovascular disease; 
HF, heart failure; HFH, HF hospitalisation; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, 
percutaneous coronary intervention.  
Table 8-2: Past medical history stratified by CMR-proven MI.    
8.2.3 Drug history – medication on admission, in-hospital 
treatment and medication at discharge 
Table 8-3 summarises the drug history of participants stratified by the presence 
or absence of evidence of MI on CMR.  Those with MI were more often treated 
with antiplatelets and statins, whereas those with no MI more commonly 
received anticoagulants, both on admission and at discharge.  The in-hospital 
treatment received by both groups was similar.   
 All CMR 
(n = 52) 
No CMR-proven MI 
(n = 38) 
CMR-proven MI 
(n = 14) 
p-value 
Admission medication 
CV medication 
Antiplatelet 17 (33) 8 (21) 9 (64) <0.01 
Anticoagulant 25 (48) 22 (58) 3 (21) 0.02 
Statin 36 (69) 23 (61) 13 (93) 0.025 
Loop diuretic 22 (42) 14 (37) 8 (57) 0.19 
Furosemide-equivalent 
dose (mg) 
80 [40-120] 80 [40-120] 80 [50-120] 0.67 
Thiazide 7 (13) 6 (16) 1 (7) 0.42 
MRA 1 (2) 1 (3) 0 (0) 0.54 
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ACEI/ARB 34 (65) 22 (58) 12 (86) 0.061 
Beta-blocker 36 (69) 25 (66) 11 (79) 0.38 
CCB 24 (46) 17 (45) 7 (50) 0.74 
Digoxin 3 (6) 2 (5) 1 (7) 0.80 
 
Diabetic medication 
(n = 29) 
25 (86) 
(n = 21) 
17 (81) 
(n = 8) 
8 (100) 
 
0.18 
Insulin 10 (34) 4 (19) 6 (75) <0.01 
Non-CV medication 
Bronchodilator 19 (37) 13 (34) 6 (43) 0.57 
Antidepressant 14 (27) 9 (24) 5 (36) 0.39 
In-hospital treatment 
Furosemide 51 (98) 38 (100) 13 (93) 0.096 
IV (>1 dose) 40 (78) 28 (74) 12 (92) 0.24 
IV (1 dose) 4 (8) 3 (8) 1 (8) 
 
Oral 7 (14) 7 (18) 0 (0) 
 
IV nitrate 3 (6) 3 (8) 0 (0) 0.28 
Dopamine 0 (0) 0 (0) 0 (0) 
 
Oxygen 22 (42) 15 (39) 7 (50) 0.50 
CPAP 1 (2) 1 (3) 0 (0) 0.54 
Discharge medication 
CV medication 
Antiplatelet 13 (25) 4 (11) 9 (64) <0.001 
Anticoagulant 37 (71) 32 (84) 5 (36) <0.001 
Statin 36 (69) 23 (61) 13 (93) 0.025 
Loop diuretic 51 (98) 37 (97) 14 (100) 0.54 
Furosemide-equivalent 
dose (mg) 
80 [60-120] 80 [80-80] 80 [40-120] 0.76 
Thiazide 2 (4) 1 (3) 1 (7) 0.45 
ACEI/ARB 34 (65) 23 (61) 11 (79) 0.23 
MRA 10 (19) 6 (16) 4 (29) 0.30 
Beta-blocker 43 (83) 31 (82) 12 (86) 0.73 
CCB 15 (29) 10 (26) 5 (36) 0.51 
Digoxin 14 (27) 11 (29) 3 (21) 0.59 
 
Diabetic medication 
(n = 29) 
25 (86) 
(n = 21) 
17 (81) 
(n = 8) 
8 (100) 
 
0.18 
Insulin 11 (38) 5 (24) 6 (75) 0.011 
Values are mean [standard deviation], median [Q1-Q3], or n (%). ACEI, angiotensin converting enzyme 
inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CMR, cardiac magnetic 
resonance; CPAP, continuous positive airway pressure; CV, cardiovascular; IV, intravenous; MRA, 
mineralocorticoid receptor antagonist.   
Table 8-3: Admission medication, in-hospital treatment and discharge 
medication stratified by CMR-proven MI.   
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8.2.4 Investigations 
The baseline ECG, CXR and laboratory results of those with and without CMR-
proven previous MI are presented in Table 8-4.  Those with CMR evidence of MI 
had less AF on ECG (36% vs. 71%; p = 0.02), but more alveolar oedema on CXR 
(79% vs. 39%; p = 0.012) than those with no CMR-proven MI.  The mean 
haemoglobin level was lower in those with MI than those without (111 vs. 126; p 
= 0.018, respectively).  There were no other significant differences in 
haematology and biochemistry results between the groups.   
 All CMR 
(n = 52) 
No CMR-proven MI 
(n = 38) 
CMR-proven MI 
(n = 14) 
p-value 
ECG 
Rate (bpm) 85 [25] 88 [25] 76 [22] 0.12 
AF 32 (62) 27 (71) 5 (36) 0.02 
Bundle branch block 8 (15) 7 (18) 1 (7) 0.32 
LVH 4 (8) 2 (5) 2 (14) 0.28 
Q waves 7 (13) 3 (8) 4 (29) 0.053 
T-wave inversion 24 (46) 15 (39) 9 (64) 0.11 
QRS duration (ms) 97 [22] 97 [24] 96 [20] 0.91 
QTc (ms) 450 [33] 451 [35] 445 [26] 0.60 
CXR 
Cardiomegaly 39 (75) 31 (82) 8 (57) 0.071 
Upper lobe venous 
diversion 
36 (69) 26 (68) 10 (71) 0.83 
Interstitial oedema 14 (27) 8 (21) 6 (43) 0.12 
Alveolar oedema 26 (50) 15 (39) 11 (79) 0.012 
Perihilar oedema 22 (42) 15 (39) 7 (50) 0.50 
Pleural effusion(s) 27 (52) 21 (55) 6 (43) 0.43 
Haematology 
Hb (g/L) 122 [20] 126 [19] 111 [19] 0.018 
Anaemia 25 (48) 17 (45) 8 (57) 0.43 
WCC (x 109/L) 8.3 [2.7] 8.1 [2.3] 8.7 [3.6] 0.45 
Biochemistry 
NT-proBNP 27 (52) 20 (53) 7 (50) 0.87 
NT-proBNP (pg/mL) 1542 [978-4535] 2175 [1259-4562] 1041 [326-1915] 0.076 
BNP 32 (62) 21 (55) 11 (79) 0.13 
BNP (pg/mL) 399 [204-829] 421 [229-785] 256 [197-1017] 0.83 
hsTnI 37 (71) 27 (71) 10 (71) 0.98 
hsTnI (ng/L) 16 [7-34] 19 [5-54] 13 [9-24] 0.34 
Elevated hsTnI 12 (32) 11 (41) 1 (10) 0.076 
Na+ (mmol/L) 138 [3] 138 [3] 138 [5] 0.99 
Hyponatraemia 3 (6) 2 (5) 1 (7) 0.80 
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K+ (mmol/L) 4.4 [0.6] 4.4 [0.5] 4.4 [0.7] 0.78 
Urea (mmol/L) 8.1 [4.7] 8.3 [5.2] 7.5 [3.3] 0.59 
Creatinine (µmol/L) 99 [37] 101 [40] 93 [26] 0.51 
eGFR 
(mL/min/1.73m2) 
64 [20] 63 [20] 66 [21] 0.56 
eGFR <60 mL/min/ 
1.73m2 
20 (38) 14 (37) 6 (43) 0.69 
Albumin (g/L) 34 [4] 35 [4] 33 [4] 0.37 
Hypoalbuminaemia 26 (50) 18 (47) 8 (57) 0.53 
CRP (mg/L) 12 [7-21] 11 [7-21] 13 [3-32] 0.96 
Elevated CRP 29 (56) 21 (55) 8 (57) 0.90 
Glucose (mmol/L) 6.6 [5.3-8.5] 6.5 [5.3-8.6] 7.5 [5.5-8.4] 0.83 
Values are mean [standard deviation], median [Q1-Q3], or n (%). AF, atrial fibrillation; AV, atrioventricular; 
BNP, B-type natriuretic peptide; CMR, cardiac magnetic resonance; CRP, C-reactive protein; CXR, chest x-
ray; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; hsTnI, high-
sensitivity troponin I; K+, potassium; LGE, LVH, left ventricular hypertrophy; Na+, sodium; NT-proBNP, N-
terminal prohormone BNP; WCC, white cell count.     
Table 8-4: ECG, CXR and laboratory results stratified by CMR-proven MI.   
Table 8-5 details the echocardiography findings of patients stratified by CMR-
proven previous MI.  There were no significant differences in cardiac structure or 
function on echocardiography between the groups.   
 All CMR 
(n = 52) 
No CMR-proven MI 
(n = 38) 
CMR-proven MI 
(n = 14) 
p-value 
LV structure and systolic function 
LVEDD (mm/m2) 24 [3] 24 [3] 25 [3] 0.38 
LVESD (mm/m2) 15 [5] 15 [5] 17 [4] 0.23 
LVEF (%) 59 [7] 59 [6] 58 [8] 0.79 
S' lateral (cm/s) 7.0 [2.2] 7.0 [2.5] 7.0 [1.3] 0.95 
Septal wall thickness 
(mm) 
13 [3] 13 [2] 13 [3] 0.72 
Posterior wall 
thickness (mm) 
13 [2] 12 [2] 13 [3] 0.68 
LVH 30 (58) 22 (58) 8 (57) 0.96 
LV diastolic function 
E/A 1.4 [1.1] 1.1 [0.5] 1.6 [1.5] 0.43 
Deceleration time 
(ms) 
210 [73] 212 [75] 205 [71] 0.74 
E' average (cm/s) 8.0 [2.9] 8.2 [3.1] 7.3 [2.1] 0.33 
E/e' average 15.0 [6.2] 14.7 [6.6] 15.7 [5.5] 0.64 
Diastolic dysfunction 28 (60) 18 (55) 10 (71) 0.28 
LA volume (mL/m2) 42 [16] 42 [14] 45 [20] 0.48 
LA dilatation 44 (85) 33 (87) 11 (79) 0.46 
RV structure and function 
RVEDD (mm) 33 [6] 33 [7] 33 [4] 0.91 
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TAPSE (mm) 21 [5] 20 [5] 23 [4] 0.098 
Estimated RVSP 
(mmHg) 
40 [16] 43 [16] 33 [15] 0.14 
Valve disease 
Mild/moderate valve 
disease 
39 (75) 29 (76) 10 (71) 0.72 
Values are mean [standard deviation], median [Q1-Q3], or n (%). CMR, cardiac magnetic resonance; LA, left 
atrial; LV, left ventricular; LVEDD, LV end-diastolic dimension; LVEF, LV ejection fraction; LVESD, LV end-
systolic dimension; LVH, LV hypertrophy; RV, right ventricular; RVEDD, RV end-diastolic dimension; RVSP, 
RV systolic pressure; TAPSE, tricuspid annular plane systolic excursion.   
Table 8-5: Echocardiography findings stratified by CMR-proven MI.   
8.2.5 Cardiac magnetic resonance imaging 
Table 8-6 details the CMR findings stratified by CMR-proven MI.  LVEF and 
ventricular volumes were comparable in those with and without MI.  Those with 
ischaemic LGE had higher mean RVEF (58% vs. 52%; p = 0.036), but less LA 
dilatation (46% vs. 78%; p = 0.034) than those with no ischaemic LGE.  Those 
with ischaemic LGE were less likely to have non-ischaemic LGE (14% vs. 47%; p = 
0.03).  Native T1 and ECV were not significantly different between those with 
and without ischaemic LGE (mean 1315 vs. 1278 ms; p = 0.086, and 30.2% vs. 
28.0%; p = 0.096, respectively), as was the global MPRI (median 1.48 vs. 1.57; p 
= 0.69, respectively).   
 All CMR 
(n = 52) 
No CMR-proven MI 
(n = 38) 
CMR-proven MI 
(n = 14) 
p-value 
LV structure and function 
LVEDV (mL/m2) 76 [22] 74 [24] 82 [18] 0.29 
LVESV (mL/m2) 31 [13] 30 [13] 34 [13] 0.32 
LVSV (mL/m2) 45 [11] 44 [12] 48 [8] 0.34 
CI (L/min/m2) 3.2 [0.9] 3.1 [0.9] 3.4 [0.8] 0.40 
LVEF (%) 60 [7] 60 [7] 59 [8] 0.59 
MAPSE (mm) 13 [3] 12 [3] 14 [4] 0.15 
WMSI 1.1 [0.2]  1.1 [0.2] 1.1 [0.2] 0.44 
LV mass (g/m2) 68 [22] 66 [23] 73 [12] 0.25 
LVH 28 (54) 17 (45) 11 (79) 0.03 
LA structure 
LA volume (mL/m2) 68 [22] 68 [19] 67 [30] 0.80 
LA dilatation 34 (69) 28 (78) 6 (46) 0.034 
RV structure and function 
RVEDV (mL/m2) 81 [28] 82 [32] 78 [13] 0.64 
RVESV (mL/m2) 38 [16] 40 [18] 33 [10] 0.19 
RVSV (mL/m2) 43 [16] 42 [18] 45 [9] 0.58 
225 
 
RVEF (%) 54 [9] 52 [9] 58 [8] 0.036 
TAPSE (mm) 19 [5] 18 [5] 20 [5] 0.32 
LGE 
Non-ischaemic LGE 20 (38) 18 (47) 2 (14) 0.03 
T1 mapping 
Native T1 (ms) 1287 [67] 1278 [69] 1315 [53] 0.086 
ECV (%) 28.6 [4.2] 28.0 [3.9] 30.2 [4.4] 0.096 
ECV >30% 20 (42) 12 (34) 8 (62) 0.089 
Adenosine stress perfusion imaging 
MPRI 1.52 [1.37-1.86] 1.57 [1.39-1.86] 1.48 [1.29-1.89] 0.69 
MPRI <1.4 13 (32) 9 (31) 4 (33) 0.89 
Values are mean [standard deviation], median [Q1-Q3], or n (%). CMR, cardiac magnetic resonance; CI, 
cardiac index; ECV, extracellular volume; LA, left atrial; LGE, late gadolinium enhancement; LV, left 
ventricular; LVEDV, LV end-diastolic volume; LVEF, LV ejection fraction; LVESV, LV end-systolic volume; 
LVH, LV hypertrophy; LVSV, LV stroke volume; MAPSE, mitral annular plane systolic excursion; MPRI, 
myocardial-perfusion reserve index; RV, right ventricular; RVEDV, RV end-diastolic volume; RVEF, RV 
ejection fraction; RVESV, RV end-systolic volume; RVSV, RV stroke volume; TAPSE, tricuspid annular plane 
systolic excursion; WMSI, wall motion score index.   
Table 8-6: CMR findings stratified by CMR-proven MI.    
8.2.6 Invasive coronary angiography, physiology and 
haemodynamics 
Table 8-7 summarises the invasive coronary angiography, physiology and 
haemodynamics stratified by the presence or absence of CMR evidence of MI.  
Those with ischaemic LGE had a greater burden of obstructive epicardial CAD 
than those without (85% vs. 42%; p <0.01, respectively).  There was no 
difference in the prevalence of endothelium-independent CMD between the 
those with and without CMR-proven MI (70% vs. 68%; p = 0.91, respectively), but 
those with imaging evidence of MI had a lower IMR (median 13 vs. 28; p <0.01, 
respectively).  There were no other significant differences in invasive findings 
between the groups.    
 All CMR No CMR-proven MI CMR-proven MI p-value 
 (n = 44) (n = 31) (n = 13)  
Obstructive epicardial 
CAD 
24 (55) 13 (42) 11 (85) <0.01 
 (n = 35) (n = 25) (n = 10)  
Endothelium-independent 
CMD 
24 (69) 17 (68) 7 (70) 0.91 
CFR 2.1 [1.3-2.7] 2.4 [1.3-2.8] 1.8 [1.6-2.3] 0.41 
CFR <2.0 15 (43) 9 (24) 6 (43) 0.18 
IMR 23 [13-39] 28 [18-42] 13 [12-23] <0.01 
IMR ≥25 18 (51) 15 (39) 3 (21) 0.23 
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 (n = 22) (n = 18) (n = 4)  
Endothelium-dependent 
CMD 
4 (18) 4 (22) 0 (0) 0.30 
 (n = 39) (n = 27) (n =12)  
LVEDP (mmHg) 11 [8-15] 11 [8-15] 11 [9-12] 0.82 
LVEDP ≥12 mmHg 15 (38) 13 (48) 2 (17) 0.062 
Values are mean [standard deviation], median [Q1-Q3], or n (%). CAD, coronary artery disease; CFR, 
coronary flow reserve; CMD, coronary microvascular dysfunction; CMR, cardiac magnetic resonance; IMR, 
index of microcirculatory resistance; LVEDP, left ventricular end-diastolic pressure.   
Table 8-7: Invasive coronary angiography, physiology and haemodynamics 
stratified by CMR-proven MI.  
8.3 Correlates of previous myocardial infarction 
Table 8-8 describes the correlates of CMR-proven MI.  Ischaemic LGE was 
associated with a past history of CAD (ϕ = 0.38; p <0.01), MI (ϕ = 0.46; p 
<0.001), and revascularisation (ϕ = 0.36; p <0.01) and was inversely correlated 
with AF (ϕ = -0.38; p <0.01).  CMR-proven MI was associated with obstructive 
epicardial CAD on invasive angiography (ϕ = 0.39; p <0.01) and was negatively 
correlated with non-ischaemic LGE (ϕ = -0.30; p = 0.03) and IMR (rpb = 0.42; p = 
0.012).   
 
CMR-proven MI p-value 
History of CAD 0.38 <0.01 
History of MI 0.46 <0.001 
History of revascularisation 0.36 <0.01 
AF -0.38 <0.01 
Non-ischaemic LGE -0.30 0.03 
Obstructive CAD 0.39 <0.01 
Endothelium-independent CMD 0.02 0.91 
IMR -0.42 0.012 
Endothelium-dependent CMD -0.22 0.32 
AF, atrial fibrillation; CAD, coronary artery disease; CFR, coronary flow reserve; CMD, coronary 
microvascular dysfunction; ECV, extracellular volume; hsTnI, high-sensitivity troponin I; IMR, index of 
microcirculatory resistance; LGE, late gadolinium enhancement; LVEDP, left ventricular end-diastolic 
pressure; MI, myocardial infarction.   
Table 8-8: Correlates of CMR-proven MI.   
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8.4 Extracellular volume 
A total of 48 patients had pre- and post-contrast T1 mapping for quantification 
of extracellular volume (ECV).  Of these, 20 (42% [95% CI 28-56%]) had an 
elevated ECV (defined as an ECV >30%), consistent with diffuse myocardial 
fibrosis (Figure 8-3).    
 
ECV, extracellular volume.   
Figure 8-3: Study participants stratified by ECV.   
8.4.1 Baseline characteristics 
Table 8-9 details selected baseline characteristics of patients stratified by ECV.  
The baseline demographics of both groups were similar but those with a high 
ECV had a lower BMI (mean 29 vs. 33 kg/m2; p = 0.033) and had a longer hospital 
stay (median 10 vs. 6 days; p <0.01) than those with a normal ECV.  Symptoms 
and signs of HF were not significantly different between the groups.   
Those with a normal and abnormal ECV had similar rates of a pre-existing HF 
diagnosis, previous HF hospitalisation and previous CAD.  Other major 
comorbidities were not significantly different between those with a normal and 
high ECV.   
20
28
ECV >30% ECV ≤30%
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Patients with a high ECV more frequently had T-wave inversion on ECG than 
those with a normal ECV (75% vs. 25%; p <0.001, respectively).  Haematology and 
biochemistry laboratory results were generally fairly similar, and there were no 
statistically significant differences in echocardiography findings between the 
groups.   
 
All ECV 
(n = 48) 
ECV ≤30% 
(n = 28) 
ECV >30% 
(n = 20) 
p-value 
Demographics 
Age (years) 72 [9] 72 [8] 73 [11] 0.83 
Female sex 22 (46) 15 (54) 7 (35) 0.20 
BMI (kg/m2) 32 [6] 33 [6] 29 [6] 0.033 
Hospitalisation details 
Length of stay (days) 7 [5-11] 6 [4-9] 10 [7-14] <0.01 
History of CAD 
Any CAD 15 (31) 8 (29) 7 (35) 0.64 
MI 8 (17) 4 (14) 4 (20) 0.60 
Revascularisation 7 (15) 6 (21) 1 (5) 0.11 
ECG 
T-wave inversion 22 (46) 7 (25) 15 (75) <0.001 
Biochemistry 
NT-proBNP (pg/mL) 1915 [978-4535] 1385 [1171-2819] 3252 [570-9000] 0.51 
BNP (pg/mL) 376 [197-856] 301 [200-725] 785 [197-1684] 0.25 
hsTnI (ng/L) 16 [7-34] 16 [4-33] 19 [13-34] 0.40 
CRP (mg/L) 11 [7-20] 10 [7-17] 16 [5-30] 0.36 
Echocardiography 
LVEDV (mL/m2) 43 [16] 39 [13] 48 [18] 0.069 
LVESV (mL/m2) 18 [8] 16 [7] 20 [9] 0.074 
LVEF (%) 59 [7] 60 [7] 58 [7] 0.30 
LVH 28 (58) 16 (57) 12 (60) 0.84 
Diastolic dysfunction 25 (58) 13 (48) 12 (75) 0.084 
LA dilatation 41 (85) 24 (86) 17 (85) 0.94 
Values are mean [standard deviation], median [Q1-Q3], or n (%). BMI, body mass index; BNP, B-type 
natriuretic peptide; CAD, coronary artery disease; CRP, C-reactive protein; ECV, extracellular volume; 
hsTnI, high-sensitivity troponin I; LA, left atrial; LVEDV, left ventricular end-diastolic volume; LVEF, left 
ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVH, left ventricular hypertrophy; 
MI, myocardial infarction; NT-proBNP, N-terminal prohormone BNP.   
Table 8-9: Baseline investigation results stratified by ECV.    
8.4.2 Study investigations 
Table 8-10 details the CMR and invasive coronary assessment findings stratified 
by ECV.  Those with increased ECV had more LVH (75% vs. 43%; p = 0.027) and 
larger RV volumes (RVEDV 93 vs. 73 mL/m2; p = 0.018, and RVESV 49 vs. 39 
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mL/m2; p = 0.036) than those with a normal ECV.  Patients with a high ECV had 
had a lower MPRI than those with a normal ECV (median 1.37 vs. 1.70; p = 0.012, 
respectively).  Those with a high ECV were much more likely to have obstructive 
CAD on angiography than those with a normal ECV (78% vs. 36%; p <0.01, 
respectively).  The frequency of endothelium-independent and -dependent CMD 
were similar in both groups.     
 All ECV 
(n = 48) 
ECV ≤30% 
(n = 28) 
ECV >30% 
(n = 20) 
p-value 
CMR 
LVEF (%) 61 [7] 61 [7] 60 [7] 0.74 
LV mass (g/m2) 68 [21] 64 [16] 75 [25] 0.061 
LVH 27 (56) 12 (43) 15 (75) 0.027 
LA dilatation 33 (69) 20 (71) 13 (65) 0.64 
RVEDV (mL/m2) 81 [29] 73 [22] 93 [34] 0.018 
RVESV (mL/m2) 38 [17] 39 [11] 49 [20] 0.036 
Ischaemic LGE 13 (27) 5 (18) 8 (40) 0.089 
Non-ischaemic LGE 18 (38) 9 (32) 9 (45) 0.36 
MPRI 1.52 [1.37-1.86] 1.70 [1.47-1.97] 1.37 [1.26-1.55] 0.012 
MPRI <1.4 13 (32) 4 (17) 9 (53) 0.018 
Invasive coronary assessment 
 (n = 40) (n = 22) (n = 18)  
Obstructive epicardial CAD 22 (55) 8 (36) 14 (78) <0.01 
 (n = 31) (n = 19) (n = 12)  
Endothelium-independent 
CMD 
22 (71) 14 (74) 8 (67) 0.68 
CFR 2.3 [1.6-2.7] 2.3 [1.5-2.8] 2.2 [1.8-2.5] 0.90 
CFR <2.0 13 (42) 8 (42) 5 (42) 0.98 
IMR 23 [13-40] 28 [14-45] 18 [13-23] 0.096 
IMR ≥25 17 (55) 13 (68) 4 (33) 0.056 
 (n = 20) (n = 14) (n = 6)  
Endothelium-dependent CMD 4 (20) 3 (21) 1 (17) 0.81 
 (n = 35) (n = 20) (n = 15)  
LVEDP (mmHg) 10 [8-15] 10 [9-15] 11 [7-15] 0.95 
Values are mean [standard deviation], median [Q1-Q3], or n (%). CAD, coronary artery disease; CFR, 
coronary flow reserve; CMD, coronary microvascular dysfunction; CMR, cardiac magnetic resonance; ECV, 
extracellular volume; IMR, index of microcirculatory resistance; LA, left atrial; LGE, late gadolinium 
enhancement; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction; LVH, 
left ventricular hypertrophy; MPRI, myocardial-perfusion reserve index; RVEDV, right ventricular end-
diastolic volume; RVESV, right ventricular end-systolic volume.   
Table 8-10: CMR and invasive coronary assessment findings stratified by 
ECV.   
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8.4.3 Correlates of extracellular volume 
Tables 8-11 and 8-12 summarise the correlates of ECV expressed as a binary and 
continuous variable, respectively.  An elevated ECV (>30%) was strongly 
correlated with obstructive CAD (ϕ = 0.41; p <0.01) and was inversely associated 
with BMI (rpb = -0.31; p = 0.033), MPRI (rpb = -0.38; p = 0.017) and IMR (rpb = -
0.38; p = 0.036).   
 
ECV >30% p-value 
BMI (kg/m2) -0.31 0.033 
MPRI -0.38 0.017 
MPRI <1.4 0.38 0.017 
Obstructive CAD 0.41 <0.01 
Endothelium-independent CMD -0.075 0.69 
IMR -0.38 0.036 
IMR ≥25 -0.27 0.061 
Endothelium-dependent CMD -0.055 0.82 
BMI, body mass index; BNP, B-type natriuretic peptide; CAD, coronary artery disease; CMD, coronary 
microvascular dysfunction; CMR, cardiac magnetic resonance; ECV, extracellular volume; IMR, index of 
microcirculatory resistance; LGE, late gadolinium enhancement; LV, left ventricular; MPRI, myocardial-
perfusion reserve index.   
Table 8-11: Correlates of ECV >30% (binary).   
When expressed as a continuous variable, ECV was associated with obstructive 
CAD (rpb = 0.40; p = 0.011) and was inversely correlated with BMI (r = -0.31; p = 
0.029) (Figure 8-4), MPRI (r = -0.41; p <0.01), IMR (r = -0.41; p = 0.023) and a 
high IMR (rpb = -0.40; p <0.01).   
 
ECV p-value 
BMI (kg/m2) -0.31 0.029 
MPRI -0.41 <0.01 
MPRI <1.4 0.34 0.032 
Obstructive CAD 0.40 0.011 
Endothelium-independent CMD -0.22 0.23 
IMR -0.41 0.023 
IMR ≥25 -0.40 <0.01 
Endothelium-dependent CMD 0.037 0.88 
BMI, body mass index; BNP, B-type natriuretic peptide; CAD, coronary artery disease; CMD, coronary 
microvascular dysfunction; CMR, cardiac magnetic resonance; CRP, C-reactive protein; ECV, extracellular 
volume; IMR, index of microcirculatory resistance; LGE, late gadolinium enhancement; LVEDV, left 
ventricular end-diastolic volume; MPRI, myocardial-perfusion reserve index.   
Table 8-12: Correlates of ECV (continuous).   
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BMI, body mass index; ECV, extracellular volume.   
Figure 8-4: Scatterplot of ECV correlation with BMI. 
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8.5 Myocardial-perfusion reserve index 
Forty-six participants had rest and adenosine stress perfusion imaging, of whom 
41 had suitable imaging for semi-quantitative assessment of myocardial-
perfusion reserve index (MPRI).  Thirteen of the 41 participants had a global 
MPRI <1.4 (32% [95% CI 19-48%]), consistent with inducible myocardial ischaemia 
(Figure 8-5).   
 
MPRI, myocardial-perfusion reserve index.   
Figure 8-5: Study participants stratified by MPRI.   
8.5.1 Baseline characteristics 
Selected baseline characteristics of participants based on the presence or 
absence of inducible ischaemia on CMR are presented in Table 8-13.  There were 
no major differences in baseline demographics or past medical history based on 
MPRI, with the exception of a smoking history which was significantly more 
prevalent in those with an abnormal compared with a normal MPRI (77% vs. 36%; 
p = 0.014, respectively).  
Natriuretic peptides and hsTnI levels were similar in both groups.  The median 
CRP was lower in those with an abnormal than normal MPRI (7 vs. 13 mg/L; p = 
0.041, respectively), but the proportion of patients with an elevated CRP was 
13
28
MPRI <1.4 MPRI ≥1.4
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not significantly different (46% vs. 54%; p = 0.66, respectively).  
Echocardiography findings were similar in both groups.   
 
All MPRI 
(n = 41) 
MPRI <1.4 
(n = 28) 
MPRI ≥1.4 
 (n = 13) 
p-value 
Demographics 
Age (years) 74 [8] 73 [8] 75 [9] 0.44 
Female sex 18 (44) 13 (46) 5 (38) 0.63 
BMI (kg/m2) 30 [5] 31 [5] 29 [5] 0.35 
Smoking history 20 (49) 10 (36) 10 (77) 0.014 
CAD history 
Any CAD 14 (34) 9 (32) 5 (38) 0.69 
MI 7 (17) 6 (21) 1 (8) 0.28 
Revascularisation 9 (22) 7 (25) 2 (15) 0.49 
Biochemistry 
NT-proBNP (pg/mL) 2079 [912-4960] 1915 [978-4535] 2242 [570-5385] 0.97 
BNP (pg/mL) 421 [197-856] 465 [233-801] 197 [147-856] 0.37 
hsTnI (ng/L) 18 [9-36] 16 [5-38] 24 [14-36] 0.33 
Elevated hsTnI (ng/L) 10 (33) 8 (35) 2 (29) 0.76 
CRP (mg/L) 11 [6-22] 13 [7-36] 7 [3-16] 0.041 
Elevated CRP 21 (51) 15 (54) 6 (46) 0.66 
Echocardiography 
LVEF (%) 59 [7] 60 [7] 57 [6] 0.15 
LVH 27 (66) 20 (71) 7 (54) 0.27 
Diastolic dysfunction 24 (63) 15 (58) 9 (75) 0.30 
LA dilatation 36 (88) 25 (89) 11 (85) 0.67 
Values are mean [standard deviation], median [Q1-Q3], or n (%). BMI, body mass index; BNP, B-type 
natriuretic peptide; CAD, coronary artery disease; CRP, C-reactive protein; ECG, electrocardiogram; hsTnI, 
high-sensitivity troponin I; LA, left atrial; LVEF, left ventricular ejection fraction; LVH, left ventricular 
hypertrophy; MI, myocardial infarction; MPRI, myocardial-perfusion reserve index; NT-proBNP, N-terminal 
prohormone BNP.   
Table 8-13: Selected baseline characteristics stratified by MPRI.   
8.5.2 Study investigations 
Table 8-14 summarises the CMR findings based on the presence or absence of an 
inducible ischaemia.  There was no significant difference in cardiac structure of 
function on volumetric analysis.  Rates of both ischaemic and non-ischaemic LGE 
were similar in those with and without inducible ischaemia, but ECV was 
significantly higher in those with abnormal compared with normal global MPRI 
(30.3% vs. 27.6%; p = 0.031, respectively).   
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Those with and without inducible ischaemia on CMR did not have significantly 
different rates of obstructive epicardial CAD on invasive coronary angiography 
(69% vs. 52%; p = 0.33, respectively).  There were also similar rates of 
endothelium-independent (57% vs. 61%; p = 0.86) and -dependent CMD (0% vs. 
18%; p = 0.36) in those with and without imaging evidence of inducible 
ischaemia.     
 All MPRI 
(n = 41) 
MPRI <1.4 
(n = 28) 
MPRI ≥1.4 
(n = 13) 
p-value 
CMR 
LVEF (%) 61 [7] 60 [7] 62 [7] 0.55 
LVH 23 (56) 14 (50) 9 (69) 0.25 
LA dilatation 28 (68) 18 (64) 10 (77) 0.42 
Any LGE 25 (61) 15 (54) 10 (77) 0.15 
Ischaemic LGE 12 (29) 8 (29) 4 (31) 0.89 
Non-ischaemic LGE 15 (37) 9 (32) 6 (46) 0.39 
Native T1 (ms) 1288 [61] 1276 [51] 1314 [75] 0.06 
ECV (%) 28.5 [3.7] 27.6 [3.6] 30.3 [3.3] 0.031 
ECV >30% 17 (42) 8 (30) 9 (69) 0.018 
Invasive coronary assessment 
 (n = 34) (n = 21) (n = 13)  
Obstructive CAD 20 (59) 11 (52) 9 (69) 0.33 
 (n = 25) (n = 18) (n = 7)  
Endothelium-independent 
CMD 
15 (60) 11 (61) 4 (57) 0.86 
CFR 2.4 [1.8-2.7] 2.4 [1.8-2.7] 2.3 [1.1-3.1] 0.55 
CFR <2.0 8 (20) 5 (18) 3 (23) 0.69 
IMR 23 [13-32] 23 [13-39] 18 [13-32] 0.95 
IMR ≥25 12 (29) 9 (32) 3 (23) 0.55 
 (n = 15) (n = 11) (n = 4)  
Endothelium-dependent 
CMD 
2 (13) 2 (18) 0 (0) 0.36 
LVEDP (mmHg) 12 [10-15] 13 [9-15] 11 [10-18] 0.87 
Values are mean [standard deviation], median [Q1-Q3], or n (%). CAD, coronary artery disease; CFR, 
coronary flow reserve; CMD, coronary microvascular dysfunction; CMR, cardiac magnetic resonance; ECV, 
extracellular volume; IMR, index of microcirculatory resistance; LA, left atrial; LGE, late gadolinium 
enhancement; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction; LVH, 
left ventricular hypertrophy; MPRI, myocardial-perfusion reserve index.   
Table 8-14: CMR and invasive coronary assessment findings stratified by 
MPRI.   
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8.5.3 Correlates of myocardial-perfusion reserve index 
Tables 8-15 and 8-16 summarise the correlates of MPRI as binary and continuous 
variable, respectively.  An abnormally low MPRI was associated with a smoking 
history (ϕ = -0.38; p = 0.013) and an elevated ECV (ϕ = 0.38; p = 0.017).   
 
MPRI <1.4 p-value 
Smoking history 0.38 0.013 
ECV (%) 0.34 0.032 
ECV >30% 0.38 0.017 
Obstructive CAD 0.17 0.35 
Endothelium-independent CMD -0.036 0.86 
Endothelium-dependent CMD -0.24 0.40 
CAD, coronary artery disease; CMD, coronary microvascular dysfunction; ECV, extracellular volume; MPRI, 
myocardial-perfusion reserve index.   
Table 8-15: Correlates of MPRI <1.4 (binary).   
When expressed as a continuous variable, MPRI had a strong negative correlation 
with ECV (r = -0.41; p <0.01) (Figure 8-6) and a strong positive correlation with a 
previous history of MI (rpb = 0.46; p <0.01).    
 
MPRI p-value 
History of MI 0.46 <0.01 
ECV (%) -0.41 <0.01 
Elevated ECV (>30%) -0.38 0.017 
Obstructive CAD -0.16 0.31 
Endothelium-independent CMD 0.22 0.30 
Endothelium-dependent CMD 0.04 0.89 
CAD, coronary artery disease; CFR, coronary flow reserve; CMD, coronary microvascular dysfunction; CMR, 
cardiac magnetic resonance; ECV, extracellular volume; LA, left atrial; LVEDV, left ventricular end-diastolic 
volume; MI, myocardial infarction; MPRI, myocardial-perfusion reserve index.   
Table 8-16: Correlates of MPRI (continuous).   
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ECV, extracellular volume; MPRI, myocardial-perfusion reserve index.   
Figure 8-6: Scatterplot of MPRI correlation with ECV.   
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8.6 Outcomes related to cardiac magnetic resonance 
imaging findings 
8.6.1 Previous myocardial infarction 
Mortality 
No differences in mortality were observed in those with or without ischaemic 
LGE on CMR (Figures 8-7, 8-8, 8-9, 8-10).   
 
Figure 8-7: Kaplan-Meier curves for all-cause mortality by CMR-proven MI.    
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Figure 8-8: Kaplan-Meier curves for CV mortality by CMR-proven MI.     
 
Figure 8-9: Kaplan-Meier curves for HF mortality by CMR-proven MI.    
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Figure 8-10: Kaplan-Meier curves for non-CV mortality by CMR-proven MI.    
Hospitalisations 
There were no significant differences in the rates of hospitalisations due to any 
cause, CV causes or HF between those with and without CMR-proven MI (Figures 
8-11, 8-12, 8-13).  However, those with CMR-proven MI had more non-CV 
hospitalisations than those without (Figure 8-14).   
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Figure 8-11: Kaplan-Meier curves for all-cause hospitalisation by CMR-
proven MI.       
 
Figure 8-12: Kaplan-Meier curves for CV hospitalisation by CMR-proven MI.     
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Figure 8-13: Kaplan-Meier curves for HF hospitalisation by CMR-proven MI.     
 
Figure 8-14: Kaplan-Meier curves for non-CV hospitalisation by CMR-proven 
MI.  
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8.6.2 Extracellular volume 
Mortality and hospitalisations 
There was no difference in mortality rates between those with a normal or 
elevated ECV (Figure 8-15).  However, those with an elevated ECV had 
significantly more hospitalisations than those with a normal ECV (Figure 8-16), 
due to both CV (Figure 8-17) and non-CV reasons (Figure 8-18).   
 
Figure 8-15: Kaplan-Meier curves for all-cause mortality by ECV.    
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Figure 8-16: Kaplan-Meier curves for all-cause hospitalisation by ECV.   
 
Figure 8-17: Kaplan-Meier curves for CV hospitalisation by ECV.    
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Figure 8-18: Kaplan-Meier curves for non-CV hospitalisation by ECV.    
8.6.3 Myocardial-perfusion reserve index 
Mortality and hospitalisations 
There was no significant difference in mortality or hospitalisations between 
those with and without an MPRI <1.4 (Figures 8-19, 8-20).   
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Figure 8-19: Kaplan-Meier curves for all-cause mortality by MPRI.    
 
Figure 8-20: Kaplan-Meier curves for all-cause hospitalisation by MPRI.    
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8.7 Complications of cardiac magnetic resonance 
imaging 
There were no adverse events related to CMR imaging.  Five patients attended 
for CMR but were unable to tolerate the scan due to claustrophobia or back 
pain.  A further four patients were unable to tolerate the entire CMR protocol, 
and these scans were truncated.  Two patients were unable to be scanned due 
to significant magnetic interference with the surface ECG, making ECG gating 
impossible.  The majority of patients (63%) experienced typical symptoms during 
the adenosine infusion (i.e. dyspnoea, chest tightness, flushing), all of which 
subsided with discontinuation of the infusion.  No arrhythmia was documented in 
any patient during the adenosine infusion.   
8.8 Summary 
Of the 52 patients that underwent CMR, 14 (27%) had ischaemic LGE consistent 
with previous MI.  As expected, those with ischaemic LGE more commonly had a 
previous clinical history of CAD, MI and coronary revascularisation, but had less 
AF, than those with no ischaemic LGE.  Importantly, 57% of those with CMR-
proven MI had no clinical history of MI and 18% of those with no history of MI had 
CMR-proven MI, suggesting a high burden of clinically unrecognised MI in the 
HFpEF population.  Predictably, ischaemic LGE was associated with obstructive 
epicardial CAD.  However, there was no difference in the prevalence of 
endothelium-independent or -dependent CMD between the those with and 
without CMR evidence of MI.     
Of the 48 participants that had pre- and post-contrast T1 mapping, 20 (42%) had 
an elevated ECV (>30%) consistent with diffuse myocardial fibrosis.  Those with a 
high ECV had a lower BMI and longer hospital stay than those with a normal ECV.  
Patients with an elevated ECV had more T-wave inversion on ECG and LVH on 
CMR than those with a normal ECV, raising the possibility that some patients 
with a high ECV had an underlying cardiomyopathy.  Indeed, a single-centre 
study reported that 13% of patients hospitalised with HFpEF had wild-type 
transthyretin-related amyloidosis (ATTR).268  This is a particularly relevant in 
light of recent evidence that tafamidis has prognostic and symptomatic in 
patients with ATTR.268  Although it is possible that some study participants could 
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have had clinically unrecognised ATTR, patients with a strong clinical suspicion 
of hypertrophic or infiltrative cardiomyopathy were excluded from the study 
(see Chapter 3).  Furthermore, none of the study participants had 
echocardiographic features of hypertrophic/infiltrative cardiomyopathy or a 
typical LGE pattern suggestive of cardiac amyloidosis.  In two study participants, 
the CMR LGE/ECV findings prompted further evaluation with 99mTc-DPD 
scintigraphy, both of which were negative for ATTR.  An elevated ECV was 
strongly correlated with obstructive epicardial CAD (see Chapter 5).  The 
frequency of endothelium-independent and -dependent CMD was similar in those 
with a normal and abnormal ECV, however, ECV was inversely associated with 
IMR (see Chapter 6).    
Thirteen of the 41 participants (32%) that had semi-quantitative perfusion 
imaging had evidence of inducible myocardial ischaemia (i.e. global MPRI <1.4).  
Those with inducible ischaemia were more likely to have a smoking history than 
those without.  MPRI had a strong negative correlation with ECV, suggesting that 
chronic ischaemia may contribute to diffuse myocardial fibrosis in HFpEF.  
Interestingly, those with and without inducible ischaemia on CMR did not have 
significantly different rates of obstructive epicardial CAD on invasive coronary 
angiography.  Similarly, there was no significant difference in rates of either 
endothelium-independent or -dependent CMD between those with and without 
inducible ischaemia.  The reason why MPRI did not identify patients with 
obstructive CAD is uncertain but it may be due to the presence of CMD, the 
absence of reversible ischaemia in the context of non-viable myocardium, or 
collateral perfusion of a territory supplied by a stenosed or occluded epicardial 
coronary artery.  There is no general consensus regarding the MPRI threshold 
used to define ischaemia with variable thresholds used in different studies, 
therefore, a different cut-point may have had better diagnostic accuracy.269  
Furthermore, I assessed global MPRI which may not be significantly influenced by 
limited areas of myocardial ischaemia.  MPRI assessed on the coronary artery 
territory level may have better identified those with and without regional 
ischaemia.   
No difference in mortality was observed in those with or without ischaemic LGE 
on CMR, however, those with CMR-proven MI had more non-CV hospitalisations 
than those without.  The reason for this is unclear, but it may be related to the 
248 
 
higher burden of non-CV comorbidities in the MI group. Those with an elevated 
ECV had significantly more hospitalisations than those with a normal ECV, 
suggesting that ECV may represent a non-invasive prognostic biomarker in 
HFpEF.   
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Chapter 9 Discussion 
9.1 Main findings 
Heart failure is a major cause of morbidity and mortality worldwide.  Although 
estimates of the prevalence of HFpEF vary by the study population, study design 
and LVEF cut-off used, most studies report that HFpEF now accounts for around 
half of the HF population.270  While outcomes in HFpEF appear better than in 
HFrEF, hospitalisation and mortality rates remain high.8  In contrast to HFrEF, no 
treatment has so far been shown to provide clear prognostic benefit in patients 
with HFpEF, and outcomes have not improved in recent decades.18   
The heterogeneity of the HFpEF population and the consistently neutral results 
of RCTs has led many to argue that a “one-size-fits-all” treatment is unlikely to 
demonstrate benefit in unselected patients with HFpEF.271  Instead, establishing 
the sub-phenotype of HFpEF (e.g. those with a specific CV abnormality or 
comorbidity) might identify more homogeneous groups that could gain benefit 
from specific treatments.   
Recent studies suggest that CAD and CMD may play an important role in a 
substantial group of patients with HFpEF.148,231  The systematic literature review 
presented in Chapter 2 found disparate and inconsistent prevalence estimates of 
CAD in HFpEF cohorts.  Similarly, studies assessing CMD in HFpEF have reported 
variable results due to heterogenous definitions of CMD and methods of assessing 
coronary microvascular function.  Despite the popular hypothesis that coronary 
endothelial dysfunction plays a central role in the pathophysiology of HFpEF, the 
evidence for this is currently limited.61  This prospective, multicentre study is 
the first to systematically assess the prevalence of CAD, CMD and coronary 
endothelial dysfunction in an unselected HFpEF cohort using reference standard 
invasive investigations.   
I screened a total of 2285 near-consecutive patients hospitalised with suspected 
HF.  Of these, 628 (27%) were confirmed to have a diagnosis of HFpEF.  106 
HFpEF patients (17%) met the inclusion criteria and agreed to participate in the 
study.  The major reasons for exclusion were significant frailty (i.e. CFS [Clinical 
Frailty Scale] >6; n = 196, 38%), severe renal impairment (i.e. eGFR <30 
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mL/min/1.73m2; n = 104, 20%), and lack of capacity to consent (n = 88, 17%).  
Patients with HFpEF who were excluded from the study were significantly older, 
more often female, and had higher BNP levels than those who were recruited.  
Twenty-three patients (22% of those enrolled) did not undergo invasive coronary 
angiography or CMR, predominantly due to a decline in participants’ health, 
functional status or renal function making proceeding with the study 
investigations inappropriate or unsafe.  Those who did not proceed to the study 
investigations had a longer hospital stay than those that underwent the study 
investigations (median 12 vs. 7 days; p = 0.004, respectively).  There were no 
other significant differences in the baseline demographics or investigation 
results between the groups.  Overall, a total of 83 participants (78%) underwent 
invasive coronary angiography or CMR.  Seventy-five participants (71%) 
underwent invasive coronary angiography, 62 (58%) had guidewire-based 
coronary physiology testing, and 41 (39%) underwent vasoreactivity testing.  
Fifty-two participants (49%) underwent CMR and 44 (42%) had both invasive 
coronary angiography and CMR.   
The mean age of the participants was 72 years and 50% were female.  Almost all 
patients were Caucasian, with only 3% coming from minority ethnic backgrounds.  
Half of patients were obese, with a mean BMI of 33 kg/m2, and there was a high 
burden of frailty (39% had a CFS score ≥4).  Almost all participants (98%) were in 
NYHA class III or IV at presentation and two-thirds had a de novo diagnosis of HF.  
Thirty percent of patients had a previous history of CAD, 23% had a previous MI 
and 19% had previously had coronary revascularisation.  The typical 
comorbidities associated with HFpEF were highly prevalent in the cohort, 
including hypertension (75%), AF (62%) and diabetes (51%).  The mean LVEF on 
echocardiography was 59% and natriuretic peptides were significantly elevated 
(median BNP 382 pg/mL and NT-proBNP 1532 pg/mL).  The vast majority of 
patients (92%) had structural heart disease (i.e. LVH or LA dilatation), and the 
remainder had diastolic dysfunction.  Overall, I feel that my study population is 
representative of ‘real world’ patients hospitalised with HFpEF.   
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9.1.1 Obstructive epicardial CAD in HFpEF 
In this hospitalised HFpEF cohort, the prevalence of obstructive epicardial CAD 
on invasive assessment was 51%.  In population studies and RCTs, CAD is reported 
to be present in 40-50% of patients with HFpEF (see Chapter 2).  Studies which 
document CAD angiographically report higher rates, however, these have almost 
exclusively been carried out on convenience cohorts undergoing clinically 
indicated coronary angiography.  It is unclear whether this higher prevalence 
represents referral bias or whether there is an underappreciation of the burden 
of CAD in HFpEF based on clinical criteria alone.  A retrospective single-centre 
convenience cohort of 376 HFpEF patients reported “anatomically significant” 
CAD (defined as >50% luminal stenosis, previous MI or any previous 
revascularisation) in 68% of patients148, and an autopsy series of 124 patients 
with a premortem diagnosis of HF and LVEF ≥40% reported “anatomically 
significant” CAD (≥50% luminal stenosis) in 65% of patients208.  One prospective 
single-centre study of 108 patients with HFpEF (n = 75) and HFmrEF (n = 33) 
found obstructive CAD (defined as >70% luminal stenosis or ≥50% stenosis and 
FFR ≥0.80) in 64% of patients.199  More patients in each of these latter two 
studies had a clinical history of CAD (53% and 65%, respectively) when compared 
with my cohort (35%).  This likely reflects the inclusion of patients with HFmrEF, 
with similar demographics to patients with HFrEF, in these studies.  The clinical 
characteristics of my cohort are reasonably consistent with contemporary 
epidemiological and RCT HFpEF populations.18,272,273    
In my study, half of patients with obstructive epicardial coronary disease had no 
clinical history of CAD.  These findings highlight the high burden of clinically 
unrecognised CAD in the HFpEF population and are supported by other recent 
studies.  Trevisan and colleagues found that 42% of patients with HFpEF and 
obstructive epicardial CAD had no clinical history of CAD199, while Mohammed 
and colleagues reported anatomically significant CAD at post-mortem in 32% of 
HFpEF patients without known CAD208.  International guidelines recommend 
screening patients with HFpEF for CAD2,3, however, a recent large registry study 
found that non-invasive and invasive ischaemia testing was performed in only 8% 
and 6% of HFpEF patients, respectively, within 90 days following first HF 
hospitalisation.274   
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Interestingly, I found that a semi-quantitative CMR ischaemia testing (using 
MPRI) did not predict obstructive epicardial CAD on invasive coronary 
angiography.  I defined inducible ischaemia as an MPRI <1.4 which was previously 
reported to accurately detect obstructive epicardial CAD and CMD in patients 
with angina251, however, there is no general consensus regarding the MPRI 
threshold used to define ischaemia with variable thresholds used in different 
studies, therefore, a different cut-point may have had better diagnostic 
accuracy.269  Furthermore, I assessed global MPRI which may not be significantly 
influenced by limited areas of myocardial ischaemia.  MPRI assessed on the 
coronary artery territory level may have better identified those with and without 
regional ischaemia.  
The lack of correlation of non-invasive ischaemia testing with angiographic CAD 
in HFpEF was previously reported by Hwang and colleagues who found an overall 
accuracy of stress testing to classify CAD of only 66%, with no significant 
difference between various modalities (i.e. nuclear perfusion imaging, stress 
echocardiography and exercise ECG).148  The reason why non-invasive ischaemia 
testing did not identify patients with obstructive CAD is unclear but it might due 
to the presence of CMD, the absence of inducible ischaemia in the presence of 
non-viable myocardium, or collateral perfusion provided by another epicardial 
coronary artery.    
Over a median follow-up period of 18 months, there was no significant 
difference in mortality between those with and without obstructive CAD.  The 
number of deaths during follow-up was small, therefore, no meaningful 
conclusion can be reached regarding the association between CAD and mortality 
in the cohort.  Nonetheless, study participants with obstructive epicardial CAD 
had significantly more hospitalisations (for any cause, CV causes or HF) than 
those without obstructive CAD, suggesting that obstructive epicardial CAD may 
precipitate HF decompensation in some patients with HFpEF.  These findings 
align with a recent retrospective observational study and a registry-based study, 
both of which suggest that HFpEF patients with CAD have poorer outcomes than 
those without CAD.148,190  Event rates in this study were lower than those 
reported in epidemiological HFpEF studies8,12,13, but higher than in RCTs14–16.  
This reflects the intermediate risk of my study cohort who were younger and less 
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frail with fewer comorbidities than patients in epidemiological studies, but 
older, frailer and more comorbid than RCT HFpEF populations.   
There are few available data on the impact of revascularisation in patients with 
CAD in the setting of HFpEF and these are conflicting.  The Coronary Artery 
Surgery Study (CASS) registry found that CABG did not improve mortality in 
patients with HFpEF207, and a small study including 27 patients with acute 
hypertensive HF and an LVEF >40% showed that pulmonary oedema recurred in 
patients with CAD and HFpEF despite revascularisation206.  However, two 
retrospective non-randomised studies reported significantly better survival 
following revascularisation in HFpEF patients with CAD compared with those who 
were not revascularised, although these data are difficult to interpret because 
of selection bias or other confounding.148,178  Only eight participants (21% of 
those with obstructive disease) in my cohort underwent percutaneous coronary 
intervention, therefore, I was unable to evaluate the association between 
revascularisation and outcomes.   
9.1.2 CMD in HFpEF 
On invasive guidewire-based coronary physiological testing, 66% of patients had 
evidence of endothelium-independent CMD; 69% of those with no obstructive 
epicardial CAD had endothelium-independent CMD.  Several studies have been 
published documenting CMD in HFpEF cohorts, however, these have generally 
been small and/or convenience cohorts undergoing clinically indicated 
investigation for evaluation of CAD (see Chapter 2).  One small prospective study 
investigated 30 HFpEF patients and a clinical indication for coronary angiography 
with invasive coronary physiological testing.226  The prevalence of CMD in this 
cohort was 37% (defined as CFR ≤2.0 and IMR ≥23), but 73% if CMD was defined 
as CFR ≤2.0 or IMR ≥23.  These results are limited by referral bias and other 
factors, such as the inclusion of patients with ischaemia with no obstructive CAD 
(INOCA) with a high burden of CMD.135,275  A prospective multicentre study 
(PROMIS-HFpEF) recruited 202 ambulatory HFpEF patients and assessed CMD 
using echocardiography-derived CFR of the LAD.231  CMD was reported in 75% of 
patients using a CFR threshold of <2.5 (compared with 65% using the same 
threshold in my study).  In PROMIS-HFpEF, LVEF threshold for inclusion was ≥40% 
and elevated natriuretic peptides were not a requirement for inclusion.  
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Epicardial CAD was not systematically excluded, therefore, clinically 
unrecognised obstructive CAD (present in 39% of our cohort) could potentially 
confound these results.  Echocardiography-derived CFR has been validated 
against PET and invasive CFR in small cohorts.123,276  Thirty-five percent of the 
patients in this study were obese and, although this technique appears to be 
technically feasible in such patients, agreement with myocardial flow reserve on 
PET was relatively weak.277    
Both CFR and IMR are commonly used to assess endothelium-independent 
coronary microvascular function.  However, these indices measure different 
aspects of microvascular function: CFR represents the flow ratio between resting 
and hyperaemic conditions; IMR represents microvascular resistance during 
hyperaemia.  I was, therefore, able to describe different patterns of CMD in the 
study population.  Thirty-one percent of the cohort had abnormalities of both 
flow reserve and microvascular resistance and 35% had discordant CFR/IMR 
results.  These findings are comparable to a previous study in INOCA patients and 
a recent small study of HFpEF patients (n = 30, discussed above).226,244  The 
clinical characteristics and outcomes of my patients was similar in those with 
different mechanisms of CMD.   
The concept that the coronary microvasculature may play a central role in the 
pathophysiology of HFpEF was proposed by Paulus and Tschöpe in 2013.61  They 
hypothesised that comorbidities induce a systemic pro-inflammatory state, with 
coronary microvascular endothelial inflammation and dysfunction.  This results 
in adverse myocardial and vascular remodelling, leading to LV diastolic 
dysfunction and clinical HF (see Chapter 1).  This paradigm was based on a series 
of small studies of human endomyocardial tissue specimens.  However, the 
patients studied were a highly selected group who were considerably younger 
and without the usual comorbidity profile of the typical HFpEF patient (see 
Chapter 2).  Despite this, studies reporting evidence of impaired coronary 
microvascular function and rarefaction in patients with HFpEF have given 
support to this theory, suggesting that their findings could reflect coronary 
microvascular endothelial dysfunction.208,231  In PROMIS-HFpEF, CMD was 
correlated with a lower reactive hyperaemia index, a measure of peripheral 
endothelial dysfunction.231  However, CFR was not associated with 
comorbidities, such as diabetes and hypertension, suggesting that CMD may be 
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related to other mechanisms (e.g. myocardial fibrosis, microvascular 
rarefaction), rather than comorbidity-induced systemic inflammation.   
My study is the first to assess endothelium-dependent coronary vasomotor 
function in vivo in a HFpEF population using the reference standard invasive 
assessment with intra-coronary ACh administration.  During vasoreactivity 
testing, only 24% of patients assessed had evidence of coronary microvascular 
endothelial dysfunction (endothelium-dependent CMD).  Furthermore, I found no 
correlation between endothelium-independent and -dependent mechanisms of 
CMD.  These findings suggest that CMD in HFpEF is predominantly due to 
endothelium-independent structural abnormalities, such as abnormal vascular 
remodelling, microvascular rarefaction and extrinsic vascular compression, 
rather than endothelial dysfunction.  Although it is possible that these structural 
abnormalities could be the end-stage result of previous endothelial dysfunction, 
a minority of hospitalised HFpEF patients appear to have active coronary 
microvascular endothelial dysfunction.  These findings are consistent with the 
neutral outcomes of several trials of therapies targeting NO-cGMP-PKG 
signalling, including the soluble guanylate cyclase stimulatory vericiguat67, the 
phosphodiesterase-5 inhibitor sildenafil68, organic nitrates69 and inorganic 
nitrites70, and sacubitril-valsartan71.     
Although several studies have shown CMD to be prevalent in HFpEF, causality has 
yet to be established.  It has been suggested that, rather than primary CMD 
leading to myocardial remodelling and HFpEF, it may occur as a secondary 
consequence of the myocardial remodelling and diastolic dysfunction seen in 
HFpEF.278  Nevertheless, recent studies report that subclinical CMD and high-
sensitivity cardiac troponin elevations predict future HFpEF.279,280  Early 
identification of patients with CMD could, therefore, help detect patients at risk 
for progression to HFpEF who could potentially benefit from targeted therapies.   
During follow-up, I found no significant difference in outcomes between those 
with and without endothelium-independent or -dependent CMD.  Only one other 
study has reported outcomes in HFpEF relating to CMD.  Allan and colleagues 
assessed 32 HFpEF patients with a clinical indication for coronary angiography 
and reported lower survival free of HF hospitalisation in patients with “overt 
CMD” (abnormal CFR and IMR) versus those without “overt CMD”.227  However, 
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this was a convenience cohort with very few patients and events, so the clinical 
relevance of this is unclear.   
9.1.3 Myocardial infarction and fibrosis in HFpEF 
Twenty-seven percent of participants that underwent contrast enhanced CMR 
had ischaemic LGE consistent with previous MI.  Fifty-seven percent of those 
with CMR-proven MI had no clinical history of MI and 18% of those with no history 
of MI had CMR-proven MI, suggesting a high burden of clinically unrecognised MI 
in the HFpEF population.  As documented in the systematic review in Chapter 2, 
the prevalence of previous MI reported in HFpEF cohorts is variably reported.  
One prospective single-centre observational study of 154 patients with suspected 
HFpEF found evidence of clinically unrecognised MI in 10% of patients based on 
LGE imaging.281  Mohammed and colleagues reported a prevalence of MI at 
autopsy of 42% and 20% on gross and microscopic pathology, respectively, in 124 
patients with a premortem diagnosis of HF and LVEF ≥40%.208  The prevalence 
estimate based on this study is consistent with the intermediate risk of my 
cohort between the former lower risk (predominantly ambulatory patients, 
lower natriuretic peptides) and latter higher risk (historical cohort, lower LVEF 
threshold) study populations.  The identification of patients with previous MI is 
important as these patients can gain prognostic benefit from secondary 
prevention and anti-remodelling drug therapy.282–285    
Several studies have suggested that myocardial fibrosis may play an important 
role in causing or contributing to myocardial stiffness and diastolic dysfunction 
in HFpEF.44,208  ECV is a non-invasive measure of diffuse myocardial fibrosis and, 
in this study, 42% of patients had a high ECV (>30%).  I found that ECV was 
inversely correlated with global MPRI, which is consistent with the results of a 
recent small study of 19 HFpEF patients.232  These findings suggest that chronic 
sub-clinical ischaemia may contribute to diffuse myocardial fibrosis in HFpEF.  
Furthermore, consistent with previous studies which report that diffuse fibrosis 
is associated with poor outcomes in HFpEF286,287, I found that patients with a 
high ECV had significantly more hospitalisations than those with a normal ECV.   
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9.1.4 Summary 
Overall, over 90% of participants in this cohort had evidence of macrovascular 
and/or microvascular CAD (Figures 9-1 and 9-2).  Obstructive epicardial CAD was 
present in around half of HFpEF patients and those with obstructive CAD had 
significantly more hospitalisations than those without obstructive disease.  
Various treatments are available for epicardial CAD which might improve 
symptoms and/or outcomes in HFpEF.   
Of those without obstructive epicardial CAD, over 80% of patients had CMD 
(endothelium-independent or -dependent).  Like HFpEF, CMD is a heterogeneous 
condition and I have demonstrated a variety of different mechanisms (including 
impaired flow reserve, high microvascular resistance and endothelial 
dysfunction) which can occur in isolation or in combination.  As such, it is 
unlikely that therapies targeting a specific process (e.g. coronary microvascular 
endothelial dysfunction) will be effective in treating most patients with HFpEF.  
In this cohort, endothelium-independent mechanisms of CMD predominated, 
with only a minority of patients having evidence of coronary endothelial 
dysfunction.  This has important implications for future treatments directed at 
CMD in patients with HFpEF.   
 
CAD, coronary artery disease; ED-CMD, endothelium-dependent coronary microvascular dysfunction; EI-
CMD, endothelium-independent coronary microvascular dysfunction; FFR, fractional flow reserve.   
Figure 9-1: Overview of invasive coronary assessment findings.   
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Values are % [95% CI].  
CAD, coronary artery disease; CMD, coronary microvascular dysfunction; CMR, cardiac magnetic resonance; 
MI, myocardial infarction.   
Figure 9-2: Prevalence of CAD, CMD, and imaging evidence of impaired 
myocardial perfusion, MI and diffuse myocardial fibrosis.   
9.2 Strengths 
I believe that this study has many strengths.  Firstly, the screening and 
recruitment processes were systematic.  I prospectively screened near-
consecutive patients admitted with suspected HF at three large hospitals five 
days per week for 19 months.  I screened all admissions to the coronary care 
units, cardiology wards and medical receiving units in addition to screening 
echocardiogram requests at all three sites, therefore, I believe I was able to 
identify almost all patients admitted with suspected HF.   
All patients enrolled had a diagnosis of HFpEF based on the ESC HF guidelines, 
necessitating clinical symptoms and signs of HF, an LVEF ≥50%, elevated 
natriuretic peptides, and evidence of structural heart disease and/or diastolic 
dysfunction on echocardiography.  Median natriuretic peptides were markedly 
elevated and >90% of patients had structural heart disease (i.e. LVH and/or LA 
dilatation).   
The demographics of this cohort are in accordance with contemporary 
population-based studies in HFpEF, with the exception of ethnicity (discussed 
below).  The typical comorbidities typically associated with HFpEF were highly 
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prevalent in this cohort, including hypertension, AF, CKD, anaemia, and 
obstructive airways disease.  Interestingly, the proportion of patients with a 
previous history of CAD in my cohort is identical to the prevalence estimate of 
hospital-based cohorts in the meta-analysis presented in Chapter 2.   
Frailty has been increasingly recognised as an important (but often poorly 
defined) feature of many patients with HFpEF.  Recruitment of frail patients to 
clinical studies is challenging and, therefore, these patients are frequently 
excluded from many studies, especially those involving invasive procedures.  I 
assessed the degree of frailty in all patients recruited using the CFS.239  Although 
patients with severe frailty were not included, patients with mild or moderate 
frailty made up a large proportion of the overall study cohort.    
Overall, I feel this cohort is representative of ‘real world’ hospitalised HFpEF 
patients.  Selection bias was minimal due to the prospective and near-
consecutive screening process.  The recruited patients all had a diagnosis of 
HFpEF in accordance with the current ESC guidelines.2  The demographics and 
clinical characteristics of my cohort are comparable to HFpEF populations in 
contemporary epidemiological studies.257,258  Consequently, I believe that the 
findings of this study are generalisable to ‘real world’ patients hospitalised with 
HFpEF.   
Another strength of the study is the population size, which was large taking into 
account the demographics of the study population, the prospective and 
systematic nature of recruitment, and the invasive investigations involved.  This 
is only the second study to systematically perform invasive coronary angiography 
in a HFpEF population.  Trevisan and colleagues performed coronary angiography 
on an identical number of patients as this study (n = 75).199  This is, therefore, 
the joint largest prospective systematic coronary angiography study in HFpEF.   
Possibly the greatest strength of this study was the use of reference standard 
invasive and non-invasive investigations to comprehensively assess the 
macrovascular and microvascular coronary structure and function.  I was able to 
assess the burden of obstructive epicardial CAD and examine the different 
mechanisms of CMD in the study cohort.  This is the largest (and only unselected) 
study to invasively assess endothelium-independent CMD (n = 62), and the first 
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study (invasive or non-invasive) to assess coronary endothelial function in vivo (n 
= 41) in a HFpEF population.  I was also able to assess the myocardial 
consequences of CAD and CMD.  Using CMR, I assessed the burden of previous MI 
and diffuse myocardial fibrosis, as well as myocardial ischaemia.  I was, 
therefore, able to compare invasively-assessed CAD and CMD with non-invasive 
measures of myocardial infarction, fibrosis and ischaemia.   
Finally, comprehensive outcome data (death and hospitalisations) was available 
for all patients over a median follow-up of 18 months.  This is the first 
prospective systematic study to report outcomes based on epicardial CAD on 
coronary angiography.  One small study (n = 32) of selected HFpEF patients 
recently reported outcomes related to endothelium-independent CMD at 12 
months’ follow-up.  However, this is the first study to report outcomes related 
to the presence of endothelium-independent and -dependent CMD in a 
prospectively recruited HFpEF cohort.   
9.3 Weaknesses 
This study is limited by the high drop-out rate of patients recruited prior to 
invasive and non-invasive investigation.  Due to the logistics of performing this 
study within the limits of a busy regional clinical service, there was a significant 
delay in performing invasive coronary angiography (median 97 days from 
presentation).  Twenty-three patients that were recruited did not undergo the 
study investigations.  For the majority, this was due to a decline in health, 
functional status or renal function prior to the investigations being performed, 
making it clinically inappropriate or unsafe to proceed with the imaging studies.  
This reflects the demographics of the unselected HFpEF population I studied, 
who are predominantly elderly with some degree of frailty and a high burden of 
comorbidities.  I considered that these patients might represent a higher-risk 
group, however, there was no significant difference in mortality or 
hospitalisations between those that did and did not undergo the study 
investigations during follow-up (Appendix VIII, IX).   
The inclusion criteria were designed to be as broad as possible in order to 
accurately represent an unselected ‘real world’ HFpEF population.  However, it 
was necessary to exclude specific groups of patients for safety reasons.  Notably, 
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those with significant renal dysfunction (eGFR <30 mL/min/1.73m2) were 
excluded to facilitate the safe administration of contrast agents during the study 
investigations.  Although many participants had a degree of frailty, those with 
severe frailty (i.e. CFS >6), in whom invasive coronary angiography was 
considered clinically inappropriate or an excessive risk, were excluded.  The 
requirement for invasive investigation limited recruitment of elderly and frail 
patients (who comprise a significant proportion of the HFpEF population), which 
slightly limits the generalisability of the study results to the HFpEF population at 
large.     
As discussed above, this cohort were almost exclusively Caucasian.  Although this 
is relatively consistent with the Scottish population259, patients from minority 
ethnic backgrounds are under-represented in clinical research studies and the 
study findings may not be applicable in other ethnic groups.260   I recruited only 
hospitalised patients who are likely to represent an advanced HFpEF phenotype, 
therefore, these results may not be representative of the ambulatory HFpEF 
population.  Indeed, patients with hospitalised HF are generally older, have a 
higher burden of comorbidities and poorer outcomes than ambulatory HF 
patients.288  Data on the relative proportions of patients with acute and chronic 
HFpEF are limited.  The percentage of patients with acute HFpEF that develop 
chronic HF is unclear.  Similarly, how many patients with chronic HFpEF will 
subsequently be hospitalised with acute decompensated HF is unknown.  The 
ESC-HF Long-term Registry recruited unselected HF patients over a two-year 
period.  Acute HF presentations accounted for 47% of the total HFpEF patients 
recruited, whereas only 38% of patients with HFrEF presented acutely; 28% of 
acute HF presentations were de novo and 72% represented decompensation of 
chronic HF.288  Quality of life following hospitalisation for HFpEF is poor and HF 
re-hospitalisations are high, therefore, the it is likely that a substantial 
proportion of patients hospitalised with acute HFpEF will go on to develop 
chronic HF.18,289  
It was not always possible to perform all investigations in all patients recruited 
due for various reasons (e.g. coronary vasoreactivity testing was contraindicated 
in the majority of patients with obstructive epicardial CAD), however, 
guidewire-based coronary microvascular assessment was performed in all but 
one of those without obstructive CAD, and the majority of those with obstructive 
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coronary disease.  FFR was used to assess the haemodynamic significance of 
intermediate (50-70%) epicardial stenoses, however, it was not routinely 
measured in arteries with a stenosis <50% or ≥70%, therefore, it is possible that a 
minority of patients with angiographically mild or severe disease might have 
been incorrectly classified as having non-flow-limiting or flow-limiting CAD, 
respectively.  For practical reasons, it was only possible to perform physiological 
assessment of one major epicardial coronary artery.  Although CMD is commonly 
thought to be a global myocardial phenomenon, it is possible that we may not 
have detected regional microvascular dysfunction in other coronary territories.2   
The definition of endothelium-independent CMD used in my study (i.e. CFR <2.0 
and/or IMR ≥25) is consistent with the contemporary literature in other 
populations.  However, CFR and IMR are continuous measures and the thresholds 
used do not accurately represent the spectrum of coronary microvascular 
function.  I defined coronary endothelial dysfunction based on the contemporary 
literature and the international standards for the diagnostic criteria of coronary 
vasomotion disorders developed by the Coronary Vasomotion Disorders 
International Study Group (COVADIS).146  However, invasive assessment of both 
endothelium-independent and -dependent CMD have been assessed 
predominantly in patients with chest pain syndromes and have not been 
validated in the HFpEF population.  Furthermore, invasive assessment of the 
coronary microvasculature is not routinely performed in clinical practice and 
there is likely to be a degree of inter-observer variability in these assessments.  
However, the operators who performed the invasive coronary assessments in this 
study have extensive experience in performing these measurements in other 
research studies with a high degree of repeatability.267   
The delay between recruitment and performing the invasive coronary assessment 
may have impacted on the results of coronary microvascular testing.  Elevated 
LV filling pressures can cause or contribute to CMD as a result of extravascular 
compression.266  Invasively-assessed LV end-diastolic pressure was normal in over 
half of the study participants, but this likely would not have been the case had 
the invasive assessment been performed during the index hospitalisation.   
Finally, this study was limited by the lack of an age- and comorbidity-matched 
control group.  It was not possible to recruit a healthy control group due to the 
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ethical issues regarding invasive assessment in healthy patients.  I considered 
the option of including a control group of patients undergoing clinically indicated 
coronary angiography (e.g. patients with INOCA or those with aortic stenosis 
being worked up for intervention).  However, no groups were suitable for 
comparison to the HFpEF cohort.  Patients with INOCA are significantly younger 
than those with HFpEF and a large proportion of these patients have CMD and/or 
coronary endothelial dysfunction as the underlying cause of their symptoms.135  
In aortic stenosis, the high LV wall stress and haemodynamic load result in 
significant alterations in coronary microvascular function.290  Despite the lack of 
a control group, previous studies have assessed the prevalence of CMD in non-
HFpEF populations, and the prevalence is considerably higher in HFpEF when 
compared with diabetic and hypertensive cohorts.291-293  In the 2019 Scottish 
Health Survey, the prevalence of ischaemic heart disease (defined as a history of 
MI or angina) in the Scottish population was 13% in those aged 65-74 years and 
23% in those aged >75 years.265  However, data on the prevalence of 
angiographically documented CAD in unselected patients is limited.  A pooled 
analysis assessed the prevalence of obstructive CAD in patients referred for 
investigation of suspected CAD.88  In patients presenting with dyspnoea, the 
prevalence of obstructive CAD in those aged 60-69 years was 27% in men and 14% 
in women, and in those aged >70 years was 32% in men and 12% in women.  
Therefore, the prevalence of angiographically documented CAD in my HFpEF 
cohort (51% overall, 63% in men, 38% in women) is significantly higher than 
would be expected in age-matched patients in the general population.   
9.4 Future research relating to this study 
One of the major aims of this study was to determine how prevalent obstructive 
epicardial CAD is in the HFpEF population.  Various treatments, including 
medications and coronary revascularisation, are available which provide 
symptomatic and/or prognostic benefit in broad populations with CAD.  As none 
of these trials have included patients with HFpEF, there is currently no 
knowledge of the efficacy of any of these treatments in the HFpEF population.  
To date, no therapies have been shown to have any convincing clinical benefit in 
HFpEF, therefore, identifying a potentially treatable comorbidity (obstructive 
epicardial CAD) in a large subgroup of the HFpEF population has promising 
implications.   
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This study can inform the design of an RCT to answer the question of whether 
revascularisation of obstructive CAD in HFpEF will result in clinical benefit in 
HFpEF.  I have demonstrated that it is practical to recruit HFpEF patients with a 
high burden of comorbidities and mild or moderate frailty, and safely perform 
invasive coronary procedures.  I have shown that HFpEF patients with 
obstructive CAD have a significantly higher rate of hospitalisations, 
predominantly due to HF, than those without obstructive disease.  This suggests 
that CAD may play an important role in exacerbating symptoms and provoking 
decompensation in HFpEF.  Treatment directed at CAD might, therefore, 
improve quality of life and outcomes in HFpEF patients.   
This study also provides invaluable information regarding the mechanisms of CMD 
in HFpEF.  I have demonstrated that CMD in HFpEF is due to a variety of 
mechanisms.  It is, therefore, unlikely that therapies targeting one specific 
pathophysiological process will be effective in treating the majority of HFpEF.  
In this cohort, only a minority of patients had evidence of endothelial 
dysfunction.  This will inform future treatments directed at CMD in patients with 
HFpEF.  Although CMD (as categorised by thresholds derived from other 
populations) was highly prevalent in this HFpEF population, the clinical 
significance of this is unclear.  In contrast to obstructive epicardial CAD, 
patients with and without CMD had similar outcomes, therefore, the rationale 
for trials of treatments directed at CMD in HFpEF appear more limited.   
9.5 Conclusions 
Both obstructive epicardial CAD and CMD are common in hospitalised patients 
with HFpEF and each may be a therapeutic target.  Patients with HFpEF and 
obstructive epicardial CAD had significantly more hospitalisations than those 
without obstructive CAD.  This study provides the justification for, and the basis 
for the design of, an RCT assessing the prognostic impact of treating CAD in 
HFpEF.   
Although it has been hypothesised that CMD may be due to endothelial 
dysfunction in HFpEF, it appears to be predominantly due to endothelium-
independent mechanisms.  This may have important implications for future 
treatments directed at CMD in patients with HFpEF.   
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PARTICIPANT INFORMATION SHEET: STAGE 1 
 
STUDY TITLE: Coronary Artery Disease in Heart Failure with Preserved Ejection Fraction 
 
 
1. Invitation  
We would like to invite you to take part in our study. This involves having tests performed to help work out 
if a lack of blood getting to the heart muscle may be a cause of heart failure in some people. Before you 
decide whether or not to take part we would like you to understand why the research is being done and 
what it will involve for you. We can read through the information sheet with you and answer any questions 
you may have.  
 
2. Why have I been asked to take part? 
You have been invited to participate in this study because you have been admitted to hospital with 
suspected heart failure. This is a condition where the heart does not pump blood around the body as well 
as it should do. You have also had a heart scan (echocardiogram) showing that your heart muscle appears 
to be pumping well. This means you may have a type of heart failure called heart failure with preserved 
ejection fraction, or HF-PEF. 
 
Patients with HF-PEF commonly experience shortness of breath, leg swelling and tiredness. Unfortunately, 
we do not have a good understanding of the underlying causes and we are currently looking for better 
treatments for this condition. 
 
3. Why is the study being carried out? 
Our aim is to look at whether a lack of blood getting to the heart muscle causes HF-PEF in some people. 
The most common cause of a lack of blood getting to the heart muscle is due to narrowings of the heart 
arteries. If there are narrowings of the heart arteries, treatments are available which could potentially 
improve quality of life. We will perform tests to try and establish what proportion of people admitted to 
hospital with HF-PEF has narrowings of the heart arteries that could potentially benefit from these 
treatments.  
 
The next page provides an overview of the tests included in the study.   
 
 
 
Queen Elizabeth University Hospital     Enquiries to: Dr Christopher Rush 
Office Block, Ground Floor, Zone 0.01, Office 0.05  Telephone: 0141 452 5877 
1345 Govan Road      E-mail: Christopher.Rush@glasgow.ac.uk 
Glasgow  G51 4TF 
                                                                                        
 
266 
Version 6.0   23rd March 2017 
 
Flow diagram of study  
 
 
 
 
 
 
 
 
 
 
 
 
267 
Version 6.0   23rd March 2017 
4. Do I have to take part? 
No – participation is entirely voluntary, and if you do decide to take part you can stop at any time. 
Whatever you decide to do, your medical care will not be affected. 
 
5. What will be involved if I decide to take part? 
If you agree to take part, we would first like to take a blood test from you to check for N-terminal 
prohormone B-type natriuretic peptide (NT-proBNP). This tests how well the heart is pumping. Having 
blood taken can be uncomfortable and some people feel faint. 
 
x If the blood test is negative, this means you do not have heart failure and you will not be asked to 
participate further in the study.  
 
x If the blood test is positive, a doctor involved in the study will visit you during your hospital stay to 
discuss whether or not you would like to take part in stage 2 of the study.  
 
x If you agree to participate in the study, the research doctor will look at your medical records as part 
of the research. 
 
If you meet the criteria to enter the next stage of the study, you will be invited to participate in stage 2.  
This involves undergoing further tests to examine the blood supply to the heart muscle and detect any 
narrowings of the heart arteries (see below). You will also be asked to provide one further blood test and a 
urine sample.  
 
x Heart MRI scan – this is a scan performed when you are lying in a short tunnel which holds a large 
magnet. It takes 60 minutes to complete. The magnet creates field changes to create a detailed 
picture of the heart. A contrast agent is given during the scan – this is a colourless liquid used to 
highlight parts of the heart on the scan. Special medication is also given during the scan to look for 
evidence of restricted blood flow to the heart muscle. If you are not able to have an MRI (for 
example, if you have a pacemaker) you will not be asked to have this scan.  
 
x Coronary angiogram and pressure wire studies – this test allows the doctors to examine the 
arteries supplying your heart muscle in detail. A small hollow tube is placed in an artery at the wrist 
(radial artery) to allow passage of fine catheters and thin wires to your heart. Less commonly, an 
artery in the groin is used. A contrast agent is injected and moving x-ray pictures are taken to 
visualise your heart arteries. A pressure wire is a very thin wire that can be passed down the heart 
arteries. Special medication is given and the wire is used to determine if any narrowings of the 
heart arteries are restricting blood flow to the heart muscle or not.  
 
6. What are the risks involved in taking part? 
There are no risks involved in taking part in stage 1 of the study.  
 
7. Will my taking part in the study be kept confidential? 
All the information collected about you in relation to the study will be kept strictly confidential. Your 
medical notes may be looked at by members of the research team and by representatives of the study 
Sponsor (NHS Greater Glasgow and Clyde) in relation to your taking part in the study and to ensure the 
study has been carried out appropriately. 
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8. What will happen to the results of the research study? 
The results of the research study will be stored on a computer database and are likely to be published in 
medical journals which will be available to the general public. Reports or publications resulting from the 
study will not contain any personal details. A summary sheet of the research findings will be provided to 
participants on completion of the study.  
 
9. Who is organising and funding the research? 
The University of Glasgow is performing the study and the project is funded by the Chief Scientist Office. 
NHS Greater Glasgow and Clyde will sponsor the study, i.e. manage and monitor the conduct of the study. 
 
Thank you for taking the time to read this information leaflet.  
 
If you have any questions regarding the study, please contact:  
 
Study doctor 
Dr Christopher Rush 
Clinical Research Fellow 
Telephone: 0141 452 5877   
E-mail: Christopher.Rush@glasgow.ac.uk 
 
Supervisors 
Professor John McMurray  Professor Mark Petrie 
Telephone: 0141 330 3479  Telephone: 0141 330 2000 
 
Independent doctor 
Dr Martin Mitchell Lindsay 
Telephone: 0141 951 5431 
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PARTICIPANT INFORMATION SHEET: STAGE 2 
 
STUDY TITLE: Coronary Artery Disease in Heart Failure with Preserved Ejection Fraction 
 
 
1. Invitation 
We would like to invite you to take part in stage 2 of our study. This research involves having tests 
performed to help work out if a lack of blood getting to the heart muscle may be a cause of heart failure in 
some people. Before you decide whether or not to take part we would like you to understand why the 
research is being done and what it will involve for you. We can read through the information sheet with 
you and answer any questions you may have.  
 
2. What is the purpose of the study and why have I been invited to take part? 
You have been invited to participate in this study because you have been admitted to hospital with heart 
failure. This is a condition where the heart does not pump blood around the body as well as it should do. In 
stage 1 of the study you had a blood test which confirmed that you have heart failure. You have also had a 
heart scan (echocardiogram) showing that your heart muscle appears to be pumping well. This means that 
you have a specific type of heart failure called heart failure with preserved ejection fraction, or HF-PEF.  
 
Patients with HF-PEF commonly experience shortness of breath, leg swelling and tiredness. Unfortunately, 
we do not have a good understanding of the underlying causes and we are currently looking for better 
treatments for this condition. 
 
Our aim is to look at whether a lack of blood getting to the heart muscle causes HF-PEF in some people. 
The most common cause of a lack of blood getting to the heart muscle is due to narrowings of the heart 
arteries. If there are narrowings of the heart arteries, treatments are available which could potentially 
improve quality of life. These include medications and treatments to open up the heart arteries.  
 
We will perform tests to try and establish what proportion of people admitted to hospital with HF-PEF has 
narrowings of the heart arteries that could potentially benefit from these treatments.  
 
The next page provides an overview of the tests included in the study.   
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3. Do I have to take part? 
No ʹ taking part in this study is entirely voluntary and your decision. If you take part you will be given this 
information sheet and asked to sign a consent form. If you decide to take part you are free to withdraw at 
any time without giving a reason. A decision to withdraw at any time or a decision not to take part will not 
affect the standard of care you receive.  
 
4. What will happen to me if I would like to take part in stage 2 of the study? 
You have already taken the stage 1 of the study which involved having a blood test taken which confirmed 
that you have heart failure. If you agree to take participate in stage 2 of the study, we will ask you to 
undergo further tests to examine the blood supply to the heart muscle and detect any narrowings of the 
heart arteries (see below). You will also be asked to provide one further blood test and a urine sample.  
 
x Blood test – you will be asked to provide a blood sample. We will check for substances in the blood 
that may help identify people with a lack of blood getting to the heart muscle. Approximately 10mls 
(two teaspoons) of blood will be taken.  
 
x Urine test – you will be asked to provide a urine sample. We will check for substances in the urine 
that may help identify people with a lack of blood getting to the heart muscle. As women who are 
pregnant are not able to take part in this study, we may require an additional urine sample to 
perform a pregnancy test.   
 
x Heart MRI scan – this is a scan performed when you are lying in a short tunnel which holds a large 
magnet. It takes 60 minutes to complete. The magnet creates field changes to generate a detailed 
picture. The scanner does not touch you and you will be unaware of these field changes. The scan is 
noisy so earphones will be provided with music playing during the test. A contrast agent will be 
given to you during the scan into a small tube (cannula) in your arm. The contrast agent is a 
colourless liquid used to highlight parts of the heart on the scan. Special medication called 
adenosine (which increases the blood flow in the heart arteries) will also be given into the cannula 
during the scan to look for evidence of restricted blood flow to the heart muscle. If you are not able 
to have an MRI (for example, if you have a pacemaker) this will be discussed with you and you will 
not be asked to have this scan. 
 
x Coronary angiogram and pressure wire studies – these tests allow the doctors to examine the 
arteries supplying your heart muscle in detail. You will be awake for the test and can be given 
medication to help you relax. At the start of the procedure you will feel a needle being passed into 
the skin in the wrist to inject local anaesthetic. A small hollow tube is placed in an artery at the 
wrist (radial artery) to allow passage of fine catheters and thin wires to your heart. Less commonly, 
an artery in the groin is used. A contrast agent is injected and moving x-ray pictures are taken to 
visualise your heart arteries. These pictures are projected onto a screen and the doctor is able to 
see any narrowings of the large heart arteries which may be restricting blood flow to the heart 
muscle. A pressure wire is a very thin wire that is passed down the same catheter used to do the 
angiogram. The pressure wire is passed down the heart arteries and two special medications 
(adenosine and acetylcholine) are given to increase the blood flow to the heart muscle. The wire is 
used to determine whether any narrowings seen on the angiogram are restricting blood flow to the 
heart muscle or not. If the angiogram does not show any significant narrowings of the large heart 
arteries, the pressure wire is used to assess blood flow in the small heart arteries which cannot be 
seen on a standard angiogram.  
 
The heart MRI scan will take place at the Queen Elizabeth University Hospital during your hospital 
admission or within two weeks of your discharge from hospital. The coronary angiogram and pressure wire 
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studies will take place at the Golden Jubilee National Hospital in Clydebank within eight weeks of your 
discharge from hospital. You will receive a letter and phone call with the appointment date and time from 
the study doctor. A taxi will be organised to and from this appointment free of charge.  
 
TŚe ǁaǇ ƚŚaƚ ǁe fŽůůŽǁ a ƉeƌƐŽŶ͛Ɛ ƉƌŽgƌeƐƐ ŝŶ a ƐƚƵdǇ ůŝŬe ƚŚŝƐ ŝƐ bǇ eŶƚeƌŝŶg ƚŚeŝƌ deƚaŝůƐ ŝŶƚŽ a ŶaƚŝŽŶaů 
database, which uses hospital notes to record when you come into hospital. This database is run by the 
NHS and is confidential. Any information gathered is only available to the doctors running this study. It 
does not require any participation from you, and no one will contact you as part of this process. If you 
agree to take part in the study at this stage, we will enter you details into this database. The information 
gathered from this database may be used for future ethically approved research.  
 
5. When will I get the results of the test? 
The results of the coronary angiogram and pressure wire studies will be explained to you on the same day 
as you have the test. If there are narrowed arteries supplying blood to the heart muscle this will be 
explained to you. If a narrowed artery is identified, and you agree with your specialist doctor, they may 
proceed to treating the identified problem during the same procedure. A small inflatable balloon on the tip 
of a narrow tube is passed down the heart artery until its tip reaches the narrowed section. The balloon is 
gently inflated so that it squashes the fatty tissues responsible for narrowing the artery. A stent (a short 
tube made of stainless steel mesh) may also be inserted. The stent stays in the artery and often has a 
special drug coating to prevent the artery re-narrowing. 
 
The heart MRI scan takes more time to interpret so the results will not be available on the day. The scan 
will be reviewed and the report will be included in your medical records so that your consultant or GP will 
be able to discuss the results at your next routine visit. Any unexpected findings seen on the scan will be 
discussed with a specialist x-ray doctor and highlighted to your consultant or GP, who will be able to 
discuss the findings with you. 
 
6. What are the possible benefits of taking part? 
It is hoped that by taking part in this study you will be providing valuable information to help us work out if 
a lack of blood supply to the heart muscle causes HF-PEF in some patients. These tests may help discover 
the underlying cause of your heart failure which we might not otherwise find out if you were not 
participating in the study.  
 
Although this study is designed to provide information that may help patients in the future, rather than the 
volunteers participating, the tests we carry out may identify people who might benefit from treatment to 
improve blood flow to the heart muscle. Any treatment you receive is not part of the study and will be 
carried out following current best practice. You may or may not benefit directly from taking part in the 
study, however, the information we get from this study may help us give better treatment to patients with 
HF-PEF in the future.  
 
7. What are the possible disadvantages of taking part? 
Heart MRI scan – some patients find the scan claustrophobic. It can be noisy but you will be given 
earphones so you can listen to music. Some patients find having the needle placed in their arm 
uncomfortable and may feel faint but the pain does not last long. There is a small risk of bleeding, bruising 
or infection at the site. Your kidney function will be checked before the scan to ensure it is safe to give you 
the special dye. The medication given to increase blood flow to the heart (adenosine) is very safe. 
Adenosine has a very short duration of action, and there are usually no lasting effects. However, this 
medication can cause a short period of breathlessness, flushing or chest pain which can be unpleasant. 
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Serious side effects are very rare (less than 1 in 1500) and include: a slow or fast heartbeat (which may 
require medication or an electric shock), severe chest pain or breathlessness. 
 
Coronary angiogram and pressure wire studies – there are some risks associated with this procedure and 
it is important that you understand these before deciding whether you would like to take part. The most 
common side effect is bleeding or bruising in the wrist (or groin area) and there may be some mild 
discomfort for a few days. There is also a risk of infection where the needle enters the skin. Serious 
complications (risk of heart attack, stroke or dying) are rare and are estimated to occur in less than 1 in 500 
people. There is a small risk of causing damage to a heart artery from the pressure wire (less than 1 in 300 
people). You are exposed to x-rays during the procedure to take pictures of the arteries and check the 
position of the catheters, but this will be kept to a minimum. X-rays are a form of radiation which can be 
harmful. The dose of radiation you will receive during the study is equivalent to just over 3 years of 
background radiation. Background radiation is the radiation we are exposed to all the time from natural 
sources. The dye used can sometimes make patients feel unwell or cause an allergic reaction. This happens 
in around 1 in 100 people having an angiogram but there are medicines available to treat this. The 
medications given to increase blood flow to the heart are very safe. The effects of adenosine are described 
above. Like adenosine, acetylcholine has a very short duration of action and there are usually no lasting 
effects. However, it can also cause a short period of breathlessness, flushing or chest pain which can be 
unpleasant. More serious side effects occur in less than 1 in 100 people and include: a slow or fast 
heartbeat, severe chest pain or breathlessness (which may require treatment with medication).  
 
If a narrowed artery is identified, your doctor may proceed to treating the identified problem with a stent 
during the same procedure. The risk of serious complications (risk of heart attack, stroke or dying) 
associated with insertion of a stent are estimated to occur in less than 1 in 100 people. Around 1 in 20 
patients that have a stent inserted will develop a re-narrowing (called re-stenosis) of the artery within the 
stent which can be dealt with by further stenting. 
 
8. What if something goes wrong? 
If something goes wrong as a result of a study procedure, we may ask you to remain in hospital for a short 
time or overnight for close monitoring. In the event of a procedure not going to plan we will explain clearly 
what has happened and discuss the relevant options available to you. There are no special compensation 
aƌƌangemenƚƐ if ƚaking paƌƚ in ƚhiƐ ƌeƐeaƌch pƌojecƚ haƌmƐ ǇoƵ͘ If ǇoƵ aƌe haƌmed dƵe ƚo Ɛomeone͛Ɛ 
negligence, then you may have grounds for legal action but you may have to pay for it. The normal NHS 
complaints mechanisms are available if you wish to complain or have any concerns. 
 
9. Will my taking part in this study be kept confidential? 
If you consent to take part in the study, the research doctor may view your medical records for purposes of 
analysing the results. Representatives of the Sponsor, NHS Greater Glasgow and Clyde, may also look at 
these in relation to checking the study has been carried out appropriately. All information collected about 
you during the course of the research will be kept strictly confidential. Any information which leaves the 
hospital will have your name and address removed so that you cannot be recognised.  
 
10. Will my GP be informed that I am taking part? 
With your consent, we would like to inform your GP that you are participating in this study. We would like 
to provide your GP with the results of the tests we perform.  
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11. What will happen to the results of the research study? 
The results of the research study will be stored on a computer database and are likely to be published in 
medical journals which will be available to the general public. Reports or publications from the study will 
not contain any personal details. A summary sheet of the research findings will be provided to participants 
on completion of the study. 
 
12. Who is organising and funding the research? 
The University of Glasgow is performing the study and the project is funded by the Chief Scientist Office. 
NHS Greater Glasgow and Clyde will sponsor the study, i.e. manage and monitor the conduct of the study. 
 
13. Who has reviewed the study? 
This study has been approved by one of the West of Scotland Research Ethics Service Committees, which is 
an independent panel. 
 
Thank you for taking the time to read this information leaflet.  
 
If you have any questions regarding the study, please contact:  
 
Study doctor 
Dr Christopher Rush 
Clinical Research Fellow 
Telephone: 0141 452 5877   
E-mail: Christopher.Rush@glasgow.ac.uk 
 
Supervisors 
Professor John McMurray  Professor Mark Petrie 
Telephone: 0141 330 3479  Telephone: 0141 330 2000 
 
Independent doctor 
Dr Martin Mitchell Lindsay 
Telephone: 0141 951 5431 
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PARTICIPANT INFORMATION SHEET 
 
STUDY TITLE: Coronary Artery Disease in Heart Failure with Preserved Ejection Fraction 
 
 
1. Invitation 
We would like to invite you to take part in our study. This research involves having tests performed to help 
work out if a lack of blood getting to the heart muscle may be a cause of heart failure in some people. Before 
you decide whether or not to take part we would like you to understand why the research is being done and 
what it will involve for you. We can read through the information sheet with you and answer any questions 
you may have.  
 
2. What is the purpose of the study and why have I been invited to take part? 
You have been invited to participate in this study because you have been admitted to hospital with heart 
failure. This is a condition where the heart does not pump blood around the body as well as it should do. 
You have had a blood test which confirms that you have heart failure. You have also had a heart scan 
(echocardiogram) showing that your heart muscle appears to be pumping well. This means that you have a 
specific type of heart failure called heart failure with preserved ejection fraction, or HF-PEF.  
 
Patients with HF-PEF commonly experience shortness of breath, leg swelling and tiredness. Unfortunately, 
we do not have a good understanding of the underlying causes and we are currently looking for better 
treatments for this condition. 
 
Our aim is to look at whether a lack of blood getting to the heart muscle causes HF-PEF in some people. The 
most common cause of a lack of blood getting to the heart muscle is due to narrowings of the heart arteries. 
If there are narrowings of the heart arteries, treatments are available which could potentially improve quality 
of life. These include medications and treatments to open up the heart arteries.  
 
We will perform tests to try and establish what proportion of people admitted to hospital with HF-PEF has 
narrowings of the heart arteries that could potentially benefit from these treatments.  
 
The next page provides an overview of the tests included in the study.   
 
 
 
 
Queen Elizabeth University Hospital     Enquiries to: Dr Christopher Rush 
Office Block, Ground Floor, Zone 0.01, Office 0.05  Telephone: 0141 452 5877 
1345 Govan Road      E-mail: Christopher.Rush@glasgow.ac.uk 
Glasgow  G51 4TF 
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Flow diagram of study 
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3. Do I have to take part? 
No ʹ taking part in this study is entirely voluntary and your decision. If you take part you will be given this 
information sheet and asked to sign a consent form. If you decide to take part you are free to withdraw at 
any time without giving a reason. A decision to withdraw at any time or a decision not to take part will not 
affect the standard of care you receive.  
 
4. What will happen to me if I would like to take part in the study? 
If you agree to take participate in the study, we will ask you to undergo further tests to examine the blood 
supply to the heart muscle and detect any narrowings of the heart arteries (see below). You will also be 
asked to provide one further blood test and a urine sample.  
 
x Blood test – you will be asked to provide a blood sample. We will check for substances in the blood 
that may help identify people with a lack of blood getting to the heart muscle. Approximately 10mls 
(two teaspoons) of blood will be taken.  
 
x Urine test – you will be asked to provide a urine sample. We will check for substances in the urine 
that may help identify people with a lack of blood getting to the heart muscle. As women who are 
pregnant are not able to take part in this study, we may require an additional urine sample to perform 
a pregnancy test.   
 
x Heart MRI scan – this is a scan performed when you are lying in a short tunnel which holds a large 
magnet. It takes 60 minutes to complete. The magnet creates field changes to generate a detailed 
picture. The scanner does not touch you and you will be unaware of these field changes. The scan is 
noisy so earphones will be provided with music playing during the test. A contrast agent will be given 
to you during the scan into a small tube (cannula) in your arm. The contrast agent is a colourless 
liquid used to highlight parts of the heart on the scan. Special medication called adenosine (which 
increases the blood flow in the heart arteries) will also be given into the cannula during the scan to 
look for evidence of restricted blood flow to the heart muscle. If you are not able to have an MRI (for 
example, if you have a pacemaker) this will be discussed with you and you will not be asked to have 
this scan. 
 
x Coronary angiogram and pressure wire studies – these tests allow the doctors to examine the 
arteries supplying your heart muscle in detail. You will be awake for the test and can be given 
medication to help you relax. At the start of the procedure you will feel a needle being passed into 
the skin in the wrist to inject local anaesthetic. A small hollow tube is placed in an artery at the wrist 
(radial artery) to allow passage of fine catheters and thin wires to your heart. Less commonly, an 
artery in the groin is used. A contrast agent is injected and moving x-ray pictures are taken to visualise 
your heart arteries. These pictures are projected onto a screen and the doctor is able to see any 
narrowings of the large heart arteries which may be restricting blood flow to the heart muscle. A 
pressure wire is a very thin wire that is passed down the same catheter used to do the angiogram. 
The pressure wire is passed down the heart arteries and two special medications (adenosine and 
acetylcholine) are given to increase the blood flow to the heart muscle. The wire is used to determine 
whether any narrowings seen on the angiogram are restricting blood flow to the heart muscle or not. 
If the angiogram does not show any significant narrowings of the large heart arteries, the pressure 
wire is used to assess blood flow in the small heart arteries which cannot be seen on a standard 
angiogram.  
 
The heart MRI scan will take place at the Queen Elizabeth University Hospital during your hospital admission 
or within two weeks of your discharge from hospital. The coronary angiogram and pressure wire studies will 
take place at the Golden Jubilee National Hospital in Clydebank within eight weeks of your discharge from 
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hospital. You will receive a letter and phone call with the appointment date and time from the study doctor. 
A taxi will be organised to and from this appointment free of charge.  
 
The ǁaǇ ƚhaƚ ǁe fŽůůŽǁ a ƉeƌƐŽŶ͛Ɛ ƉƌŽgƌeƐƐ ŝŶ a ƐƚƵdǇ like this is by entering their details into a national 
database, which uses hospital notes to record when you come into hospital. This database is run by the NHS 
and is confidential. Any information gathered is only available to the doctors running this study. It does not 
require any participation from you, and no one will contact you as part of this process. If you agree to take 
part in the study at this stage, we will enter you details into this database. The information gathered from 
this database may be used for future ethically approved research.  
 
5. When will I get the results of the test? 
The results of the coronary angiogram and pressure wire studies will be explained to you on the same day 
as you have the test. If there are narrowed arteries supplying blood to the heart muscle this will be explained 
to you. If a narrowed artery is identified, and you agree with your specialist doctor, they may proceed to 
treating the identified problem during the same procedure. A small inflatable balloon on the tip of a narrow 
tube is passed down the heart artery until its tip reaches the narrowed section. The balloon is gently inflated 
so that it squashes the fatty tissues responsible for narrowing the artery. A stent (a short tube made of 
stainless steel mesh) may also be inserted. The stent stays in the artery and often has a special drug coating 
to prevent the artery re-narrowing. 
 
The heart MRI scan takes more time to interpret so the results will not be available on the day. The scan will 
be reviewed and the report will be included in your medical records so that your consultant or GP will be 
able to discuss the results at your next routine visit. Any unexpected findings seen on the scan will be 
discussed with a specialist x-ray doctor and highlighted to your consultant or GP, who will be able to discuss 
the findings with you. 
 
6. What are the possible benefits of taking part? 
It is hoped that by taking part in this study you will be providing valuable information to help us work out if 
a lack of blood supply to the heart muscle causes HF-PEF in some patients. These tests may help discover 
the underlying cause of your heart failure which we might not otherwise find out if you were not participating 
in the study.  
 
Although this study is designed to provide information that may help patients in the future, rather than the 
volunteers participating, the tests we carry out may identify people who might benefit from treatment to 
improve blood flow to the heart muscle. Any treatment you receive is not part of the study and will be carried 
out following current best practice. You may or may not benefit directly from taking part in the study, 
however, the information we get from this study may help us give better treatment to patients with HF-PEF 
in the future.  
 
7. What are the possible disadvantages of taking part? 
Heart MRI scan – some patients find the scan claustrophobic. It can be noisy but you will be given earphones 
so you can listen to music. Some patients find having the needle placed in their arm uncomfortable and may 
feel faint but the pain does not last long. There is a small risk of bleeding, bruising or infection at the site. 
Your kidney function will be checked before the scan to ensure it is safe to give you the special dye. The 
medication given to increase blood flow to the heart (adenosine) is very safe. Adenosine has a very short 
duration of action, and there are usually no lasting effects. However, this medication can cause a short period 
of breathlessness, flushing or chest pain which can be unpleasant. Serious side effects are very rare (less 
than 1 in 1500) and include: a slow or fast heartbeat (which may require medication or an electric shock), 
severe chest pain or breathlessness. 
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Coronary angiogram and pressure wire studies – there are some risks associated with this procedure and it 
is important that you understand these before deciding whether you would like to take part. The most 
common side effect is bleeding or bruising in the wrist (or groin area) and there may be some mild discomfort 
for a few days. There is also a risk of infection where the needle enters the skin. Serious complications (risk 
of heart attack, stroke or dying) are rare and are estimated to occur in less than 1 in 500 people. There is a 
small risk of causing damage to a heart artery from the pressure wire (less than 1 in 300 people). You are 
exposed to x-rays during the procedure to take pictures of the arteries and check the position of the 
catheters, but this will be kept to a minimum. X-rays are a form of radiation which can be harmful. The dose 
of radiation you will receive during the study is equivalent to just over 3 years of background radiation. 
Background radiation is the radiation we are exposed to all the time from natural sources. The dye used can 
sometimes make patients feel unwell or cause an allergic reaction. This happens in around 1 in 100 people 
having an angiogram but there are medicines available to treat this. The medications given to increase blood 
flow to the heart are very safe. The effects of adenosine are described above. Like adenosine, acetylcholine 
has a very short duration of action and there are usually no lasting effects. However, it can also cause a short 
period of breathlessness, flushing or chest pain which can be unpleasant. More serious side effects occur in 
less than 1 in 100 people and include: a slow or fast heartbeat, severe chest pain or breathlessness (which 
may require treatment with medication).  
 
If a narrowed artery is identified, your doctor may proceed to treating the identified problem with a stent 
during the same procedure. The risk of serious complications (risk of heart attack, stroke or dying) associated 
with insertion of a stent are estimated to occur in less than 1 in 100 people. Around 1 in 20 patients that 
have a stent inserted will develop a re-narrowing (called re-stenosis) of the artery within the stent which can 
be dealt with by further stenting. 
 
8. What if something goes wrong? 
If something goes wrong as a result of a study procedure, we may ask you to remain in hospital for a short 
time or overnight for close monitoring. In the event of a procedure not going to plan we will explain clearly 
what has happened and discuss the relevant options available to you. There are no special compensation 
aƌƌangemenƚƐ if ƚaking paƌƚ in ƚhiƐ ƌeƐeaƌch pƌojecƚ haƌmƐ ǇoƵ͘ If ǇoƵ aƌe haƌmed dƵe ƚo Ɛomeone͛Ɛ 
negligence, then you may have grounds for legal action but you may have to pay for it. The normal NHS 
complaints mechanisms are available if you wish to complain or have any concerns. 
 
9. Will my taking part in this study be kept confidential? 
If you consent to take part in the study, the research doctor may view your medical records for purposes of 
analysing the results. Representatives of the Sponsor, NHS Greater Glasgow and Clyde, may also look at 
these in relation to checking the study has been carried out appropriately. All information collected about 
you during the course of the research will be kept strictly confidential. Any information which leaves the 
hospital will have your name and address removed so that you cannot be recognised.  
 
10. Will my GP be informed that I am taking part? 
With your consent, we would like to inform your GP that you are participating in this study. We would like 
to provide your GP with the results of the tests we perform.  
  
11. What will happen to the results of the research study? 
The results of the research study will be stored on a computer database and are likely to be published in 
medical journals which will be available to the general public. Reports or publications from the study will not 
contain any personal details. A summary sheet of the research findings will be provided to participants on 
completion of the study. 
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12. Who is organising and funding the research? 
The University of Glasgow is performing the study and the project is funded by the Chief Scientist Office. 
NHS Greater Glasgow and Clyde will sponsor the study, i.e. manage and monitor the conduct of the study. 
 
13. Who has reviewed the study? 
This study has been approved by one of the West of Scotland Research Ethics Service Committees, which is 
an independent panel. 
 
Thank you for taking the time to read this information leaflet.  
 
If you have any questions regarding the study, please contact:  
 
Study doctor 
Dr Christopher Rush 
Clinical Research Fellow 
Telephone: 0141 452 5877   
E-mail: Christopher.Rush@glasgow.ac.uk 
 
Supervisors 
Professor John McMurray  Professor Mark Petrie 
Telephone: 0141 330 3479  Telephone: 0141 330 2000 
 
Independent doctor 
Dr Martin Mitchell Lindsay 
Telephone: 0141 951 5431 
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PATIENT CONSENT FORM: STAGE 1 
 
STUDY TITLE: Coronary Artery Disease in Heart Failure with Preserved Ejection Fraction 
 
 
I confirm that I have read and understand the information sheet dated 23/03/2017  
(version 6.0) for stage 1 of the above study. I have had the opportunity to consider  
the information, ask questions and have had these answered satisfactorily. 
 
I understand that my participation is voluntary and that I am free to withdraw at any  
time without giving any reason, without my medical care or legal rights being affected. 
 
I agree to a sample of blood being taken for analysis of N-terminal B-type natriuretic  
peptide (NT-proBNP). 
 
I understand that sections of my medical notes may be looked at by the research  
team, and by representatives of the Sponsor, NHS Greater Glasgow and Clyde, where  
it is relevant to my taking part in the research. I give permission for these people to  
have access to my records.  
 
I agree to take part in the above study.  
 
 
 
----------------------------------  -----------------------  ---------------------------------- 
Name of participant   Date    Signature 
 
 
 
----------------------------------  -----------------------  ---------------------------------- 
Name of researcher   Date    Signature 
(3 copies: 1 for patient, 1 for medical notes, 1 for site file) 
  
  
  
  
   Please initial the box 
  
Queen Elizabeth University Hospital     Enquiries to: Dr Christopher Rush 
Office Block, Ground Floor, Zone 0.01, Office 0.05  Telephone: 0141 452 5877 
1345 Govan Road      E-mail: Christopher.Rush@glasgow.ac.uk 
Glasgow  G51 4TF 
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PATIENT CONSENT FORM: STAGE 2 
 
STUDY TITLE: Coronary Artery Disease in Heart Failure with Preserved Ejection Fraction 
 
 
I confirm that I have read and understand the information sheet dated 23/03/2017  
(version 6.0) for stage 2 of the above study. I have had the opportunity to consider  
the information, ask questions and have had these answered satisfactorily. 
 
I understand that my participation is voluntary and that I am free to withdraw at any  
time without giving any reason, without my medical care or legal rights being affected. 
 
I agree to undergo a coronary angiogram with pressure wire studies and provide a  
blood and urine sample. 
 
I agree to undergo a heart MRI scan (if you are unable to have an MRI scan you will not  
be asked to undergo this test and you should not initial this box). 
 
I understand that sections of my medical notes may be looked at by the research  
team and by representatives of the Sponsor, NHS Greater Glasgow and Clyde, where  
it is relevant to my taking part in the research. I give permission for these people to  
have access to my records.  
 
I agree to my details being entered into the database at Information Services Division  
of NHS Scotland for use during this study and future ethically approved research. 
 
I agree to my GP being informed of my participation in the study.  
 
I agree to take part in the above study.  
 
----------------------------------  -----------------------  ---------------------------------- 
Name of participant   Date    Signature 
 
 
----------------------------------  -----------------------  ---------------------------------- 
Name of researcher   Date    Signature 
(3 copies: 1 for patient, 1 for medical notes, 1 for site file) 
  
  
  
  
   Please initial the box 
  
  
Queen Elizabeth University Hospital     Enquiries to: Dr Christopher Rush 
Office Block, Ground Floor, Zone 0.01, Office 0.05  Telephone: 0141 452 5877 
1345 Govan Road      E-mail: Christopher.Rush@glasgow.ac.uk 
Glasgow  G51 4TF 
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PATIENT CONSENT FORM 
 
STUDY TITLE: Coronary Artery Disease in Heart Failure with Preserved Ejection Fraction 
 
 
I confirm that I have read and understand the information sheet dated 23/03/2017  
(version 1.0) for the above study. I have had the opportunity to consider the  
information, ask questions and have had these answered satisfactorily. 
 
I understand that my participation is voluntary and that I am free to withdraw at any  
time without giving any reason, without my medical care or legal rights being affected. 
 
I agree to undergo a coronary angiogram with pressure wire studies and provide a blood  
and urine sample. 
 
I agree to undergo a heart MRI scan (if you are unable to have an MRI scan you will not  
be asked to undergo this test and you should not initial this box). 
 
I understand that sections of my medical notes may be looked at by the research  
team and by representatives of the Sponsor, NHS Greater Glasgow and Clyde, where  
it is relevant to my taking part in the research. I give permission for these people to  
have access to my records.  
 
I agree to my details being entered into the database at Information Services Division  
of NHS Scotland for use during this study and future ethically approved research. 
 
I agree to my GP being informed of my participation in the study.  
 
I agree to take part in the above study.  
 
----------------------------------  -----------------------  ---------------------------------- 
Name of participant   Date    Signature 
 
 
----------------------------------  -----------------------  ---------------------------------- 
Name of researcher   Date    Signature 
(3 copies: 1 for patient, 1 for medical notes, 1 for site file) 
Queen Elizabeth University Hospital     Enquiries to: Dr Christopher Rush 
Office Block, Ground Floor, Zone 0.01, Office 0.05  Telephone: 0141 452 5877 
1345 Govan Road      E-mail: Christopher.Rush@glasgow.ac.uk 
Glasgow  G51 4TF 
 
  
  
  
  
   Please initial the box 
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GP INFORMATION LETTER 
 
STUDY TITLE: Coronary Artery Disease in Heart Failure with Preserved Ejection Fraction 
 
 
Dear Doctor, 
 
I am currently carrying out a research project involving patients with heart failure and preserved ejection 
fraction (HF-PEF) and your patient has kindly agreed to take part in the study. 
 
Patient name: 
 
CHI number: 
 
This study is aiming to investigate the prevalence and role of coronary artery disease in an unselected 
cohort of patients admitted to hospital with HF-PEF. Patients are recruited on admission to hospital and 
those who agree to participate in the study are invited to attend the Golden Jubilee National Hospital 
following discharge for a study visit.  
 
Within eight weeks of discharge, they will attend the Golden Jubilee National Hospital for coronary 
angiography with pressure wire assessment. Patients with no contraindication will also undergo a cardiac 
MRI scan at the Queen Elizabeth University Hospital during their hospital admission or within two weeks of 
discharge from hospital. We will write to you with the results of these investigations. After this study visit 
your patient has no further commitment to the study. The study does not involve taking any additional 
medication.  
 
If you require any further information, please do not hesitate to contact me on the above telephone 
number or e-mail address. 
 
Yours sincerely,  
 
 
 
Dr Christopher Rush 
Clinical Research Fellow 
University of Glasgow 
 
Investigators:  Dr Christopher Rush, Professor John McMurray, Professor Mark Petrie, Professor Colin 
Berry, Professor Keith Oldroyd, Professor Rhian Touyz, Dr Ross Campbell, Dr Clare Murphy 
Queen Elizabeth University Hospital     Enquiries to: Dr Christopher Rush 
Office Block, Ground Floor, Zone 0.01, Office 0.05  Telephone: 0141 452 5877 
1345 Govan Road      E-mail: Christopher.Rush@glasgow.ac.uk 
Glasgow  G51 4TF 
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Appendix VIII: Kaplan-Meier curves for all-cause mortality in participants 
who did and did not undergo study investigations.   
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Appendix IX: Kaplan-Meier curves for all-cause hospitalisation in 
participants who did and did not undergo study investigations.   
0
10
20
30
40
50
60
70
80
90
10
0
Cu
m
ula
tiv
e 
pe
rc
en
ta
ge
 (%
)
83 71 53 45 34 29 22Study investigations
23 16 15 15 10 8 7No study investigations
Number at risk:
0 3 6 9 12 15 18
Months since recruitment
No study investigations
Study investigations
All-cause hospitalisation
Log-rank p-value 0.75
287 
List of References 
1.  Arnold JMO, Liu P, Howlett J, Ignaszewski A, Leblanc MH, Kaan A, Pearce 
C, Sinclair L, Pearce S, Prentice C. Ten year survival by NYHA functional 
class in heart failure outpatients referred to specialized multidisciplinary 
heart failure clinics 1999 to 2011. Eur Heart J; 2013;34:P1505–P1505.  
2.  Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk 
V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, 
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope 
LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the 
diagnosis and treatment of acute and chronic heart failure. Eur J Heart 
Fail; 2016;18:891–975.  
3.  Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow 
GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, 
Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, 
Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL, American College of 
Cardiology Foundation, American Heart Association Task Force on Practice 
Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: 
a report of the American College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines. J Am Coll Cardiol 
2013;62:e147-239.  
4.  Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, 
Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder 
TG, Böhm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, 
Wedel H, Hjalmarson Å, Wikstrand J, Kotecha D, Beta-blockers in Heart 
Failure Collaborative Group. Beta-blockers for heart failure with reduced, 
mid-range, and preserved ejection fraction: an individual patient-level 
analysis of double-blind randomized trials. Eur Heart J 2018;39:26–35.  
5.  Fröhlich H, Rosenfeld N, Täger T, Goode K, Kazmi S, Hole T, Katus HA, 
Atar D, Cleland JGF, Agewall S, Clark AL, Frankenstein L, Grundtvig M. 
Epidemiology and long-term outcome in outpatients with chronic heart 
failure in Northwestern Europe. Heart 2019; Aug;105(16):1252-1259.  
288 
6.  Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan 
M, Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiade M. The Global Health 
and Economic Burden of Hospitalizations for Heart Failure Lessons Learned 
From Hospitalized Heart Failure Registries. J Am Coll Cardiol 
2014;63:1123–1133.  
7.  Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison 
M, Hemingway H, Cleland JG, McMurray JJV, Rahimi K. Temporal trends 
and patterns in heart failure incidence: a population-based study of 4 
million individuals. Lancet 2018;391:572–580.  
8.  Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. 
Trends in Prevalence and Outcome of Heart Failure with Preserved 
Ejection Fraction. N Engl J Med 2006;355:251–259.  
9.  Ho JE, Gona P, Pencina MJ, Tu JV, Austin PC, Vasan RS, Kannel WB, 
D’Agostino RB, Lee DS, Levy D. Discriminating clinical features of heart 
failure with preserved vs. reduced ejection fraction in the community. Eur 
Heart J 2012;33:1734–1741.  
10.  Ho JE, Enserro D, Brouwers FP, Kizer JR, Shah SJ, Psaty BM, Bartz TM, 
Santhanakrishnan R, Lee DS, Chan C, Liu K, Blaha MJ, Hillege HL, van der 
Harst P, van Gilst WH, Kop WJ, Gansevoort RT, Vasan RS, Gardin JM, Levy 
D, Gottdiener JS, de Boer RA, Larson MG. Predicting Heart Failure With 
Preserved and Reduced Ejection Fraction: The International Collaboration 
on Heart Failure Subtypes. Circ Heart Fail 2016;9:e003116.  
11.  Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray 
JJV. What Have We Learned About Patients With Heart Failure and 
Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-
PRESERVE? J Am Coll Cardiol 2012;60:2349–2356.  
12.  Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. 
Outcome of Heart Failure with Preserved Ejection Fraction in a Population-
Based Study. N Engl J Med 2006;355:260–269.  
13.  Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang 
289 
R, Killian JM, Roger VL. A Contemporary Appraisal of the Heart Failure 
Epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 
2015;175:996.  
14.  Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell 
N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, 
Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, 
Sweitzer NK, Yang S, McKinlay SM, TOPCAT Investigators. Spironolactone 
for Heart Failure with Preserved Ejection Fraction. N Engl J Med 
2014;370:1383–1392.  
15.  Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, 
Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE 
Investigators. Irbesartan in patients with heart failure and preserved 
ejection fraction. N Engl J Med 2008;359:2456–2467.  
16.  Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, 
PEP-CHF Investigators. The perindopril in elderly people with chronic heart 
failure (PEP-CHF) study. Eur Heart J 2006;27:2338–2345.  
17.  Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival 
of patients with heart failure with preserved or reduced left ventricular 
ejection fraction: an individual patient data meta-analysis. Eur Heart J 
2012;33:1750–1757.  
18.  Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with 
preserved ejection fraction. Nat Rev Cardiol 2017;14:591–602.  
19.  Borlaug BA, Nishimura RA, Sorajja P, Lam CSP, Redfield MM. Exercise 
hemodynamics enhance diagnosis of early heart failure with preserved 
ejection fraction. Circ Heart Fail 2010;3:588–595.  
20.  Holland DJ, Prasad SB, Marwick TH. Contribution of exercise 
echocardiography to the diagnosis of heart failure with preserved ejection 
fraction (HFpEF). Heart 2010;96:1024–1028.  
21.  Opitz CF, Hoeper MM, Gibbs JSR, Kaemmerer H, Pepke-Zaba J, Coghlan JG, 
Scelsi L, D’Alto M, Olsson KM, Ulrich S, Scholtz W, Schulz U, Grünig E, 
290 
Vizza CD, Staehler G, Bruch L, Huscher D, Pittrow D, Rosenkranz S. Pre-
Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A 
Pathophysiological Continuum. J Am Coll Cardiol 2016;68:368–378.  
22.  Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected 
heart failure and preserved left ventricular systolic function suffer from 
&quot;diastolic heart failure&quot; or from misdiagnosis? A prospective 
descriptive study. BMJ 2000;321:215–218.  
23.  Samson R, Jaiswal A, Ennezat PV, Cassidy M, Le Jemtel TH. Clinical 
Phenotypes in Heart Failure With Preserved Ejection Fraction. J Am Heart 
Assoc 2016;5:e002477.  
24.  Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow 
RO, Huang CC, Deo RC. Phenomapping for Novel Classification of Heart 
Failure With Preserved Ejection Fraction. Circulation 2015;131:269–279.  
25.  Lam CSP, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass 
DA, Redfield MM. Cardiac Structure and Ventricular-Vascular Function in 
Persons With Heart Failure and Preserved Ejection Fraction From Olmsted 
County, Minnesota. Circulation 2007;115:1982–1990.  
26.  Zile MR, Baicu CF, Gaasch WH. Diastolic Heart Failure — Abnormalities in 
Active Relaxation and Passive Stiffness of the Left Ventricle. N Engl J Med 
2004;350:1953–1959.  
27.  Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer 
RJ. Burden of systolic and diastolic ventricular dysfunction in the 
community: appreciating the scope of the heart failure epidemic. JAMA 
2003;289:194–202.  
28.  Kranias EG, Hajjar RJ. Modulation of Cardiac Contractility by the 
Phopholamban/SERCA2a Regulatome. Circ Res 2012;110:1646–1660.  
29.  Bonow RO, Bacharach SL, Green MV, Kent KM, Rosing DR, Lipson LC, Leon 
MB, Epstein SE. Impaired left ventricular diastolic filling in patients with 
coronary artery disease: assessment with radionuclide angiography. 
Circulation 1981;64:315–323.  
291 
30.  Borbely A, van der Velden J, Papp Z, Bronzwaer JGF, Edes I, Stienen GJM, 
Paulus WJ. Cardiomyocyte Stiffness in Diastolic Heart Failure. Circulation 
2005;111:774–781.  
31.  Sasayama S, Nonogi H, Miyazaki S, Sakurai T, Kawai C, Eiho S, Kuwahara M. 
Changes in diastolic properties of the regional myocardium during pacing-
induced ischemia in human subjects. J Am Coll Cardiol 1985;5:599–606.  
32.  Krüger M, Linke WA. Titin-based mechanical signalling in normal and 
failing myocardium. J Mol Cell Cardiol 2009;46:490–498.  
33.  Cazorla O, Freiburg A, Helmes M, Centner T, McNabb M, Wu Y, Trombitás 
K, Labeit S, Granzier H, Gregorio CC, Granzier H, Labeit S. Differential 
expression of cardiac titin isoforms and modulation of cellular stiffness. 
Circ Res 2000;86:59–67.  
34.  Krüger M, Linke WA. Protein kinase-A phosphorylates titin in human heart 
muscle and reduces myofibrillar passive tension. J Muscle Res Cell Motil 
2006;27:435–444.  
35.  Krüger M, Kötter S, Grützner A, Lang P, Andresen C, Redfield MM, Butt E, 
dos Remedios CG, Linke WA. Protein kinase G modulates human 
myocardial passive stiffness by phosphorylation of the titin springs. Circ 
Res 2009;104:87–94.  
36.  Raskin A, Lange S, Banares K, Lyon RC, Zieseniss A, Lee LK, Yamazaki KG, 
Granzier HL, Gregorio CC, McCulloch AD, Omens JH, Sheikh F. A novel 
mechanism involving four-and-a-half LIM domain protein-1 and 
extracellular signal-regulated kinase-2 regulates titin phosphorylation and 
mechanics. J Biol Chem 2012;287:29273–29284.  
37.  Hidalgo C, Hudson B, Bogomolovas J, Zhu Y, Anderson B, Greaser M, Labeit 
S, Granzier H. PKC phosphorylation of titin’s PEVK element: a novel and 
conserved pathway for modulating myocardial stiffness. Circ Res 
2009;105:631–638.  
38.  van Heerebeek L, Borbély A, Niessen HWM, Bronzwaer JGF, van der Velden 
J, Stienen GJM, Linke WA, Laarman GJ, Paulus WJ. Myocardial Structure 
292 
and Function Differ in Systolic and Diastolic Heart Failure. Circulation 
2006;113:1966–1973.  
39.  van Heerebeek L, Hamdani N, Falcao-Pires I, Leite-Moreira AF, 
Begieneman MPV, Bronzwaer JGF, van der Velden J, Stienen GJM, Laarman 
GJ, Somsen A, Verheugt FWA, Niessen HWM, Paulus WJ. Low Myocardial 
Protein Kinase G Activity in Heart Failure With Preserved Ejection 
Fraction. Circulation 2012;126:830–839.  
40.  Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile 
MR, Voors AA, Lefkowitz MP, Packer M, McMurray JJV, Solomon SD, 
PARAMOUNT Investigators. Impaired Systolic Function by Strain Imaging in 
Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol 
2014;63:447–456.  
41.  Borlaug BA, Olson TP, Lam CSP, Flood KS, Lerman A, Johnson BD, Redfield 
MM. Global cardiovascular reserve dysfunction in heart failure with 
preserved ejection fraction. J Am Coll Cardiol 2010;56:845–854.  
42.  Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L, 
Dwivedi G, Patel K, Steendijk P, Ashrafian H, Henning A, Frenneaux M. 
Heart Failure With Preserved Ejection Fraction Is Characterized by 
Dynamic Impairment of Active Relaxation and Contraction of the Left 
Ventricle on Exercise and Associated With Myocardial Energy Deficiency. J 
Am Coll Cardiol 2009;54:402–409.  
43.  Mohammed SF, Borlaug BA, Roger VL, Mirzoyev SA, Rodeheffer RJ, Chirinos 
JA, Redfield MM. Comorbidity and Ventricular and Vascular Structure and 
Function in Heart Failure With Preserved Ejection Fraction: A Community-
Based Study. Circ Hear Fail 2012;5:710–719.  
44.  Borlaug BA, Lam CSP, Roger VL, Rodeheffer RJ, Redfield MM. Contractility 
and ventricular systolic stiffening in hypertensive heart disease insights 
into the pathogenesis of heart failure with preserved ejection fraction. J 
Am Coll Cardiol 2009;54:410–418.  
45.  Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal Relationship 
293 
and Prognostic Significance of Atrial Fibrillation in Heart Failure Patients 
With Preserved Ejection Fraction: A Community-Based Study. Circulation 
2013;128:1085–1093.  
46.  Lam CSP, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. 
Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. 
A Community-Based Study. J Am Coll Cardiol 2009;53:1119–1126.  
47.  Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA. Right heart 
dysfunction in heart failure with preserved ejection fraction. Eur Heart J 
2014;35:3452–3462.  
48.  Borlaug BA, Kane GC, Melenovsky V, Olson TP. Abnormal right ventricular-
pulmonary artery coupling with exercise in heart failure with preserved 
ejection fraction. Eur Heart J 2016;37:3293.2-3302.  
49.  Mohammed SF, Hussain I, Abou Ezzeddine OF, Takahama H, Kwon SH, 
Forfia P, Roger VL, Redfield MM. Right ventricular function in heart failure 
with preserved ejection fraction: a community-based study. Circulation 
2014;130:2310–2320.  
50.  Dauterman K, Pak PH, Maughan WL, Nussbacher A, Ariê S, Liu CP, Kass DA. 
Contribution of external forces to left ventricular diastolic pressure. 
Implications for the clinical use of the Starling law. Ann Intern Med 
1995;122:737–742.  
51.  Phan TT, Shivu GN, Abozguia K, Davies C, Nassimizadeh M, Jimenez D, 
Weaver R, Ahmed I, Frenneaux M. Impaired Heart Rate Recovery and 
Chronotropic Incompetence in Patients With Heart Failure With Preserved 
Ejection Fraction. Circ Hear Fail 2010;3:29–34.  
52.  Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, Kass 
DA. Impaired chronotropic and vasodilator reserves limit exercise capacity 
in patients with heart failure and a preserved ejection fraction. 
Circulation 2006;114:2138–2147.  
53.  Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P, 
Voors AA, Dominjon F, Henon-Goburdhun C, Pannaux M, Böhm M, 
294 
prEserveD left ventricular ejectIon fraction chronic heart Failure with 
ivabradine studY (EDIFY) Investigators. Effect of ivabradine in patients 
with heart failure with preserved ejection fraction: the EDIFY randomized 
placebo-controlled trial. Eur J Heart Fail 2017;19:1495–1503.  
54.  Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, 
Weiner RB, Houstis NE, Eisman AS, Hough SS, Lewis GD. Mechanisms of 
Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: The 
Role of Abnormal Peripheral Oxygen Extraction. Circ Hear Fail 2015;8:286–
294.  
55.  Kitzman DW, Nicklas B, Kraus WE, Lyles MF, Eggebeen J, Morgan TM, 
Haykowsky M. Skeletal muscle abnormalities and exercise intolerance in 
older patients with heart failure and preserved ejection fraction. Am J 
Physiol Circ Physiol 2014;306:H1364–H1370.  
56.  Haykowsky MJ, Brubaker PH, Stewart KP, Morgan TM, Eggebeen J, Kitzman 
DW. Effect of Endurance Training on the Determinants of Peak Exercise 
Oxygen Consumption in Elderly Patients With Stable Compensated Heart 
Failure and Preserved Ejection Fraction. J Am Coll Cardiol 2012;60:120–
128.  
57.  Akiyama E, Sugiyama S, Matsuzawa Y, Konishi M, Suzuki H, Nozaki T, Ohba 
K, Matsubara J, Maeda H, Horibata Y, Sakamoto K, Sugamura K, Yamamuro 
M, Sumida H, Kaikita K, Iwashita S, Matsui K, Kimura K, Umemura S, Ogawa 
H. Incremental Prognostic Significance of Peripheral Endothelial 
Dysfunction in Patients With Heart Failure With Normal Left Ventricular 
Ejection Fraction. J Am Coll Cardiol 2012;60:1778–1786.  
58.  Haykowsky MJ, Herrington DM, Brubaker PH, Morgan TM, Hundley WG, 
Kitzman DW. Relationship of Flow-Mediated Arterial Dilation and Exercise 
Capacity in Older Patients With Heart Failure and Preserved Ejection 
Fraction. Journals Gerontol Ser A Biol Sci Med Sci 2013;68:161–167.  
59.  Verma A, Solomon SD. Diastolic Dysfunction as a Link Between 
Hypertension and Heart Failure. Med Clin North Am 2009;93:647–664.  
295 
60.  Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, 
Baicu CF, Massie BM, Carson PE, I-PRESERVE Investigators. Prevalence and 
Significance of Alterations in Cardiac Structure and Function in Patients 
With Heart Failure and a Preserved Ejection Fraction. Circulation 
2011;124:2491–2501.  
61.  Paulus WJ, Tschöpe C. A Novel Paradigm for Heart Failure With Preserved 
Ejection Fraction. J Am Coll Cardiol 2013;62:263–271.  
62.  Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von 
Schlippenbach J, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP, 
Tschöpe C. Cardiac Inflammation Contributes to Changes in the 
Extracellular Matrix in Patients With Heart Failure and Normal Ejection 
Fraction. Circ Hear Fail 2011;4:44–52.  
63.  Tschöpe C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck 
PL, Pauschinger M, Poller WC, Kühl U, Kandolf R, Schultheiss HP. High 
Prevalence of Cardiac Parvovirus B19 Infection in Patients With Isolated 
Left Ventricular Diastolic Dysfunction. Circulation 2005;111:879–886.  
64.  Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, 
Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and 
Committees. Effects of candesartan in patients with chronic heart failure 
and preserved left-ventricular ejection fraction: the CHARM-Preserved 
Trial. Lancet 2003;362:777–781.  
65.  de Denus S, O’Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, Jutras M, 
Lavoie J, Solomon SD, Pitt B, Pfeffer MA, Rouleau JL. Spironolactone 
Metabolites in TOPCAT - New Insights into Regional Variation. N Engl J Med 
2017;376:1690–1692.  
66.  Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai 
AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau 
JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, 
McKinlay SM, Pitt B. Regional variation in patients and outcomes in the 
Treatment of Preserved Cardiac Function Heart Failure With an 
Aldosterone Antagonist (TOPCAT) trial. Circulation 2015;131:34–42.  
296 
67.  Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, 
Ponikowski P, Shah SJ, Solomon SD, Scalise A-V, Mueller K, Roessig L, 
Gheorghiade M. Vericiguat in patients with worsening chronic heart failure 
and preserved ejection fraction: results of the SOluble guanylate Cyclase 
stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-
PRESERVED) study. Eur Heart J 2017;38:1119–1127.  
68.  Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, 
LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, 
Givertz MM, Ofili EO, O’Connor CM, Felker GM, Goldsmith SR, Bart BA, 
McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez 
EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, RELAX Study 
Investigators. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity 
and Clinical Status in Heart Failure With Preserved Ejection Fraction. JAMA 
2013;309:1268.  
69.  Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, 
LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, 
Reeves GR, Tedford RJ, Tang WHW, McNulty SE, Velazquez EJ, Shah MR, 
Braunwald E, NHLBI Heart Failure Clinical Research Network. Isosorbide 
Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J 
Med 2015;373:2314–2324.  
70.  Borlaug BA, Anstrom KJ, Lewis GD, Shah SJ, Levine JA, Koepp GA, Givertz 
MM, Felker GM, LeWinter MM, Mann DL, Margulies KB, Smith AL, Tang 
WHW, Whellan DJ, Chen HH, Davila-Roman VG, McNulty S, Desvigne-
Nickens P, Hernandez AF, Braunwald E, Redfield MM. Effect of Inorganic 
Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure 
With Preserved Ejection Fraction. JAMA 2018;320:1764.  
71.  Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, 
Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van 
Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov 
SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr 
Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, PARAGON-HF 
Investigators and Committees. Angiotensin–Neprilysin Inhibition in Heart 
297 
Failure with Preserved Ejection Fraction. N Engl J Med 2019;381(17):1609-
1620.  
72.  van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton 
M, Coats AJS, Poole-Wilson PA, Flather MD, SENIORS Investigators. Beta-
blockade with nebivolol in elderly heart failure patients with impaired and 
preserved left ventricular ejection fraction: Data From SENIORS (Study of 
Effects of Nebivolol Intervention on Outcomes and Rehospitalization in 
Seniors With Heart Failure). J Am Coll Cardiol 2009;53:2150–2158.  
73.  Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, 
Aronow WS, Adams KF, Gheorghiade M. Effects of digoxin on morbidity and 
mortality in diastolic heart failure: the ancillary digitalis investigation 
group trial. Circulation 2006;114:397–403.  
74.  Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, 
Marwick TH. Effect of If-Channel Inhibition on Hemodynamic Status and 
Exercise Tolerance in Heart Failure With Preserved Ejection Fraction. J Am 
Coll Cardiol 2013;62:1330–1338.  
75.  Pal N, Sivaswamy N, Mahmod M, Yavari A, Rudd A, Singh S, Dawson DK, 
Francis JM, Dwight JS, Watkins H, Neubauer S, Frenneaux M, Ashrafian H. 
Effect of Selective Heart Rate Slowing in Heart Failure With Preserved 
Ejection Fraction. Circulation 2015;132:1719–1725.  
76.  Edelmann F, Bobenko A, Gelbrich G, Hasenfuss G, Herrmann-Lingen C, 
Duvinage A, Schwarz S, Mende M, Prettin C, Trippel T, Lindhorst R, Morris 
D, Pieske-Kraigher E, Nolte K, Düngen HD, Wachter R, Halle M, Pieske B. 
Exercise training in Diastolic Heart Failure (Ex-DHF): rationale and design 
of a multicentre, prospective, randomized, controlled, parallel group trial. 
Eur J Heart Fail 2017;19:1067–1074.  
77.  Hasenfuß G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson 
F, Malek F, Heyden J Van der, Lang I, Petrie MC, Cleland JGF, Leon M, 
Kaye DM, REDUCE LAP-HF Study Investigators. A transcatheter intracardiac 
shunt device for heart failure with preserved ejection fraction (REDUCE 
LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet 
298 
2016;387:1298–1304.  
78.  Feldman T, Mauri L, Kahwash R, Litwin S, Ricciardi MJ, van der Harst P, 
Penicka M, Fail PS, Kaye DM, Petrie MC, Basuray A, Hummel SL, Forde-
McLean R, Nielsen CD, Lilly S, Massaro JM, Burkhoff D, Shah SJ, REDUCE 
LAP-HF I Investigators and Study Coordinators. Transcatheter Interatrial 
Shunt Device for the Treatment of Heart Failure With Preserved Ejection 
Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in 
Patients With Heart Failure]). Circulation 2018;137:364–375.  
79.  Camici PG, Crea F. Coronary Microvascular Dysfunction. N Engl J Med 
2007;8356:830–840.  
80.  Herrmann J, Kaski JC, Lerman A. Coronary microvascular dysfunction in 
the clinical setting: from mystery to reality. Eur Heart J 2012;33:2771–
2783.  
81.  Chilian WM, Eastham CL, Marcus ML. Microvascular distribution of coronary 
vascular resistance in beating left ventricle. Am J Physiol Circ Physiol 
1986;251:H779–H788.  
82.  Wilson RF, Marcus ML, White CW. Prediction of the physiologic significance 
of coronary arterial lesions by quantitative lesion geometry in patients 
with limited coronary artery disease. Circulation 1987;75:723–732.  
83.  Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, 
Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, 
Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, 
Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, ESC 
Scientific Document Group. 2019 ESC Guidelines for the diagnosis and 
management of chronic coronary syndromes. Eur Heart J 2020;41:407-477.  
84.  Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, 
Bugiardini R, Crea F, Cuisset T, Mario C Di, Ferreira JR, Gersh BJ, Gitt AK, 
Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, 
Senior R, Taggart DP, van der Wall EE, Vrints CJM, ESC Committee for 
Practice Guidelines. 2013 ESC guidelines on the management of stable 
299 
coronary artery disease. Eur Heart J 2013;34:2949–3003.  
85.  Douglas PS, Ginsburg GS. The evaluation of chest pain in women. N Engl J 
Med 1996;334:1311–1315.  
86.  Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, 
Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, 
Ohman EM, American Heart Association Council on Clinical Cardiology, 
Society of Geriatric Cardiology. Acute coronary care in the elderly, part I: 
Non-ST-segment-elevation acute coronary syndromes: a scientific 
statement for healthcare professionals from the American Heart 
Association Council on Clinical Cardiology: in collaboration with the 
Society of Geriatric Cardiology. Circulation 2007;115:2549–2569.  
87.  Zellweger MJ, Hachamovitch R, Kang X, Hayes SW, Friedman JD, Germano 
G, Pfisterer ME, Berman DS. Prognostic relevance of symptoms versus 
objective evidence of coronary artery disease in diabetic patients. Eur 
Heart J 2004;25:543–550.  
88.  Juarez-Orozco LE, Saraste A, Capodanno D, Prescott E, Ballo H, Bax JJ, 
Wijns W, Knuuti J. Impact of a decreasing pre-test probability on the 
performance of diagnostic tests for coronary artery disease. Eur Hear J - 
Cardiovasc Imaging 2019; 20(11):1198-1207.  
89.  Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, 
Paul N, Clouse ME, Shapiro EP, Hoe J, Lardo AC, Bush DE, de Roos A, Cox 
C, Brinker J, Lima JAC. Diagnostic performance of coronary angiography by 
64-row CT. N Engl J Med 2008;359:2324–2336.  
90.  Meijs MFL, Meijboom WB, Prokop M, Mollet NR, van Mieghem CAG, 
Doevendans PA, de Feyter PJ, Cramer MJ. Is there a role for CT coronary 
angiography in patients with symptomatic angina? Effect of coronary 
calcium score on identification of stenosis. Int J Cardiovasc Imaging 
2009;25:847–854.  
91.  Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas 
PS, Foody JM, Gerber TC, Hinderliter AL, King SB, Kligfield PD, Krumholz 
300 
HM, Kwong RYK, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, 
Sabik JF, Shaw LJ, Sikkema JD, Smith CR, Smith SC, Spertus JA, Williams S 
V. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis 
and Management of Patients With Stable Ischemic Heart Disease. 
Circulation 2012;60:e44-e164.   
92.  Mark DB, Shaw L, Harrell FE, Hlatky MA, Lee KL, Bengtson JR, McCants CB, 
Califf RM, Pryor DB. Prognostic Value of a Treadmill Exercise Score in 
Outpatients with Suspected Coronary Artery Disease. N Engl J Med 
1991;325:849–853.  
93.  Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR, Chaitman BR, Kaiser 
GC, Alderman E, Killip T. Long-term survival of medically treated patients 
in the Coronary Artery Surgery Study (CASS) Registry. Circulation 
1994;90:2645–2657.  
94.  Mark DB, Nelson CL, Califf RM, Harrell FE, Lee KL, Jones RH, Fortin DF, 
Stack RS, Glower DD, Smith LR. Continuing evolution of therapy for 
coronary artery disease. Initial results from the era of coronary 
angioplasty. Circulation 1994;89:2015–2025.  
95.  Toth G, Hamilos M, Pyxaras S, Mangiacapra F, Nelis O, De Vroey F, Di 
Serafino L, Muller O, Van Mieghem C, Wyffels E, Heyndrickx GR, Bartunek 
J, Vanderheyden M, Barbato E, Wijns W, De Bruyne B. Evolving concepts of 
angiogram: fractional flow reserve discordances in 4000 coronary stenoses. 
Eur Heart J 2014;35:2831–2838.  
96.  Park SJ, Kang SJ, Ahn JM, Shim EB, Kim YT, Yun SC, Song H, Lee JY, Kim 
WJ, Park DW, Lee SW, Kim YH, Lee CW, Mintz GS, Park SW. Visual-
Functional Mismatch Between Coronary Angiography and Fractional Flow 
Reserve. JACC Cardiovasc Interv 2012;5:1029–1036.  
97.  Tonino PAL, De Bruyne B, Pijls NHJ, Siebert U, Ikeno F, van`t Veer M, 
Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy 
PA, Fearon WF. Fractional Flow Reserve versus Angiography for Guiding 
Percutaneous Coronary Intervention. N Engl J Med 2009;360:213–224.  
301 
98.  Pijls NHJ, Van Gelder B, Van der Voort P, Peels K, Bracke FA, Bonnier HJ, 
El Gamal MI. Fractional Flow Reserve. A useful index to evaluate the 
influence of an epicardial coronary stenosis on myocardial blood flow. 
Circulation 1995;92:3183–3193.  
99.  Meyers DG, Neuberger JS, He J. Cardiovascular Effect of Bans on Smoking 
in Public Places. J Am Coll Cardiol 2009;54:1249–1255.  
100.  Critchley JA, Capewell S. Smoking cessation for the secondary prevention 
of coronary heart disease. In: Critchley JA, ed. Cochrane Database of 
Systematic Reviews Chichester, UK: John Wiley & Sons, Ltd; 2003. p. 
CD003041.  
101.  Massimo F, Piepoli U, Corrà W, Benzer B, Bjarnason-Wehrens P, Dendale D, 
Gaita H, Mcgee M, Mendes J, Niebauer AD, Olsen Z, Schmid JP. Secondary 
prevention through cardiac rehabilitation: from knowledge to 
implementation. A position paper from the Cardiac Rehabilitation Section 
of the European Association of Cardiovascular Prevention and 
Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010;17:1–17.  
102.  Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, 
Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, 
Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar 
N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC, ESC Scientific 
Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and 
cardiovascular diseases developed in collaboration with the EASD. Eur 
Heart J 2020;44:255-323.   
103.  Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, 
Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday 
A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, 
Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific 
Document Group. 2019 ESC/EAS Guidelines for the management of 
dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart 
J 2020;41:111-188.  
104.  Ferrari R, Pavasini R, Camici PG, Crea F, Danchin N, Pinto F, Manolis A, 
302 
Marzilli M, Rosano GMC, Lopez-Sendon J, Fox K. Anti-anginal drugs–beliefs 
and evidence: systematic review covering 50 years of medical treatment. 
Eur Heart J 2019;40:190–194.  
105.  Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, Bangalore 
S. Percutaneous Coronary Intervention Versus Optimal Medical Therapy in 
Stable Coronary Artery Disease. Circ Cardiovasc Interv 2012;5:476–490.  
106.  De Bruyne B, Pijls NHJ, Kalesan B, Barbato E, Tonino PAL, Piroth Z, Jagic 
N, Möbius-Winkler S, Mobius-Winckler S, Rioufol G, Witt N, Kala P, 
MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee 
P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF, FAME 2 Trial 
Investigators. Fractional flow reserve-guided PCI versus medical therapy in 
stable coronary disease. N Engl J Med 2012;367:991–1001.  
107.  Yusuf S, Zucker D, Passamani E, Peduzzi P, Takaro T, Fisher L, Kennedy J, 
Davis K, Killip T, Norris R, Morris C, Mathur V, Varnauskas E, Chalmers T. 
Effect of coronary artery bypass graft surgery on survival: overview of 10-
year results from randomised trials by the Coronary Artery Bypass Graft 
Surgery Trialists Collaboration. Lancet 1994;344:563–570.  
108.  Lee PH, Ahn JM, Chang M, Baek S, Yoon SH, Kang SJ, Lee SW, Kim YH, Lee 
CW, Park SW, Park DW, Park SJ. Left Main Coronary Artery Disease. J Am 
Coll Cardiol 2016;68:1233–1246.  
109.  Dzavik V, Ghali WA, Norris C, Mitchell LB, Koshal A, Saunders LD, Galbraith 
PD, Hui W, Faris P, Knudtson ML, Alberta Provincial Project for Outcome 
Assessment in Coronary Heart Disease (APPROACH) Investigators. Long-
term survival in 11,661 patients with multivessel coronary artery disease in 
the era of stenting: A report from the Alberta Provincial Project for 
Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. 
Am Heart J 2001;142:119–126.  
110.  Gada H, Kirtane AJ, Kereiakes DJ, Bangalore S, Moses JW, Généreux P, 
Mehran R, Dangas GD, Leon MB, Stone GW. Meta-Analysis of Trials on 
Mortality After Percutaneous Coronary Intervention Compared With 
Medical Therapy in Patients With Stable Coronary Heart Disease and 
303 
Objective Evidence of Myocardial Ischemia. Am J Cardiol 2015;115:1194–
1199.  
111.  Shaw LJ, Berman DS, Maron DJ, Mancini GBJ, Hayes SW, Hartigan PM, 
Weintraub WS, O’Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman 
J, Slomka P, Heller G V., Germano G, Gosselin G, Berger P, Kostuk WJ, 
Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, 
Boden WE. Optimal Medical Therapy With or Without Percutaneous 
Coronary Intervention to Reduce Ischemic Burden. Circulation 
2008;117:1283–1291.  
112.  Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler 
RE, Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, Desvigne-
Nickens P, Sopko G, Rouleau JL. Coronary-Artery Bypass Surgery in Patients 
with Ischemic Cardiomyopathy. N Engl J Med 2016;374:1511–1520.  
113.  Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, 
Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, 
Kristensen SD, Niebauer J, Richter DJ, Seferović PM, Sibbing D, Stefanini 
GG, Windecker S, Yadav R, Zembala MO, ESC Scientific Document Group. 
2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 
2019;40:87–165.  
114.  Garcia S, Sandoval Y, Roukoz H, Adabag S, Canoniero M, Yannopoulos D, 
Brilakis ES. Outcomes After Complete Versus Incomplete Revascularization 
of Patients With Multivessel Coronary Artery Disease. J Am Coll Cardiol 
2013;62:1421–1431.  
115.  Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, 
Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, 
Ferrazzi P, Petrie MC, O’Connor CM, Panchavinnin P, She L, Bonow RO, 
Rankin GR, Jones RH, Rouleau JL. Coronary-Artery Bypass Surgery in 
Patients with Left Ventricular Dysfunction. N Engl J Med 2011;364:1607–
1616.  
116.  Perera D, Clayton T, Petrie MC, Greenwood JP, O’Kane PD, Evans R, 
Sculpher M, Mcdonagh T, Gershlick A, de Belder M, Redwood S, Carr-White 
304 
G, Marber M. Percutaneous Revascularization for Ischemic Ventricular 
Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial: 
Percutaneous Coronary Intervention for Ischemic Cardiomyopathy. JACC 
Hear Fail 2018;6:517–526.  
117.  Patel MR, Peterson ED, Dai D, Brennan JM, Redberg RF, Anderson HV, 
Brindis RG, Douglas PS. Low Diagnostic Yield of Elective Coronary 
Angiography. N Engl J Med 2010;362:886–895.  
118.  Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: 
an update. Eur Heart J 2014;35:1101–1111.  
119.  Murthy VL, Naya M, Taqueti VR, Foster CR, Gaber M, Hainer J, Dorbala S, 
Blankstein R, Rimoldi O, Camici PG, Di Carli MF. Effects of Sex on Coronary 
Microvascular Dysfunction and Cardiac Outcomes. Circulation 
2014;129:2518–2527.  
120.  Schindler TH, Dilsizian V. Coronary Microvascular Dysfunction: Clinical 
Considerations and Noninvasive Diagnosis. JACC Cardiovasc Imaging 
2020;13:140-155.  
121.  Johnson NP, Gould KL. Clinical evaluation of a new concept: resting 
myocardial perfusion heterogeneity quantified by markovian analysis of 
PET identifies coronary microvascular dysfunction and early atherosclerosis 
in 1,034 subjects. J Nucl Med 2005;46:1427–1437.  
122.  Panting JR, Gatehouse PD, Yang GZ, Grothues F, Firmin DN, Collins P, 
Pennell DJ. Abnormal subendocardial perfusion in cardiac syndrome X 
detected by cardiovascular magnetic resonance imaging. N Engl J Med 
2002;346:1948–1953.  
123.  Lethen H, Tries HP, Brechtken J, Kersting S, Lambertz H. Comparison of 
transthoracic Doppler echocardiography to intracoronary Doppler 
guidewire measurements for assessment of coronary flow reserve in the 
left anterior descending artery for detection of restenosis after coronary 
angioplasty. Am J Cardiol 2003;91:412–417.  
124.  Feher A, Sinusas AJ. Quantitative Assessment of Coronary Microvascular 
305 
Function: Dynamic Single-Photon Emission Computed Tomography, Positron 
Emission Tomography, Ultrasound, Computed Tomography, and Magnetic 
Resonance Imaging. Circ Cardiovasc Imaging 2017;10.  
125.  Ford TJ, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology, 
diagnostic advances and therapeutic need. Heart 2018;104:284–292.  
126.  van de Hoef TP, van Lavieren MA, Damman P, Delewi R, Piek MA, 
Chamuleau SAJ, Voskuil M, Henriques JPS, Koch KT, de Winter RJ, Spaan 
JAE, Siebes M, Tijssen JGP, Meuwissen M, Piek JJ. Physiological Basis and 
Long-Term Clinical Outcome of Discordance Between Fractional Flow 
Reserve and Coronary Flow Velocity Reserve in Coronary Stenoses of 
Intermediate Severity. Circ Cardiovasc Interv 2014;7:301–311.  
127.  Melikian N, Vercauteren S, Fearon WF, Cuisset T, MacCarthy PA, 
Davidavicius G, Aarnoudse W, Bartunek J, Vanderheyden M, Wyffels E, 
Wijns W, Heyndrickx GR, Pijls NHJ, De Bruyne B. Quantitative assessment 
of coronary microvascular function in patients with and without epicardial 
atherosclerosis. EuroIntervention 2010;5:939–945.  
128.  Luo C, Long M, Hu X, Huang Z, Hu C, Gao X, Du Z. Thermodilution-derived 
coronary microvascular resistance and flow reserve in patients with 
cardiac syndrome X. Circ Cardiovasc Interv 2014;7:43–48.  
129.  Solberg OG, Ragnarsson A, Kvarsnes A, Endresen K, Kongsgård E, Aakhus S, 
Gullestad L, Stavem K, Aaberge L. Reference interval for the index of 
coronary microvascular resistance. EuroIntervention 2014;9:1069–1075.  
130.  Ng MKC, Yeung AC, Fearon WF. Invasive assessment of the coronary 
microcirculation: superior reproducibility and less hemodynamic 
dependence of index of microcirculatory resistance compared with 
coronary flow reserve. Circulation 2006;113:2054–2061.  
131.  Lanza GA, Colonna G, Pasceri V, Maseri A. Atenolol versus amlodipine 
versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J 
Cardiol 1999;84:854–856.  
132.  Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-
306 
converting enzyme inhibition on exercise-induced angina and ST segment 
depression in patients with microvascular angina. J Am Coll Cardiol 
1994;23:652–657.  
133.  Fábián E, Varga A, Picano E, Vajo Z, Rónaszéki A, Csanády M. Effect of 
simvastatin on endothelial function in cardiac syndrome X patients. Am J 
Cardiol 2004;94:652–655.  
134.  Pauly DF, Johnson BD, Anderson RD, Handberg EM, Smith KM, Cooper-
DeHoff RM, Sopko G, Sharaf BM, Kelsey SF, Merz CNB, Pepine CJ. In women 
with symptoms of cardiac ischemia, nonobstructive coronary arteries, and 
microvascular dysfunction, angiotensin-converting enzyme inhibition is 
associated with improved microvascular function: A double-blind 
randomized study from the National Heart, Lung and Blood Institute 
Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J 2011;162:678–
684.  
135.  Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, 
Eteiba H, Shaukat A, Lindsay M, Robertson K, Hood S, McGeoch R, McDade 
R, Yii E, Sidik N, McCartney P, Corcoran D, Collison D, Rush C, 
McConnachie A, Touyz RM, Oldroyd KG, Berry C. Stratified Medical Therapy 
Using Invasive Coronary Function Testing in Angina. J Am Coll Cardiol 
2018;72:2841–2855.  
136.  Shaw J, Anderson T. Coronary endothelial dysfunction in non-obstructive 
coronary artery disease: Risk, pathogenesis, diagnosis and therapy. Vasc 
Med 2016;21:146–155.  
137.  Vane JR, Anggård EE, Botting RM, Botting RM. Regulatory functions of the 
vascular endothelium. N Engl J Med 1990;323:27–36.  
138.  Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO. 
Contribution of Nitric Oxide to Metabolic Coronary Vasodilation in the 
Human Heart. Circulation 1995;92:320–326.  
139.  Ong P, Athanasiadis A, Borgulya G, Mahrholdt H, Kaski JC, Sechtem U. High 
Prevalence of a Pathological Response to Acetylcholine Testing in Patients 
307 
With Stable Angina Pectoris and Unobstructed Coronary Arteries. J Am Coll 
Cardiol 2012;59:655–662.  
140.  Halcox JPJ, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, 
Nour KRA, Quyyumi AA. Prognostic value of coronary vascular endothelial 
dysfunction. Circulation 2002;106:653–658.  
141.  Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of 
normal and constriction of atherosclerotic coronary arteries caused by the 
cold pressor test. Circulation 1988;77:43–52.  
142.  Morita K, Tsukamoto T, Naya M, Noriyasu K, Inubushi M, Shiga T, Katoh C, 
Kuge Y, Tsutsui H, Tamaki N. Smoking cessation normalizes coronary 
endothelial vasomotor response assessed with 15O-water and PET in 
healthy young smokers. J Nucl Med 2006;47:1914–1920.  
143.  Mudge GH, Grossman W, Mills RM, Lesch M, Braunwald E. Reflex Increase in 
Coronary Vascular Resistance in Patients with Ischemic Heart Disease. N 
Engl J Med 1976;295:1333–1337.  
144.  Al-Badri A, Wei J, Mehta PK, Landes S, Petersen JW, Anderson RD, Samuels 
B, Azarbal B, Handberg EM, Li Q, Minissian M, Shufelt C, Pepine CJ, Bairey 
Merz CN. Acetylcholine versus cold pressor testing for evaluation of 
coronary endothelial function. PLoS One 2017;12.  
145.  Ong P, Camici PG, Beltrame JF, Crea F, Shimokawa H, Sechtem U, Kaski 
JC, Noel Bairey Merz C. International standardization of diagnostic criteria 
for microvascular angina. Int J Cardiol 2017;250:16–20.  
146.  Beltrame JF, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U, Shimokawa H, 
Bairey Merz CN. International standardization of diagnostic criteria for 
vasospastic angina. Eur Heart J 2015;ehv351.  
147.  Yasue H, Takizawa A, Nagao M, Nishida S, Horie M, Kubota J, Omote S, 
Takaoka K, Okumura K. Long-term prognosis for patients with variant 
angina and influential factors. Circulation 1988;78:1–9.  
148.  Hwang SJ, Melenovsky V, Borlaug BA. Implications of Coronary Artery 
308 
Disease in Heart Failure With Preserved Ejection Fraction. J Am Coll 
Cardiol 2014;63:2817–2827.  
149.  Bonow RO. Left Ventricular Diastolic Dysfunction as a Cause of Congestive 
Heart Failure. Ann Intern Med 1992;117:502.  
150.  Serizawa T, Vogel WM, Apstein CS, Grossman W. Comparison of acute 
alterations in left ventricular relaxation and diastolic chamber stiffness 
induced by hypoxia and ischemia. Role of myocardial oxygen supply-
demand imbalance. J Clin Invest 1981;68:91–102.  
151.  Mann T, Brodie BR, Grossman W, McLaurin LP. Effect of angina on the left 
ventricular diastolic pressure-volume relationship. Circulation 
1977;55:761–766.  
152.  Labovitz AJ, Lewen MK, Kern M, Vandormael M, Deligonal U, Kennedy HL. 
Evaluation of left ventricular systolic and diastolic dysfunction during 
transient myocardial ischemia produced by angioplasty. J Am Coll Cardiol 
1987;10:748–755.  
153.  Kass DA, Midei M, Brinker J, Maughan WL. Influence of coronary occlusion 
during PTCA on end-systolic and end-diastolic pressure-volume relations in 
humans. Circulation 1990;81:447–460.  
154.  Tschöpe C, Westermann D. Heart failure with normal ejection fraction. 
Pathophysiology, diagnosis, and treatment. Herz 2009;34:89–96.  
155.  Gaasch WH. Congestive heart failure in patients with normal left 
ventricular systolic function: a manifestation of diastolic dysfunction. Herz 
1991;16:22–32.  
156.  Hasselberg NE, Haugaa KH, Sarvari SI, Gullestad L, Andreassen AK, Smiseth 
OA, Edvardsen T. Left ventricular global longitudinal strain is associated 
with exercise capacity in failing hearts with preserved and reduced 
ejection fraction. Eur Heart J Cardiovasc Imaging 2015;16:217–224.  
157.  Yip GWK, Zhang Q, Xie JM, Xie JM, Liang YJ, Liu YM, Yan B, Lam YY, Yu 
CM. Resting global and regional left ventricular contractility in patients 
309 
with heart failure and normal ejection fraction: insights from speckle-
tracking echocardiography. Heart 2011;97:287–294.  
158.  Carluccio E, Biagioli P, Alunni G, Murrone A, Leonelli V, Pantano P, 
Biscottini E, Paulus WJ, Ambrosio G. Advantages of deformation indices 
over systolic velocities in assessment of longitudinal systolic function in 
patients with heart failure and normal ejection fraction. Eur J Heart Fail 
2011;13:292–302.  
159.  Tan YT, Wenzelburger F, Lee E, Heatlie G, Leyva F, Patel K, Frenneaux M, 
Sanderson JE. The pathophysiology of heart failure with normal ejection 
fraction: exercise echocardiography reveals complex abnormalities of both 
systolic and diastolic ventricular function involving torsion, untwist, and 
longitudinal motion. J Am Coll Cardiol 2009;54:36–46.  
160.  Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred 
reporting items for systematic reviews and meta-analyses: the PRISMA 
statement. BMJ 2009;339:b2535.  
161.  Goyal P, Almarzooq ZI, Horn EM, Karas MG, Sobol I, Swaminathan RV, 
Feldman DN, Minutello RM, Singh HS, Bergman GW, Wong SC, Kim LK. 
Characteristics of Hospitalizations for Heart Failure with Preserved 
Ejection Fraction. Am J Med 2016;129:635.e15-635.e26.  
162.  Cheng YL, Sung SH, Cheng HM, Huang JT, Guo CY, Hsu PF, Yu WC, Chen 
CH. Prognostic Comparison of the Estimations of Renal Function in Patients 
With Acute Heart Failure. Circ J 2019;83:767–774.  
163.  Greenberg B, Peterson ED, Berger JS, Laliberté F, Zhao Q, Germain G, 
Lejeune D, Wu JW, Lefebvre P, Fonarow GC. Ejection fraction, B-type 
natriuretic peptide and risk of stroke and acute myocardial infarction 
among patients with heart failure. Clin Cardiol 2019;42:277–284.  
164.  Matsushita K, Harada K, Miyazaki T, Miyamoto T, Kohsaka S, Iida K, 
Yamamoto Y, Nagatomo Y, Yoshino H, Yamamoto T, Nagao K, Takayama M. 
Younger- vs Older-Old Patients with Heart Failure with Preserved Ejection 
Fraction. J Am Geriatr Soc 2019;67:2123–2128.  
310 
165.  Miró Ò, Gil V, Martín-Sánchez FJ, Jacob J, Herrero P, Alquézar A, Llauger 
L, Aguiló S, Martínez G, Ríos J, Domínguez-Rodríguez A, Harjola VP, Müller 
C, Parissis J, Peacock WF, Llorens P, Research Group on Acute Heart 
Failure of the Spanish Society of Emergency Medicine (ICA-SEMES Research 
Group) Researchers. Short-term outcomes of heart failure patients with 
reduced and preserved ejection fraction after acute decompensation 
according to the final destination after emergency department care. Clin 
Res Cardiol 2018;107:698–710.  
166.  Takei M, Kohsaka S, Shiraishi Y, Goda A, Nagatomo Y, Mizuno A, Suzino Y, 
Kohno T, Fukuda K, Yoshikawa T. Heart Failure With Midrange Ejection 
Fraction in Patients Admitted for Acute Decompensation: A Report from 
the Japanese Multicenter Registry. J Card Fail 2019;25:666-673.  
167.  Guisado-Espartero ME, Salamanca-Bautista P, Aramburu-Bodas Ó, Conde-
Martel A, Arias-Jiménez JL, Llàcer-Iborra P, Dávila-Ramos MF, Cabanes-
Hernández Y, Manzano L, Montero-Pérez-Barquero M. Heart failure with 
mid-range ejection fraction in patients admitted to internal medicine 
departments: Findings from the RICA Registry. Int J Cardiol 2018;255:124–
128.  
168.  Kang J, Park JJ, Cho YJ, Oh IY, Park HA, Lee SE, Kim MS, Cho HJ, Lee HY, 
Choi JO, Hwang KK, Kim KH, Yoo BS, Kang SM, Baek SH, Jeon ES, Kim JJ, 
Cho MC, Chae SC, Oh BH, Choi DJ. Predictors and Prognostic Value of 
Worsening Renal Function During Admission in HFpEF Versus HFrEF: Data 
From the KorAHF (Korean Acute Heart Failure) Registry. J Am Heart Assoc 
2018;7.  
169.  Zhang Y, Zhang J, Butler J, Yang X, Xie P, Guo D, Wei T, Yu J, Wu Z, Gao 
Y, Han X, Zhang X, Wen S, Anker SD, Filippatos G, Fonarow GC, Gan T, 
Zhang R, China-HF Investigators. Contemporary Epidemiology, 
Management, and Outcomes of Patients Hospitalized for Heart Failure in 
China: Results From the China Heart Failure (China-HF) Registry. J Card 
Fail 2017;23:868–875.  
170.  Zacharias M, Joffe S, Konadu E, Meyer T, Kiernan M, Lessard D, Goldberg 
RJ. Clinical epidemiology of heart failure with preserved ejection fraction 
311 
(HFpEF) in comparatively young hospitalized patients. Int J Cardiol 
2016;202:918–921.  
171.  Nichols GA, Reynolds K, Kimes TM, Rosales AG, Chan WW. Comparison of 
Risk of Re-hospitalization, All-Cause Mortality, and Medical Care Resource 
Utilization in Patients With Heart Failure and Preserved Versus Reduced 
Ejection Fraction. Am J Cardiol 2015;116:1088–1092.  
172.  Kajimoto K, Sato N, Takano T, Investigators of the Acute Decompensated 
Heart Failure Syndromes (ATTEND) registry. Relation of Left Ventricular 
Ejection Fraction and Clinical Features or Co-morbidities to Outcomes 
Among Patients Hospitalized for Acute Heart Failure Syndromes. Am J 
Cardiol 2015;115:334–340.  
173.  Caughey MC, Avery CL, Ni H, Solomon SD, Matsushita K, Wruck LM, 
Rosamond WD, Loehr LR. Outcomes of Patients With Anemia and Acute 
Decompensated Heart Failure With Preserved Versus Reduced Ejection 
Fraction (from the ARIC Study Community Surveillance). Am J Cardiol 
2014;114:1850–1854.  
174.  Clarke CL, Grunwald GK, Allen LA, Barón AE, Peterson PN, Brand DW, 
Magid DJ, Masoudi FA. Natural history of left ventricular ejection fraction 
in patients with heart failure. Circ Cardiovasc Qual Outcomes 2013;6:680–
686.  
175.  Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, 
Hernandez AF, Fonarow GC, Get With the Guidelines Scientific Advisory 
Committee and Investigators. Trends in patients hospitalized with heart 
failure and preserved left ventricular ejection fraction: prevalence, 
therapies, and outcomes. Circulation 2012;126:65–75.  
176.  West R, Liang L, Fonarow GC, Kociol R, Mills RM, O’Connor CM, Hernandez 
AF. Characterization of heart failure patients with preserved ejection 
fraction: a comparison between ADHERE-US registry and ADHERE-
International registry. Eur J Heart Fail 2011;13:945–952.  
177.  Mogensen UM, Ersbøll M, Andersen M, Andersson C, Hassager C, Torp-
312 
Pedersen C, Gustafsson F, Køber L. Clinical characteristics and major 
comorbidities in heart failure patients more than 85 years of age compared 
with younger age groups. Eur J Heart Fail 2011;13:1216–1223.  
178.  Rossi JS, Flaherty JD, Fonarow GC, Nunez E, Gattis Stough W, Abraham 
WT, Albert NM, Greenberg BH, O’Connor CM, Yancy CW, Young JB, 
Davidson CJ, Gheorghiade M. Influence of coronary artery disease and 
coronary revascularization status on outcomes in patients with acute heart 
failure syndromes: a report from OPTIMIZE-HF (Organized Program to 
Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). 
Eur J Heart Fail 2008;10:1215–1223.  
179.  Ezekowitz JA, Lee DS, Tu JV, Newman AM, McAlister FA. Comparison of 
One-Year Outcome (Death and Rehospitalization) in Hospitalized Heart 
Failure Patients With Left Ventricular Ejection Fraction <50% Versus Those 
With Ejection Fraction ≥50%. Am J Cardiol 2008;102:79–83.  
180.  Shah R, Wang Y, Foody JM. Effect of statins, angiotensin-converting 
enzyme inhibitors, and beta blockers on survival in patients ≥65 years of 
age with heart failure and preserved left ventricular systolic function. Am 
J Cardiol 2008;101:217–222.  
181.  Yancy CW, Lopatin M, Stevenson LW, Marco T De, Fonarow GC, ADHERE 
Scientific Advisory Committee and Investigators. Clinical Presentation, 
Management, and In-Hospital Outcomes of Patients Admitted With Acute 
Decompensated Heart Failure With Preserved Systolic Function. J Am Coll 
Cardiol 2006;47:76–84.  
182.  Lenzen M, Scholte op Reimer WJM, Boersma E, Vantrimpont PJMJ, Follath 
F, Swedberg K, Cleland J, Komajda M. Differences between patients with a 
preserved and a depressed left ventricular function: a report from the 
EuroHeart Failure Survey. Eur Heart J 2004;25:1214–1220.  
183.  Ibrahim SA, Burant CJ, Kent Kwoh C. Elderly hospitalized patients with 
diastolic heart failure: lack of gender and ethnic differences in 18-month 
mortality rates. J Gerontol A Biol Sci Med Sci 2003;58:56–59.  
313 
184.  Ibrahim NE, Song Y, Cannon CP, Doros G, Russo P, Ponirakis A, Alexanian C, 
Januzzi JL. Heart failure with mid-range ejection fraction: 
characterization of patients from the PINNACLE Registry. ESC Hear Fail 
2019;6:784-792.  
185.  Tromp J, Teng TH, Tay WT, Hung CL, Narasimhan C, Shimizu W, Park SW, 
Liew HB, Ngarmukos T, Reyes EB, Siswanto BB, Yu CM, Zhang S, Yap J, 
MacDonald M, Ling LH, Leineweber K, Richards AM, Zile MR, Anand IS, Lam 
CSP. Heart failure with preserved ejection fraction in Asia. Eur J Heart 
Fail 2019;21:23–36.  
186.  Iorio A, Senni M, Barbati G, Greene SJ, Poli S, Zambon E, Di Nora C, Cioffi 
G, Tarantini L, Gavazzi A, Sinagra G, Di Lenarda A. Prevalence and 
prognostic impact of non-cardiac co-morbidities in heart failure 
outpatients with preserved and reduced ejection fraction: a community-
based study. Eur J Heart Fail 2018;20:1257–1266.  
187.  Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, 
Wehrens XHT, Deswal A. Impact of Noncardiac Comorbidities on Morbidity 
and Mortality in a Predominantly Male Population With Heart Failure and 
Preserved Versus Reduced Ejection Fraction. J Am Coll Cardiol 
2012;59:998–1005.  
188.  Magaña-Serrano JA, Almahmeed W, Gomez E, Al-Shamiri M, Adgar D, 
Sosner P, Herpin D, I PREFER Investigators. Prevalence of heart failure with 
preserved ejection fraction in Latin American, Middle Eastern, and North 
African Regions in the I PREFER study (Identification of Patients With Heart 
Failure and PREserved Systolic Function: an epidemiological regional 
study). Am J Cardiol 2011;108:1289–1296.  
189.  Huusko J, Kurki S, Toppila I, Purmonen T, Lassenius M, Gullberg E, Wirta 
SB, Ukkonen H. Heart failure in Finland: clinical characteristics, mortality, 
and healthcare resource use. ESC Hear Fail 2019;6:603-612.   
190.  Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, Braun OÖ, 
Savarese G, Dahlström U, Lund LH. Significance of Ischemic Heart Disease 
in Patients With Heart Failure and Preserved, Midrange, and Reduced 
314 
Ejection Fraction. Circ Hear Fail 2017;10.  
191.  Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola 
VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, 
Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G. 
Epidemiology and one-year outcomes in patients with chronic heart failure 
and preserved, mid-range and reduced ejection fraction: an analysis of the 
ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574–1585.  
192.  Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Tadaki S, Ushigome R, 
Yamauchi T, Takahashi J, Shimokawa H, CHART-2 Investigators. Prognostic 
Impact of Statin Use in Patients With Heart Failure and Preserved Ejection 
Fraction. Circ J 2015;79:574–582.  
193.  Allen LA, Magid DJ, Gurwitz JH, Smith DH, Goldberg RJ, Saczynski J, Thorp 
ML, Hsu G, Sung SH, Go AS. Risk factors for adverse outcomes by left 
ventricular ejection fraction in a contemporary heart failure population. 
Circ Heart Fail 2013;6:635–646.  
194.  Kaneko H, Suzuki S, Yajima J, Oikawa Y, Sagara K, Otsuka T, Matsuno S, 
Kano H, Uejima T, Koike A, Nagashima K, Kirigaya H, Sawada H, Aizawa T, 
Yamashita T. Clinical characteristics and long-term clinical outcomes of 
Japanese heart failure patients with preserved versus reduced left 
ventricular ejection fraction: A prospective cohort of Shinken Database 
2004–2011. J Cardiol 2013;62:102–109.  
195.  Edelmann F, Stahrenberg R, Gelbrich G, Durstewitz K, Angermann CE, 
Düngen HD, Scheffold T, Zugck C, Maisch B, Regitz-Zagrosek V, Hasenfuß 
G, Pieske BM, Wachter R. Contribution of comorbidities to functional 
impairment is higher in heart failure with preserved than with reduced 
ejection fraction. Clin Res Cardiol 2011;100:755–764.  
196.  Gomez-Soto FM, Romero SP, Bernal JA, Escobar MA, Puerto JL, Andrey JL, 
Almenara J, Gomez F. Mortality and morbidity of non-systolic heart failure 
treated with angiotensin-converting enzyme inhibitors: a propensity-
adjusted case-control study. Int J Cardiol 2010;139:276–282.  
315 
197.  Miura Y, Fukumoto Y, Shiba N, Miura T, Shimada K, Iwama Y, Takagi A, 
Matsusaka H, Tsutsumi T, Yamada A, Kinugawa S, Asakura M, Okamatsu S, 
Tsutsui H, Daida H, Matsuzaki M, Tomoike H, Shimokawa H. Prevalence and 
clinical implication of metabolic syndrome in chronic heart failure. Circ J 
2010;74:2612–2621.  
198.  Castillo JC, Anguita MP, Jimenez M, BADAPIC group. Outcome of Heart 
Failure with Preserved Ejection Fraction: A Multicentre Spanish Registry. 
Curr Cardiol Rev 2009;5:334–342.  
199.  Trevisan L, Cautela J, Resseguier N, Laine M, Arques S, Pinto J, Orabona 
M, Barraud J, Peyrol M, Paganelli F, Bonello L, Thuny F. Prevalence and 
characteristics of coronary artery disease in heart failure with preserved 
and mid-range ejection fractions: A systematic angiography approach. Arch 
Cardiovasc Dis 2018;111:109–118.  
200.  Koller L, Kleber M, Goliasch G, Sulzgruber P, Scharnagl H, Silbernagel G, 
Grammer T, Delgado G, Tomaschitz A, Pilz S, März W, Niessner A. C-
reactive protein predicts mortality in patients referred for coronary 
angiography and symptoms of heart failure with preserved ejection 
fraction. Eur J Heart Fail 2014;16:758–766.  
201.  Schmaltz HN, Southern DA, Maxwell CJ, Knudtson ML, Ghali WA, 
APPROACH Investigators. Patient sex does not modify ejection fraction as a 
predictor of death in heart failure: insights from the APPROACH cohort. J 
Gen Intern Med 2008;23:1940–1946.  
202.  Arques S, Bonello L, Roux E, Sbragia P, Pieri B, Gelisse R, Paganelli F. 
Angiographic coronary artery disease associated with hypertensive heart 
failure and normal ejection fraction. Insights from a prospective 
monocenter study. Int J Cardiol 2008;130:75–77.  
203.  Felker GM, Stough WG, Shaw LK, O’Connor CM. Anaemia and coronary 
artery disease severity in patients with heart failure. Eur J Heart Fail 
2006;8:54–57.  
204.  East MA, Peterson ED, Shaw LK, Gattis WA, O’Connor CM. Racial 
316 
differences in the outcomes of patients with diastolic heart failure. Am 
Heart J 2004;148:151–156.  
205.  Arques S, Ambrosi P, Gelisse R, Roux E, Lambert M, Habib G. Prevalence of 
angiographic coronary artery disease in patients hospitalized for acute 
diastolic heart failure without clinical and electrocardiographic evidence 
of myocardial ischemia on admission. Am J Cardiol 2004;94:133–135.  
206.  Kramer K, Kirkman P, Kitzman D, Little WC. Flash pulmonary edema: 
association with hypertension and reoccurrence despite coronary 
revascularization. Am Heart J 2000;140:451–455.  
207.  Judge KW, Pawitan Y, Caldwell J, Gersh BJ, Kennedy JW. Congestive heart 
failure symptoms in patients with preserved left ventricular systolic 
function: analysis of the CASS registry. J Am Coll Cardiol 1991;18:377–382.  
208.  Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, 
Redfield MM. Coronary Microvascular Rarefaction and Myocardial Fibrosis in 
Heart Failure With Preserved Ejection Fraction. Circulation 2015;131:550–
559.  
209.  Badar AA, Perez-Moreno AC, Hawkins NM, Brunton APT, Jhund PS, Wong 
CM, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Gardner 
RS, Petrie MC, McMurray JJV. Clinical characteristics and outcomes of 
patients with angina and heart failure in the CHARM (Candesartan in Heart 
Failure Assessment of Reduction in Mortality and Morbidity) Programme. 
Eur J Heart Fail 2015;17:196–204.  
210.  Badar AA, Perez-Moreno AC, Hawkins NM, Jhund PS, Brunton APT, Anand 
IS, McKelvie RS, Komajda M, Zile MR, Carson PE, Gardner RS, Petrie MC, 
McMurray JJV. Clinical Characteristics and Outcomes of Patients With 
Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients 
With Heart Failure and Preserved Systolic Function Trial. Circ Heart Fail 
2015;8:717–724.  
211.  Gerber Y, Weston SA, Enriquez-Sarano M, Berardi C, Chamberlain AM, 
Manemann SM, Jiang R, Dunlay SM, Roger VL. Mortality Associated With 
317 
Heart Failure After Myocardial Infarction. Circ Hear Fail 2016;9:e002460.  
212.  Desta L, Jernberg T, Spaak J, Hofman-Bang C, Persson H. Heart failure 
with normal ejection fraction is uncommon in acute myocardial infarction 
settings but associated with poor outcomes: a study of 91 360 patients 
admitted with index myocardial infarction between 1998 and 2010. Eur J 
Heart Fail 2016;18:46–53.  
213.  Desta L, Jernberg T, Löfman I, Hofman-Bang C, Hagerman I, Spaak J, 
Persson H. Incidence, Temporal Trends, and Prognostic Impact of Heart 
Failure Complicating Acute Myocardial Infarction. JACC Hear Fail 
2015;3:234–242.  
214.  Antonelli L, Katz M, Bacal F, Makdisse MRP, Correa AG, Pereira C, Franken 
M, Fava AN, Serrano Junior CV, Pesaro AEP. Heart failure with preserved 
left ventricular ejection fraction in patients with acute myocardial 
infarction. Arq Bras Cardiol 2015;105:145–150.  
215.  van Diepen S, Chen AY, Wang TY, Alexander KP, Ezekowitz JA, Peterson 
ED, Roe MT. Influence of heart failure symptoms and ejection fraction on 
short- and long-term outcomes for older patients with non-ST-segment 
elevation myocardial infarction. Am Heart J 2014;167:267-273.  
216.  Bennett KM, Hernandez AF, Chen AY, Mulgund J, Newby LK, Rumsfeld JS, 
Hochman JS, Hoekstra JW, Ohman EM, Gibler WB, Roe MT, Peterson ED. 
Heart failure with preserved left ventricular systolic function among 
patients with non-ST-segment elevation acute coronary syndromes. Am J 
Cardiol 2007;99:1351–1356.  
217.  Hellermann JP, Jacobsen SJ, Redfield MM, Reeder GS, Weston SA, Roger 
VL. Heart failure after myocardial infarction: Clinical presentation and 
survival. Eur J Heart Fail 2005;7:119–125.  
218.  Velazquez E, Francis GS, Armstrong PW, Aylward PE, Diaz R, O’Connor CM, 
White HD, Henis M, Rittenhouse LM, Kilaru R, van Gilst W, Ertl G, Maggioni 
AP, Spac J, Weaver WD, Rouleau JL, McMurray JJV, Pfeffer MA, Califf RM, 
VALIANT registry. An international perspective on heart failure and left 
318 
ventricular systolic dysfunction complicating myocardial infarction: the 
VALIANT registry. Eur Heart J 2004;25:1911–1919.  
219.  Møller JE, Brendorp B, Ottesen M, Køber L, Egstrup K, Poulsen SH, Torp-
Pedersen C, Bucindolol Evaluation in Acute Myocardial Infarction Trail 
Group. Congestive heart failure with preserved left ventricular systolic 
function after acute myocardial infarction: clinical and prognostic 
implications. Eur J Heart Fail 2003;5:811–819.  
220.  Xue Z, Li W, Ma C, Nie S, Dong J, Liu X, Kang J, Lü Q, Du X, Wang X, Chen 
F, Zhou Y, Lü S, Huang F, Gu C, Wu X. Coronary stenting versus bypass 
surgery in heart failure patients with preserved ejection fraction. Chin 
Med J (Engl) 2012;125:1000–1004.  
221.  Sun LY, Tu JV, Bader Eddeen A, Liu PP. Prevalence and Long-Term Survival 
After Coronary Artery Bypass Grafting in Women and Men With Heart 
Failure and Preserved Versus Reduced Ejection Fraction. J Am Heart Assoc 
2018;7.  
222.  Dalén M, Lund LH, Ivert T, Holzmann MJ, Sartipy U. Survival After Coronary 
Artery Bypass Grafting in Patients With Preoperative Heart Failure and 
Preserved vs Reduced Ejection Fraction. JAMA Cardiol 2016;1:530–538.  
223.  Marui A, Nishiwaki N, Komiya T, Hanyu M, Tanaka S, Kimura T, Sakata R, 
CREDO-Kyoto CABG Registry Cohort-2 Investigators. Comparison of 5-Year 
Outcomes After Coronary Artery Bypass Grafting in Heart Failure Patients 
With Versus Without Preserved Left Ventricular Ejection Fraction (from the 
CREDO-Kyoto CABG Registry Cohort-2). Am J Cardiol 2015;116:580–586.  
224.  Holper EM, Brooks MM, Kim LJ, Detre KM, Faxon DP, BARI Investigators. 
Effects of heart failure and diabetes mellitus on long-term mortality after 
coronary revascularization (from the BARI Trial). Am J Cardiol 
2007;100:196–202.  
225.  Holper EM, Blair J, Selzer F, Detre KM, Jacobs AK, Williams DO, Vlachos H, 
Wilensky RL, Coady P, Faxon DP, Percutaneous Transluminal Coronary 
Angioplasty Registry and Dynamic Registry Investigators. The impact of 
319 
ejection fraction on outcomes after percutaneous coronary intervention in 
patients with congestive heart failure: An analysis of the National Heart, 
Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty 
Registry and Dynamic Registry. Am Heart J 2006;151:69–75.  
226.  Dryer K, Gajjar M, Narang N, Lee M, Paul J, Shah AP, Nathan S, Butler J, 
Davidson CJ, Fearon WF, Shah SJ, Blair JEA. Coronary microvascular 
dysfunction in patients with heart failure with preserved ejection fraction. 
Am J Physiol Heart Circ Physiol 2018;314:H1033–H1042.  
227.  Allan T, Dryer K, Fearon WF, Shah SJ, Blair JEA. Coronary microvascular 
dysfunction and clinical outcomes in patients with heart failure with 
preserved ejection fraction. J Card Fail 2019; 25(10):843-845  
228.  van Empel VPM, Mariani J, Borlaug BA, Kaye DM. Impaired Myocardial 
Oxygen Availability Contributes to Abnormal Exercise Hemodynamics in 
Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc 2014;3.  
229.  Xu Z, Gu HP, Gu Y, Sun W, Yu K, Zhang XW, Kong XQ. Increased index of 
microcirculatory resistance in older patients with heart failure with 
preserved ejection fraction. J Geriatr Cardiol 2018;15:687–694.  
230.  Sucato V, Evola S, Novo G, Sansone A, Quagliana A, Andolina G, Assennato 
P, Novo S. Angiographic Evaluation of Coronary Microvascular Dysfunction 
in Patients with Heart Failure and Preserved Ejection Fraction. 
Microcirculation 2015;22:528–533.  
231.  Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, Beussink-Nelson 
L, Ljung Faxén U, Fermer ML, Broberg MA, Gan LM, Lund LH. Prevalence 
and correlates of coronary microvascular dysfunction in heart failure with 
preserved ejection fraction: PROMIS-HFpEF. Eur Heart J 2018;39:3439–
3450.  
232.  Löffler AI, Pan JA, Balfour PC, Shaw PW, Yang Y, Nasir M, Auger DA, 
Epstein FH, Kramer CM, Gan LM, Salerno M. Frequency of Coronary 
Microvascular Dysfunction and Diffuse Myocardial Fibrosis (Measured by 
Cardiovascular Magnetic Resonance) in Patients With Heart Failure and 
320 
Preserved Left Ventricular Ejection Fraction. Am J Cardiol 2019; 
124:1584-1589.  
233.  Kato S, Saito N, Kirigaya H, Gyotoku D, Iinuma N, Kusakawa Y, Iguchi K, 
Nakachi T, Fukui K, Futaki M, Iwasawa T, Kimura K, Umemura S. 
Impairment of Coronary Flow Reserve Evaluated by Phase Contrast Cine-
Magnetic Resonance Imaging in Patients With Heart Failure With Preserved 
Ejection Fraction. J Am Heart Assoc 2016;5.  
234.  Srivaratharajah K, Coutinho T, deKemp R, Liu P, Haddad H, Stadnick E, 
Davies RA, Chih S, Dwivedi G, Guo A, Wells GA, Bernick J, Beanlands R, 
Mielniczuk LM. Reduced Myocardial Flow in Heart Failure Patients With 
Preserved Ejection Fraction. Circ Heart Fail 2016;9.  
235.  Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschöpe C, 
Leite-Moreira AF, Musters R, Niessen HWM, Linke WA, Paulus WJ, Hamdani 
N. Myocardial Microvascular Inflammatory Endothelial Activation in Heart 
Failure With Preserved Ejection Fraction. JACC Hear Fail 2016;4:312–324.  
236.  van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, 
Kupreishvili K, Ijsselmuiden AJJ, Schalkwijk CG, Bronzwaer JGF, Diamant 
M, Borbély A, van der Velden J, Stienen GJM, Laarman GJ, Niessen HWM, 
Paulus WJ. Diastolic Stiffness of the Failing Diabetic Heart. Circulation 
2008;117:43–51.  
237.  Fukuta H, Little WC. Observational studies of statins in heart failure with 
preserved systolic function. Heart Fail Clin 2008;4:209–216.  
238.  Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, 
McMurray JJV, Mant J, NICE Guideline Development Group for Acute Heart 
Failure. The diagnostic accuracy of the natriuretic peptides in heart 
failure: systematic review and diagnostic meta-analysis in the acute care 
setting. BMJ 2015;350:h910.  
239.  Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, 
Mitnitski A. A global clinical measure of fitness and frailty in eldery 
people. Can Med Assoc J 2005;5:489–495.  
321 
240.  Kern MJ, Lerman A, Bech JW, De Bruyne B, Eeckhout E, Fearon WF, Higano 
ST, Lim MJ, Meuwissen M, Piek JJ, Pijls NHJ, Siebes M, Spaan JAE. 
Physiological Assessment of Coronary Artery Disease in the Cardiac 
Catheterization Laboratory A Scientific Statement From the American 
Heart Association Committee on Diagnostic and Interventional Cardiac 
Catheterization, Council on Clinical Cardiology. 2006;114(12):1321-41.  
241.  Ong P, Athanasiadis A, Borgulya G, Vokshi I, Bastiaenen R, Kubik S, Hill S, 
Schäufele T, Mahrholdt H, Kaski JC, Sechtem U. Clinical usefulness, 
angiographic characteristics, and safety evaluation of intracoronary 
acetylcholine provocation testing among 921 consecutive white patients 
with unobstructed coronary arteries. Circulation 2014;129:1723–1730.  
242.  Ong P, Athanasiadis A, Sechtem U. Intracoronary Acetylcholine Provocation 
Testing for Assessment of Coronary Vasomotor Disorders. J Vis Exp 
2016;114:54295.     
243.  Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, Lennon 
R, Rihal C, Lerman LO, Lerman A. Long-term administration of endothelin 
receptor antagonist improves coronary endothelial function in patients 
with early atherosclerosis. Circulation 2010;122:958–966.  
244.  Lee BK, Lim HS, Fearon WF, Yong AS, Yamada R, Tanaka S, Lee DP, Yeung 
AC, Tremmel JA. Invasive evaluation of patients with angina in the 
absence of obstructive coronary artery disease. Circulation 
2015;131:1054–1060.  
245.  Al Suwaidi J, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. 
Long-Term Follow-Up of Patients With Mild Coronary Artery Disease and 
Endothelial Dysfunction. Circulation 2000;101:948–954.  
246.  Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion 
recovery for detecting myocardial infarction using gadolinium-delayed 
hyperenhancement. Magn Reson Med 2002;47:372–383.  
247.  Petersen SE, Aung N, Sanghvi MM, Zemrak F, Fung K, Paiva JM, Francis JM, 
Khanji MY, Lukaschuk E, Lee AM, Carapella V, Kim YJ, Leeson P, Piechnik 
322 
SK, Neubauer S. Reference ranges for cardiac structure and function using 
cardiovascular magnetic resonance (CMR) in Caucasians from the UK 
Biobank population cohort. J Cardiovasc Magn Reson 2017;19:18.  
248.  Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, 
Pennell DJ, Rumberger JA, Ryan T, Verani MS. Standardized Myocardial 
Segmentation and Nomenclature for Tomographic Imaging of the Heart. 
Circulation 2002;105:539–542.  
249.  Al-Saadi N, Nagel E, Gross M, Bornstedt A, Schnackenburg B, Klein C, 
Klimek W, Oswald H, Fleck E. Noninvasive detection of myocardial 
ischemia from perfusion reserve based on cardiovascular magnetic 
resonance. Circulation 2000;101:1379–1383.  
250.  Nagel E, Klein C, Paetsch I, Hettwer S, Schnackenburg B, Wegscheider K, 
Fleck E. Magnetic resonance perfusion measurements for the noninvasive 
detection of coronary artery disease. Circulation 2003;108:432–437.  
251.  Liu A, Wijesurendra RS, Liu JM, Forfar JC, Channon KM, Jerosch-Herold M, 
Piechnik SK, Neubauer S, Kharbanda RK, Ferreira VM. Diagnosis of 
Microvascular Angina Using Cardiac Magnetic Resonance. J Am Coll Cardiol 
2018;71:969–979.  
252.  Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. 
Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a 
comprehensive review. J Cardiovasc Magn Reson 2017;18:89.  
253.  Kellman P, Wilson JR, Xue H, Ugander M, Arai AE. Extracellular volume 
fraction mapping in the myocardium, part 1: evaluation of an automated 
method. J Cardiovasc Magn Reson 2012;14:63.  
254.  Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, 
Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, Schulz-Menger J, 
Schelbert EB. Myocardial T1 mapping and extracellular volume 
quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) 
and CMR Working Group of the European Society of Cardiology consensus 
statement. J Cardiovasc Magn Reson 2013;15:92.  
323 
255.  Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, Vogel-Claussen J, 
Turkbey EB, Williams R, Plein S, Tee M, Eng J, Bluemke DA. Normal values 
for cardiovascular magnetic resonance in adults and children. J Cardiovasc 
Magn Reson 2015;17:29.  
256.  Januzzi JL, Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation 
in patients with heart failure: on behalf of the third Universal Definition of 
Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J 
2012;33:2265–2271.  
257.  Pfeffer MA, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection 
Fraction In Perspective. Circ Res 2019;124:1598–1617.  
258.  Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, 
Filippatos G, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van 
Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, 
Voors AA. Non-cardiac comorbidities in heart failure with reduced, mid-
range and preserved ejection fraction. Int J Cardiol 2018;271:132–139.  
259.  Release 3A: Scotland’s Census. Census 2011: Detailed characteristics on 
Ethnicity, Identity, Language and Religion in Scotland. 
https://www.scotlandscensus.gov.uk/news/census-2011-detailed-
characteristics-ethnicity-identity-language-and-religion-scotland. 
Accessed: 12 October 2020.  
260.  Mensah GA. Black and Minority Health 2019: More Progress Is Needed. J Am 
Coll Cardiol 2019;74:1264–1268.  
261.  Rosenthal RL. The 50% Coronary Stenosis. Am J Cardiol 2015;115:1162–
1165.  
262.  Tonino PAL, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, 
MacCarthy PA, van`t Veer M, Pijls NHJ. Angiographic Versus Functional 
Severity of Coronary Artery Stenoses in the FAME Study. J Am Coll Cardiol 
2010;55:2816–2821.  
263.  Kajimoto K, Sato N, Takano T, investigators of the Acute Decompensated 
Heart Failure Syndromes (ATTEND) registry. Functional mitral regurgitation 
324 
at discharge and outcomes in patients hospitalized for acute 
decompensated heart failure with a preserved or reduced ejection 
fraction. Eur J Heart Fail 2016;18:1051–1059.  
264.  Bertrand PB, Schwammenthal E, Levine RA, Vandervoort PM. Exercise 
Dynamics in Secondary Mitral Regurgitation: Pathophysiology and 
Therapeutic Implications. Circulation 2017;135:297–314.  
265.  Scottish Health Survey 2019 - Volume 1: Main Report. 
https://www.gov.scot/publications/scottish-health-survey-2019-volume-1-
main-report. Accessed: 4 October 2020.  
266.  Herck PL Van, Carlier SG, Claeys MJ, Haine SE, Gorissen P, Miljoen H, 
Bosnians JM, Vrints CJ. Coronary microvascular dysfunction after 
myocardial infarction: Increased coronary zero flow pressure both in the 
infarcted and in the remote myocardium is mainly related to left 
ventricular filling pressure. Heart 2007;93:1231–1237.  
267.  Payne AR, Berry C, Doolin O, McEntegart M, Petrie MC, Lindsay MM, Hood 
S, Carrick D, Tzemos N, Weale P, McComb C, Foster J, Ford I, Oldroyd KG. 
Microvascular Resistance Predicts Myocardial Salvage and Infarct 
Characteristics in ST-Elevation Myocardial Infarction. J Am Heart Assoc 
2012;1.  
268.  Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, 
Waddington-Cruz M, Kristen A V., Grogan M, Witteles R, Damy T, Drachman 
BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley 
S, Schumacher J, Stewart M, Sultan MB, Rapezzi C. Tafamidis Treatment 
for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 
2018;379:1007–1016.  
269.  Thomson LEJ, Wei J, Agarwal M, Haft-Baradaran A, Shufelt C, Mehta PK, 
Gill EB, Johnson BD, Kenkre T, Handberg EM, Li D, Sharif B, Berman DS, 
Petersen JW, Pepine CJ, Bairey Merz CN. Cardiac magnetic resonance 
myocardial perfusion reserve index is reduced in women with coronary 
microvascular dysfunction. A National Heart, Lung, and Blood Institute-
sponsored study from the Women’s Ischemia Syndrome Evaluation. Circ 
325 
Cardiovasc Imaging 2015;8.  
270.  Redfield MM. Heart Failure with Preserved Ejection Fraction. N Engl J Med 
2016;375:1868–1877.  
271.  Shah SJ, Katz DH, Deo RC. Phenotypic Spectrum of Heart Failure with 
Preserved Ejection Fraction. Heart Fail Clin 2014;10:407–418.  
272.  Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, Anker 
SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra 
VK, Cleland J, Comin-Colet J, Duengen HD, Echeverría Correa LE, 
Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens 
S, Katova T, Køber L, Lelonek M, Linssen G, Lund LH, O’Meara E, Merkely 
B, Milicic D, Oh BH, Perrone SV, Ranjith N, Saito Y, Saraiva JF, Shah S, 
Seferovic PM, Senni M, Sibulo Jr AS, Sim D, Sweitzer NK, Taurio J, 
Vinereanu D, Vrtovec B, Widimský Jr J, Yilmaz MB, Zhou J, Zweiker R, 
Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, 
Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, 
McMurray JJV. Baseline Characteristics of Patients With Heart Failure and 
Preserved Ejection Fraction in the PARAGON-HF Trial. Circ Heart Fail 
2018;11.  
273.  Lam CSP, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical 
course of heart failure with preserved ejection fraction. Eur J Heart Fail 
2011;13:18–28.  
274.  Doshi D, Ben-Yehuda O, Bonafede M, Josephy N, Karmpaliotis D, Parikh MA, 
Moses JW, Stone GW, Leon MB, Schwartz A, Kirtane AJ. Underutilization of 
Coronary Artery Disease Testing Among Patients Hospitalized With New-
Onset Heart Failure. J Am Coll Cardiol 2016;68:450–458.  
275.  Sara JD, Widmer RJ, Matsuzawa Y, Lennon RJ, Lerman LO, Lerman A. 
Prevalence of Coronary Microvascular Dysfunction Among Patients With 
Chest Pain and Nonobstructive Coronary Artery Disease. JACC Cardiovasc 
Interv 2015;8:1445–1453.  
276.  Saraste M, Koskenvuo J, Knuuti J, Toikka J, Laine H, Niemi P, Sakuma H, 
326 
Hartiala J. Coronary flow reserve: measurement with transthoracic 
Doppler echocardiography is reproducible and comparable with positron 
emission tomography. Clin Physiol 2001;21:114–122.  
277.  Olsen RH, Pedersen LR, Snoer M, Christensen TE, Ghotbi AA, Hasbak P, 
Kjaer A, Haugaard SB, Prescott E. Coronary flow velocity reserve by 
echocardiography: feasibility, reproducibility and agreement with PET in 
overweight and obese patients with stable and revascularized coronary 
artery disease. Cardiovasc Ultrasound 2016;14:22.  
278.  Nelson MD, Wei J, Bairey Merz CN. Coronary microvascular dysfunction and 
heart failure with preserved ejection fraction as female-pattern 
cardiovascular disease: the chicken or the egg? Eur Heart J 2018;39:850–
852.  
279.  Evans JDW, Dobbin SJH, Pettit SJ, Di Angelantonio E, Willeit P. High-
Sensitivity Cardiac Troponin and New-Onset Heart Failure: A Systematic 
Review and Meta-Analysis of 67,063 Patients With 4,165 Incident Heart 
Failure Events. JACC Heart Fail 2018;6:187–197.  
280.  Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, 
Hainer J, Bibbo CF, Dorbala S, Blankstein R, Di Carli MF. Coronary 
microvascular dysfunction and future risk of heart failure with preserved 
ejection fraction. Eur Heart J 2018;39:840–849.  
281.  Kanagala P, Cheng ASH, Singh A, McAdam J, Marsh AM, Arnold JR, Squire 
IB, Ng LL, McCann GP. Diagnostic and prognostic utility of cardiovascular 
magnetic resonance imaging in heart failure with preserved ejection 
fraction – implications for clinical trials. J Cardiovasc Magn Reson 
2018;20:4.  
282.  Collins R, Peto R, Hennekens C, Doll R, Bubes V, Buring J, Dushkesas R, 
Gaziano M, Brennan P, Meade T, Rudnicka A, Hansson L, Warnold I, 
Zanchetti A, Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the 
primary and secondary prevention of vascular disease: collaborative meta-
analysis of individual participant data from randomised trials. Lancet 
2009;373:1849–1860.  
327 
283.  Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, 
Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' 
(CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: 
Prospective meta-analysis of data from 90 056 participants in 14 
randomised trials of statins. Lancet 2005;366:1267–1278.  
284.  Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, Heart Outcomes 
Prevention Evaluation Study Investigators. Effects of an Angiotensin-
Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-
Risk Patients. N Engl J Med 2000;342:145–153.  
285.  Freemantle N, Cleland J, Young P, Mason J, Harrison J. β blockade after 
myocardial infarction: Systematic review and meta regression analysis. Br 
Med J 1999;318:1730–1737.  
286.  Roy C, Slimani A, de Meester C, Amzulescu M, Pasquet A, Vancraeynest D, 
Beauloye C, Vanoverschelde JL, Gerber BL, Pouleur AC. Associations and 
prognostic significance of diffuse myocardial fibrosis by cardiovascular 
magnetic resonance in heart failure with preserved ejection fraction. J 
Cardiovasc Magn Reson 2018;20:55.  
287.  Duca F, Kammerlander AA, Zotter-Tufaro C, Aschauer S, Schwaiger ML, 
Marzluf BA, Bonderman D, Mascherbauer J. Interstitial Fibrosis, Functional 
Status, and Outcomes in Heart Failure With Preserved Ejection Fraction: 
Insights From a Prospective Cardiac Magnetic Resonance Imaging Study. 
Circ Cardiovasc Imaging 2016;9.   
288. Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, 
Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Fazlibegovic E, Fonseca 
C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, 
Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, 
Seferovic P, Temizhan A, Tousoulis D, Tavazzi L, HFA of the ESC. Are 
hospitalized or ambulatory patients with heart failure treated in 
accordance with European Society of Cardiology guidelines? Evidence from 
12 440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart 
Fail; 2013;15:1173–1184. 
328 
289.  Warraich HJ, Kitzman DW, Whellan DJ, Duncan PW, Mentz RJ, Pastva AM, 
Nelson MB, Upadhya B, Reeves GR. Physical Function, Frailty, Cognition, 
Depression, and Quality of Life in Hospitalized Adults ≥60 Years With Acute 
Decompensated Heart Failure With Preserved Versus Reduced Ejection 
Fraction. Circ Hear Fail; 2018;11:e005254.  
290.  McConkey HZR, Marber M, Chiribiri A, Pibarot P, Redwood SR, Prendergast 
BD. Coronary Microcirculation in Aortic Stenosis. Circ Cardiovasc Interv 
2019;12.  
291.  Galderisi M, Capaldo B, Sidiropulos M, Derrico A, Ferrara L, Turco A, 
Guarini P, Riccardi G, Dedivitiis O. Determinants of Reduction of Coronary 
Flow Reserve in Patients With Type 2 Diabetes Mellitus or Arterial 
Hypertension Without Angiographically Determined Epicardial Coronary 
Stenosis. Am J Hypertens 2007;20:1283–1290.  
292.  Galderisi M, Desimone G, Cicala S, Parisi M, Derrico A, Innelli P, Dedivitiis 
M, Mondillo S, Dedivitiis O. Coronary Flow Reserve in Hypertensive Patients 
With Hypercholesterolemia and Without Coronary Heart Disease. Am J 
Hypertens 2007;20:177–183.  
293.  Nemes A, Forster T, Geleijnse ML, Kutyifa V, Neu K, Soliman OII, Cate FJ 
ten, Csanády M. The additional prognostic power of diabetes mellitus on 
coronary flow reserve in patients with suspected coronary artery disease. 
Diabetes Res Clin Pract 2007;78:126–131.  
 
 
